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9:00 a.m.
901-209 Impact of Renal Function on Coronary Plaque 
Characteristics in Patients with Acute Myocardial 
Infarction: An Intravascular Ultrasound Analysis
Young Joon Hong, Gary S. Mintz, Sang Wook Kim, Teruo Okabe, Augusto D. Pichard, 
Lowell F. Satler, Ron Waksman, Kenneth M. Kent, William O. Suddath, Neil J. Weissman, 
Washington Hospital Center, Washington, DC, Cardiovascular Research Foundation, 
New York, NY
Background: Previous studies have shown that renal insufficiency is an independent 
predictor of significant coronary artery disease and is associated with subclinical 
atherosclerosis.
Methods: We used intravascular ultrasound to assess plaque morphology and 
morphometry in 100 acute myocardial infarction (AMI) pts (39 ST segment elevation and 
61 non-ST segment elevation MI) with varying degrees of renal dysfunction according 
to creatinine clearance (CrCl): Group I [CrCl >70 ml/min (n=36)]; Group II [CrCl 30 to 69 
ml/min (n=35)]; Group III [CrCl <30 ml/min, (n=29, including 12 hemodialysis patients)].
Results: Group III pts were oldest and had most diabetes. Although no significant 
differences were found in lesion site plaque burden and remodeling pattern among the 
3 groups, lesions were longest, reference segment plaque burden was greatest, culprit 
lesion plaque ruptures were more common, and rupture plaque cavities were largest in 
Group III (Table). Plaque rupture (r=-0.258, p=0.010), reference segment plaque burden 
(r=-0.358, p<0.001), and plaque cavity area (r=-0.366, p=0.013) all correlated with CrCl. 
Group I
(n=36)
Group II
(n=35)
Group III
(n=29) p value
Patient age (yrs) 57±12 62±15 69±11 0.021
Diabetes, # (%) 9 (25.0) 14 (40.0) 22 (75.9) <0.001
IVUS lesion length (mm) 15.0±11.0 14.7±9.5 19.7±9.6 0.035
Reference segment plaque burden (%) 30±12 33±9 41±9 <0.001
Remodeling index 1.06±0.23 1.08±0.28 1.09±0.19 0.882
Arc of calcium (º) 110±86 109±91 151±94 0.424
Plaque rupture, # (%) 12 (33.3) 14 (40.0) 19 (65.5) 0.026
Multiple plaque rupture, # (%) 4 (11.1) 4 (11.4) 10 (34.5) 0.023
Plaque cavity CSA (mm2) 1.29±0.46 1.43±1.08 2.40±1.37 0.008
Plaque rupture length (mm) 1.75±0.87 2.06±1.34 2.74±1.48 0.070
Conclusions: A significant decrease in renal function (CrCl <30 ml/min) was associated 
with more diffuse atherosclerosis (longer lesions with larger reference segment plaque 
burden) and more unstable plaque morphology (more frequent single and multiple plaque 
ruptures) in pts with AMI. This may contribute to the worse acute and chronic outcomes 
in these pts.
9:00 a.m.
901-210 Intermediate Volume Operators Attempt Percutaneous 
Coronary Intervention (PCI) of Chronic Total Occlusions 
(CTO) More Frequently than Low or High Volume 
Operators: An Analysis From the ACC/NCDR Database 
of 45,826 CTO Patients
J. Aaron Grantham, John A. Spertus, Mikhail Kosiborod, David M. Safley, John A. 
House, Steven P. Marso, Mid America Heart Institute of Saint Luke’s Hospital, Kansas 
City, MO, University of Missouri-Kansas City, Kansas City, MO
Background: PCI of CTO alleviates angina and improves survival, yet attempt rates for 
this high risk time consuming procedure are low. Whether operator total PCI volume is 
related to attempt rate in PCI of CTO is unknown.
Methods: Using the ACC/NCDR version 3.04 dataset we analyzed a sample of 45,826 
patients (pts) who had ≥ 1 CTO and, were free from nonSTEMI or STEMI within 7 days. 
Attempt rate was calculated as the number of pts with ≥ 1 attempted PCI of CTO within 
90 days of index angiogram divided by the total number of pts with CTO per operator. 
Annualized total PCI volumes were estimated for each operator and pts stratified into 
3 groups: those treated by low (<150PCI/yr), intermediate (150-299PCI/yr), and high 
volume operators (>300PCI/yr).
Results: The overall attempt rate was 14% (6,528 pts). There were no differences 
between groups in age, gender or renal function. Intermediate volume operators had the 
highest attempt rate (Figure). The % of operators who attempted ≥1 CTO were 53%, 90%, 
and 19% in the low, intermediate and high volume groups (3 way p<0.001).
Conclusions: Intermediate volume operators attempt PCI more frequently than either 
low or high volume operators suggesting that inadequate operator experience and high 
work intensity are both contributing to the decision to not offer PCI to the overwhelming 
majority of pts with CTO. 
9:00 a.m.
901-211 Angiographic and Clinical Outcomes Among 1,317 
Patients Treated with the Endeavor Zotarolimus-eluting 
Stent for Native Coronary Artery Disease: 2-year High-
risk Subgroup Analysis
David E. Kandzari, Martin B. Leon, William Wijns, Ian T. Meredith, Jean Fajadet, 
Medtronic, Santa Rosa, CA
Background: The Endeavor zotarolimus-eluting stent (ZES) has been evaluated in four 
clinical trials for treatment of de novo coronary artery lesions: (1) the Endeavor I first-in-
human study; (2) the Endeavor II randomized comparison with a bare metal stent; (3) the 
Endeavor II continued access registry; and (4) the Endeavor III randomized comparison 
with sirolimus-eluting stents. To determine the consistency and durability of benefit with 
the Endeavor stent, angiographic and clinical outcomes among 1,317 patients treated 
with ZES in these four trials were combined for analysis among subgroups at high risk for 
restenosis and repeat revascularization.
Methods: Protocol-specified follow-up angiography was performed at 8 or 12 months for 
patient subgroups (N=657), and clinical follow-up was complete at 9 months, 12 months, 
and 2 years after the index procedure for all 1,317 patients.
Results: Diabetes mellitus was present in 22.5% of patients, the mean reference vessel 
diameter was 2.73 mm, and the mean lesion length was 14.59 mm. At 8 months, the mean 
in-stent late lumen loss was 0.60±0.48 mm, and in-stent angiographic binary restenosis 
occurred in 9.9% of patients. At 9 months, the rate of major adverse cardiac events (MACE) 
was 7.6%, and the target lesion revascularization (TLR) rate was 4.9%. Neither target 
vessel failure nor MACE varied significantly relative to diabetes status, vessel diameter, or 
lesion length. At 12 months, the rate of stent thrombosis was 0.3%, with no cases of late 
stent thrombosis. The 2-year clinical follow-up for subgroup analysis according to diabetes 
status, lesion length, and vessel diameter will be available in March 2007.
Conclusion: The use of the Endeavor ZES for treatment of de novo coronary artery 
lesions is associated with sustained and consistently low rates of TLR, MACE, and stent 
thrombosis. The 2-year clinical follow-up data, considering the new Dublin definitions will 
further clarify the safety and efficacy of the Endeavor ZES in higher-risk patient and lesion 
subsets.
9:00 a.m.
901-212 Percutaneous Circulatory Support During High Risk 
Angioplasty Procedures: A Multicenter Experience with 
Impella Technology
Karim Benali, Jose Henriques, ABIOMED, Inc., Danvers, MA, Academic Medical Centre, 
Amsterdam, The Netherlands
Background: Advances in catherization procedures and technology have produced 
a series of challenges for clinicians, who are faced with more complex and higher risk 
percutaneous coronary intervention (PCI) cases. These interventions are performed 
on patients with severe comorbidities, complex lesions, and/or increased susceptibility 
to hemodynamic instability. The benefits of prophylactic circulatory support in reducing 
major hemodynamic compromise during high risk PCI are well-documented. In this study 
we present the largest European multicenter reported experience with Impella 2.5, a 
miniaturized percuatneous ventricular assist device, for patients undergoing high risk PCI 
procedures.
Methods: A retrospective data analysis that includes over 100 patients supported with 
Impella 2.5 (ABIOMED, Inc) will be presented. The preliminary analysis on the first 50 
patients is reported in this abstract. The pump was used either in hemodynamically stable 
(72%), urgent (24%) or emergent (4%) situations. The population had a mean age of 
71±10 years and 78% were male. Medical histories included chronic heart failure (72%), 
prior acute myocardial infarction (50%), diabetes (40%), renal insufficiency (24%), prior 
stroke (20%) and chronic obstructive pulmonary disease (20%). The average ejection 
fraction was 25±10%. In 95% of the cases, the target vessel was in an unprotected left 
main or the last remaining vessel.
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Results: Overall, 90% of the patients presented with 2 or more severe comorbidities. 
All patients were successfully implanted with the device. There was no intra-procedural 
deaths. The 30-day mortality was 6% (2 deaths post procedure and one after discharge). 
Adverse event rates were low, similar to what has been reported elsewhere ( stroke 
0%, limb ischemia 2%, bleeding requiring transfusion 4%, severe infection 2%, vascular 
complication 8%).
Conclusions: This study demonstrated that the Impella 2.5 is safe and potentially 
effective in supporting patients during high risk PCI procedures. The ease of use of the 
technology and high survival rate provide a compelling incentive to implement the Impella 
2.5 for circulatory support during high risk PCI procedures.
9:00 a.m.
901-213 Successful Thermal Coaptation of Patent Foramen 
Ovale: First Experience and Temporal Histopathologic 
Healing in a Porcine Model
Hidehiko Hara, Elena Ladich, Renu Virmani, David Auth, Joseph Eichinger, Deborah 
Sheffield, Mark Reisman, Robert S. Schwartz, Minneapolis Heart Institute Foundation, 
Minneapolis, MN
Background: Percutaneous patent foramen ovale (PFO) closure with implantable devices 
is now routine, and limits embolic complications. A novel method for PFO closure without 
an implanted device uses radiofrequency (RF)-based thermal energy to seal the PFO 
tunnel. We examined the healing response to temporal histopathologic events after 
thermal PFO closure in swine to characterize safety and efficacy of this strategy.
Methods: Domestic swine were studied over time following thermal PFO closure. Three 
animals were euthanized within 1 hour, 5 at 7, 28 days, and 5 at 60 days. Gross and 
histopathologic findings were examined.
Results: RF energy was successfully delivered in all cases. Acute results showed edema, 
hemorrhage and myocyte necrosis. Minimal thrombus formation occurred on the left atrial 
endocardial surface at the treatment site. At day 7, transmural thermal effects were seen 
through the atrial wall, and in 3 of 5 cases there was extension to the epicardial surface. At 
day 28, minimal thermal injury remained, with excellent scar formation. Collagen, matrix, 
and neovascularization occurred in all cases (Figure). No animal suffered adverse events 
prior to euthanasia at day 60.
Conclusions: RF based PFO closure device uses no implantable device, is feasible, safe, 
and effective in swine. Thermal tunnel healing is nearly complete by 4 weeks, consisting 
dense collagen formation and tunnel closure. This technique may allow effective PFO 
closure without a need for implanted devices.
9:00 a.m.
901-214 Ostial Versus Crossover Stenting With Sirolimus-
Eluting Stent for the Treatment of Ostial Left Anterior 
Descending Artery Lesions
Koichi Kishi, Yoshikazu Hiasa, Hirotoshi Chen, Shinichiro Miyazaki, Riyo Ogura, 
Yoshikazu Ohara, Naoki Suzuki, Kenichiro Yuba, Hitoshi Miyajima, Takefumi Takahashi, 
Shinobu Hosokawa, Ryuji Ohtani, Tokushima Red Cross Hospital, Komatsushima, 
Japan
Background: Percutaneous coronary intervention in ostial lesions of left anterior 
descending artery (LAD) have higher restenosis rates and the risk of plaque shift to left 
circumflex artery (LCX). The aim of this study was to evaluate the clinical and angiographic 
outcomes of ostial versus crossover stenting with sirolimus-eluting stent (SES) for ostial 
LAD lesions. Methods: From August 2004 to January 2006, 74 consecutive patients (pts) 
(62 men, mean age 69 ± 9 years) with de novo ostial LAD lesions without ostial LCX 
narrowing were treated with single SES. Intravascular ultrasound was performed in all pts 
during the procedure. Results: Thirty-six pts were treated with SES stenting at the ostial 
LAD without jeopardizing the ostial LCX, and 38 pts were treated with crossover SES 
stenting from distal left main trunk across the LCX with final kissing balloon dilatation. 
Baseline clinical and angiographic characteristics were comparable between the 2 
groups. The use of debulking atherectomy prior to stenting was similar between the 2 
groups (directional coronary atherectomy: 31% vs. 37%, rotablator: 14% vs. 16%). The 
mean post-intervention minimal lumen diameter (MLD) and reference diameter (RD) were 
significantly larger in the crossover group (MLD: 3.03 ± 0.47 mm vs. 3.32 ± 0.66 mm, 
p<0.05, RD: 3.45 ± 0.40 mm vs. 3.72 ± 0.51 mm, p<0.05). The mean 9-month follow-up 
MLD and RD were significantly larger in the crossover group (MLD: 2.56 ± 0.67 mm vs. 
2.86 ± 0.55 mm, p<0.05, RD: 3.18 ± 0.56 mm vs. 3.53 ± 0.41 mm, p<0.05). One acute 
thrombosis occurred in the crossover group (2.6%). Although the 9-month angiographic 
restenosis rate was similar between the 2 groups (3% vs. 0%), the ostial LCX stenosis 
tended to occur more frequently in the ostial group (8% vs. 0%, p=0.07). Conclusions: 
SES implantation for ostial LAD lesions, either ostial or crossover stenting, appears safe 
with low rates of restenosis. However, crossover stenting may be superior to ostial stenting 
in terms of avoiding the development of ostial LCX stensosis during follow-up period.
9:00 a.m.
901-215 Are Angiographic Restenosis Criteria Functionally 
Relevant In Evaluation Of Jailed Side Branch Lesions 
At Follow-up Angiograms?
Bon Kwon Koo, Kyung-Woo Park, Eui-Keun Choi, Yong-Seok Cho, Woo-Young Chung, 
Hae-Young Lee, Hyun-Jai Kang, In-Ho Chae, Dong-Ju Choi, Hyo-Soo Kim, Byung-Hee 
Oh, Young-Bae Park, Yoon-Shik Choi, Seoul National Univsersity Hospital, Seoul, South 
Korea
Backgrounds: Quantitative coronary angiography (QCA) is not always accurate in 
evaluation of ostial lesions. Previous study showed that angiographic evaluation of jailed 
side branch lesions overestimates the functitonal severity of these lesions. We performed 
this study to evaluate the relationship between QCA and functional significance of jailed 
side branch lesions at a follow-up angiogram.
Methods: Fractional flow reserve (FFR) was measured using RADI 4 pressure wire in 
patients with jailed side branch lesions (reference diameter>2mm, lesion length<10mm) 
after drug-eluting stent at routine 6 months follow-up angiogram. Patients with regional 
wall motion abnormalities and significant luminal narrowing at the parent vessel were 
excluded. FFR was measured at 5mm distal and proximal to the ostial lesion of the jailed 
side branches.
Results: Sixty-seven lesions (LAD 73%, Cypher 70%) were consecutively enrolled 
and FFR was successfully measured in 66 lesions (LAD 49, LCX 12, RCA 4 lesions). 
Reference diameter, percent stenosis and lesion length of main branch/side branch 
lesions were 2.9±0.4/2.3±0.3 mm, 18±18/70±15% and 27±9/7.2±2.7mm, respectively. 
FFR at main branch was 0.96±0.04 and side branch, 0.87±0.09. There was a negative 
correlation between FFR and percent stenosis at jailed side branch lesions (r=-0.27, 
p=0.03). However, no lesion <75% stenosis was functionally significant and only 16% 
among lesions ≥ 75% stenosis had FFR<0.75. Restenosis rates by different criteria are 
as follows: 50% restenosis: 91%, 75% restenosis: 40% and functional criteria(FFR<0.75): 
only 8%. Conclusion: QCA overestimates the functional significance of jailed side branch 
lesions. More strict angiographic criteria should be applied in evaluation of treatment 
success of side branch lesion at a follow-up angiogram.
9:00 a.m.
901-216 Safety and Efficacy of Desensitization Procedure in 
pts with Aspirin Sensitivity Undergoing Percutaneous 
Coronary Stenting
Roberta Rossini, Giuseppe Musumeci, Mario Scuri, Paolo Invernizzi, Paolo Ferrazzi, 
Antonello Gavazzi, Cardiovascular Dpt Ospedali Riuniti di Bergamo, Bergamo, Italy
Background: with the widespread of drug eluting stents (DES) in coronary percutaneous 
interventions (PCI), aspirin therapy has become mandatory. However, some patients 
(pts) are unable to tolerate acetylsalicylic acid (aspirin) due to sensitivity, which can limit 
percutaneous coronary revascularization.
Aim: to test safety and efficacy of a new standard desensitization procedure, using 
escalating low doses of aspirin in pts with acetylsalicylic acid sensitivity.
Methods and Results: Out of 721 pts with coronary artery disease, eighteen (age 
62.2±8.8 yrs; 15 male) had a history of aspirin sensitivity (2.5%). They were admitted 
for acute coronary syndrome (N=10) or stable angina (N=8). Six pts had respiratory 
sensitivity (asthma and/or rhinitis), and 12 had experienced cutaneous reactions (urticaria 
and/or angioedema). All pts underwent the challenge desensitization procedure. None 
received pretreatment with antihistamines or corticosteroids, and beta-blockers were 
withheld 24 hours before desensitization. Six sequential doses of aspirin (1, 5, 10, 20, 
40, and 100 mg) were administered orally, with the procedure lasting 5.5 hours. Blood 
pressure, pulse, cutaneous, nasoocular, or pulmonary reactions were monitored closely 
until 4 hours after the procedure. The desensitization procedure was successful in 15 pts 
(83.3%). No serious adverse reaction occurred: two pts (both with a history of chronic 
idiopathic urticaria) developed cutaneous reaction which resolved with corticosteroids and 
antihistamines; one pt (with frequent asthma attacks) experienced shortness of breath 
associated with bronchospasm, which resolved immediately after the administration of 
corticosteroids. All pts but 2 underwent PCI (1.5 stent/pt, DES 75%, stent length 27.3±7.2 
mm, multivessel PCI 37.5%) and were discharged on dual antiplatelet therapy. At six-
month follow-up, all pts well tolerated aspirin. No major adverse cardiac event occurred.
Conclusions: this desensitization procedure seems to be safe and effective in the vast 
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majority of pts with cutaneous or respiratory aspirin sensitivity. Complex PCI procedures 
can be performed also in such pts, without increasing the risk of stent thrombosis.
9:00 a.m.
901-217 Physiologic Evaluation Of Myocardial Bridging: A New 
Analysis For An Old Disease
Bon Kwon Koo, Jung-Won Suh, Wook-Jin Chung, Hae-Young Lee, Hyun-Jai Kang, 
Young-Suk Cho, In-Ho Chae, Dong-Ju Choi, Hyo-Soo Kim, Woo-Young Chung, Byung-
Hee Oh, Young-Bae Park, Seoul National Univsersity Hospital, Seoul, South Korea
Background: Myocardial bridging is the most common congenital coronary anomaly. 
It is infrequently associated with myocardial ischemia, however, it is difficult to assess 
the functional significance of this lesion due to its dynamic nature. We performed this 
study to assess the hemodynamic relevance of myocardial bridges using a pressure wire. 
Methods: 24 patients with lone myocardial bridging lesions were consecutively enrolled 
(systolic compression >50% by visual estimation). Baseline angiogram was obtained after 
intracoronary nitroglycerine administration and angiographic data of diastolic and systolic 
phases were obtained. Then fractional flow reserve (FFR) and pressure parameters 
were measured. Diastolic FFR was calculated by off-line analysis. Dobutamine stress-
FFR (DS-FFR) was performed with intravenous dobutamine infusion while keeping the 
pressure wire across the lesion. Results: Mean age was 60±9 years and 63% were 
male. No lesion was functionally significant according to baseline FFR/diastolic FFR. 
After dobutamine infusion, percent stenosis and lesion length were aggravated and 
diastolic FFR was lowered. However, FFR was not changed (Table). Two lesions became 
functionally significant after dobutamine infusion. Conclusion: Dobutamine increased the 
morphologic and functional significance of myocardial bridging. Diastolic FFR should be 
used in functional assessment of myocardial bridging.
Baseline Post-Dobutamine P value
Percent stenosis 66±13% 85±9% 0.002
Lesion length 23±7mm 26±7mm 0.05
FFR 0.92±0.05 0.91±0.06 0.08
Diastolic FFR 0.89±0.07 0.83±0.11 0.007
E-POSTER SESSION
902 
ePoster Session 902
Sunday, March 25, 2007, 10:00 a.m.-11:00 a.m.
10:00 a.m.
902-209 The Effect of Contrast Induced Nephropathy on Long-
Term Renal Function
Hee-Suk Min, Ji-Hyun Kim, Bon-Kwon Koo, Jung-Won Suh, Hae-Young Lee, Hyun-Jae 
Kang, Young-Seok Cho, Woo-Young Chung, In-Ho Chae, Dong-Ju Choi, Hyo-Soo Kim, 
Byung-Hee Oh, Young-Bae Park, Seoul national university college of medicine, Seoul, 
South Korea
Background: While even modest increases in serum creatinine (SCr) have been 
associated with an increase in long-term mortality, a pathophysiological link between 
the two is still unknown. The purpose of this study is to address whether contrast 
induced nephropathy (CIN) has influences on long-term renal function and to find a new 
definition of CIN. Methods: Database from two prospective studies on CIN after coronary 
catheterization (RECOVER and PROMISS; total n=542) was reviewed. 253 patients 
(mean age: 65.26 years, female: 32%, mean CCr: 51.68 mL/min per 1.73m2) with records 
of SCr values till six months after the procedure were selected. Creatinine clearance 
(CCr) was calculated by Cockroft-Gault equation. CCr levels of six months before the 
procedure were also analyzed in 130 patients. Results: When the patients were classified 
according to peak increment in SCr within 48hr after the procedure (ΔScr48hr), the 
change in CCr during 6 month follow-up was significantly lower in patients with ΔScr48hr 
≥0.2mg/dL than in those with < 0.2mg/dL. The same findings were shown even when 
the patients were classified according to baseline CCr (table). There was no significant 
change in CCr levels of 6 months before the procedure and baseline in both groups. 
Conclusions: Periprocedural Scr increment influenced on 6 month renal function change 
only in patients with ΔScr ≥0.2mg/dL. These findings suggest that ΔScr ≥0.2mg/dL can be 
a new definition of CIN that can predict the long-term renal function deterioration. 
Increment in SCr within 
48hr (mg/dL)
Baseline 
CCr
CCr after 
6months
Change in 
CCr p-value
Total 
(n=253)
<0.2 (207) 53.03 53.99 0.96
<0.001≥0.2 (46) 45.64 39.64 -6.00
CCr <45 
(n=74)
<0.2 (n=53) 36.35 36.79 0.44 0.009≥0.2 (21) 28.18 25.13 -3.05
45≤CCr<60 
(n=118)
<0.2 (103) 52.86 54.51 1.64
<0.001≥0.2 (15) 53.16 47.51 -5.65
CCr>60 
(n=61)
<0.2 (51) 70.68 70.83 0.15 0.020≥0.2 (10) 71.02 58.28 -12.74
10:00 a.m.
902-210 Drug Eluting Stents in Patients With Diabetes Mellitus: a 
Meta-analysis of Randomized Trials
Giuseppe Patti, Vincenzo Pasceri, Annunziata Nusca, Andrea D’Ambrosio, Germano 
Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-Medico University, 
Rome, Italy, Interventional Cardiology Unit, San Filippo Neri Hospital, Rome, Italy
Background: The real impact of drug eluting stents (DES) on angiographic and clinical 
end-points in diabetic patients (pts) remains to be evaluated; in particular, no extensive 
data are available about the relative effect of DES vs bare metal stents (BMS) on the 
incidence of death and myocardial infarction (MI) during follow-up and there is a concern 
about the use of DES in insulin-dependent diabetic pts.
Methods: We searched data from randomized trials comparing DES and BMS in pts 
with diabetes mellitus during a follow-up of at least 6 months. Main clinical outcomes 
were: target lesion revascularization (TLR), death and MI. Angiographic outcome was the 
incidence of binary in-stent restenosis.
Results: A total of 8 randomized trials reporting post-hoc outcome analyses on the sub-
population of diabetic pts and 1 trial specifically enrolling diabetic pts were found. TLR 
occurred in 8% of pts receiving DES vs 27% of those assigned to BMS (OR 0.23, 016-
0.34; P<0.00001). In-stent restenosis was detected in 8% of pts randomized to DES vs 
41% of those treated with BMS (OR 0.13, 0.09-0.20; P<0.00001). There was no significant 
difference in the incidence of death (2% in both groups, OR 1.04, 0.45-2.43; P=0.92). MI 
occurred in 3% of pts assigned to DES vs 7% of those assigned to BMS, with a significant 
53% risk reduction in the first group (OR 0.47, 0.26-0.88; P=0.02). The benefit of DES in 
reducing in-stent restenosis was greatest in non insulin-dependent diabetic pts (OR 0.17, 
0.11-0.26; P<0.00001), but remained highly significant in insulin-dependent diabetic pts 
(OR 0.22, 0.13-0.37; P<0.00001).
Conclusions: Diabetic pts receiving DES have a significantly lower risk of restenosis and 
TLR compared with those treated with BMS. This reduction was observed both in non 
insulin-dependent and in insulin-dependent pts. Use of DES in diabetic pts may decrease 
the incidence of MI during follow-up, whereas rates of death in DES and BMS groups 
were similar.
10:00 a.m.
902-211 The Endeavor V Registry: ‘Real-world’ 12-month Safety 
and Efficacy Data for the Endeavor Zotarolimus-eluting 
Stent
Chaim Lotan, Ian T. Meredith, Martin T. Rothman, Medtronic, Inc, Santa Rosa, CA
Background: Endeavor V is an open-label, nonrandomized, multicenter global registry 
of patients receiving the Endeavor zotarolimus-eluting, phosphorylcholine-polymer stent 
(ZES) for the treatment of coronary artery disease. To reflect real-world clinical practice, 
consecutive patients are enrolled without clinical or angiographic exclusion.
Methods: Consecutive patients (maximum 100/site) undergoing any percutaneous 
coronary revascularization are enrolled at centers in Australia, Asia Pacific, Europe, India, 
Israel, New Zealand, and South America for a planned total enrollment of 8,000 patients 
treated with ZES. The primary endpoint is major adverse cardiac events (MACE) at 1 
year. Secondary endpoints include MACE at 30 days and 6 months; device, lesion, and 
procedure success rates; and rates of stent thrombosis at 24 hours, <30 days, and >30 
days postprocedure.
Results: Since October 2005, more than 5000 patients receiving the Endeavor stent have 
been enrolled. At present, among 2500 patients, clinical and angiographic characteristics 
include the following: diabetes mellitus, 34.6%; vessel caliber <2.5 mm, 38% stent length 
> 30 mm, 20% in-stent restenosis, 15%; bifurcations, 16.5%. Lesion success was 99.5%, 
and procedural success was 95% One-year results for 750 patients enrolled in the 
Endeavor V registry will be available in March 2007.
Conclusion: Interim analysis from the Endeavor V registry indicate high procedural and 
early clinical outcomes among patients treated with ZES in clinical settings beyond those 
previously studied in systematic trials. Clinical outcomes among over 750 patients with 
1-year follow-up should provide confirmation of the safety and efficacy of the Endeavor 
stent in a broad, unselected patient population reflecting real-world clinical practice.
10:00 a.m.
902-212 The Radial Approach to Percutaneous Coronary 
Intervention is Associated with a Lower Risk for 
Complications Regardless of Radial Procedure Volume: 
A report from the American College of Cardiology 
National Cardiovascular Data Registry (ACC-NCDR)
Sunil V. Rao, Fang-Shu Ou, Tracy Wang, Richard E. Shaw, Ralph Brindis, John S. 
Rumsfeld, Eric D. Peterson, The Duke Clinical Research Institute, Durham, NC, 
American College of Cardiology, Washington, DC
Background: Studies comparing the radial (r-PCI) with the femoral (f-PCI) approach to 
percutaneous coronary intervention have not included centers with low r-PCI volume.
Methods: Data on 305,425 PCI procedures in the ACC-NCDR (2004-2006) were 
analyzed to evaluate variation in use of r-PCI and outcomes across centers. Logistic 
regression was used to evaluate the adjusted association between r-PCI use & procedural 
complications (including bleeding, ischemic, & vascular outcomes).
Results: r-PCI accounted for 1.33% of the total procedures (N=4,074) & use varied 
across centers (0 to 71%). Patients who underwent r-PCI had higher BMI & more often 
had peripheral vascular disease. Compared with f-PCI, r-PCI had longer fluoroscopy 
time (13.20 vs. 11.50 min, p<0.0001) but did not involve more contrast use. r-PCI had 
significantly lower incidence of any bleeding or vascular complication (0.96 vs. 2.38%, 
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p<0.0001 and 0.15 vs. 1.06%, p<0.0001 respectively). These findings were consistent 
across centers regardless of r-PCI volume. After adjustment for confounders & center 
clustering, r-PCI was associated with significantly lower risk for any complication (Table).
Conclusions: Use of r-PCI is infrequent overall, but varies across centers. r-PCI is 
independently associated with lower risk of complications, even in centers with infrequent 
r-PCI use. These data support wider application of r-PCI to improve PCI outcomes.
Table. Association between r-PCI and any complication (f-PCI as reference) 
Model OR (95% confidence interval)
p-
value
Unadjusted 0.56 (0.44-0.70) < 0.001
Adjusted for patient differences 0.71 (0.57-0.89) 0.003
Adjusted for patient differences, procedure 
differences, and center clustering 0.69 (0.57-0.84)
< 
0.001
10:00 a.m.
902-213 Clinical and Angiographic Predictors of High Degree 
Atrio-Ventricular Block After Percutaneous Septal 
Myocardial Ablation: Multivariate Analysis of 65 
Consecutive Patients
Mario Araya, Federico De Marco, Thierry Lefèvre, Andrés Rosas Ramos, Yves 
Louvard, Marie-Christine Malergue, Bertrand Cormier, Marie-Claude Morice, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: Transluminal Alcohol Septal Myocardial Ablation (TASH) bears a significant 
risk of atrioventricular block (AVB). Pre-procedural electrocardiographic (ECG) and 
procedural risk factors have been previously identified (left bundle branch block, type 1 
AVB, no echocardiographic guidance, bolus injection).
Aim of the study: To identify angiographic characteristics associated with post procedure 
AVB.
Methods: Between 2001 and 2006, a group of 65 consecutive patients, without prior 
pace-maker implantation (PM), referred for a first TASH procedure were analyzed. The 
dominant septal (S) branch was defined as the biggest septal branch, and the distance 
between ostial LAD and the S treated was measured by QCA. We performed univariate 
and multivariate analysis to identify predictors of post-procedural AVB.
Results: High degree post-procedural AVB (HD AVB) incidence was 23/65 (35.4%). 
Permanent PM was required in 5/65 (7.7%). Predictors of HD AVB were by univariate 
analysis: 
No HD AVB, n=42 HD AVB, n=23 p value
Age (years) 52.1 ± 18.9 60.0 ± 14.4 p=0.09
Septum thickness (mm) 22.5 ± 3.0 23.6 ± 4.3 NS
Ejection fraction (%) 66 ± 7 62 ± 11 p=0.09
Pre procedure gradient (mmHg) 100 ± 41 107 ± 42 NS
Previous LBBB or type 1 BAV 7% 22% p=0.09
Post procedure CPK Peak (U/l) 1019 ± 618 959 ± 395 NS
Ethanol volume (ml) 2.1 ± 0.8 2.0 ± 1.0 NS
Numbers of S treated 1.1 ± 0.4 1.3 ± 0.5 NS
First septal treated 55% 83% p=0.03
First dominant S treated 38% 61% p=0.08
Ostial LAD - dominant S1 (mm) 13.3 ± 7.7 22.1 ± 5.1 p=0.002
By multivariate analysis, only age (OR 1.037, 95%CI 1.000+1.077, p=0.053), 1st S 
treated (OR 4.439, 95%CI 1.104+17.843, p=0.036) and ostial LAD - dominant S1 (OR 
1.279, 95%CI 1.011-1.617, p=0.040) were the only independent predictors of HD AVB.
Conclusions: Beyond standard predictors we identified for the first time the role of septal 
anatomy in predicting peri-procedural high degree AVB. Alcoholisation of a first Septal, 
particularly if it is the biggest one and when not proximally located, carries the highest 
risk.
10:00 a.m.
902-214 Comparison of Mid-term Results of Left Main Disease 
Treatment by Risk Stratification Systems
Jin-Ho Choi, Jun Hyung Kim, Wang-Soo Lee, Soo Jin Cho, Jeong Hoon Yang, Joo-Yong 
Hahn, Seunghyuk Choi, Sang Hoon Lee, Young Tak Lee, Jeong Euy Park, Hyeon-Cheol 
Gwon, Samsung Medical Center, Sungkunkwan University School of Medicine, Seoul, 
South Korea
Background: The safety and efficacy of left main stenting compared to bypass surgery 
is still a matter of debate. Use of risk stratification system may be helpful for prediction of 
periprocedural risk and choice of best treatment strategy.
Methods: From April 1997 to February 2006, 565 consecutive patients were treated with 
left main revascularization using bare metal stent (BMS) (N=67); drug-eluting stent (DES) 
(N=100), or CABG (N=398). Baseline Euroscore and Parsonnet score were calculated for 
all patients and cumulative incidence of six-month major adverse cardiac and cerebral 
events (MACCE) was evaluated.
Results: The cumulative incidence of MACCE was significantly higher in BMS when 
compared to DES (26.9% versus 4.0%, hazard ratio [HR], 0.138, [95% CI, 0.047 to 
0.407]; p<0.001) or compared to CABG (26.9% versus 6.5%, HR, 0.229, [95% CI, 0.125 
to 0.417]; p<0.001), and it was comparable between DES and CABG (4.0% versus 6.5%, 
p=NS). On multivariate analysis, Euroscore, Parsonnet score, shock before procedure and 
left ventricular ejection fraction were independent predictors of MACCE. The cumulative 
incidence of MACCE of DES was comparable to CABG even in the highest quartile of 
Euroscore or Parsonnet score (P=NS).
Conclusions: DES implantation for left main disease may be feasible and has favorable 
clinical midterm result not only in low risk subgroup but also in high risk subgroup, if 
selected carefully. Our results suggest that a randomized study comparing bypass 
surgery can be justified.
10:00 a.m.
902-215 Clinical Correlates of Restenosis Following Coronary 
Implantation of Drug-Eluting Stents
Probal Roy, Vikram Raya, Teruo Okabe, Tina L. Pinto Slottow, Daniel H. Steinberg, 
Kimberly Smith, Zhenyi Xue, Natalie Gevorkian, Lowell F. Satler, Kenneth K. Kent, 
William O. Suddath, Augusto D. Pichard, Ron Waksman, Washington Hospital Center, 
Washington, DC
Background: The efficacy of drug-eluting stents (DES) in reducing restenosis has not 
been uniform across all patient and lesion subsets. The study aims to identify clinical and 
procedural factors which correlate with DES restenosis.
Methods: The clinical and procedural characteristics of 171 (229 lesions) consecutive 
patients with DES restenosis were compared with 2522 (4564 lesions) consecutive 
DES patients without restenosis. Univariate and multivariate regression analysis were 
performed to detect predictors of DES restenosis.
Results: Patients with DES restenosis were more likely to be younger (62.70±11.04 
vs. 65.23±11.61 p=0.001), and present with unstable angina (p=0.001), hypertension 
(p<0.001), and peripheral vascular disease (p=0.038). These patients underwent longer 
procedures (70.38±51.07 min vs.59.72±47.74 p=0.003) and had more renal insufficiency 
(p=0.001). There was less IVUS guided stent implantation (p=0.0105), less primary 
stenting (p=0.004), and longer total stented length (35.21±19.48mm vs.24.26±12.55 
p<0.001) with more stents/patient (1.61±0.75 vs. 1.16±0.45 p<0.001) in the DES 
restenosis group. Multivariate analysis detected longer total stented length as the major 
correlate for DES restenosis.Other correlates were age, hypertension, longer procedural 
times, and less IVUS guided stent implantation (Table).
Conclusions: Minimizing the number of stents and total stented length, along with 
utilizing IVUS guidance, may potentially reduce DES restenosis.
Table. Predictors of DES restenosis by multivariate regression analysis
Predictor Odds ratio [95% CI] P value
Age 0.980 [0.967-0.994] 0.006
Hypertension 2.215 [1.305-3.429] 0.002
Procedural length 1.004 [1.001-1.006] 0.005
Lack of IVUS guidance 1.681 [1.185-2.387] 0.004
Total Stented length 1.063 [1.053-1.074] <0.0001
Restenotic Lesion 1.312 [0.731-2.355] 0.363
PVD 1.457 [0.596-2.222] 0.080
Hyperlipidemia 1.257 [0.766-2.062] 0.366
10:00 a.m.
902-216 Outcomes of Bivalirudin in Moderate and High Risk 
Patients with Acute Coronary Syndromes and Renal 
Insufficiency: An ACUITY Substudy
Ajay J. Kirtane, Roxana Mehran, George Dangas, Steven Manoukian, Frederick Feit, 
Thomas Stuckey, Magnus Ohman, Martial Hamon, Angel Cequier, David Cohen, 
Charles Pollack, James Hoekstra, Stuart Pocock, Bernard Gersh, Joseph Stella, Michel 
Bertrand, Walter Desmet, Gregg W. Stone, Columbia University Medical Center, New 
York, NY, Cardiovascular Research Foundation, New York, NY
Background: Renal insufficiency is an important predictor of adverse outcomes after PCI 
and in pts with ACS. The safety and efficacy of current anti-thrombotic regimens in this 
population have not been extensively studied.
Methods: In the ACUITY trial, 13,819 moderate and high risk ACS pts undergoing early 
invasive management were randomized to bivalirudin alone (BIV), BIV+glycoprotein IIb/
IIIa inhibition (BIV+GPI), or heparin+GPI (H+GPI). Clinical outcomes in pts with baseline 
renal insufficiency (CrCl <60 ml/min) were compared by randomized treatment.
Results: Baseline renal insufficiency was present in 2468 (17.9%) pts, in whom the mean 
CrCl was 46.2±11.6 ml/min. Mean age was 74 yrs, 29% had diabetes, and 59% had 
elevated cardiac markers. As seen in the Figure, the 30 day rate of the composite net 
clinical endpoint of death/MI/unplanned revasc/major bleeding was similar among pts 
treated with BIV (16.1%), H+GPI (16.8%), and BIV+GPI (19.5%). Composite ischemia 
(death/MI/unplanned revasc) occurred with similar frequency among the 3 study arms, but 
the rate of major bleeding was significantly lower with BIV compared to H+GPI (Figure).
Conclusion: Bivalirudin monotherapy compared to H+GPI results in significantly lower 
rates of major hemorrhagic complications and similar net clinical benefit at 30 days in the 
high-risk subgroup of pts with ACS and baseline renal insufficiency. One year adjudicated 
outcomes will be presented. 
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902-217 The Clinical characteristics of Early vs. Late stent 
thrombosis: A Multicenter Analysis.
Seok-Jae Hwang, Kyung-Woo Park, Jung-Won Suh, Hae-Young Lee, Hyun-Jae Kang, 
Bon-Kwon Koo, Young-Seok Cho, Woo-Young Chung, In-Ho Chae, Dong-Ju Choi, 
Taehoon Ahn, Junghan Yoon, Hyeon-Cheol Gwon, Seung-Jea Tahk, Myung-Ho Jeong, 
Ki-Bae Seung, Yangsoo Jang, Seung-Jung Park, Hyo-Soo Kim, Byung-Hee Oh, Young-
Bae Park, Yoon-Sik Choi, Seoul National University Hospital, Seoul, South Korea
Background:Stent thrombosis(ST) is a major cause of death and morbidity after drug 
eluting stent(DES) implantation. Thrombotic risk is considered to be higher in DES 
compared with BMS, even years after stent implantation. Therefore, we investigated the 
clinical characteristics of stent thrombosis according to the time point of its occurrence.
Methods:This was a multi-center study, where we collected data of consecutive ST 
patients who underwent DES implantation from May, 2004, through June, 2006 at 10 
centers. All information was sent to a core center, where the clinical, angiographic 
and procedural characteristics of ST patients were analyzed. Possible ST as well as 
angiographically proven ST was defined as ST in this study. Acute and subacute ST were 
categorized as early ST. 
Results:A total of 99 patients had 103 cases of ST(Cypher: 56(54%), TAXUS: 47(46%)). 
Ninty two were angiographically confirmed ST and 11 were possible ST. 65 cases occurred 
early(6.2±6.4 days) and 38 cases late(326±219 days) after DES implantation. Clinically, 
early ST patients were significantly older(62±10 vs. 57±10 years old, p=0.013) and had 
a greater tendency to be diabetic(42% vs 22%, p= 0.05) compared with late ST patients. 
There were more patients with renal insufficiency in the late ST group, which was only 
marginally significant(0% vs 8%, p=0.05). Angiographically, early ST patients compared 
with late ST patients had significantly smaller post-intervention MLD (2.54±0.45mm vs 
2.78±0.35mm, p=0.006) and an insignificant tendency to have more calcified lesions(25% 
vs 11%, p=0.121) and instent restenosis(9% vs 0% p=0.083). Early ST compared with 
late ST presented more frequently as cardiogenic shock(38% vs 8%, p=0.003). The 
frequency of successful treatment by either PCI or CABG was similar between early and 
late ST(84% vs 79%). The mortality rate was also similar between the two groups(23% 
vs 14%, p=0.305). 
Conclusions:Old age, diabetes, and severe lesion characteristics were more frequently 
associated with early ST compared with late ST. However, the mortality rate was similar 
between the two groups. Our data suggests that pathophysiologic mechanism of ST may 
differ according to the time point of its occurrence.
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903-209 Primary Percutaneous Coronary Intervention May 
Improve Survival Compared With Thrombolysis In End-
stage Renal Dialysis Patients With Prior Ischemic Heart 
Disease
Rajiv Gupta, Vahakn B. Shahinian, Prashant Kumar, Yong-Fang Kuo, Fen Wei Wang, 
Barry F. Uretsky, UTMB, Galveston, TX
Introduction Patients with end-stage renal disease on dialysis (ESRD) have not been 
studied in ST segment elevation myocardial infarction (STEMI) trials with primary 
percutaneous coronary intervention (PCI) or thrombolysis.
Hypothesis: We hypothesized that primary PCI is superior to thrombolysis for the 
treatment of STEMI in patients with ESRD.
Methods: ESRD patients with STEMI treated with primary PCI (n=573) or thrombolysis 
(n=120) during 1999-2000 were identified from the US Renal Data System (USRDS) 
database.
Results: Thrombolysis patients were older (70 ± 10 vs 66 ± 12 years, p=0.002), with a 
higher percentage of whites (80% vs 70%, p=0.016) compared with primary PCI patients. 
There was similar overall mortality in both groups. However, in the subset of ESRD 
patients with a history of ischemic heart disease, overall mortality (HR 1.81, CI 1.24-2.64, 
p=0.001) and cardiovascular mortality (HR 1.98, CI 1.23-3.17, p=0.004) was higher with 
thrombolysis versus primary PCI (Figure).
Conclusions: Primary PCI is associated with improved survival compared with 
thrombolysis for treatment of STEMI in ESRD patients with a history of prior ischemic 
heart disease. 
11:00 a.m.
903-210 Durable Clinical Benefit Following Sirolimus-Eluting 
Stent (Cypher) Deployment on the Outcome of Patients 
with Chronic Total Occlusions: Multicenter Registry in 
Asia 4-Year Results
Sunao Nakamura, Jang-Ho Bae, Yeo H. Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan
Background and Purpose: We already reported that utilizing Sirolimus-eluting stent 
(SES) in patients with chronic total occlusions (CTO) demonstrated on dramatic reduction 
of restenosis rate. However, late (≥3 years) durability of Cypher™ stent benefit is still 
unknown. Methods: Complete clinical follow-up to 4 years is being analyzed for 106 
patients, 122 lesions who received Cypher™ stents in patient with CTOs (male 73.6%, 
mean age 70.6) (defined as TIMI flow grade 0 and the age of occlusions was more than 
3 months; LAD 50.8%, LCX 26.2%, RCA 23.0%). Results: See table PCI: longterm 
outcomefor clinical results. Conclusions: Clinical benefit provided by the Cypher™ stent 
is durable and late net benefit appears to be incremental. 
Number of patients/lesions 106/122
Procedural success (%) 100
MACE at 30 days (%) 0
Reference diameter (mm) 2.88 ± 0.70
MLD post procedure (mm) 2.78 ± 0.65
MLD at 12 months (mm) 2.70 ± 0.72
MLD at 36 months (mm) 2.64 ± 0.71
MLD at 48 months (mm) 2.60 ± 0.79
Restenosis rate at 12 months (%) 4.7
Restenosis rate at 36months (%) 5.7
Restenosis rate at 48months (%) 5.7
Target vessel failure at 48 months (%) 11.3
11:00 a.m.
903-211 Are Paclitaxel-eluting Stents Safe And Effective 
Compared To Bare Metal Stents? Long-term Results 
From The Taxus Meta-analysis
Gregg W. Stone, Stephen G. Ellis, Antonio Colombo, Keith D. Dawkins, Eberhard Grube, 
Donald Baim, Joerg Koglin, Columbia University Medical Center/The cardiovascular 
Research Foundation, NY, NY
Background. Recent studies have suggested safety risks of drug-eluting stents (DES) 
compared to bare metal stents (BMS). These reports have been limited by lack of access 
to patient level data and potential selection bias. We therefore performed a patient level 
meta-analysis of the 4 principal double-blind, randomized TAXUS trials.
Methods. A total of 3,445 patients with single de novo native coronary lesions were 
randomized in TAXUS II, IV, V and VI to polymer-based paclitaxel-eluting TAXUS stents 
vs. otherwise equivalent BMS. Follow-up is complete through 4 years for TAXUS II and 
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IV, 3 years for TAXUS VI and 2 years for TAXUS V. Event rates were assessed by Kaplan-
Meier estimates to include the latest follow-up data from all pts.
Results. Mean age was 62.2 ± 10.7 yrs, 27.7% were female, and 23.6% had diabetes. 
Mean RVD and lesion length were 2.73 mm and 15.2 mm, and 68% of lesions were type 
B2 or C.. Multiple stents were implanted in 20% of patients. The 4 year Kaplan-Meier 
event rates appear in the Table. Stent thrombosis occurred in 12 pts in each group within 
1 year (0.70%), and in 8 TAXUS pts vs. 2 BMS pts after 1 year (0.46% vs. 0.11%, p=0.02). 
There were no significant differences, however, in the rates of death or MI between 
TAXUS and BMS.
Conclusions. This patient level meta-analysis with multi year follow-up demonstrates 
that in single de novo coronary lesions, paclitaxel-eluting TAXUS stents markedly reduce 
clinical restenosis with a similar overall safety profile to BMS. 
Taxus BMS P
Death, any 6.3% 7.0% 0.50
- Death, cardiac 2.6% 3.1% 0.53
- Death, non cardiac 3.8% 4.0% 0.73
MI, any 7.4% 6.6% 0.63
- MI, Q wave 1.5% 1.2% 0.40
- MI, non Q wave 6.1% 5.5% 0.90
Death or MI, any 12.8% 12.5% 0.92
Death, any or Q-wave MI 7.5% 8.1% 0.75
Stent thrombosis 1.3% 0.9% 0.29
Target lesion revascularization 10.5% 20.4% <0.0001
11:00 a.m.
903-212 Role of Renal Function in Vascular Access 
Complication Rates in Patients Undergoing 
Percutaneous Coronary Procedures using Arteriotomy 
Closure Devices.
Emad F. Aziz, Jacqueline Tamis-Holland, Sripal Bangalore, Dan Musat, Zlata Platzman, 
Deborah Tormey, Ashraf Fawzy, Galen Leung, Eyal Herzog, David L. Coven, Mun K. 
Hung, St. Luke’s-Roosevelt Hospital Center, New York City, NY
Background:
Access closure devices(ACD) use has increased following percuatenous tranfemoral 
coronary procedures(PTCP), however, their safety in patiens with chronic kidney disease 
(CKD) is not known. Therefore, we evaluated the complication rates of ACDs among 
patients with CKD.
Methods: 610 consecutive patients who underwent PTCP and ACD were retrospectively 
studied. Patients were grouped according to their creatinine clearance (CrCl) calculated 
by the Cockcroft-Gault formula using the National Kidney Foudation classification system; 
Stage I (CrCl≥90); Stage II (60-89); Stage III (30-59); Stage IV (15-29); and Stage V (≤15). 
Primary endpoints were pseudoaneurysm, retroperitoneal hematoma, femoral artery 
thrombosis, surgical vascular repair and groin infection.
Results: Among 610 patients 283 (46%) had PCI. The primary endpoint was seen in 66 
(10.8%) patients. Univariate predictor of primary outcome were lower CrCl (p<0.001), 
and presence of PVD (p=0.03). There were an inverse relationship between CrCl and 
complication rate (see graph). CKD was the strongest independent predictor for the 
primary endpoint (OR 1.032; 95% CI-1.019-1.046, p<0.0001), driven by higher infection 
(p<0.0001), thrombosis (p=0.003) and hematoma (p=0.007).
Conclusions: Renal function plays a significant role in predicting the rate of vascular 
access site complications. Worsening renal function is associated with higher vascular 
access site complications largely driven by an increased infection rate. 
11:00 a.m.
903-213 Immediate Improvement In Coronary Flow Reserve 
After Alcohol Septal Ablation In Patients With 
Hypertrophic Obstructive Cardiomyopathy
Wissam A. Jaber, Eric H. Yang, Rick A. Nishimura, Amir Lerman, Mayo Clinic, Rochester, 
MN
Background Patients with hypertrophic obstructive cardiomyopathy (HOCM) are 
known to have reduced coronary flow reserve (CFR), the mechanism of which is not 
well understood. Alcohol-induced septal ablation (SA) reduces obstruction and improves 
symptoms in patients with HOCM. The objective of this study is to define the effect of 
SA on CFR.
Methods Patients with symptomatic HOCM underwent coronary flow assessment with a 
Doppler flow wire placed in the mid left anterior descending coronary artery (LAD) distal 
to the septal perforator. CFR was determined with the use of intracoronary adenosine and 
was measured immediately before and after SA. Simultaneous left ventricular (LV) and 
aortic pressures were recorded.
Results Eleven patients with symptomatic HOCM (age 61±14, 5 males, 4 hypertensive, 
2 smokers) were studied, 7 of whom had CFR measured after SA. After SA, LV outflow 
tract gradient decreased in all patients. There was no change however in mean left atrial 
pressure or the time constant of relaxation. The CFR was low at baseline, and increased 
in all patients after SA, as did the diastolic/systolic flow velocity ratio. Coronary resistance 
increased, but LAD flow did not change (Table).
Conclusions In patients with symptomatic HOCM, reduced CFR is at least in part due to 
decreased coronary resistance, rather than chronic remodeling. SA leads to immediate 
increase in CFR by reducing the contraction load on the LV, without improvement in 
diastolic function. 
Variable Baseline (±SD)
Post ablation 
(±SD) p
CFR 1.96±0.55 2.71±1.0 0.005
LV outflow tract gradient (mmHg) 46±20 4±6 <0.0001
Diastolic/systolic coronary velocity 
ratio 4.3±2.7 1.93±0.85 0.07
Coronary resistance (mmHg/L/min) 637±345 851±360 0.044
LAD blood flow (ml/min) 63.5±32 55.2±13 0.5
Heart rate (beats/min) 70 71 0.6
LV end diastolic pressure (mmHg) 29±5 25±7 0.17
Minimum LV pressure (mmHg) 15.5±4 14.5±3 0.4
Left atrial pressure (mmHg) 17.3±4.5 18.6±3.5 0.4
LV relaxation constant (ms) 54±8 56±10 0.4
11:00 a.m.
903-214 “Cone Crush”, A Variant of Modified T-Stenting 
Technique for Coronary Bifurcation Lesions: Bench 
Testing, Clinical Feasibility, and In-Hospital Outcomes
Sanjay Rajdev, Alfonso Suarez, Kalgi A. Modi, Brigitta C. Brott, Raed A. Aqel, Vijay K. 
Misra, William B. Hillegass, University of Alabama at Birmingham, Birmingham, AL
Background: Multiple two stent techniques exist for coronary artery bifurcation lesion 
(CABL). Circumferential scaffolding of the side branch (SB) ostium without excessive main 
vessel (MV) protrusion is optimal. We describe a simple technique to yield a trumpeted 
cone of ostial SB stent with minimal MV protrusion.
Methods: Cone Crush Technique (CCT): The SB and MV are predilated. SB stent is 
positioned followed by MV stent or protection balloon(BAL). The proximal marker on 
SB stent is confirmed to be touching the body of the undeployed MV stent or BAL in 
orthogonal projections. SB stent is deployed and delivery BAL is pulled back several 
millimeters and reinflated to very high pressure to form a trumpeted cone of minimally 
protruding SB stent. SB wire removed if angiography confirms a satisfactory SB result. 
MV protection BAL and/or MV stent is expanded to crush the proximal end of SB stent. 
SB stent is recrossed and kissing noncompliant BAL inflation performed. Bench test: 
CCT in a waterlogged plexiglass bifurcation model with intravascular ultrasound. Clinical 
feasibility: 53 patients underwent drug eluting stenting using two stents for CABL. 27 
underwent “conventional” bifurcation stenting using T, V, Y or crush stenting (CVTs). 26 
underwent CCT stenting. Baseline clinical, lesion and procedural characteristics were 
similar for both groups.
Results: Bench testing revealed full SB ostial coverage with a small cone of minimally 
protruding trumpeted stent in MV. Clinical: Success rates for re-crossing the SB stent 
were 74% with CVTs and 77% with CCT. Time spent attempting/recrossing the SB was 
less for CCT than CVTs. Post-procedural myocardial infarction defined as CK-MB > 15 
(MI) in patients with normal pre-procedural CK-MB was 15.4% (4/26) in CVTs and 4.2% 
(1/24) in CCT, (p=0.186). In-hospital adverse events (MI/stent thrombosis/dissection) with 
CVTs was 18.5% (5/27) (1 stent thrombosis and MI, 1 dissection, 3 MIs) and 3.8% (1/26) 
(1 MI) with CCT ( p=0.083).
Conclusions: Stenting with a two stent technique for bifurcation lesions using CCT which 
optimizes SB stent protrusion into the MV is feasible, faster, and has favorable in-hospital 
outcomes compared with existing bifurcation stenting techniques.
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903-215 Rotational Atherectomy Prior to the Stenting with 
Sirolimus-Eluting Stent for Diffuse In-Stent Restenosis: 
Multicenter Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo H. Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan
Background: Diffuse in-stent restenosis (D-ISR) is still challenging problem and optimal 
treatment has not been established. 
Methods: To compare the efficacy and safety of stenting with Sirolimus-eluting stent 
(SES) versus rotational atherectomy (mean burr/artery ratio 0.70, mean burr size 1.97) 
prior to stenting with SES for the treatment of D-ISR, we assessed baseline clinical and 
angiographic characteristics, in-hospital and 12-month major adverse cardiac event 
(MACE) in 488 consecutive patients. Patients were divided into 297 patients, 347 lesions 
treated with one or more SES and 191 patients, 243 lesions treated with rotational 
atherectomy prior to SES. 
Results: The baseline clinical characteristics between 2 groups were similar. See table 
for the clinical results. 
Conclusion: Rotational atherectomy prior to Sirolimus-eluting stent provided an 
advantage in terms of long-term clinical and angiographic outcomes. 
SES Rota+SES p
Number of patients/lesions 297/347 191/243 -
In-hospital Procedural success (%) 100 100 NS
MACE (%) 0 0 -
Lesion length (mm) 30.5 ± 12.6 29.8 ± 13.8 NS
MLD post (mm) 2.68 ± 0.58 2.80 ± 0.70 NS
12-month MACE (%) 0 0 -
Angiographic restenosis (%) 12.8 5.2 <0.05
Repeat PCI (%) 9.4 3.7 <0.05
In-lesion late loss 0.30 ± 0.29 0.10 ± 0.14 <0.05
11:00 a.m.
903-216 Measures of Aspirin Resistance and Clopidogrel 
Resistance Do Not Correlate with Post Percutaneous 
Coronary Intervention Markers of Myonecrosis
Ashesh N. Buch, Suman Singh, Kimberly A. Smith, Rebecca Torguson, Zhenyi Xue, Natalie 
Gevorkian, Jana Fournadjieva, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, 
Augusto D. Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Aspirin and clopidogrel protect against thrombotic events during 
percutaneous coronary intervention (PCI). CK-MB enzyme release after PCI has been 
identified as an adverse prognostic indicator. We aimed to determine if there was any 
correlation between measures of aspirin resistance, degree of thienopyridine specific 
P2Y12 platelet receptor inhibition, and post PCI CK-MB release.
Methods: We prospectively studied 330 elective PCI patients (drug-eluting stents), all 
pre-treated with aspirin and clopidogrel. Patients with acute coronary syndromes and 
those on GP IIb/IIIa inhibitors were excluded. Serum assays of aspirin resistance (Ultegra 
Rapid Platelet Function Assay-ASA, Accumetrics, CA) and clopidogrel resistance (Rapid 
Platelet RPFAP2Y12, Accumetrics, CA) were performed pre-PCI. Serum troponin-I and 
CK-MB were measured at 8, 16, and 24 hours after PCI.
Results: We detected only 12 patients (3.7%) with aspirin resistance unit (ARU) 
measurement of ≥ 550. Mean platelet reactivity unit (PRU, measure of inhibition of P2Y12 
activity) was 192.2 ± 95.4. There was no correlation between the level of ARU or PRU and 
post PCI troponin-I or CK-MB release at any time point. A positive correlation was found 
between levels of ARU and PRU (Figure). TVR-MACE rate at 6 months was 8.2% with no 
correlation between ARU or PRU and the release of cardiac enzymes nor the occurrence 
of adverse cardiac events.
Conclusion: This study does not support routine measurements of aspirin and clopidogrel 
resistance 
11:00 a.m.
903-217 Impact of Plaque Composition on Troponin Elevation 
After Percutaneous Coronary Intervention: Virtual 
Histology-IVUS Analysis
Young Joon Hong, Gary S. Mintz, Sang Wook Kim, Teruo Okabe, Augusto D. Pichard, 
Lowell F. Satler, Ron Waksman, Kenneth M. Kent, William O. Suddath, Neil J. Weissman, 
Washington Hospital Center, Washington, DC, Cardiovascular Research Foundation, 
New York, NY
Background: Percutaneous coronary intervention (PCI) is often complicated by 
postprocedural myocardial necrosis as manifested by elevated cardiac markers.
Methods: We investigated the relationship between preintervention coronary plaque 
characteristics determined by intravascular ultrasound-virtual histology (IVUS-VH) on 
troponin-I (TnI) elevation after PCI of 59 native coronary lesions in 59 consecutive pts (20 
stable angina and 39 unstable angina) with normal pre-PCI TnI. Pts were divided into two 
groups according to the presence/absence of post-PCI TnI elevation more than 3 times 
upper limit of normal: [TnI elevation (n=28) vs. no TnI elevation (n=31)].
Results: There was a male predominance (75% vs. 48%, p=0.036) and LDL-cholesterol 
level was significantly higher in pts with TnI elevation vs pts without TnI elevation after PCI 
(108±46mg/dl vs. 86±31mg/dl, p=0.044). Lesion plaque burden and reference segment 
plaque composition and plaque burden were similar between the two groups. Lesion 
remodeling index and % lesion necrotic core area were significantly larger and lesion 
length was longer in pts with post-PCI TnI elevation than in pts without post-PCI TnI 
elevation (Table). Post-PCI TnI levels correlated with % lesion necrotic core area (r=0.290, 
p=0.026) and remodeling index (r=0.258, p=0.048). 
TnI elevation
(n=28)
No TnI elevation
(n=31) p value
Lesion plaque component (%)
Fibrous 59.43±10.46 61.94±12.48 0.409
Fibrofatty 17.46±10.51 23.65±15.24 0.078
Dense calcium 5.93±4.98 3.74±3.47 0.059
Necrotic core 17.14±11.08 10.77±6.30 0.008
Remodeling index 1.06±0.14 0.96±0.11 0.007
Lesion length 16.3±8.9 12.0±5.0 0.050
Conclusions: IVUS-VH analysis demonstrates that post-PCI TnI elevation occurs in 
longer lesions with a larger necrotic core and more positive remodeling.
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904-209 The Effect of Nesiritide on Kidney Function in Patients 
with Advanced Chronic Kidney Disease Undergoing 
Contrast Angiographic Procedures
Andrew R. Weintraub, Carey Kimmelstiel, Marvin A. Konstam, James Udelson, Pamela 
Field, Christine Delano, John Griffith, Mark Sarnak, Tufts-New England Medical Center, 
Boston, MA
Contrast -induced nephropathy (CIN) is a common cause of acute renal failure. Exogenous 
recombinant B-type natriuretic peptide (nesiritide (NSR)) has been shown to have a 
salutary effect on kidney hemodynamics. The effect of NSR in patients with advanced 
chronic kidney disease (CKD) who are exposed to contrast medium (CM) is unknown. We 
explored the effect of NSR on kidney function in patients at high risk for CIN.
Methods: 50 patients with CKD and a stable GFR< 40 ml/min/1.73m2 undergoing 
angiographic procedures were prospectively randomized in a double blind fashion 
to receive NSR (at FDA approved heart failure dosing) in conjunction with standard 
preventive therapy (ST) for CIN (n-acetylcysteine and pre/post procedure hydration) vs. 
ST alone. The primary endpoint was defined by a 0.5 mg/dl increase in serum creatinine 
at 72 hours (hrs). Patients with heart failure exacerbation were excluded.
Results: Over a 72-hr follow-up, patients randomized to receive NSR experienced no 
significant effect on kidney function compared to ST alone. (TABLE) 
Time
Nesiritide
Serum Cr
Mean (mg/dl) + SD
(n=24)
Control
Serum Cr
Mean (mg/dl) + SD
(n=25)
p-value
Baseline 2.32 + 0.57 2.41 + 0.63 0.6
24 Hours 2.24 + 0.50 2.25 + 0.70 0.97
48 Hours 2.19 + 0.48 2.35 + 0.70 0.4
72 Hours 2.16 + 0.63 2.44 + 0.75 0.17
0.5 mg/dl Serum Cr Increase: n(%) 1 (4.2) 3 (12.0) 0.32
Absolute Δ Serum Cr
72 Hrs- Baseline
Mean (mg/dl) ± SD
-0.14 ± 0.37 0.03 ± 0.42 0.15
Overall change in creatinine from baseline to 72 hrs (Control Mean ± SD: 0.03 ± 0.42 vs. 
NSR: -0.14 ± 0.37 mg/dl p=0.15) trended favorably in the NSR group.
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Conclusion: In this pilot study, the addition of NSR to ST for CIN does not affect kidney 
function in patients with CKD undergoing contrast angiographic procedures. Event rates 
for CIN were low despite advanced CKD. Exploration of a salutary effect of NSR in CIN 
will require a larger clinical trial.
Noon
904-210 Clinical Results of Percutaneus Coronary Intervention 
for Chronic Total Occlusion: Predictive Factor for 
Procedural Failure in Recent Technical Development 
and New Stiff Guide wire Era
Masanori Shiba, Masato Nakamura, Masaki Hori, Makoto Utsunomiya, Naohiko 
Nemoto, Shingo Ito, Hirotaka Komatsu, Masamichi Wada, Rintaro Nakajima, HIsao 
Hara, kazuyuki Ishii, Yoshinori Nagashima, Kaoru Sugi, Takuro Takagi, Toho university 
ohashi medical center, tokyo, Japan
Background: Revascularization of chronic total occlusion (CTO) is one of the major 
remaining problems in the field of percutaneus coronary intervention (PCI). However, some 
new guide wire and recent technical development may have improved it. We investigated 
our procedural results, and clarified the predictive factor of procedural failure.
Methods: We studied consecutive 157 cases of PCI for CTO (defined as duration 
>3months). All procedures were guided by well-visualized distal vessel anatomy by 
bilateral simultaneous angiography. We used the Confianza Pro (tapered special stiff wire 
for CTO) in selected cases. If we struggled in sub-intimal space with single wire, parallel 
wire method (PWM) using second wire was chosen after that. And if it was hard to cross 
the CTO with balloon, anchor balloon technique (ABT) was attempted.
Results: Distribution of attempted CTO cases were RCA 48%, LAD 32%, LCX 20%. 
Lesion characteristics of CTO was reference vessel diameter 2.82±0.7mm,occluded 
length 27.5±19mm, and 54% of cases with no determinable duration of occlusion. Details 
of Lesion morphology were tapered occlusion 40.1%, occlusion at side branch 25.4%, 
moderate or severe calcification 47.1%, marked tortuosity 42.0%, and bridge collateral 
31.8%. Confianza Pro was used in 60.5% of all cases. Total procedural success rate 
was 82.3% (including 7pts who required second session for revascularization). PWM 
was required in 47.1% of all cases, and succeeded with 68.9% in these selected 
cases. ABT was necessary for 13.7% of successful patients. During these procedures, 
amount of 231±77ml contrast media and 82.1±38min of fluoroscopy time were required. 
In multivariate analysis, predictive factor for procedural failure is moderate or severe 
calcification (odds ratio, 8.8; 95%CI, 1.19-65.6; P=0.03)
Conclusions: Although more severe cases were attempted, we thought procedural 
success rate has improved than its historical rate. New stiff guide wire and PWM, ABT 
contribute to these results. However, calcification at CTO is the independent predictor for 
procedural failure still in this era.
Noon
904-211 Two-Year Outcomes in Real World Experience With 
Taxus Paclitaxel-Eluting Stent in a Prospective, 
Multicenter, Consecutively-Enrolling US Registry: 
ARRIVE 1
John M. Lasala, J. Tift Mann, Brian Armstrong, Mirle Kellet, Stephen Mascioli, 
Washington Universtity St. Louis, St. Louis, MO
Objective: Whether the long-term safety and effectiveness of drug-eluting stents 
observed in clinical trials translates to wide-spread use in the more complex populations 
treated in routine practice is not known. The ARRIVE 1 registry has compiled data on real-
world usage, safety, and clinical events for the TAXUS® Express® paclitaxel-eluting stent.
Methods: Each of the 48 community-based US sites enrolled up to 75 consecutive patients 
receiving TAXUS stents. Anti-platelet therapy included long-term aspirin and 6 months 
clopidogrel. Clinical follow-up was conducted at 1, 6, 12 and 24 months to collect data 
on TAXUS-related cardiac events (death, myocardial infarction [MI] and re-intervention) 
and stent thrombosis. Additional 12-month observation was conducted in patients with re-
interventions. Events were adjudicated by an independent Clinical Events Committee.
Findings: Overall, 2585 patients with 3768 lesions in 3069 vessels received 4206 stents. 
Two-year follow-up is available for 2319 (90%) patients. At 2-years, the rate of TAXUS-
related cardiac events was 9.9% (n=230), including rates of 8.2% (n=189) re-intervention, 
1.3% (n=30) cardiac death, and 2.4% (n=55) MI. Stent thrombosis occurred in 2.9% 
(n=67) of patients. Outcomes in high-risk subsets are shown in the table.
Conclusions: In this “all-comers” study involving community-based sites, the long-term 
durability and safety of the TAXUS stent is demonstrated in the broad spectrum of disease 
routinely treated in interventional labs. 
TAXUS stent usage and related major cardiac events in high-risk subsets at 2 years 
Diabetes Long Lesions (>20 mm)
Small Vessels 
(≤2.75mm)
Acute 
MI Bifurcations
Multiple TAXUS 
Stents
Multivessel 
Stenting
Patients
enrolled - % (n)
30.8
(795)
24.2
(625)
40.5
(1046)
9.8
(254)
7.8
(201)
39.9
(1032)
16.7
(431)
Patients with 2-year 
follow-up - % (n)
87.7
(697)
94.4
(590)
92.1
(963)
88.6
(225)
94.0
(189)
92.7
(957)
92.1
(397)
Major cardiac
events - % 11.8 12.7 12.0 10.2 13.2 13.1 14.4
Myocardial Infarction - % 3.3 3.7 3.2 2.7 1.1 3.9 4.0
Cardiac Death - % 2.2 1.5 1.7 1.8 2.1 1.6 2.3
Re-interventions - % 8.8 10.2 9.7 7.6 11.8 11.0 11.6
Stent thrombosis - % 3.9 4.6 3.8 3.6 4.3 4.5 4.8
Rates are per patient
Noon
904-212 Predictors of Major Vascular Complications in Patients 
Undergoing Percutaneous Coronary Intervention: 
Insights from the REPLACE-2 Trial
Reza Fazel, Michele D. Voeltz, Frederick Feit, Michael J. Attubato, S. Tanveer Rab, Habib 
Samady, Sunil V. Rao, Steven V. Manoukian, Emory University School of Medicine, 
Atlanta, GA, New York University School of Medicine, New York, NY
Background: Major vascular complications (MVC) are associated with significant 
morbidity in patients undergoing percutaneous coronary intervention (PCI). We sought to 
determine the baseline and procedural predictors of MVC in contemporary PCI.
Methods: We reviewed the REPLACE-2 Trial and defined MVC as major bleeding at the 
vascular access site or surgical vascular repair. We used stepwise logistic regression 
to determine predictors of MVC. Candidate variables for inclusion in the model (based 
on P< 0.05) were age, gender, systolic BP, GFR, urgent PCI, diabetes mellitus, LVEF, 
BMI, sheath dwell time, platelet count, pre-PCI thienopyridine or heparin, treatment group 
(bivalirudin [BIV] vs. GP IIb/IIIa inhibitor plus heparin [GPI+H]), vascular closure device 
use, and an interaction term of the latter two variables.
Results: 5667 (94%) patients had complete data and were included in our analysis. 
MVC occurred in 1.9% of patients and were less frequent for BIV vs. GPI+H (1.17% 
vs. 2.61%, unadjusted OR 0.44, p<0.0001). After multivariable adjustment, predictors of 
MVC included treatment group, vascular closure device use, sheath dwell time, GFR, and 
gender. The c-statistic was 0.71 and the test for goodness-of-fit indicated satisfactory fit.
Conclusions: In PCI, GPI+H use, vascular closure device use, sheath dwell time, 
impaired renal function, and female gender are independent predictors of MVC. Altering 
treatment strategy with regard to the three modifiable factors may reduce the risk of MVC 
in PCI.
Predictors of Major Vascular Complications in PCI
Variable Odds Ratio 95% CI P-value
Treatment group (GPI+H vs. BIV) 2.38 1.61 - 3.82 <0.0001
Vascular closure device (n= 1400) 1.85 1.18 - 2.90 0.007
Sheath dwell time (in hours) 1.06 1.03 - 1.09 <0.0001
GFR <60 ml/min/1.73 m2 1.70 1.08 - 2.68 0.02
Female gender 2.30 1.53 - 3.46 <0.0001
Noon
904-213 Three-year clinical and echographic follow-up after 
Percutaneous Edwards Aortic Valve Implantation for 
Severe Aortic Stenosis in Compassionate Patients.
Hélène Eltchaninoff, Christophe Tron, Fabrice Bauer, Damien Brunet, Sydney Tapiero, 
Brahim Baala, Alain Cribier, Rouen University Hospital, Rouen, France
Background: The Edwards percutaneous heart valve (PHV) is an equine pericardium 
bioprosthesis sutured onto a balloon expandable stent. From February 2004 to April 2005, 
37 patients with end-stage aortic stenosis, multiple comorbidities (Parsonnet score: 47+/-
6), formally declined for surgical valve replacement, were included on compassionate 
basis in 2 consecutive studies (I-REVIVE/RECAST) aimed at assessing the feasibility, 
efficacy and durability of PHV implantation.
Methods: PHV was implanted by the antegrade approach in 30/37 cases. Clinical and 
echocardiographic outcomes were assessed serially at one day, one week, one month, 3 
months and every 6 months thereafter.
Results: Successful implantation was obtained in 27 patients with a final valve area 
(AVA) of 1.70 +/- 0.10 cm² and a transvalvular gradient of 9.0 +/- 2.0 mmHg. One month 
major adverse events were 26% including 6 death of non cardiac cause. PHV dysfunction 
was observed in no case. Despite critically ill at the time of implantation, 9 patients are 
currently alive with a follow-up > 18 mos ( 3 years in 2 patients), NYHA class I and return 
to normal life. As shown on the figure, PHV function remained unchanged during follow-
up in the 27 patients.
Conclusions: Close clinical and echographic follow-up already demonstrate the 3 years 
durability of PHV. Ongoing prospective studies will further determine the place of this 
promising new therapeutic alternative in non operable patients with calcific AS. 
Noon
904-214 Predictors of Irreversible Events After Percutaneous 
Coronary Intervention in Unprotected Left Main Lesions
Federico De Marco, Mario Araya, Jose Antonio Fernandez-Diaz, Olivier Darremont, 
Yves Louvard, Philippe Garot, Thierry Unterseeh, Marie-Claude Morice, Thierry Lefevre, 
Institut Cardiovasculaire Paris Sud, Massy, France
Background: Percutaneous treatment of left main (LM) lesions represents a high risk 
intervention. Objective of this study was to evaluate the impact of baseline clinical and 
angiographic characteristics on one year outcome. 
Methods: A group of 291 consecutive patients treated in 4 French centers for unprotected 
LM stenosis was included in the LM TAXUS Pilot study between March 2003 and 
June 2005. We performed univariate and multivariate analysis to identify predictors of 
“irreversible events” at 1 year follow-up. Irreversible events were defined as the composite 
of any death, stroke, Q-wave MI and CABG. Variables differing in the two groups with a 
level of p significance <0.10 were entered in multivariate analysis.
Results: At mean FU of 13.3 ± 2.1 months cumulative irreversible events occurred in 
17/291 patients (5.8%), including CABG in 1.0%, Q-wave MI in 0%, stroke in 0.3% and 
death in 4.8%. Variables taken into account in the test were: age, EF, Euroscore, general 
risk factors, clinical indication, presence of 3-vessel disease and angiographic variables 
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before and after PCI. 
No Irreversible 
Events Group
Irreversible Events 
Group
Patients (n) 274 17 NA
Age (years) 68.5 ± 11.5 72.9 ± 9.4 p=0.09
Hypertension (%) 64% 74% NS
Diabetes (%) 27% 59% p=0.01
Dyslipidemia (%) 64% 36% p=0.02
Smoker (%) 44% 35% NS
Family history (%) 21% 0 % p=0.02
Previous MI (%) 11% 12% NS
EF (%) 61 ± 13 56 ± 12 NS
Euroscore (pts) 4.7 ± 3.4 6.3 ± 2.3 p=0.06
3 vessel disease (%) 25% 40% NS
Distal lesion (%) 77% 94% p=0.10
Two stents (bif subgroup 
only) 40% 67% p=0.05
Stenosis main branch (%) 70 ± 12 72 ± 14 NS
Stenosis side branch (%) 43 ± 31 61 ± 30 p=0.04
Post PCI stenosis main 
branch (%) 7 ± 8 6 ± 9 NS
Post PCI stenosis side 
branch (%) 9 ± 10 5 ± 9 NS
By multivariate analysis, only diabetes (OR 3.32, 95%CI 1.07-10.24, p=0.037) and no 
dyslipidemia (0R 3.32, 95% CI 0.08-0.82, p=0.022) remained as independent predictors 
of irreversible events at one year follow-up.
Conclusions: The risk of irreversible events after LM stenting, using the TAXUS stent is 
relatively low in this high risk population. Diabetes appears as the strongest predictor of 
events at one year follow-up.
Noon
904-215 Metabolic Syndrome as a Predictor of Restenosis in 
Diabetic Patients Presenting with Acute Coronary 
Syndrome or Angina
Carlos A. Hubbard, John M. Galla, Saif Anwaruddin, Samir Kapadia, Richard A. 
Krasuski, Matthew C. Becker, Cleveland Clinic Foundation, Cleveland, OH
Background: The metabolic syndrome has been defined as a constellation of well 
established cardiovascular risk factors and is common in the diabetic patient population. 
The effect of metabolic syndrome on rates of restenosis after percutaneous coronary 
intervention in this high risk population has not been clearly established.
Methods: 256 patients who presented with acute coronary syndrome (ACS) or anginal 
symptoms and had previously received coronary artery stents were identified from a group 
of 5239 consecutive diabetic patients undergoing diagnostic angiography. World Health 
Organization (WHO) criteria were used to classify these patients as having metabolic 
syndrome (n=154) or as diabetic controls (n=59). Baseline characteristics and laboratory 
data were prospectively collected for all patients at the time of initial intervention. Bivariate 
and multivariate analyses were performed comparing the prevalence of target vessel in-
stent restenosis in both cohorts.
Results: Restenosis was present in 61.7% (n=95) of the metabolic syndrome cohort 
and 44.1% (n=26) of the controls (p=0.02). Of the WHO criteria for metabolic syndrome, 
both hypertension (p<0.01) and body mass index (p<0.05) correlated with restenosis, 
whereas hypertriglyceridemia (p=.06) and low high-density lipoprotein levels (p=.08) did 
not correlate with restenosis. Multivariate analysis controlling for common demographics 
and use of drug-eluting stents revealed a trend towards increased restenosis in the 
metabolic syndrome cohort (odds ratio=1.9, p=0.05).
Conclusion: The presence of metabolic syndrome suggests a nearly two-fold increase in 
the risk of restenosis in the diabetic population presenting with ACS or anginal symptoms. 
The majority of this effect may be the result of an increased prevalence of hypertension 
and elevated body mass index in this cohort. This supports early and aggressive 
intervention aimed at reduction of blood pressure and body mass index in this high risk 
population.
Noon
904-216 Post-Coronary Intervention Recurrent Ischemia In 
the Presence of Adequate Platelet Inhibition by Dual 
Antiplatelet Therapy: What Are We Overlooking?
Paul A. Gurbel, Kevin P. Bliden, Irene Navickas, Udaya S. Tantry, Eli Cohen, Sinai Center 
for Thrombosis Research, Baltimore, MD, Haemoscope Corporation, Niles, IL
Background: Despite therapy with COX-1 and P2Y12 inhibitors, recurrent ischemic events 
occur suggesting that mechanisms other than inadequate aspirin- and clopidogrel-induced 
platelet inhibition may be involved. Here, we investigated the characteristics of enzymatic 
and platelet-fibrin interactions in addition to aspirin and clopidogrel responsiveness using 
the TEG hemostasis analyzer in patients who experienced recurrent ischemic events 
after stenting, despite dual antiplatelet therapy.
Methods: In 192 patients undergoing elective stenting, ADP- and AA-induced platelet 
aggregation measured by the TEG PlateletMapping assay, rate of enzymatic reaction 
(TEG R), and thrombin-induced platelet-fibrin clot strength (TEG MA) were measured 
before the procedure. Patients were followed for six months to determine the occurrence 
of adverse events (cardiovascular death, MI, stroke, or unstable angina).
Results: 36 patients experienced recurrent ischemic events. 7 patients (19%) with 
ischemic events had >75% platelet inhibition by both aspirin and clopidogrel, indicative of 
high responsiveness to dual antiplatelet therapy, as compared to < 75% inhibition in the 
remaining patients with ischemia (p< 0.05). Patients with ischemic events and adequate 
platelet inhibition had a more rapid TEG R and a greater TEG MA (p < 0.05 for both) vs. 
ischemic patients with inadequate platelet inhibition.
Conclusion: Patients with adequate inhibition by dual antiplatlet therapy who experience 
recurrent ischemia after stenting are characterized by an enzymatic hypercoagulable 
state. These results would indicate that the achievement of an adequate level of protection 
against a recurrent thrombotic event may require the combination of antiplatelet and 
anticoagulant therapy in selected patients. These patients can be identified pre-procedure 
by TEG.
Noon
904-217 The Incidence of Contrast-Induced Nephropathy With 
Iomeprol is Similar to the Incidence of Contrast-Induced 
Nephropathy With Iopamidol
Mitsuru Abe, Takeshi Kimura, Yoshihisa Nakagawa, Yutaka Furukawa, Masaharu Akao, 
Masanao Toma, Toshihiro Tamura, Ryoji Taniguchi, Kozo Hoshino, Tamaki Suyama, 
Masao Imai, Takeshi Morimoto, Toru Kita, Kyoto University Hospital, Kyoto, Japan
Background: Contrast-induced nephropathy (CIN) is defined as an elevation in serum 
creatinine (Cr) concentration ≥ 0.5mg/dl within 5 days after cardiac catheterization. CIN 
is the third leading cause of hospital-acquired renal failure accounting for 10% of all 
cases and has been associated with increased long-term mortality. Iomeprol is a newer 
nonionic iodinated contrast agent and is the most popular one in the European Union 
countries. Because the incidence of CIN with iomeprol is unknown at present, elucidating 
the incidence of CIN with iomeprol will help cardiologists to take preventive measures for 
high risk patients.
Methods: We retrospectively examined all patients who underwent cardiac catheterization 
in our department at Kyoto University Hospital from January 2003 to December 
2004. Patients on hemodialysis before catheterization were excluded. We compared 
the incidence of CIN with iomeprol with the incidence of CIN with iopamidol because 
iopamidol is one of the most popular contrast agents in the world and the incidence of CIN 
with iopamidol was reported to be significantly lower than other contrast agents.
Results: Of 1159 patients, iomeprol was administered to 647 patients (55.8%) and 
iopamidol was administered to 512 patients (44.2%). The incidence of CIN with iomeprol 
(4.3% (28 of the 647 patients), 95% CI: 3.0-6.2%) is similar to the incidence of CIN 
with iopamidol (3.5% (18 of the 512 patients), 95% CI: 2.2-5.5%). Baseline clinical and 
procedural characteristics, which had been reported as risk factors for CIN, were as 
follows (iomeprol vs iopamidol): male gender (72.8% vs 69.9%, p=0.3), older age (≥70 
years) (54.9% vs 52.9%, p=0.5), renal insufficiency (Cr ≥ 1.2mg/dl) (22.6% vs 21.1%, 
p=0.5), use of high volume contrast (≥200ml) (38.8% vs 34.3%, p=0.1), anemia (21.5% 
vs 19.2%, p=0.4), diabetes mellitus (32.9% vs 40.2%, p=0.01), congestive heart failure 
(19.8% vs 18.2%, p=0.5) and peripheral arterial disease (21.2% vs 24.4%, p=0.2). 
Logistic regression model adjusting for these risk factors showed the odds ratio of CIN 
with iomeprol were 1.2 (95% CI: 0.6-2.3).
Conclusion: The incidence of CIN with iomeprol seemed similar to that with iopamidol.
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905-209 Robust Impact of Chronic Kidney Disease on Long-
Term Survival in Patients Undergoing Revascularization 
of Severe Unprotected Left Main Coronary Artery 
Stenosis.
John M. Galla, Matthew C. Becker, Saif Anwaruddin, Thomas P. Carrigan, Sachin S. 
Goel, Marlene Goormastic, Nicholas G. Smedira, A. Michael Lincoff, Arman T. Askari, 
Cleveland Clinic, Cleveland, OH
Background: Chronic kidney disease (CKD) has been associated with adverse events 
in patients with coronary artery disease. However, the effect of CKD on treatment-related 
outcomes in patients with severe unprotected left main coronary artery (ULMCA) stenosis 
remains poorly defined.
Methods: Consecutive patients with severe (≥50%) ULMCA stenosis were prospectively 
identified between January 2004 and May 2006. We sought to assess the relationship 
between CKD as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) 
and revascularization procedure in this cohort of patients. Proportional hazards regression 
analyses was performed to evaluate the effect of CKD on 1-year survival in this cohort.
Results: 1415 patients were found to have severe ULMCA stenosis and of these 471 
(33.3%) were unprotected and received consideration for revascularization. Median serum 
creatinine (mg/dl) and creatinine clearance (CrCl, by Cockroft-Gault in mL/min/1.73m2) for 
patients managed medically (MM), or undergoing percutaneous coronary intervention 
(PCI) or coronary artery bypass grafting (CABG) group were 1.3/59, 1.7/53 and 1.2/78 
(p=0.04) respectively. Kaplan-Meier estimates of 1-year survival for each group by K/
DOQI CKD stage are presented in Table 1.
Conclusions: Kidney function is a powerful predictor of long-term survival in patients with 
ULMCA stenosis in the MM and CABG groups. The absence of an association between 
more severe CKD and PCI is an interesting finding worth further exploration.
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Table 1. Long-term survival of patients with severe ULMCA stenosis by 
CKD stage and treatment arm.
CrCl (mL/min/1.73m^2) <30 30-60 60-90 >90
MM (n=66) 4 (6%) 31 (47%) 18 (27%) 13 (20%)
1-Year Survival 0% 67% 83% 85% p=0.001
PCI (n=52) 11 (21%) 19 (37%) 14 (27%) 8 (15%)
1-Year Survival 58% 71% 86% 75% p=0.55
CABG (n=353) 16 (5%) 86 (24%) 118 (33%) 133 (38%)
1-Year Survival 67% 84% 90% 97% p<0.001
1:00 p.m.
905-210 A Prospective, Randomized Trial of Bivalirudin in 
Acute Coronary Syndromes: One Year Results from the 
ACUITY Trial
Gregg W. Stone, Michel E. Bertrand, A. Michael Lincoff, Jeffrey W. Moses, E. Magnus 
Ohman, Harvey D. White, Stuart J. Pocock, James H. Ware, Brent T. McLaurin, David A. 
Cox, Fred Feit, Antonio Colombo, Philip Aylward, Angel R. Cequir, Harald Darius, Walter 
Desmet, Ramin Ebrahimi, Martial Hamon, Lars H. Rasmussen, Hans-Jurgen Rupprecht, 
James Hoekstra, Charles Pollack, Alexandra J. Lansky, Roxana Mehran, Columbia 
University Medical Center/Catdiovascular Research Foundation, New York, NY
Background. An invasive management strategy is recommended in moderate-high 
risk pts with acute coronary syndromes (ACS), with aspirin, clopidogrel, heparin and 
glycoprotein IIb/IIIa inhibitors (GPI). Nonetheless, ACS pts remain at significant risk for 
death and MI, and hemorrhagic complications are frequent. The thrombin-specific agent 
bivalirudin (with or without GPI) may improve outcomes in ACS.
Methods. A prospective, randomized trial was performed at 450 sites in 17 countries 
in which 13,819 pts with moderate-high risk ACS were assigned to 1 of 3 treatment 
regimens started in the ER: heparin (unfractionated or enoxaparin) + GPI, bivalirudin + 
GPI, or bivalirudin alone. Three primary endpoints were pre-specified: ischemic events 
(death, MI or unplanned revasc), non-CABG major bleeding, and composite ischemia 
or major bleeding.
Results. Median pt age was 63 yrs (range 21-95), 30% were female, 28% had diabetes. 
Baseline cardiac markers were abnormal in 57% of pts, and 35% had dynamic ST-
segment changes. Pts were managed with PCI in 56%, CABG in 11% and medically in 
33%. Thirty day results appear in the Table.
Conclusions. In pts with moderate-high risk ACS managed invasively with GPI, bivalirudin 
and heparin result in similar 30-day outcomes. Bivalirudin alone results in similar 30-day 
rates of ischemia with significantly less major bleeding, thereby improving net clinical 
outcomes. One year results will be ready for first presentation in March 2007. 
30-day outcomes Heparin + GPI (N=4,603)
Bivalirudin 
+ GPI
(N=4,604)
P1
Bivalirudin 
alone
(N=4,612)
P2
Composite ischemia 7.3% 7.7% 0.39 7.8% 0.32
- Death 1.3% 1.5% 0.48 1.6% 0.31
- Myocardial infarction 4.9% 5.0% 0.93 5.4% 0.33
- Unplanned 
revascularization 2.3% 2.7% 0.23 2.4% 0.74
Major bleeding 5.7% 5.3% 0.38 3.0% <0.001
Composite ischemia or 
bleeding 11.7% 11.8% 0.93 10.1% 0.015
P1 = H+GPI vs. B+GPI. P2=H+GPI vs. B alone
1:00 p.m.
905-211 A Prospective Registry to Evaluate an Implantation 
of Sirolimus-Eluting Stent in Bifurcation Lesions: 
Comparison of Simple versus Complex Stenting 
Techniques; Long-Term Clinical Outcome from The j-
Cypher Registry
Toshihiro Tamura, Kazuaki Mitsudo, Takeshi Kimura, Kazushige Kadota, Hideki Abe, 
Yoshiaki Yokoi, Shinichiro Toyoshima, Takaaki Isshiki, Ryozo Tatami, Makoto Muto, 
Shigeru Saito, Naoto Inoue, Yoshiharu Murata, on behalf of the j-CYPHER Registry 
investigators, The Department of Cardiovascular Medicine, Kyoto University Hospital, 
Kyoto, Japan
Background: Although various approaches using Sirolimus-eluting stents(SES) 
in coronary bifurcations have been proposed, the optimal strategy has not been 
established.
Methods:Design of the j-Cypher Registry was multi-center prospective enrollment of 
consecutive patients receiving SES from 41 centers in Japan. As of Aug 28, 2006, one-
year follow-up data were available in 5003 lesions underwent successful implantation of 
SES. Among them, we identified 642 patients(693 lesions) who were treated with SES 
in bifurcation lesions including acute myocardial infarction and left main coronary artery 
disease. 599 lesions were treated with stenting of the main vessel and provisional stenting 
of the side branch and 94 lesions were treated with elective stenting of the main vessel 
and side branch. We divided into simple technique( finally stenting only main vessel: 
group S) and complex technique(finally stenting main vessel and side branch: group C). 
Two strategies were selected according to the operators’ discretion. We compared one-
year clinical outcome of both strategies.
Results:293 lesions(42.3%) were true bifurcations. Only 34 lesions(5.7%) among those 
which were treated with provisional stenting of the side branch crossed to the group C 
and no lesion crossed to group S from elective two stenting. 516 patients(565 lesions) 
were included in group S and 126 patients(128 lesions) in group C. 4 methods of two 
stenting were used: T-stenting(58.6%), Culotte stenting(21.1%), Crush stenting(18.0%), 
and Kissing stenting(2.3%). There was no significant differences between group S 
and group C in cardiac death(1.9% vs 4.0%,p=0.21), myocardial infarction(2.1% vs 
1.6%,p=0.69) at one-year. However the incidence of target lesion revascularization(8.7% 
vs 2.1%,p=0.001), cumulative major adverse cardiac events(14.3% vs 5.2%,p=0.001) 
and stent thrombosis(3.2% vs 0.4%, p=0.012) was significantly higher in group C than 
in group S.
Conclusions: For SES placement in bifurcation lesions, one stent technique suggests 
a good long-term outcome compared with two stent technique regarding TLR, stent 
thrombosis and MACE.
1:00 p.m.
905-212 Coronary Artery Perforations: Incidence, Predictors and 
Clinical Outcomes: Multicenter Registry in Japan
Sunao Nakamura, Hiroyuki Sato, Eiji Tada, Kensuke Fujiwara, Osamu Kakuda, Naoyuki 
Kurita, Mizuki Hirose, Shotaro Nakamura, Satoko Tahara, Koji Hozawa, Osamu 
Hirashima, Hitoshi Nakamura, Kazutoshi Yamamoto, Seiji Otani, Nobuyuki Makishima, 
Jun Koyama, New Tokyo Hospital, Chiba, Japan
Background and Purpose: The purpose of this study was to evaluate the incidence of 
coronary perforations, factors associated with the occurrence of these complications and 
in-hospital and late clinical outcomes of those patients. 
Methods: Between Apr. 1999 and Apr. 2006, 14,508 patients with 18,494 lesions were 
treated in our centers (male 69.0%, mean age 71.0: POBA 3,008, stent 14,398, DCA 160, 
rotational atherectomy 928). Coronary perforations occurred in 52 patients (0.4%) and 
were graded according to Ellis classification (42 class 2, 10 class 3). 
Results: POBA 18 (34.6%), Rota 2 (3.8%), stent 10 (19.2%), Cutting Balloon 4 (7.7%), 
guidewire induced 18 (34.6%). There are no clinical variables correlated with perforation 
occurrence. Perforations were more frequent following procedures for chronic total 
occlusions (CTO), (1.3% of 1,708 CTO patients vs. 0.2% of 12,800 non CTO patients: 
p<0.01). Perforation occurred more frequently in complex lesions (0.1% of 4,012 type A 
lesions vs. 0.3% of 14,482 type B, C lesions: p<0.05) and a higher balloon artery ratio 
(ruptured vessels/non ruptured vessels: 1.29±0.22/1.10±0.30). In-hospital 8 patients 
(15.4%) had major adverse cardiac events. Six patients (11.5%) had myocardial infarction, 
2 patients (3.8%) emergency CABG and no death. Clinical follow-up was performed for all 
52 patients after 26±16 months. Two patients had performed re-PCI and no death.
Conclusion: Coronary perforation occurred more frequently in patients with complex 
lesions especially in chronic total occlusions and utilizing a higher balloon/artery ratio.
1:00 p.m.
905-213 Percutaneous Mitral Valve Annuloplasty for Ischemic 
Mitral Regurgitation. First in Man Experience with a 
Temporary Implant.
olivier dubreuil, arsene basmadjian, bernard thibault, luc bilodeau, montreal heart 
institute, montreal, PQ, Canada
Background: Although surgical annuloplasty remains the standard treatment of severe 
ischemic mitral regurgitation (MR), its application is limited by high morbidity and mortality. 
After animal study, we evaluated the human feasibility and acute efficacy of a novel 
percutaneous annuloplasty device (PTMA-Viacor) placed in the coronary sinus (CS).
Methods: Patients referred to our institution with NYHA functional class II or III, ischemic MR 
graded 2+ to 4+, and severe coronary artery disease recurring surgical revascularization 
and mitral annuloplasty were screened. Contraindications were abnormal mitral leaflets 
or any morphological mitral apparatus abnormality. Preoperatively, under general 
anaesthesia and transesophageal echocardiography guidance, a temporary PTMA 
device was placed percutaneously through the right internal jugular vein in the CS.
Results Three patients were included with ischemic MR graded 2+ or 3. After device 
placement, MR and regurgitant volume were substantially reduced (≥ 2 grade reduction) 
via mitral annular anterior-posterior diameter (MAD A-P) reduction in 2 patients (see 
table). In one patient, the PTMA device could not be deployed due to extreme angulated 
anatomy of the CS. After device removal, all patients were subsequently operated without 
adverse events including visual inspection of the CS.
Conclusion Temporary percutaneous mitral annuloplasty in CS reduce ischemic MR by 
reducing mitral annular A-P diameter. Permanent implants are being developed. 
Patient n°1 Patient n°3
Baseline - Implant Baseline - Implant
MAD A-P diastolic, mm 37 32,3 38,4 35,5
MAD A-P systolic, mm 36 34 39 34,6
Regurgitant orifice area, cm2 0,28 0,11 0,18 0,05
Regurgitant volume (ml) 37,6 21,7 26,1 8,4
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905-214 Pathologic Findings of Coronary Bifurcation Stenting 
- DES vs BMS
Gaku Nakazawa, Michael Joner, Elena Ladich, Frank Kolodgie, Aloke V. Finn, Herman 
K. Gold, Renu Virmani, CVPath, Institute, Inc, Gaithersburg, MD, Massachusetts 
General Hospital, Boston, MA
Background: Sites of maximal atherosclerotic plaque formation are frequently observed 
in coronary bifurcations as a result of the flow disturbances. We aimed to investigate 
whether the morphologic differences observed at autopsy translate into distinguishing 
outcomes following implantation of bare-metal stents (BMS) and drug-eluting stents 
(DES), respectively.
Methods: Twenty-six atherosclerotic non-stented coronary bifurcation lesions were 
examined longitudinally for plaque formation. From our registry of 206 autopsy stented 
cases, 28 bifurcation lesions (18 with BMS and 10 with DES) were identified and analyzed 
by morphometry.
Results: Atherosclerotic plaque formation was predominantly observed in the lateral wall 
(low share lesions), while the flow divider wall was spared in most cases (72% vs 31%, 
p<0.0001). Stent thrombosis (ST) was found in 11 lesions (44%) with BMS and 8 (80%) 
with DES, while restenosis was documented in 7 lesions (39%) with BMS and 3 with 
DES (30%). Although neointimal thickness was significantly less at the flow divider site 
as compared to the lateral wall in DES, this difference was not observed in BMS cases 
(Table).
Conclusions: Plaque formation in native coronary bifurcations and neointimal growth 
following DES implantation showed substantial differences between the flow divider and 
the lateral wall site. The greater prevalence of late ST in DES compared to BMS at autopsy 
is likely related to an exaggerated delay of arterial healing at sites of flow disturbance.
Morphometric Analysis of Bifurcation Stenting
DES BMS p value
Flow divider Lateral p value Flow divider Lateral p value
neointimal thickness, 
mm
0.09±0.07 0.17±0.07 0.046 0.35±0.29 0.43±0.31 NS
Fibrin deposition, % 49.9±31.3 30.1±27.1 NS 30.0±30.6 24.4±31.8 NS
Uncovered struts, % 48.8±31.3 11.5±23.9 0.018 20.6±33.4 5.9±11.4 NS
Struts with thrombus, % 23.6±34.8 0.00±0.00 0.027 19.7±34.1 5.9±11.4 NS
1:00 p.m.
905-215 The Difference Of The Late Restenosis Between 
Sirolimus-eluting Stents And Bare Metal Stents - The 
Difference In Site, Type And Time Course Pattern Of The 
Late Restenosis-
Shingo Hosogi, Kazuaki Mitsudo, Tsuyoshi Goto, Hiroyuki Yamamoto, Yasushi Fuku, 
Kazushige Kadota, Hiroyuki Tanaka, Department of Cardiovascular Medicine, Kurashiki 
Central Hospital, Kurashiki city, Japan
Background: Many Randomized control trials demonstrated that Sirolimus-Eluting Stents 
(SES) reduce coronary angiographic restenosis compared from bare metal stents(BMS). 
However, there are few studies which compared the angiographical outcome at long-term 
(more than 1 year) between SES and BMS, especially in the real world PCI.
Methods: We defined late restenosis as the in stent restenosis at 18- to 20-month follow-
up (f/u) which occurred in the lesions without restenosis at 6- to 8-month f/u after the 
stent implantation. We compared the late restenosis rate in 462 lesions treated with SES 
with that in 2675 lesions treated with BMS for de novo lesions including complex lesions, 
retrospectively. Furthermore, we investigated the difference in the late stenosis site (in 
stent or stent edge), the late stenosis type (focal or diffuse), and the time course pattern 
of progression (newly developed type: less than 25% stenosis at mid-term f/u, or gradually 
progressed type: 25% to 50% stenosis at mid-term f/u) between the lesions treated with 
SES and BMS.
Results: Results are shown in the Table.
Conclusions: The lesions treated with SES would have higher incidence of late 
restenosis than those treated with BMS. The results suggested that the mechanism of the 
late restenosis would be different between SES and BMS. There is a possibility that the 
difference in the late restenosis might also affect the long-term clinical outcome.
Angiographical characteristics of the late in stent restenosis
SES BMS p value
Lesion No. 462 2675
No. of 6-8 months f/u 392 1913
No. of 18-20 months f/u 290 1090
late restenosis 12 (4.14%) 20 (1.83%) 0.036
in stsnt / edge restenosis 2 (16.7%) / 9 (75.0%) 13 (65.0%) / 6 (30.0%) 0.022 / 0.035
focal / diffuse restenosis 11 (91.7%) / 0 (0%) 5 (25.0%) / 13 (65.0%) 0.001 / 0.001
newly developed type 11 (91.7%) 5 (25.0%) 0.03
gradually progressed type 5 (41.7%) 17 (85.0%) 0.03
1:00 p.m.
905-216 Bivalirudin and Heparin plus Glycoprotein Inhibition 
Results in Similar Mortality and Ischemic Outcomes 
in Patients Undergoing Percutaneous Coronary 
Intervention: The DEScover Registry
Amar D. Patel, Marcus L. Williams, Steven V. Manoukian, Faith Selzer, Michele D. Voeltz, 
Chandan M. Devireddy, David O. Williams, John S. Douglas, Jr., Henry A. Liberman, 
Emory University, Atlanta, GA, Rhode Island Hospital, Providence, RI
BACKGROUND: Bivalirudin + provisional glycoprotein inhibition (BIV) results in similar 
ischemic outcomes compared to unfractionated heparin + planned glycoprotein inhibition 
(H+GPI) in patients (pts) undergoing elective or urgent PCI. However, no study has 
compared BIV to H+GPI in a contemporary PCI population, which included drug-eluting 
stents and emergency PCI. We compared mortality and ischemic outcomes in pts treated 
with either BIV and H+GPI undergoing PCI.
METHODS: DEScover enrolled pts undergoing elective, urgent, and emergent PCI from 
12/04-7/05. Baseline characteristics, clinical and angiographic data, and 6-month outcomes 
were collected. Hazard ratios (HR) are presented using BIV as the reference group.
RESULTS: Of 7752 pts, 4350 received BIV (n=1810) or H+GPI (n=2540). Provisional 
glycoprotein inhibitor use was rare in the BIV group (0.9%). BIV use was more common 
in women (p=0.003), age > 65; and, in pts with a history of diabetes (p=0.009), CVA 
(p=0.008), peripheral vascular disease (p=0.0004), PCI, CABG, MI, CHF, HTN, and 
dyslipidemia (p<0.0001 for all, unless specified). H+GPI use was more common in STEMI 
(58.2% vs. 21.8%; p<0.001). 6-month unadjusted and adjusted outcomes with propensity 
scoring are shown (Table).
CONCLUSION: The use of BIV resulted in similar rates of mortality and ischemic 
outcomes compared to H+GPI. These results support the use of BIV in a contemporary 
broad-based PCI population which includes drug-eluting stents and emergent PCI.
1:00 p.m.
905-217 Circulating Pregnancy-associated Plasma Protein-
A Levels And Long-term Prognosis In Patients With 
Chronic Stable Angina Pectoris
LUCIANO CONSUEGRA-SANCHEZ, IVANA PETROVIC, JUAN COSIN-SALES, DAVID 
W HOLT, JUAN C KASKI, JUAN C KASKI, LONDON, United Kingdom
Background: Pregnancy-associated plasma protein-A (PAPP-A) levels are increased in 
patients with acute coronary syndromes and in chronic stable angina (CSA), patients with 
complex coronary artery stenoses and extensive coronary artery disease. PAPP-A is a 
marker of clinical outcome in patients with ACS but little is known about the prognostic 
value of PAPP-A in “real-life” CSA. Only a single report in a small number of selected 
patients has been published to date.
Methods: We assessed whether PAPP-A levels predict long-term all-cause mortality in 
663 consecutive patients with CSA (169 women [25.5 %]; mean age 62.9 ± 9.7 years) 
undergoing routine diagnostic coronary angiography who were followed for a median 
of 8.8 years (interquartile range 3 - 10.6 years). Clinical, angiographic (coronary vessel 
disease and Sullivan extension score), and biochemical variables were assessed in all 
patients at study entry.
Results: 106 patients (16 %) died during follow-up. After adjusting for confounders we 
found, on a Cox proportional hazards model, that increased PAPP-A concentration (> 
4.8 mIU/L) was an independent predictor of the occurrence of all-cause mortality (HR 
1.791, 95% CI 1.038-3.088, p = 0.036). Analysis of PAPP-A quartiles in relation to 
survival showed the existence of a threshold effect whereby patients in the lowest quartile 
(PAPP-A ≤ 4.6 mIU/L) (group 1) had better clinical outcome than patients in quartiles 2, 
3 and 4 (group 2). No differences in mortality were found among patients in quartiles 2 
to 4. Compared to group 1, group 2 showed a higher prevalence of elderly people (p = 
0.002), male gender (p < 0.001) and hypertension (p = 0.054), as well a higher number of 
diseased vessels (p < 0.001) and higher Sullivan extension score (p < 0.001).
Conclusions: High PAPP-A levels (cut off point 4.8 mIU/L) predicted all-cause mortality 
during long-term follow-up in “real-life” patients with CSA. Thus PAPP-A measurements 
may be a useful marker of long-term cardiovascular risk in stable angina patients
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906-209 Preventing Contrast-induced Nephropathy in High Risk 
Patients: Does the Contrast Agent Matter?
Samin K. Sharma, Madhu Natarajan, Serge Doucet, Cezar Staniloae, Richard E. 
Katholi, Joseph L. Gelormini, Marino Labinaz, Abel E. Moreyra, Richard Solomon, Mt. 
Sinai Medical Center, New York, NY
Background: Patients with diabetes and chronic kidney disease (CKD) are considered 
at high risk for developing contrast-induced nephropathy (CIN). A prior study suggested 
the nonionic dimer iodixanol-320 (320 mgI/ml, 290 mOsmol/kg) was less likely to be 
associated with CIN compared to the nonionic monomer iohexol-350 (350 mgI/ml, 844 
mOsmol/kg) in this population. We conducted a prospective, multicenter, double-blind 
study to compare the renal tolerability of iodixanol-320 and iopamidol-370 (370 mgI/ml, 
796 mOsmol/kg).
Methods: 170 patients with diabetes and CKD (eGFR = 20-59 mL/min) enrolled in the 
CARE (Cardiac Angiography in REnally Impaired Patients) trial were randomized to 
receive either iodixanol-320 (N=92) or iopamidol-370 (N=78) for cardiac angiography 
or PCI. Serum creatinine (SCr) was measured before and at 2-5 days post-procedure. 
CIN was defined as a postdose SCr increase of ≥0.5 mg/dL. Secondary endpoints were 
a postdose SCr increase of ≥25%, or a ≥25% decrease in eGFR. Differences in CIN 
incidence were evaluated with Fisher’s exact test. Post-procedure increases in SCr were 
compared between groups using an ANCOVA model adjusted for baseline SCr levels.
Results: The two groups were comparable with respect to baseline SCr, eGFR, age, 
gender, body weight, contrast volume, hydration volume, use of NAC, % PCI vs. diagnostic 
(p>0.05). Postprocedure SCr increases of ≥0.5 mg/dL were seen more frequently after 
iodixanol (12/92, 13.0%) than after iopamidol (4/78, 5.1%), as were SCR increases ≥25% 
(iodixanol 14/92, 15.2%; iopamidol 8/78, 10.3%), or decreases ≥25% in eGFR (iodixanol 
12/92, 13.0%; iopamidol 5/78, 6.4%), but none of these differences reached statistical 
significance. Mean peak post-dose increases in SCr were significantly higher in patients 
receiving iodixanol (0.16±0.27 after iodixanol vs. 0.07±0.26 after iopamidol, p=0.013).
Conclusions: There were no statistically significant differences in the rate of CIN in 
high risk patients given iodixanol-320 or iopamidol-370 for cardiac angiography or PCI. 
Previous data suggesting a benefit to the use of the nonionic dimer iodixanol in high risk 
patients may have resulted from the choice of iohexol as the comparator agent.
2:00 p.m.
906-210 Major Bleeding is an Independent Predictor of Short-
Term Mortality in Moderate and High-Risk Acute 
Coronary Syndromes: An Analysis from the ACUITY Trial
Steven V. Manoukian, Frederick Feit, Roxana Mehran, Reza Fazel, Michele D. Voeltz, 
George Dangas, Ramin Ebrahimi, Martial Hamon, Charles V. Pollack, Jr., James 
Hoekstra, A. Michael Lincoff, Spencer B. King, III, E. Magnus Ohman, Gregg W. Stone, 
Emory University School of Medicine, Atlanta, GA
Background: Recent data support an association between major bleeding and mortality in 
acute coronary syndromes (ACS). Whether major bleeding independently predicts short-
term mortality in moderate and high-risk patients with ACS undergoing an early invasive 
strategy is unknown.
Methods: In the ACUITY Trial, 13,819 patients with moderate or high-risk ACS undergoing 
an early invasive strategy were randomly assigned to bivalirudin (BIV), BIV plus a GP 
IIb/IIIa inhibitor, or heparin (unfractionated or low-molecular-weight) plus a GP IIb/IIIa 
inhibitor (H+GPI). Using baseline and procedural variables, stepwise logistic regression 
was used to determine the association between major bleeding (non-CABG-related) and 
mortality at 30 days.
Results: Major bleeding occurred in 4.7% of patients and was less frequent in patients 
treated with BIV vs. H+GPI (3.0% vs. 5.7%, p<0.0001). Mortality was higher in patients 
with vs. without major bleeding (7.3% vs. 1.2%, p<0.0001). Major bleeding was an 
independent predictor of mortality at 30 days (OR 7.55, 95% CI 4.68-12.18, p<0.001). 
Other independent predictors of mortality included: MI (within 30 days), LVEF <50%, age 
>75 years, ECG changes or elevated cardiac markers (at entry), and prior CVA. (Table)
Conclusions: Major bleeding is a powerful independent predictor of short-term mortality 
in patients with ACS undergoing an early invasive strategy. The hemorrhagic risk of an 
antithrombotic agent is an important consideration when caring for patients with ACS.
Predictors of Mortality at 30 Days in The ACUITY Trial
Variable OR 95% CI p-value
Major Bleeding 7.55 4.68-12.18 <0.0001
MI (within 30 days) 3.96 2.45-6.42 <0.0001
LVEF < 50% 2.96 1.99-4.39 <0.0001
Age > 75 years 2.55 1.68-3.87 <0.0001
ECG Changes 2.32 1.54-3.50 <0.0001
Elevated Cardiac Markers 1.97 1.23-3.17 0.005
Prior CVA 1.94 1.09-3.44 0.024
PCI (vs. CABG) 0.29 0.18-0.47 <0.0001
2:00 p.m.
906-211 A Prospective Multicenter Randomized Comparison 
of Paclitaxel versus Sirolimus-Eluting Stents For Long 
Coronary Lesion: 6-Month Angiographic Follow-Up 
Study (Long-DES II Study): Impact of Cilostazol on 
Neointimal Hyperplasia
Seong-Wook Park, Seung-Whan Lee, Cheol Whan Lee, Myeong-Ki Hong, Seung-Jung 
Park, Hyun-Sook Kim, Jae-ki Ko, Jae-Hwan Lee, Jae-Hyeong Park, Si-Wan Choi, In-
Whan Seong, Nae-Hee Lee, Youn-Haeng Cho, Jun-Hong Kim, Asan Medical Center, 
Seoul, South Korea, Chonbuk National University Hospital, Chung-ju, South Korea
Background: The impact of cilostazol after drug-eluting stent (DES) implantation for 
long coronary lesion (lesion length ≥ 2.5mm. requiring long DES ≥ 32 mm) has not been 
evaluated.
Methods: We enrolled the 500 patients with long coronary lesion suitable for intervention 
in five centers of korea. These patients were randomly assigned to according to a two-by-
two factorial design to receive either triple therapy (aspirin plus clopidogrel plus cilostazol, 
group I, n=250) or dual antiplatelet therapy (aspirin plus clopidogrel, group II, n=250) 
for 6 months, and either paclitaxel-eluting stent (PES, n=250) or sirolimus-eluting stent 
(SES, n=250). The primary end point was in-stent late loss and the secondary end point 
was angiographic restenosis at 6 months and major adverse cardiac events (myocardial 
infarction, death, target lesion revascularization at 9 months.
Results: The baseline clinical and angiographic characteristics were similar between the 
2 groups. The lesion length (34.5±12.2 mm in group I and 34.1±11.8 in group II, p=731) 
and mean stent length (41.4±13.6 mm in group I and 40.3±12.9 in group II, p=0.348) were 
also similar between the 2 groups. In-segment binary restenosis rate was similar between 
two group (6.7% in group I vs. 11.2% in group II, p=0.104). The in-stent (0.21±0.48 mm vs. 
0.32±0.50, p=0.031) and in-segment late loss (0.34±0.48 mm vs. 0.51±0.49 mm, p=0.001) 
were smaller in group I than group II. Stent thrombosis at 9 months was similar between 
two groups (0.4% vs 0.4%, p=1.0). Incidences of 9-month death (0% in group I vs. 0.8% in 
group II, p=0.499), myocardial infarction (9.2% in group I vs. 10.4% in group II, p=0.652), 
or major adverse cardiac events (11.2% in group I vs. 16.8% in group II, p=0.071) were 
not statistically different between the two groups. But target lesion revascularization (2.8% 
vs. 6.8%, p=0.036) was lower in group I than group II.
Conclusions: The cilostazol significantly reduced neointimal hyperplasia after DES 
implantation in patients with long coronary lesions and the need of target lesion 
revascularization.
2:00 p.m.
906-212 Radial vs. Femoral Arterial Access in Emergent 
Coronary Interventions for Acute Myocardial Infarction 
with ST Segment Elevation
Jose M. Vazquez-Rodriguez, Ramon A. Calviño-Santos, Jose A. Baz-Alonso, Ramiro 
Trillo-Nouche, Jorge Salgado-Fernandez, Marcelo Sanmartin-Fernandez, Pablo Souto-
Castro, Nicolas Vazquez-Gonzalez, Andres Iñiguez-Romo, Antonio Amaro-Cendon, 
Hospital Juan Canalejo, La Coruña, Spain
Background: Radial access has some advantages over femoral access in patients 
undergoing percutaneous coronary intervention (PCI). In the sitting of urgent PCI on 
patients with ST elevation acute myocardial infarction (STEMI), the studies comparing 
both techniques are scarce.
This study aims to compare emergent radial access PCI vs. a femoral approach on 
patients with STEMI in terms of duration of the procedure, angiographic results, costs, 
incidence of ischemic events and severe vascular complications.
Methods: A total of 439 patients with suspected of STEMI within 12 hours of onset, 
referred for urgent PCI, were randomized to transradial (TR) or transfemoral (TF) arterial 
access. In the TF group a percutaneous closure device (PCD) was recommended.
Results: The sample (85 % males) average age was 61 years. In 218 patients assigned 
to the TF group and 202 assigned to the TR group an emergent PCI was performed. In 
19 patients (14 in the TR group) no PCI was indicated. A PCD was used in 193 patients 
with a success rate of 95%. The duration in minutes (mean ± SD) until the coronary 
angiography was completed (9.5 ± 4.6 vs. 11.7 ± 5.8, p<0.001), and until the first balloon 
inflation (18 ± 8 vs. 21 ± 11, p < 0.001) was longer in the TR group.
The angiographic success (residual stenosis less than 20% and achievement of TIMI 
grade 3 flow) was similar in both groups (93.2% in the TF group and 91.5% in the TR 
group, p= 0.32). The incidence of severe vascular complications was 2.3 % in the TF 
group and 0.5 % in the TR group (p=0.11). Time to discharge, both from the ICU (3.3 ± 
4.2 vs. 2.7 ± 3.4 days, p=0.15) and from the hospital (9 ± 7.2 vs. 8 ± 6.3 days, p=0.1) was 
similar for both groups. The cost (material plus hospitalization) per patient was inferior 
for the TR group (7944 ± 4722 € vs. 7012 ± 4032 €, p=0.03). The incidence of severe 
ischemic events 30 days after the intervention was similar for both groups (6.4 % TF vs. 
5.9 % TR, p 0.5).
Conclusions: Transradial arterial access for emergent coronary intervention in selected 
patients with STEMI is a safe procedure, with similar clinical and angiographic results, 
and a lower cost, than a femoral approach with additional use of percutaneous closure 
devices.
JACC  March 6, 2007  ABSTRACTS - Innovation in Intervention: i2 Summit 2007    B
Innovation in Intervention: i2
 S
um
m
it 2
0
0
7
2:00 p.m.
906-213 The QuantumCor Device for Mitral Regurgitation: A 
Radiofrequency Alternative to an Annular Ring
Richard R. Heuser, David T. Cragun, Patricia A. Takeda, Thomas Witzel, Duane Dickens, 
Phoenix Heart Center, Phoenix, AZ
Background: Ischemic mitral regurgitation (MR) is a common problem occurring in 
nearly 20% of all myocardial infarctions and results in harmful ventricular remodeling and 
an increase in morbidity and mortality. The QuantumCor device uses radiofrequency (RF) 
energy at sub-ablative temperatures to produce contraction of the mitral valve annulus 
and thereby reduce mitral regurgitation.
Methods: Eleven healthy sheep (6 with naturally-occurring MR) had RF energy 
applied for 60 mean seconds at sub-ablative temperatures to replicate a surgical mitral 
annular ring. Four segments of the posterior mitral valve annulus were heated while on 
cardiopulmonary support via a left thoracotomy with access via the atrial appendage.
Results: Nine sheep measured with intracardiac echo (ICE) before and after RF therapy 
experienced reduction of the anterior to posterior (AP) annulus distance by a mean of 
5.0 +/- 2.1 mm (P<.001). In 7 sheep, circumferential measurements were performed 
during surgery at each of the four treated segments of the posterior mitral valve annulus 
yielding a mean reduction of 17.0% +/-6.6% (P<.05). The 6 sheep with non-ischemic 
mitral regurgitation had the MR eliminated. 
Conclusions: In a sheep model, RF energy applied at sub-ablative temperatures in 
four quadrants of the posterior mitral valve annulus can reduce the anteroposterior and 
circumferential annular distance significantly and eliminate non-ischemic MR. This rapid, 
less than 4 minute, treatment will need to be confirmed in a chronic animal model to 
determine its safety and efficacy. If successful, it could lead to a novel percutaneous 
method of mitral valve annuloplasty with lower risk and morbidity than current surgical 
techniques.
2:00 p.m.
906-214 Drug-Eluting Stents for the Treatment of Left 
Main Coronary Arteries: A Comparison of Serial 
Angiographic Follow-Up with Sirolimus, Paclitaxel, 
Zotarolimus and Tacrolimus-Eluting Stent: Multicenter 
Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo H. Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan
Background and Purpose: Drug-eluting stent have been proven to be effective in 
reducing restenosis in patients with left main coronary arteries (LMT). However, no 
studies comparing different drug-eluting stents in this complex subset are yet available. 
The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel 
(PES), Zotarolimus (ZES) and Tacrolimus-eluting stent (TES) on the outcome of patients 
with LMT stenosis. 
Methods: A prospective analysis of 501 patients with 501 LMT stenosis (248 SES, 172 
PES, 52 ZES, 29 TES) in five high volume Asian centers after successful stenting in 
LMT stenosis was performed. The study endpoints were 30 days and 9 months major 
adverse cardiac events (MACE), 9 months angiographic restenosis and target lesion 
revascularization (TLR). 
Results: The baseline clinical characteristics between 4 groups are similar. See table 
for clinical results. 
Conclusion: The use of drug-eluting stents in patients with LMT stenosis was safe 
with low acute complication. Patients treated with SES showed lesser rate of restenosis 
compared with other drug-eluting stents. 
SES PES ZES TES
Number of patients 248 172 52 29
Procedural success (%) 100 100 100 100
MACE at 30 days (%) 0 0 0 0
Proximal reference diameter (mean: mm) 3.6 3.5 3.3 3.6
Stenting procedure: culotte/single/crush 75/87/86 52/40/80 22/14/16 14/10/5
Minimum lumen diameter post procedure (mean: 
mm) 3.5 3.5 3.2 3.4
Minimum lumen diameter at 9 months (mean: 
mm) 3.4 3.2 2.8 3.0
Restenosis rate at 9 months (%) 3.2* 4.7 7.7 10.3
TLR at 9 months (%) 3.2* 3.5 7.7 10.3
*p<0.05 vs ZES, TES
2:00 p.m.
906-215 Detection of In-Stent Restenosis by 64 Detector 
Computed Tomographic Coronary Angiography: 
Comparison with Quantitative Selective Coronary 
Angiography.
Harvey S. Hecht, Maja Zaric, Vladimir Jelnin, Lev Lubarsky, Manish Prakash, Lenox Hill 
Heart and Vascular Institute, New York, NY, Lenox Hill Hospital
Background: Detection of in-stent restenosis (ISR) by computed tomographic 
angiography (CTA) remains problematic.
Methods: To evaluate the ability of 64 detector CTA to accurately detect in-stent restenosis 
(ISR), 90 stents in 40 patients who underwent quantitative selective coronary angiography 
(QCA) were analyzed. Stents were subjectively evaluated by visual inspection as totally 
occluded, moderate to severe hypodensity, mild hypodensity and normal; abnormal was 
defined as occluded or moderate to severe. Using a quantitative analysis, the average 
Hounsfield unit in a 2 mm length prior to and after the stent was measured. The lowest 
Hounsfield unit in 4 separate 0.5 mm slices in the stent (IS) were averaged and compared 
to the pre stent (PS) values; abnormal was defined as IS<PS. In the QCA analysis, 
performed by a separate observer, ISR was classified as normal, 1-25%, 25-50%, 50-
75%, 75-99%, and 100%.
Results: QCA: 8 stents were 100%, 1 was 75-99%, 2 were 50-75%, 7 were 25-50%, 34 
were 1-25%, 38 were normal. Visual analysis was superior to quantitative at all levels of 
ISR. The best results were for detection of >50% ISR: 100% sensitivity, 76% specificity, 
37% positive and 100% negative predictive values.
Conclusions: 1) Visual analysis of CTA produces the best results for the evaluation of 
ISR. 2) Quantitative analysis was inaccurate; partial volume and beam hardening are 
problematic. 3) 64 detector CTA is excellent for the detection and exclusion of >50% ISR, 
at the expense of positive predictive value.
QCA Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Visual
Normal vs >0% 54 96 93 60
<25% vs >25% 78 78 47 93
<50% vs >50% 100 76 37 100
Hounsfield U.
Normal vs >0% 48 96 93 59
<25% vs >25% 56 76 63 87
<50% vs >50% 64 75 26 94
2:00 p.m.
906-216 The ResponseTo Clopidogrel Measured By A Point-
of-Care Assay Following Percutaneous Coronary 
Intervention Is Associated With Stent Thrombosis Over 
6-Month Follow-up
Matthew J. Price, Rafael Valencia, Raghava R. Gollapudi, Sarah Endemann, Curtiss 
Stinis, Justin P. Levisay, Paul S. Teirstein, Scripps Clinic, La Jolla, CA
Background: We examined the association of clopidogrel (CLOP)-induced platelet 
inhibition measured by a point-of-care assay following sirolimus-eluting stent (SES) 
implantation with stent thrombosis (ST) at 6-month follow-up (FU).
Methods: Platelet function in patients (pts) not receiving glycoprotein inhibitors was 
measured with the VerifyNow P2Y12 assay (Accumetrics, Inc) at baseline prior and 12 
hours post-procedure. Pts not on CLOP received 600-mg at the time of the procedure, 
and all received 75-mg daily for at least 3 months. ADP-induced aggregation is reported 
by the assay using P2Y12 Reaction Units (PRU). In pts receiving a loading dose, % 
inhibition (%I) due to CLOP was defined as 1-PRU(post-CLOP)/PRU(pre-CLOP). In pts 
on CLOP without a baseline value, the reference channel was used to determine %I. 
CLOP non-responsiveness (NONRESP) was defined as the lowest quartile of %I. ST was 
defined as angiographic demonstration of thrombosis or unexplained sudden death. FU 
was obtained at 6 mos. Univariate analysis was performed with Fisher’s Exact Test.
Results: P2Y12 assays were complete in 280 pts. The procedural indication was stable 
angina/ischemia in 93%. In 25% of patients, the %I was <10%. To date, ST has occurred 
in 5 pts (1.7%): 1 acute, 3 sub-acute, and 1 late (> 30 days). All ST pts were taking aspirin 
and CLOP. CLOP NONRESP was found in 4 of the 5 pts with ST (p=0.013).
Conclusions: Clopidogrel NONRESP measured at the time of SES implantation is 
associated with stent thrombosis at 6-month FU.
B    ABSTRACTS - Innovation in Intervention: i2 Summit 2007  JACC  March 6, 2007
In
no
va
ti
on
 in
 I
nt
er
ve
nt
io
n:
 i2
 S
um
m
it
 2
0
0
7
2:00 p.m.
906-217 Circulating Secretory Phospholipase A2 Activity and 
Risk of Incident Coronary Events in Healthy Men and 
Women. The EPIC-NORFOLK study
Tabassome Simon, Ziad Mallat, Joelle Benassiano, Stéphane Edhery, Carla Sebella-
Arguelles, Ariel Cohen, Virginie Huart, Nicholas J. Wareham, Robert Luben, Kay-Tee 
Khaw, Alain Tedgui, Matthijs Boekholdt, INSERM U689, Paris, France
Background: sPLA2 enzymes are involved in key immuno-inflammatory processes and 
enhance the atherogenic potential of low-density lipoproteins. We showed recently that 
circulating sPLA2 enzyme activity, which encompasses several types of sPLA2, was an 
independent predictor of coronary events in patients with acute coronary syndrome. The 
relationship between the risk of incident CAD in people free of disease and plasma sPLA2 
activity is unknown.
Methods: We investigated this association in a nested case-control study among the 
25,663 healthy subjects included in EPIC-Norfolk cohort. Cases (n = 991) were subjects 
who developed CAD during the 6 years of mean follow-up. Controls (n=1806) matched by 
age, sex, and enrolment time remained free of any cardiovascular disease during follow-
up, in EPIC-Norfolk cohort.
Results: The risk of incident CAD was associated with increasing quartiles of sPLA2 activity 
(p<0.001); After adjustment for risk factors, CRP and sPLA2 type IIA concentration, the 
odds ratios of incident CAD in the second, third and fourth quartiles of sPLA2 activity were 
1.41, 1.33, and 1.56 (p = 0.003), compared with the lowest quartile.The corresponding 
odds ratio for CRP after adjustment for sPLA2 activity was 1.55 (95%CI, 1.20 to 1.99).
sPLA2 activity and CRP were poorly correlated (r= 0.15), suggesting each biomarker 
identifies different high-risk groups.Their combined values were more informative 
for incident risk of CAD than either biomarker alone. Subjects in the highest quartiles 
of sPLA2 activity and CRP had an adjusted odds ratio of 2.89 (95%CI, 1.78 to 4.68, 
p<0.001) for CAD compared with those with the lowest quartiles of both markers.
Conclusions: Serum sPLA2 activity provides additive value to traditional risk factors and 
CRP in predicting incident CAD.
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907-209 Impact of Renal Insufficiency on Clinical Outcomes 
Following Drug-Eluting Stent Implantation
Gloria Melzi, John Cosgrave, Simon J. Corbett, Nuccia Morici, Tiziana C. Aranzulla, 
Flavio Airoldi, Iassen Michev, Alaide Chieffo, Matteo Montorfano, Mauro Carlino, 
Giuseppe M. Sangiorgi, Antonio Colombo, EMO Centro Cuore Columbus, Milan, Italy, 
San Raffaele Scientific Institute, Milan, Italy
Background: No study has specifically addressed the clinical implications of renal 
insufficiency (RI) following drug-eluting stent (DES) implantation.
Methods: All consecutive patients who underwent elective DES implantation in 
unselected de novo native coronary artery lesions between March 2003 and March 
2005 were analyzed. RI was defined as a baseline creatinine clearance <60 cm3/min 
calculated by the Cockcroft-Gault formula.
Results: Of the total cohort of 1283 patients (2269 lesions), 83 (155 lesions) had RI. 
Patients with RI were older, more likely to have hypertension and diabetes mellitus, multi-
vessel disease, lower ejection fraction and a greater use of intra-aortic balloon pump. For 
both groups mean clinical follow-up was greater than one year and comparable. Patients 
with RI had a higher incidence of peri-procedural myocardial infarction and 30-day major 
adverse cardiac events (MACE). At follow-up they also had a higher incidence of death 
and MACE, but comparable rates of myocardial infarction and repeat revascularization 
(Table). Predictors of MACE were diabetes mellitus and total stent length per patient, but 
not RI (OR 1.53, 95% CI 0.92-2.56, p=0.1). In contrast, RI was a predictor of death (OR 
2.7, 95% CI 1.14-6.59, p=0.02), as were age and ejection fraction.
Conclusions: Despite improvements in interventional techniques, patients with RI 
still represent a high-risk cohort for developing events, particularly mortality, after 
percutaneous coronary interventions.
Variable RI No RI P-value
Patients N = 83 N = 1200
Age, years 70.6 ± 8 62.4 ± 10.5 0.0001
Ejection Fraction, % 47.7 ± 10.8 53.2 ± 9.8 0.0001
Hypertension 81.9% (68) 65.5% (786) 0.002
Diabetes mellitus 41% (34) 25.7% (308) 0.004
Insulin-requiring diabetes 22.9% (19) 6.3% (76) 0.0001
Multi-vessel disease 83.1% (69) 74.5% (893) 0.08
Intra-aortic balloon pump 7.2% (6) 2.9% (35) 0.04
Clinical follow-up, days 404 ± 196 420 ± 152 0.4
Angiographic follow-up 55.4% (46) 69.6% (835) 0.01
Outcomes
Peri-procedural myocardial infarction 6% (5) 2.6% (31) 0.08
30-day death 4.8% (4) 0.2% (2) 0.0001
30-day MACE 6% (5) 0.4% (5) 0.0001
MACE 33.7% (28) 20.4% (245) 0.008
Death 10.8% (9) 2.1% (25) 0.0001
Cardiac death 8.4% (7) 1.7% (20) 0.001
Myocardial infarction 2.4% (2) 2.1% (25) 0.7
Target vessel revascularization 22.9% (19) 18.2% (218) 0.3
Target lesion revascularization 14.5% (12) 15.3% (184) 1.0
3:00 p.m.
907-210 Five Year Outcomes in a Cohort of Coronary Artery 
Disease Patients Treated With Percutaneous Coronary 
Intervention in the NHLBI Dynamic Registry: Initial 
Acute Coronary Syndrome is a Risk Factor for Future 
Ischemic Events
Zachary Gertz, Robert Wilensky, Faith Selzer, Warren K. Laskey, Oscar C. Marroquin, 
Kevin E. Kip, Ruchira Glaser, University of Pennsylvania, Philadelphia, PA, University of 
Pittsburgh, Pittsburgh, PA
Background: Long term ischemic outcomes and their risk factors are not well defined in 
a cohort comprised of PCI patients.
Methods: Consecutive patients at multiple sites undergoing PCI in 1999 in the NHLBI 
Dynamic Registry were followed prospectively for five years. Those who died in initial 
hospitalization or underwent CABG in the first 30 days were excluded. An ischemic event 
was defined as death, MI, CABG, hospitalization for angina, or new lesion PCI.
Results: Of 1856 patients with follow up, 847 (49.7%) had an ischemic event within 5 
years. The rate of death was 16%, MI 9%, new lesion PCI 13%, and angina 36%. Patients 
with ischemic events were more likely to be over 65, women, African American (AA), and 
to have DM, HTN, prior PCI or MI, severe noncardiac disease, and present with ACS as 
the indication for PCI, and were less likely to have a history of CABG. Patients who initially 
presented with ACS were significantly more likely to have new lesion PCI (15% v. 11%), 
rehospitalization for angina (40% v 29%), and an ischemic event (See figure below). AA 
(HR 1.33), Asian (HR 0.58), DM (HR 1.37), CHF (HR 1.33), three vessel disease (HR 
1.35), cardiogenic shock (HR 1.83), emergent PCI (HR 1.39), SVG lesion (HR 1.49), and 
chronic pulmonary or kidney disease (HRs 1.40 and 1.58), significantly independently 
predicted ischemic events (p<.05 for all).
Conclusions: In a CAD population undergoing PCI, the risk of ischemic events at five 
years remains high (49%), with initial ACS as one important predictor of future events. 
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907-211 First Real World Experience and Six Months Clinical 
Outcome in Patients Treated with a GenousTM 
Endothelial Progenitor Cell Capturing Stent
Marcel A. Beijk, Karel T. Koch, Jose P. Henriques, Jan Baan, Rene J. van der Schaaf, 
Marije M. Vis, Jan G. Tijssen, Jan J. Piek, Robbert J. de Winter, Academic Medical 
Center - University of Amsterdam, Amsterdam, The Netherlands
Background Clinical trials of drug-eluting stenting (DES) have demonstrated a marked 
reduction in the incidence of restenosis compared to bare metal stents, although 
restenosis still occurs. However, to date, there are concerns about the safety of DES, in 
particular with respect to delayed healing, chronic inflammatory reaction, and late stent 
thrombosis.
The GenousTM Endothelial Progenitor Cell (EPC)-capturing stent is coated with an 
antibody (CD34+) that binds circulating EPC’s which differentiate into a functional 
endothelial layer. This accelerated healing may reduce in-stent restenosis by reducing 
neointimal hyperplasia and smooth muscle cell proliferation and, in addition, may prevent 
stent related thrombosis by platelet aggregation. Furthermore, it has been shown that 
statin therapy increases the EPC number in the peripheral blood.
In this single center study, we report the 6 months clinical outcome after percutaneous 
treatment with the GenousTM EPC-attracting stent in patients treated with statins for at 
least 2 weeks prior to intervention.
Methods Between August 2005 and March 2006, 87 patients were treated with a 
GenousTM EPC-attracting stent for coronary artery stenosis. All patients were treated with 
statins for at least 2 weeks prior to PCI. Clinical follow-up was obtained after 6 months.
Results Mean age of the population was 64 years and 72 % were male. 31 % of the 
lesions were bifurcation lesions and 34,5 % of the patients had multivessel disease. Mean 
stenose length was 15 ± 10 mm. Patients received an average of 1.5 stents and a mean 
stent length was 19 ± 6 mm and mean stent diameter was 3,16 ± 0,4 mm. TIMI 3 flow 
was achieved in 99.3 % of all treated lesions. There was one side branch failure, leading 
to an in hospital MI.
During 6 months clinical follow-up, there was 1 additional MI. Target vessel revascularization 
was 3,7% (2 patients had a repeat PCI, 1 patient had a CABG and a repeat PCI), 2 
patients had a non-target vessel revascularization, and no patients died.
Conclusion The percutaneous treatment of coronary artery stenosis with a GenousTM 
EPC-attracting stent in statin-treated patients shows excellent procedural success and 
6 months clinical results.
3:00 p.m.
907-212 Transcatheter Restriction of Left Ventricular Cavity in 
Piglets
Eleftherios B. Sideris, Savvas Toumanidis, Demetrios Bramos, Efstratios Christianakis, 
Basilios Sideris, Spyridon Moulopoulos, Athenian Institute of Pediatric Cardiology, 
Athens, Greece, Department Clinical Therapeutics University of Athens, Athens, Greece
Background:Surgical resection of left ventricular aneurysms, is not always possible in high 
risk patients. Purpose of this study is to access an alternative to surgery in eliminating 
post-infarction left ventricular (LV) aneurysms in high risk patients. Transcatheter 
restriction of LV aneurysms could improve morbidity and mortality associating with 
surgery, maintaining the benefits of improved ejection fraction and wall tension.
Methods: The procedure was performed in 15 piglets, 12-16 kg, after ketamine anesthesia. 
A transcatheter patch/balloon device was introduced in the left ventricle, through a 12F 
sheath after sub-xiphoid apical needle puncture. The device consists of a balloon catheter, 
with a sleeve type polyurethane patch mounted on the balloon and a floppy disk attached 
on the tail of the patch. The patch was inflated in diameters of 15-20 mm using normal 
saline or whole blood and contrast; it was pulled to the apex of the LV, with the tail of the 
patch occluding the residual myocardial hole and the floppy disk immobilizing the patch 
on the epicardium. Fluoroscopy and echocardiography and continuous monitoring were 
used for the device placement and the animals were followed for periods of 4 days to 3 
months, when they were euthanized and had autopsies.
Results: All devices were successfully placed, restricting the left ventricular apical region. 
There was no significant change on the EKG or the blood pressure during the procedure. 
There was no case of tamponade. On follow-up all animals, except for two who develop 
severe infection did well. In autopsy the LV apical region was restricted although most 
balloons lost part of their initial volume.The residual balloon size was larger if it was 
inflated with whole blood. The patches were fully endothelialized within 2 weeks. They 
were free of thrombus.
Conclusion: Percutaneous restriction of the left ventricular apical region is feasible, 
simple and relatively safe in piglets. The method could be applicable in high risk patients. 
Feasibility clinical studies are justified.
3:00 p.m.
907-213 Perventricular non Surgical Aortic Valve Placement with 
Subsequent Use of Myocardial Plugs
Eleftherios B. Sideris, Demetrios Bramos, Efstratios Christianakis, Basilios Sideris, 
Spyridon Moulopoulos, Athenian Institute of Pediatric Cardiology, Athens, Greece
Background: Transcatheter aortic valve placement by intravascular routes can be lengthy 
and difficult. Perventricular entry is technically easier, but it usually requires surgical 
assistance. We will assess the safety and efficacy of perventricular non surgical aortic 
valve placement using myocardial plugs.
Methods: A self-expandable nitinol cage with a mono-leaflet biologic valve was inserted 
in ten piglets 10-12 kg, through 13-14 F sheaths, after left ventricular (LV) apical 
needle puncture. The valve function was assessed by fluoroscopy, angiography and 
echocardiography under continuous monitoring. A myocardial plug was placed through 
the same sheath after aortic valve placement and release. The myocardial plug consists 
of a balloon/patch with the tail going through the residual opening, immobilized by a floppy 
disc on the epicardium. The valve diameter was 15 mm and the balloon/patch diameter 
varied between 12 and 20 mm. Follow-up was performed up to 2 weeks and all animals 
had autopsies.
Results: All valves were deployed in the ascending aorta. Three with placement on 
the natural valve had fast deterioration, because of aortic insufficiency or coronary 
interference. The rest were placed above the coronaries and had good outcome. There 
was one case where the mono-cusp valve was too large and obstructive (40 mmHg 
LV- Aortic gradient). In the rest of the animals there was good leaflet movement without 
insufficiency or residual stenosis. There was no hemopericardium after myocardial plug 
placement; however in one case the sheath was pulled out by mistake prior to myocardial 
plug insertion, resulting in hemopericardium and death. Minimal bleeding and transient 
EKG changes were noticed in all cases. In autopsy all valve cages were in place with 
the aortic mono-cusp leaflet mobile. The myocardial plugs were effectively occluding the 
residual openings and the patch was partially endothelialized.
Conclusion: Perventricular aortic valve placement is fast and fairly easy, without need of 
surgery if myocardial plugs are used. The supravalvar aortic position was safer. Further 
animal testing is required prior to the use of the valve in human trials.
3:00 p.m.
907-214 The Efficacy of Pre Drug Eluting Stent Debulking by 
Directional Atherectomy for Bifurcated Lesions: A 
Multicenter Prospective Registry (PERFECT Registry)
Etsuo Tsuchikane, Tadanori Aizawa, Hideo Tamai, Yasumi Igarashi, Kenji Kawajiri, 
Noriyuki Ozawa, Shigeru Nakamura, Koji Oku, Mikihiro Kijima, Yuji Hamazaki, Toyohashi 
Heart Center, Toyohashi, Japan, Cardiovascular Institute, Tokyo, Japan
Background: Drug eluting stent (DES) significantly controls restenosis, however 
the efficacy for bifurcated lesions is still unsatisfied. These lesions sometimes require 
complex 2 stenting so that restenosis occurs particularly in side branch. Pre stent plaque 
debulking by directional atherectomy (DCA) for bifurcated lesions controls plaque shift 
and consequently enables simple stenting. Pre DES DCA has not yet been examined. 
Methods: PERFECT (PrE Rapamycin eluting stent FlExi-CuT) is a multicenter prospective 
registry aimed to examine the efficacy of pre-DES debulking by DCA. Lesions located in left 
main trunk (LMT) bifurcation, or proximal left anterior descending (LAD) or left circumflex 
(LCx) artery with a major side branch were enrolled. Intravascular ultrasound (IVUS) 
guided DCA using Flexi-Cut was conducted for main vessel. DCA of side branch was also 
performed if possible. Then Cypher stenting for main branch with/without kissing balloon 
technique was conducted. Provisional Cypher stenting for side branch was allowed when 
necessary. Serial quantitative angiography (QCA) was performed at the procedure and 
9 month follow-up (Fu). The primary endpoint was the angiographic restenosis (defined 
as diameter stenosis of more than 50%) rate. Secondary endpoint was clinical outcome 
by 1 year. Results: In Japanese 17 centers, 99 patients were enrolled (until Oct. 2005). 
Lesion locations were as follows; LMT: 81, LAD: 16, LCx: 2. DCA provided the reduction 
of percent plaque area stenosis from 82.3 to 55.8% in IVUS examination for main vessels 
without any procedural complication. Then, crossover stenting was performed in 83 and 
non-crossover stenting in 16 lesions. Additional stenting of side branch was required only 
in 2 lesions. No major adverse cardiac event was observed in hospital stay. Fu data has 
been collected in 76 patients to date. Angiographic restenosis was 1.3% (1/76) for main 
branch and 2.6% (2/76) for side branch, and target lesion revascularization rate was 1.3% 
and 1.3%, respectively. Conclusion: Pre-DES plaque debulking by DCA for bifurcated 
lesions is safe and enables simple DES stenting so that it may provide a good long-term 
outcome. Final Fu data will be presented.
3:00 p.m.
907-215 Predictors For Diffuse In-stent Restenosis After Taxus 
Sent Implantation: Analysis From The Taxus IV and V 
Trials
Masashi Kimura, Roxana Mehran, Ajay Kirtane, Jeffrey J., Stephen G. Ellis, Joerg 
Koglin, Donald S. Baim, Gregg W. Stone, Columbia University Medical Center, 
Cardiovascular Research Foundation New York, New York, NY
Background. Diffuse in-stent restenosis (ISR) is less common with drug-eluting stents 
(DES) than with bare metal stents (BMS).The clinical and angiographic predictors of 
diffuse restenosis after DES have not been described.
Methods. In the TAXUS IV and V trials, 1517 pts were randomized to receive either a 
paclitaxel-eluting stent (PES) or an identical BMS. Excluding stent thrombosis, 297 ISR 
lesions were identified (78 with PES and 219 with BMS). Focal and diffuse ISR were 
defined as ≤ and >10 mm respectively.
Results. Diffuse ISR occurred in 39.7% of PES and 78.5% of BMS restenosis cases, 
p=0.01. Baseline and procedural characteristics in 3 PES groups (focal ISR vs. diffuse 
ISR vs. non-ISR) are shown in Table. By multivariable analysis, smaller max device 
diameter (OR 0.04 [0.00-0.35], p=0.036), greater balloon/artery ratio (OR 503.9 [9.3-999], 
p=0.002), and smaller baseline RVD (OR 12.4 [1.4-114.3], p=0.026) were independent 
predictors for the diffuse restenotic pattern after PES implantation.
Conclusion. Diffuse ISR is less common with PES than BMS. Among PES pts with ISR, 
the strongest predictor of diffuse restenosis is the balloon/artery ratio. These data suggest 
excessive DES stent expansion in small vessels may negatively impact the pattern of 
restenosis. 
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PES characteristics Focal ISR(n=47)
Diffuse ISR
(n=31)
Non ISR
(n=703) p value
Age (yrs) 65.6 ± 12.7 60.1 ± 11.4 62.9 ± 10.8 0.09
Male gender (%) 63.8 64.5 71.6 0.39
Hypertension (%) 87.2 71.0 75.5 0.15
Hyperlipidemia (%) 70.2 74.2 69.9 0.88
Diabetes (%) 29.8 38.7 29.9 0.58
Insulin treated Diabetes (%) 21.4 66.7 27.6 0.01
Unstable angina (%) 25.5 29.0 33.9 0.44
ACC/AHA type C (%) 36.2 29.0 30.9 0.73
# study stents 1.34 ± 0.52 1.39 ± 0.50 1.19 ± 0.40 0.003
Maximum pressure (atm) 14.98 ± 2.70 15.90 ± 3.47 15.11 ± 2.77 0.28
Maximum device size (mm) 2.75 ± 0.46 2.69 ± 0.40 3.13 ± 0.53 <.0001
Balloon:artery ratio 1.08 ± 0.15 1.22 ± 0.22 1.12 ± 0.19 0.003
Baseline lesion length (mm) 16.42 ± 9.55 15.63 ± 6.24 15.87 ± 8.30 0.89
Total study stent length 
(mm) 27.74 ± 11.20 28.39 ± 10.65 24.96 ± 10.81 0.06
Stent length:lesion length 
ratio
1.81 (1.40, 
2.64)
1.73 (1.44, 
2.34)
1.58 (1.30, 
2.03) 0.02
Baseline RVD (mm) 2.48 ± 0.43 2.31 ± 0.41 2.75 ± 0.54 <.0001
Baseline MLD (mm) 0.82 ± 0.30 0.75 ± 0.35 0.90 ± 0.35 0.0271
Baseline DS (%) 67.07 ± 9.88 67.82 ± 12.75 67.36 ± 10.76 0.96
Final MLD (mm) 2.34 ± 0.41 2.28 ± 0.43 2.63 ± 0.50 <.0001
Final DS (%) 7.39 ± 8.92 4.15 ± 9.07 5.01 ± 10.64 0.2814
3:00 p.m.
907-216 Can Rosuvastatin Administration Before Percutaneous 
Coronary Intervention Reduce the Periprocedural 
Myocardial Injury In Patients With Stable Angina?: 
Results of a Randomized Study
Byoung-Keuk Kim, Sungjin Oh, Daesik Choi, Kyung Heui Kim, Dong Woon Jeon, Joo 
Young Yang, National health insurance corporation Ilsan hospital, Goyang-si, South 
Korea
Background: Elevation of cardiac enzyme after percutaneous coronary intervention 
(PCI), especially creatine kinase-MB (CK-MB), has been associated with early and late 
cardiac event and mortality. The aim of our study is to assess whether pretreatment 
with rosuvastatin before PCI in patients with stable angina can reduce periprocedural 
myocardial injury after PCI in a randomized study.
Methods: Seventy-six patients with stable angina without previous statin treatment were 
enrolled. Patients scheduled for elective PCI were randomized to rosuvastatin (n=38, 20 
mg/d) or control (n=38) group 7 days before the procedure. CK-MB (upper normal limit 
[UNL] 4.0 ng/ ml) and cardiac troponin I (cTnI, UNL 0.2 ng/ ml) levels were measured 
at baseline and at 6, 12, and 24 hours after PCI. Primary end-point of this study was 
to compare the incidence of periprocedural myocardial injury, defined as any CK-MB 
elevation above UNL after PCI.
Results: There was no difference in clinical, angiographic, and procedural characteristics 
between both groups. After rosuvastatin pretreatment for 7 days, there were no patients 
with abnormal elevation of CK or liver enzyme. The incidence of CK-MB elevation above 
UNL was significantly lower in the rosuvastatin group (7.9%) than the control group 
(26.3%) (p=0.032). cTnI elevation above UNL was detected in 33.3% in the rosuvastatin 
and 42.1% in the control group (p=0.480). The incidence of CK-MB elevation > 2 times 
UNL was 5.3% in the rosuvastatin group and 13.2% in the control group (p=0.215). Using 
multivariable logistic regression analysis, the only independent predictors of any CK-MB 
elevation after PCI was rosuvastatin pretreatment (OR=0.075; 95% CI=0.006-0.878; 
p=0.025).
Conclusions: This randomized trial suggests that pretreatment with rosuvastatin 20mg/d 
for 7 days can reduce the incidence of periprocedural myocardial injury after elective PCI 
in patients with stable angina.
3:00 p.m.
907-217 Depression Worsens Survival And Major Outcomes In 
Elderly Patients With Chronic Heart Failure: An Analysis 
Of 18,623 Patients In A Community Setting.
Alejandro Macchia, Simona Monte, Marilena Romero, Aldo P Maggioni, Gianni Tognoni, 
Consorzio Mario Negri Sud, Santa Maria Imbaro (CHIETI), Italy
Background: Depression (D) is common in patients with heart failure (HF) and contributes 
independently to poor clinical outcomes. However these evidences are generally limited 
to a low number of patients, mostly hospitalized.The aim of this study is to determine the 
prevalence and the association of D with major clinical outcomes among high-risk elderly 
community patients with HF.
Methods: For the identification of patients with HF with and without D we used record 
linkage analysis of hospital discharge records, prescription databases and vital statistics. 
All consecutive patients >60 years in 3 Local Health Authorities in Italy from 1/00 to 12/03 
were included. HF was defined as either: 1) Hospital discharged with CHF diagnosis 
(ICD-9: 428) and/or 2) Chronic treatment for HF identified as concomitant (<45 days) 
prescription of any combination of ACE-inhibitors, digoxin, furosemide, carvedilol, 
spironolactone, ARB-blockers. Index data was considered the chronologically first hospital 
admission or the date of the first prescription. D was identified according to exposition 
to psychotropic drugs before HF diagnosis. Follow up was extended up to one year or 
to time to occurrence of major outcomes. Cox regression analysis adjusted for major 
confounders were fitted.
Results: 18,623 patients with HF were identified. Mean age was 78,6 ± 8,6 and 11044 
(59,3%) were females. Of these, 2,405 (12.9%) were treated for D. Among patients with 
HF, those with D were significantly older and of female gender (69% vs. 58%) and more 
often presented a history of peripheral vascular disease (3.5% vs. 2.6%) and stroke (2.4% 
vs. 1.1%). Depression significantly worsened major outcomes [OR (95%CI)] including 
all cause mortality [+28% (+12% to +47%)], the composite of stroke / TIA / AMI [+36% 
(+20% to +53%)] and the rehospitalization for any reason [+18% (+9% to +27%)], but not 
rehospitalization for CHF [+0% (-20% to +24%)].
Conclusion: Among elderly community patients with HF, D is frequent and is independently 
associated with a poor clinical outcome
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908-209 Is Contrast Medium Dose a Risk Factor for the 
Development of Contrast-induced Nephropathy in 
Patients with Chronic Kidney Disease?
Richard Solomon, Madhu Natarajan, Serge Doucet, Samin K. Sharma, Cezar Staniloae, 
Richard E. Katholi, Joseph L. Gelormini, Marino Labinaz, for the CARE Investigators, 
Fletcher Allen Health Care, Burlington, VT
Background: Data from the Cardiac Angiography in REnally Impaired Patients (CARE) 
trial were evaluated to determine whether contrast-induced nephropathy (CIN) rates 
correlate with contrast dose and whether rates differ after use of the nonionic dimer 
iodixanol-320 (IOD) or the nonionic monomer iopamidol-370 (IOP).
Methods: Patients with CKD (eGFR 20-59 mL/min) undergoing cardiac angiography 
were randomized to IOP (n=204) or IOD (n=210). Serum creatinine (SCr) and eGFR 
were assessed at baseline and 2-5 days postdose. CIN was assessed using 3 metrics: 
SCr increases >0.5 mg/dL (M1); SCr increases ≥25% (M2); eGRF decreases ≥25% (M3). 
Differences in CIN incidence were evaluated with Fisher’s exact test.
Results: Gender, % diabetes, predose eGFR, contrast volume, and % PCI were 
comparable in the two groups, but mean weight was higher in the IOD group while the 
IOP group was older and received more iodine (0.62±0.36 vs. 0.53±0.31 gI/kg bw). Using 
all 3 metrics, CIN rates ranged from 4.4-9.8% after IOP and from 6.7-12.4% after IOD (all 
p=NS). In patients receiving ≤75 g iodine or ≤200 mL contrast no significant differences 
in CIN rates between the agents were found. In patients receiving >75 g/I or >200 mL 
contrast, CIN rates were significantly higher after IOD using M2 and M3.
Conclusions: The rate of CIN in high risk angiography patients is comparable after 
administration of IOP or IOD. The CIN rate was higher after larger doses of IOD but not of 
IOP. At larger doses IOD resulted in a higher incidence of CIN than IOP.
CIN by Contrast Media Exposure
Exposure
SCr Increase ≥ 0.5 
mg/dL From Baseline 
SCr Increase ≥ 25% 
From Baseline 
eGFR Decrease ≥ 25% 
From Baseline 
IOP
N (%)
IOD
N (%) P-value
IOP
N (%)
IOD
N (%) P-value
IOP
N (%)
IOD
N (%) P-value
≤75 g/I 8/173(4.6)
10/186 
(5.4) 0.744
19/173
(11.0)
19/186
(10.2) 0.813
12/173
(6.9)
16/186
(8.6) 0.556
>75 g/I 1/31(3.2)
4/24
(16.7) 0.081
1/31
(3.2)
7/24
(29.2) 0.007
0/31
(0)
5/24
(20.8) 0.002
P-value 0.727 0.037 0.181 0.008 0.043 0.089
≤200 mL 8/173(4.6)
10/175
(5.7) 0.646
19/173
(11.0)
18/175
(10.3) 0.833
12/173
(6.9)
16/175
(9.1) 0.177
>200 mL 1/31(3.2)
4/35
(11.4) 0.209
1/31
(3.2)
8/35
(22.9) 0.020
0/31
(0)
5/35
(14.3) 0.008
P-value 0.727 0.216 0.181 0.039 0.043 0.012
4:00 p.m.
908-210 A Biomarker Fingerprint of Heightened Plaque 
Metabolism in Stable Angina Patients Undergoing 
Elective PCI: Stable Angina Is Not Metabolically Stable
Rolf P. Kreutz, Kevin P. Bliden, Udaya S. Tantry, Joseph DiChiara, Paul A. Gurbel, Sinai 
Center for Thrombosis Research, Baltimore, MD
Background: Most patients with coronary artery disease (CAD) remain asymptomatic. 
Metalloproteinases (MMPs) are upregulated in atherosclerotic plaques and are 
implicated in plaque rupture and growth leading to symptoms. The effects of MMPs are 
counterregulated by MMP inhibitors (MMPIs).
Methods: We studied 84 patients with stable angina undergoing PCI (SA-PCI) and 
71 asymptomatic subjects with stable CAD (S-CAD). Pre-procedure plasma samples 
were analyzed for MMPs, MMPIs and inflammation markers (IMs) utilizing fluorokine 
multianalyte profiling assays. Patients in both groups were evenly matched for age, sex, 
and risk factors.
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Results: Patients with stable angina undergoing PCI had markedly elevated levels of 
specific MMPs (MMP-2, MMP-9), and MMPIs (alpha-2 macroglobulin, TIMP-1) compared 
to asymptomatic patients, whereas MMP-3 was higher in asymptomatic patients. (Table). 
CRP and TNF-β were higher in the group undergoing PCI (9.3±14.6 mg/l vs. 4.0±8.0 mg/l, 
p<0.01 and 44±35 vs. 30±20 pg/ml, p<0.01).
Conclusion: Our data indicate that patients coming to PCI with “stable” angina are not 
stable; their disease is very metabolically active and is indicated by a specific biomarker 
fingerprint of heightened inflammation and rapid plaque transformation that is distinctly 
different than asymptomatic patients. MMP-2 and MMP-9 should be prospectively 
investigated as markers of plaque growth and destabilization identifying the patient with 
progressing disease.
* p<0.0001, ** p<0.001
MMPs SA-PCI(n=84)
S-CAD
(n=71)
MMP-2 (ng/ml) 229 ± 256 22 ± 45*
MMP-3 (ng/ml) 4.5 ± 8.8 10.8 ± 5.7*
MMP-9 (ng/ml) 197 ± 301 3.1 ± 9.2*
MMPIs
alpha-2 Macroglobulin (mg/ml) 1.0 ± 1.7 0.19 ± 0.06*
TIMP-1 (ng/ml) 85 ± 38.2 69 ± 14.5**
4:00 p.m.
908-211 Efficacy and Safety of Pimecrolimus-Eluting Stents in 
Porcine Coronary Arteries
Ron Waksman, Rajbabu Pakala, Richard Baffour, Rufus Seabron, David Hellinga, 
Fermin ‘O’ Tio, Eric Wittchow, Sonja Hartwig, Michael Tittelbach, Claus Harder, 
Washington Hospital Center, Washington DC, DC, BIOTRONIK GmbH, Erlangen, 
Germany
Background: Pimecrolimus (PL) is an ascomycin derivative with anti-inflammatory 
and immunomodulatory capabilities, which binds specifically to the cytosolic receptor, 
macrophilin-12, and blocks transduction pathways in T cells and the inhibition of the 
synthesis of inflammatory cytokines. This study aimed to examine the safety and efficacy 
of a novel PL-eluting stent with a bioabsorbable polymer in the coronary model of 
restenosis.
Methods: Domestic swine randomly underwent intracoronary implantation of PL-eluting 
stents coated with PLLA containing 320 (n = 9), 750 (n = 9), or 1200 (n = 10) µg of PL/mm 
of stent length, stents coated with PLLA alone (n = 9), and bare metal stents BMS (Vision, 
Guidant, Santa Clara Ca, n = 8). At 28 days vessels were harvested, fixed, stained and 
analyzed by histomorphometry.
Results: PLLA and PL-eluting stents had similar endothelialization, intimal, and 
adventitial fibrin score when compared to BMS. Vessel, stent, and lumen areas were 
larger in the vessels deployed with PLLA and PL. The percentage occlusion of the PL-
eluting stents was lower when compared to the BMS (p<0.05). Though the intimal area 
and inflammation score in the vessels with PL-eluting stents were smaller, they did not 
attain statistical significance and there was no dose response effect.
Conclusion: The present data suggest that PL-eluting stents are safe, have similar 
healing profile to BMS, and may suppress inflammation leading to reduced intimal 
hyperplasia in porcine coronaries.
Effect of Pimecrolimus Eluting Stent on Vessel parameters in Porcine 
Coronary Arteries
Vessel 
Parameters Vision PLLA 320µg PL 750µg PL 1200µg PL
Stent area (mm2) 5.38 ± 0.36 6.13 ± 0.55* 6.23 ± 0.49* 6.14 ± 0.52* 6.20 ± 0.67*
Lumen area 
(mm2) 3.12 ± 0.53 4.03 ± 0.86* 4.43 ± 0.85* 4.36 ± 0.69* 4.39 ± 0.90*
Intimal area (mm2) 2.26 ± 0.64 2.10 ± 0.77 1.80 ± 0.68 1.78 ± 0.52 1.81 ± 0.60
% occlusion 41.76 ± 10.30
34.27 ± 
12.47
29.17 ± 
11.96*
29.04 ± 
8.88*
29.49 ± 
10.08*
Injury score 1.25 ± 0.46 0.70 ± 0.74 0.59 ± 0.62* 0.93 ± 0.55 0.53 ± 0.74*
Inflammation 
score
1.08 ± 0.75 0.67 ± 0.29 0.78 ± 0.24 0.85± 0.47 0.97 ± 0.40
Intimal fibrin 0.08 ± 0.15 0.15 ± 0.24 0.18 ± 0.24 0.00 ± 0.00 0.13 ± 0.23
Endothelialization 2.29 ± 0.52 2.29 ± 0.20 2.18 ± 0.34 2.44 ± 0.37 2.23 ± 0.27
* p<0.05 compared to Vision
4:00 p.m.
908-212 Can Inflammatory Markers Predict Major Adverse 
Cardiac Events (MACE) in Patients undergoing Non-
Cardiac Vascular Surgery?
Syed U. Ahmed, Eveline Lee, Omorogiuwa Williams, Paul Browning, Michael Fisher, 
Royal Liverpool University Hospital, Liverpool, United Kingdom
Background: Adverse cardiac events are common post vascular surgery. Previous data 
have suggested an association between acute coronary syndrome and inflammatory 
insults e.g. chest infection however little is known regarding the inflammatory response 
to vascular surgery. No data are available on whether this response can predict these 
cardiac events.
Methods: We performed a prospective observational study on patients undergoing non-
cardiac vascular surgery. This is defined as any form of peripheral arterial surgery and 
aortic aneurysm surgery including endovascular repair (EVAR). Blood samples for high 
sensitivity CRP, Interleukin-1 (IL-1), Interleukin-6 (IL-6), and soluble intercellular adhesion 
molecule -1 (sICAM-1) were collected pre-operatively and on day-1 post operatively. 
MACE were recorded on post-op days 1-3, defined as a rise in cardiac troponin T ≥0.06 
or new ischaemic ECG changes. Statistical analyses were performed using paired t-test. 
Data are shown as mean ± S.E.M..
Results: 47 patients were included in the study. 21 patients underwent peripheral arterial 
surgery, 16 had EVAR and 9 patients had open AAA repair. There were 11 (23%) MACE 
noted. The Eagle risk score was 1.3 ±0.12 and there was no significant difference between 
the MACE and non-MACE groups. Peri-operative rise in CRP (2.33±0.19 vs 3.30±0.22 
pre and post operatively respectively p=0.001) and IL-6 (8.47±0.90 vs 42.67±5.33 pre 
and post operatively respectively p=<0.0001) was highly significant throughout the group 
but IL-1 and sICAM-1 did not show significant change. The normalised peri-operative rise 
at day-1 in CRP (3.83±1.79 vs 0.74±0.29 in MACE and non-MACE groups respectively) 
was highly significantly different (p=0.008).
Conclusions:
1-There is selective increase in the inflammatory response peri-operatively.
2-The degree of rise in CRP predicts those who will have MACE.
3-The mechanisms underlying this selective inflammatory activation require further study 
as they may identify a high risk sub-group requiring treatment to forestall MACE.
4:00 p.m.
908-213 Comparative Analysis of Neointimal Growth on the 
Stent Struts of Sirolimus-Eluting Stents and Bare 
Metal Stents Crossing a Side Branch Using Optical 
Coherence Tomography
Mitsuyasu Terashima, Tatsuya Ito, Yoshihiro Takeda, Jean-François Surmely, Osamu 
Katoh, Tetsuo Matsubara, Etsuo Tsuchikane, Mariko Ehara, Yoshihisa Kinoshita, Kenya 
Nasu, Nobuyoshi Tanaka, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Late stent thrombosis following sirolimus-eluting stent (SES) implantation 
is a severe complication, and could be related to delayed neointimal stent coverage and 
disturbed laminar blood flow at the site of a bifurcation or a residual stenosis. Existing 
imaging tools have limitations for visualizing a thin neointimal layer. Optical coherence 
tomography (OCT) is a novel high resolution imaging technology. Using OCT, we 
examined differences in neointimal growth on the stent struts crossing a side branch 
between SES and Bare Metal Stent (BMS).
Methods: Of the 21 lesions in 20 cases treated with single stent implantation to the lesion 
involving side branches (>= 1 mm), 36 struts of 14 SES and 10 struts of 7 BMS, which 
crossed over a side branch, were analyzed 8 months after stent implantation using OCT. 
Neointimal coverage of struts was classified into either complete or incomplete coverage 
(Figure). Neointimal thickness on the covered strut was also measured.
Results: Neointimal growth was found on all stent struts both of SES and of BMS. 
Complete coverage was observed in 24 struts of SES (66.7%) and in all 10 struts of BMS 
(100%) (p < 0.05). Mean neointimal thickness for SES was significantly less than that for 
BMS (0.09 ± 0.03 mm vs 0.15 ± 0.06 mm, p < 0.01).
Conclusions: Using OCT, neointimal growth was observed on the struts both of SES 
and of BMS that were crossing a side branch. However, neointimal coverage of struts was 
delayed in SES, compared to BMS at 8 months after stent implantation.
4:00 p.m.
908-214 What Kind of Polymer Is Better for Bifurcation 
Stenting?
Yoshihisa Kinoshita, Osamu Katoh, Yasuyoshi Suzuki, Jean-François Surmely, Hiroshi 
Fujita, Tetsuo Matsubara, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Aichi, 
Japan
Background: The incidence of in-stent restenosis of bifurcation stenting (BS) remains 
high even with drug-eluting stents. One of the mechanisms is polymer damage which 
prevents a homogeneous drug distribution. We postulated that the degree of damage 
depends on the type of polymer.
Methods: Bx Velocity® stents, either coated with a permanent polymer (PEVA + PBMA: 
Cypher® stent, Cordis Corporation, Warren, NJ), or a bioabsorbable polymer (salicylic 
acid/sebacic acid polyanhydride + poly lactide anhydride: BTI stent, Bioabsorbable 
Therapeutics, Menlo Park, CA) were implanted in a bifurcation phantom model, and 
final kissing-balloon dilatation was done. BS techniques included T-stenting, culottes-
stenting, conventional crush-stenting, reverse crush-stenting, and flower-stenting (Panel 
A). Polymer damage was evaluated by electron microscopy.
Results: For both type of stents, polymer damage were observed at stent-overlapping 
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sites. The degree of damage varied according to BS strategy and polymer types. Polymer 
damage was smaller in BTI stents compared to Cypher® stents, and this particularly for 
the crush BS technique (Panel B). In BTI stents, damage consisted mainly of wrinkles, but 
polymer rupture were seen in Cypher® stents (Panel C).
Conclusions: A stent covered with a flexible polymer such as BTI Stent may be more 
suitable for BS than Cypher® stent. 
4:00 p.m.
908-215 Paclitaxel-eluting Stents For In-stent Restenosis of 
Sirolimus-eluting Stents: 12 Month Outcomes
Justin P. Levisay, Steve Lee, Curtis T. Stinis, Matthew J. Price, Raghava R. Gollapudi, 
Raphael Valencia, Garrett B. Wong, Richard A. Schatz, Paul S. Teirstein, Scripps Clinic, 
LaJolla, CA
Background: The optimal treatment for sirolimus-eluting stent (SES) restenosis is not 
known.
Methods: From March 2004 to October 2005, paclitaxel-eluting stents (PES) were 
implanted in 148 patients with 162 lesions containing SES restenosis. Acute and 12 
month clinical outcomes were determined through telephone contact and review of the 
medical record.
Results: Mean patient (pt) age was 66±12 years, 50 pts (34%) had diabetes, and 36% 
of lesions had been previously treated with bare metal stenting prior to initial SES 
implantation. Clinical FU was obtained in 100% of pts at a mean of 17 ± 4.8 months 
(range 30 months to 12 months). In-hospital major adverse cardiac events (cardiac death, 
non-fatal MI, or repeat revascularization) occurred in 16 pts (10.8%), driven entirely by 
post-procedure non-Q wave MI. TLR for entire group was 21.6% and was lowest for 
de novo SES restenosis (14%), compared to total occlusive SES restenosis (63%). 
Composite major adverse cardiac events including death, MI, stent thrombosis, and TLR 
were 23.6%.
Conclusions: PES implantation for SES failure provides excellent outcomes at 12 month 
follow-up. Our TLR rate of only 14% in pts with de novo SES restenosis is particularly 
encouraging. Efficacy is reduced in the setting of multiple prior target lesion interventions, 
total SES occlusions, and longer PES length.
Table 1: Out of Hospital MACE and Determinates of TLR in Taxus for Cypher ISR 
N (%)
MACE 35 (23.6 %)
Death 0
MI 1 (x%)
SAT 2 (1.3%)
TLR total 32 (21.6%)
TLR Subgroups: p
- PES for de novo SES ISR 8 (14%)
-Any previous Brachytherapy 9 (40%) 0.01
-Occlusive SES restenosis 12 (63%) 0.0001
-Prior POBA of SES restenosis 13 (42%) 0.048
-Any previous TLR 37 (37%) 0.009
4:00 p.m.
908-216 Impact of Combination of Glycoprotein IIb/IIIa Inhibition 
and Bivalirudin on Long-Term Outcomes Following PCI 
in Real World Clinical Practice
Dmitriy N. Feldman, Christopher L. Gade, David S. Gidseg, Alexander J. Slotwiner, 
Nickolas Juliano, Punit Goel, Linda J. Cuomo, Manish Parikh, Geoffrey Bergman, S. 
Chiu Wong, Robert M. Minutello, New York Presbyterian Hospital-Weill Medical College 
of Cornell University, New York, NY
Background: In a randomized trial (REPLACE-2), bivalirudin was found to be noninferior 
to GP IIb/IIIa blockade for the prevention of acute and long-term events. We investigated if 
the addition of GP IIb/IIIa inhibitors to bivalirudin results in improved outcomes compared 
to bivalirudin alone in current clinical practice of PCI with DES.
Methods: Using the 2004/2005 Cornell Angioplasty Registry, we studied 1,589 
consecutive pts undergoing urgent or elective PCI with peri-procedural use of bivalirudin. 
Mean clinical follow-up was 430 days.
Results: We studied 1,412 pts (88.9%) receiving bivalirudin alone and 177 (11.1%) 
receiving bivalirudin plus GP IIb/IIIa blockade. DES were used in 87% of PCI. The 
incidence of in-hospital mortality (0% vs. 0.3%, p=1.00), non-Q-wave MI (7.9% vs. 6.5%, 
p=0.52), MACE (death, stroke, emergent CABG/PCI, MI) (7.9% vs. 6.8%, p=0.22), and 
major bleeding (1.7% vs. 0.6%, p=0.14) was similar in the bivalirudin plus GP IIb/IIIa 
inhibitor versus bivalirudin alone arm. By follow-up, there was 1 (0.6%) death in the 
bivalirudin plus GP IIb/IIIa inhibitor group vs. 64 (4.5%) deaths in the bivalirudin alone 
arm (HR 0.1, 95%CI 0-0.9, p=0.04) (Figure). After multivariate Cox analysis, GP IIb/IIIa 
use in addition to bivalirudin was associated with a strong trend toward improved long-
term survival (HR 0.2, 95%CI 0-1.1, p=0.07).
Conclusions: Procedural GP IIb/IIIa blockade in addition to bivalirudin therapy in 
contemporary PCI with DES may be associated with improved long-term survival. 
4:00 p.m.
908-217 The Effect on Long Term Survival of Hematocrit Drop 
after Cardiac Catheterization: The Dartmouth Dynamic 
Registry
Sajjad A. Sabir, Aaron V. Kaplan, John E. Jayne, Bruce J. Friedman, Bruce D. Hettleman, 
Nathaniel W. Niles, James T. DeVries, John F. Robb, Craig A. Thompson, Dartmouth-
Hitchcock Medical Center, Lebanon, NH
Background: The relationship of peri-procedural decrease in hematocrit (Hct) levels on 
long term mortality in patients having cardiac catheterization is poorly understood.
Methods: This retrospective study looks at 11,448 patients who underwent cardiac 
catheterization between July 1998 and July 2006 at Dartmouth-Hitchcock Medical Center. 
Patients were divided into three categories based on the difference in Hct from baseline 
and the lowest Hct within 48 hours after cardiac catheterization [<3% (N=7482), 3-6% 
(N=2522), and >6% (N=1444)] and vital stats were ascertained.
Results: The three groups were comparable with respect to hypertension, smoking, 
family history of coronary artery disease, diabetes, and congestive heart failure (p= NS). 
Time to event analysis demonstrated no mortality differences between the <3% and 3-6% 
groups but poorer long term survival in patients with >6% Hct drop (Figure 1).
Conclusions: Drop in hematocrit after cardiac catheterization may be a useful prognostic 
marker of mortality. 
E-POSTER SESSION
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9:00 a.m.
909-209 What is the Optimal Definition of Renal Failure After 
Percutaneous Coronary Intervention? Findings From 
the Guthrie PCI Registry
Kishore J. Harjai, Amol Raizada, Pamela Orshaw, Karl Yaeger, Judy Boura, Daniel 
Sporn, Dwight Stapleton, Guthrie Clinic, Sayre, PA
Background: Renal failure (RF) occurring after PCI is defined in multiple ways. The 
prognostic value of some contemporary definitions is validated. Currently, there is no 
consensus on the optimal definition of this complication.
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Methods: In 1142 pts undergoing PCI, we assessed incidence of post-PCI RF using 
5 definitions [the old and new ACC-NCDR definitions; post-PCI increase in serum 
creatinine (δCr) >1.0 mg/dL, δCr>0.5 mg/dL, and δCr>25% above the baseline value], 
and the correlation of each definition with 6-mon death, 6-mon MACE (death, target 
vessel revascularization, or infarction), and long-term (median 859 days) death.
Results: The incidence of post-PCI RF varied widely depending on the definition 
(table). Only 2 definitions (δCr>0.5 mg/dL and δCr>25%) showed consistent univariate 
and multivariate correlations with study outcomes. After adjustment for other baseline 
characteristics, occurrence of δCr>0.5 mg/dL increased 6-mon death, MACE, and long-
term death by 6.1-, 2.1-, and 2.7-fold, respectively (p<0.05 for all). The respective odds 
ratios for δCr>25% were 3.6, 1.6, and 2.0 (p<0.05 for all). The δCr>0.5 mg/dL criterion 
discriminated well between all pts and high-risk pts, but the δCr>25% criterion occurred 
frequently in all groups (table).
Conclusions: The incidence and prognostic value of post-PCI RF vary widely 
depending on the definition used, highlighting the need for a universal definition. Of the 5 
contemporary definitions, δCr>0.5 mg/dL appears to be the optimal definition.
Incidence of Renal Failure in All Patients and Certain High-Risk Sub-
Groups
Sub-Group
ACC-NCDR
Old 
Definition
ACC-NCDR
New 
Definition
δCr>1.0
mg/dL
δCr >0.5
mg/dL δCr >25%
All Patients (n=1236),% 2.9 1.6 2.4 4.6 14.5
Age > 65 years (n=592),% 5.7 3.2 4.3 8.0 19.2
Diabetes Mellitus (n=325),% 6.2 3.4 5.1 7.4 18.9
Myocardial Infarction 
(n=553),% 4.5 2.4 3.2 6.6 17.3
Baseline Creatinine
Clearance <60 ml/min 
(n=289), %
8.3 5.2 6.9 12.8 20.1
9:00 a.m.
909-210 A Prospective, Natural History Study of Multimodality 
Invasive Imaging to Characterize Vulnerable Plaque: 
First Report of the Baseline Findings from the 
PROSPECT Trial
Gregg W. Stone, Alexandra J. Lansky, Stephane Carlier, Bernard De Bruyne, John 
McPherson, Naim Farhat, Steven Marso, Bertil Wennerblom, Roxana Mehran, Gary 
S. Mintz, Patrick Serruys, Columbia University Medical Center/The Cardiovascular 
Research Foundation, NY, NY
Background. Acute coronary syndromes (ACS) and sudden cardiac death are in most 
pts caused by rupture of a “vulnerable” plaque, typically a thin-capped fibroatheroma 
(TCFA). No large-scale prospective studies have been done to characterize the coronary 
tree with advanced imaging modalities to identify areas at future risk for plaque rupture.
Methods. In PROSPECT, 700 pts with ACS were enrolled at 37 U.S. and European 
centers and underwent angioplasty of all clinically significant lesions. Three vessel IVUS 
(8-10 cm per coronary artery) was then performed with radiofrequency domain analysis 
(virtual histology VH). Using proprietary software, quantitative coronary analysis (QCA) 
was performed every 1.5 mm of the coronary tree and co-registered with the IVUS/
VH data. Three vessel palpography was also obtained in half the patients, and MSCT 
performed in a substudy subset. Biomarkers are drawn at baseline, 30 days and 6 months 
in all pts and measured at a core lab. Pts are followed for 2 - 5 years (until a minimum of 
100 non culprit MACE events occur). 
Results. Baseline features of the 700 pts include mean age 58 yrs; 76% were male, 17% 
had diabetes, 29% qualified with recent STEMI, 65% with NSTEMI and 6% with unstable 
angina. Baseline CRP was elevated in 60% of pts, IL6 in 27%, sCD40L in 24%, MPO in 
15% and MMP-9 in 93%.
Conclusions. The first large-scale, multicenter, prospective, multi-modality imaging study 
to invasively detect vulnerable plaque has completed enrollment. In March 2007, baseline 
imaging results will be presented, including QCA/IVUS/VH co-registered data, underlying 
plaque morphology and VH TCFA number and distribution.
9:00 a.m.
909-211 Efficacy and Safety of Absorbable Metallic Stents 
With Adjunct Intracoronary Beta Radiation in Porcine 
Coronary Arteries
Ron Waksman, Rajbabu Pakala, Teruo Okabe, Richard Baffour, Rufus Seabron, David 
Hellinga, Fermin ‘O’ Tio, Eric Wittchow, Sonja Hartwig, Karl-Heinz Waldmann, Claus Harder, 
Washington Hospital Center, Washington, DC, BIOTRONIK GmbH, Erlangen, Germany
Background: Absorbable metallic stents (AMS) utilizing Mg alloys carry advantages 
over permanent metallic stents with the potential to eliminate stent thrombosis, chronic 
inflammation or artifacts with non-invasive imaging. However, these were associated with 
a modest degree of late recoil and intimal hyperplasia. This study aimed to test whether 
adjunct vascular brachytherapy (VBT) to AMS can overcome these limitations.
Methods: Juvenile domestic pig coronary arteries underwent implantation of AMS 
(Biotronik) (n=11) with prior adjunct VBT utilizing Sr/Y-90 seeds β source with a dose 
of 24 Gy at 2 mm from the source and AMS (n=11); and bare metal stent (BMS) (n=9) 
utilizing the Vision stent (Guidant, Santa Clara) implantation without VBT. At 28 days, 
vessels harvested and analyzed by histomorphometry.
Results: Vessels in the VBT+ AMS group showed characteristics of delayed healing 
and rendothelialization. Neointimal area was significantly lower in the VBT + AMS group 
(0.49 ± 0.34) compared to AMS (1.3 ± 0.62) and the BMS (2.34 ± 0.64) group (p<0.05). 
However, the vessel and stent areas were smaller in the VBT+ AMS and the AMS groups 
when compared to the BMS group. While the lumen area of the VBT+ AMS was larger 
when compared with AMS alone it was similar to the BMS group (Table).
Conclusion: VBT as adjunct therapy to AMS further reduces the intimal hyperplasia and 
improves the lumen area when compared to AMS alone but does not have impact on 
the late recoil.
Effect of Absorbable Metallic Stents with Adjunct Beta Radiation on Vessel 
Parameters
Vessel Parameters BMS AMS VBT +AMS 
Stent area (mm2) 5.31 ± 0.41 3.05 0.67* 2.97 ± 0.79*
Lumen area (mm2) 2.96 ± 0.69 1.75 ± 0.51* 2.49 ± 0.82#
Intimal area (mm2) 2.34 ± 0.64 1.30 ± 0.62* 0.49 ± 0.34* #
% occlusion 44.09 ± 10.30 41.70 ± 13.89 16.30 ± 11.65* #
Inflammation score 1.26 ± 0.88 1.46 ± 0.99 1.27 ± 0.42
Intimal fibrin 0.07 ± 0.15 0.03 ± 0.01 1.21 ± 0.37* #
Intimal smooth muscle cells 3.00 ± 0.00 2.88 ± 0.17 0.46 ± 0.75* #
Endothelialization 2.26 ± 0.49 2.09 ± 0.60 1.09 ± 0.15* #
*P<0.05 Compared to vision; # *P<0.05 Compared to AMS.
9:00 a.m.
909-212 Long-Term Durability of Endoluminal Stenting 
for Obstructive Lesions of the Subclavian Artery: 
Multicenter Registry in Japan
Sunao Nakamura, Hiroyuki Sato, Eiji Tada, Kensuke Fujiwara, Osamu Kakuda, Naoyuki 
Kurita, Mizuki Hirose, Shotaro Nakamura, Satoko Tahara, Koji Hozawa, Osamu 
Hirashima, Hitoshi Nakamura, Kazutoshi Yamamoto, Seiji Otani, Nobuyuki Makishima, 
Jun Koyama, New Tokyo Hospital, Chiba, Japan
Background: Obstructive lesions of the subclavian artery can result in arm claudication, 
symptoms of subclavian steal. 
Aim: To evaluate the safety, efficacy and durability of endovascular stenting for treating 
340 obstructive lesions of subclavian artery. 
Methods: We performed 340 cases of endoluminal stenting for 320 patients (217 males, 
65±12 years). All procedures were performed with Palmaz stents (225 cases) and Wall 
stents (115 cases), 220 cases (64.7%) were used transradial approach. Indications for 
stenting were arm claudication in 196 cases, subclavian steal syndrome in 80 cases and 
myocardial ischemia secondary to compromised flow through internal mammary grafts 
in 64 cases. 
Results: Procedural success (defined as abolition of pressure gradient across the aorta 
and subclavian artery and a residual diameter stenosis <20% without major complications 
was achieved in 337 patients (99.1%). Only one patient had a major complication 
(mediastinum hemorrhage due to subclavian artery rupture). Baseline diameter 
stenosis was reduced from 89.7% to 13.8±9.0%, mean systolic pressure difference was 
reduced 46.9±14.9 mmHg to 4.5±4.8 mmHg (p<0.01). There was no cerebral or distal 
embolization. In 318 of 340 patients (93.5%) we performed, follow-up angiography ranged 
from 6 months to 8 years (mean, 48 months). Primary angiographic patency at 5 years 
was 99% (only 3 restenosis: 1.0%). 
Conclusions: Endoluminal stenting of the subclavian artery is safe and effective with 
high technical success and these clinical benefits are durable at least 5 years.
9:00 a.m.
909-213 Morphologic Feature and Frequency of Coronary Pre-
Rupture Thin-cap Fibroatheroma in Patients With Acute 
Myocardial Infarction and Stable Angina Pectoris: A 
Three-Vessel Optical Coherence Tomography Study
Kenichi Fujii, Motomaru Masutani, Tsuyoshi Sakoda, Tohru Masuyama, Mitsumasa 
Ohyanagi, Hyogo College of Medicine, Nishinomiya, Japan
Background: It has been recognized that thin-cap fibroatheroma (TCFA) is the precursor 
of plaque rupture, which accounts for a majority of acute myocardial infarction (AMI). 
However, characteristics of TCFA have not been well assessed because TCFAs have 
a thin fibrous-cap (<65microm) that cannot be identified by current imaging modalities 
due to their insufficient resolution. We evaluated the incidence and features of TCFAs 
using optical coherence tomography (OCT) that is a new high-resolution (approximately 
10microm) imaging modality.
Methods: OCT and intravascular ultrasound (IVUS) examinations were performed using 
motorized pullback in all 3-coronary arteries for 14 AMI and 8 stable angina pectoris 
(SAP) patients. Qualitative OCT analyses for each focal atherosclerotic plaque were 
performed using the previously validated criteria. OCT criteria for TCFA was lipid-rich 
plaque with cap thickness <65microm. Quantitative IVUS measurements were also 
performed for each plaque.
Results: No procedure-related complications occurred. OCT identified 22 culprit and 73 
non-culprit focal plaques. The frequency of TCFAs at culprit site was 57% in AMI and 
0% in SAP patients (p=0.02). At least 1 TCFA was found somewhere other than on the 
culprit site in 64% for AMI and 13% for SAP patients (p=0.03). OCT and IVUS analyses 
revealed that TCFAs had greater vessel and plaque area and a higher remodeling index 
than non-TCFAs (p<0.001, p<0.001, and p=0.002, respectively). In all cohorts, TCFAs 
were clustered mainly in the proximal segments in the left coronary artery and the entire 
segments in the right coronary artery. Multiple TCFAs were identified in 36% for AMI and 
13% for SAP patients (p=0.4). In AMI patients, serum high-sensitive C-reactive protein 
(hs-CRP) level was significantly higher in patients with multiple TCFAs than in patients 
without multiple TCFAs (p=0.01).
Conclusions: Pre-rupture TCFAs were observed more frequently both at culprit and 
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non-culprit sites in AMI than SAP patients. TCFAs were mainly located in the proximal 
segments and had large remodeling index and plaque burden compared with non-TCFAs. 
In AMI patients, the prevalence of multiple TCFA was associated with a high hs-CRP 
level.
9:00 a.m.
909-214 Culotte versus T - Stenting in Bifurcation Lesions: 
Immediate Clinical and Angiographic Results and Mid-
term Clinical Follow-up
Peter Barlis, Sahin Kaplan, Konstantinos Dimopoulos, Omer Goktekin, Alessio La 
Manna, Jun Tanigawa, Carlo Di Mario, Royal Brompton Hospital, London, United 
Kingdom
Background Stenting of the main vessel with provisional stent implantation of the side 
branch (SB) is the technique of choice for treating most bifurcation lesions, since no 
advantage on restenosis has been shown by universal use of kissing stents and the 
concern for the development of sub-acute or late thrombosis in the drug-eluting stent (DES) 
era. There is no consensus however on the best technique when the provisional approach 
fails and a second stent is needed. Two possible methods are T-stenting and the culotte 
technique, but no studies have addressed the relative merits of these techniques. The 
purpose of this study was the comparison of the immediate angiographic and mid-term 
clinical results of the culotte and T-stenting techniques for bifurcation lesions using DES.
Methods Between February 2004 and October 2005, 80 patients with bifurcation lesions 
were treated with either culotte (n=45) or T-stenting (n=35). Coronary angiograms were 
analyzed using a new dedicated system (Quantitative Vascular Arteriography). All 
patients were treated with DES, either sirolimus-eluting (Cypher and Cypher Select; 
Cordis/Johnson & Johnson, Warren, New Jersey, USA) or paclitaxel-eluting (Taxus and 
Taxus Liberte, Boston Scientific, Natwick, Massachusetts, USA). Only patients with stable 
and unstable angina or non-ST-elevation myocardial infarction were included.
Results Acute procedural success was 100% for both groups. One patient in the 
culotte group had a myocardial infarction at 2 days related to sub-acute thrombosis and 
underwent repeat revascularization. Residual diameter stenosis of the SB ostium was 
3.4±7.4% in the culotte group versus 12.5±11.5% in the T-stenting group (P<0.0001). 
The culotte group had a lower target lesion revascularization rate compared to T-stenting 
(8.8% versus 25.7%, P=0.034) and a trend towards lower major cardiac adverse events 
at 9 months (20.0% versus 31.4%, P=0.087).
Conclusion Both culotte and T-stenting of bifurcation lesions using DES achieve high 
procedural success with low complication rates. The culotte technique, nevertheless, 
results in a better angiographic result at the side branch ostium with improved clinical 
outcome at 9 months.
9:00 a.m.
909-215 Illicit Drug Use Is An Independent Risk Factor For 
Coronary In-stent Restenosis
Dinesh Kumar, Neeraj Arora, Faisal Bahadur, Stephen Simpson, Gloria Caldito, Praphul 
Misra, LSU Health Sciences Center, Shreveport, LA
BACKGROUND: Percutaneous coronary interventions (PCIs) are one of the accepted 
treatment modalities in patients with coronary artery disease (CAD) with a history of Illicit 
drug use (IDU). Post PCI outcomes in stented patients with IDU have not been previously 
studied. We hypothesized that IDU is associated with poor outcomes in such patients.
METHODS: 89 Patients with angiographic diagnosis of instent restenosis/ stent occlusion 
(ISR) were identified from the catheterization laboratory data base with 16 of these patients 
demonstrating IDU. These 2 groups were compared on traditional CAD risks (i.e. diabetes, 
hypertension, dyslipidemia, family history of premature CAD, and smoking), severity of 
ISR presentation (i.e. angina versus myocardial infarction), and subsequent treatments 
performed (i.e. PCI/coronary artery bypass grafting (CABG)/ medical therapy).
RESULTS: Illicit drug users were more likely to be African-Americans (56 vs. 21%) with 
lower prevalence of hypertension (63 vs. 94%), dyslipidemia (38 vs. 88%), and family 
history of premature CAD (19 vs. 72%) (p<0.01 for all). Other than smoking, number of 
traditional risk factors were lower among drug users (1.4±1.3 vs 3.0±0.8, p<0.01) They 
were more likely to present with myocardial infarction (56 vs.13%, p<0.01), with a lower 
overall ejection fraction (44.6±12.9 vs. 57±12.4%, p<0.01). In addition, they were more 
likely to require more aggressive treatment of ISR with frequent referral for subsequent 
PCI/CABG (94 vs. 60%, p<0.01). Using multiple logistic regression analysis, IDU was 
found to be an independent predictor for presentation with myocardial infarction at the 
time of ISR (Odds Ratio 6.58; 95% Confidence Interval 1.85 to 23.26, p<0.01). IDU was 
also an independent predictor for worse outcomes with more PTCA/ CABG required for 
treatment of ISR (Odds Ratio 10.10; 95% Confidence Interval 1.27 to 83.33, p<0.01).
CONCLUSION: Illicit drug use is associated with poor outcomes in patients treated with 
stents for CAD. It is an independent risk factor for Instent Restenosis. These patients 
should be enrolled in a drug rehabilitation program soon after PCI to prevent subsequent 
adverse outcomes.
9:00 a.m.
909-216 Eliminating Unnecessary X-ray Exposure during 
Interventional Procedures: Role of Automatic 
Fluoroscopy Lockout
John C. Gurley, Guillermo Pineda, Abhishek Beshmukh, Kiran Saraff, University of 
Kentucky, Lexington, KY
Background. The ALARA principle calls for x-ray doses As Low As Reasonably 
Achievable. Needless exposure occurs when an operator activates the fluoroscopy foot 
switch while glancing at interventional equipment or physiologic data.
Methods. A head-tracking, Automatic Fluoroscopy Lockout (AFL) system was based on 
a miniature infrared camera and a reflective dot (Figure). X-ray production was enabled 
only when the reflector was directed toward the live display. The efficacy of AFL was 
evaluated during 57 unselected procedures. Foot switch and x-ray “ON” times were 
logged electronically during 1,912 sessions comprising 1,110.5 minutes of fluoroscopy.
Results. AFL reduced the exposure time in all patients. Mean exposure times were 
significantly lower with AFL (actual 1,162.5 sec vs. predicted 1,243.9 sec, P<.001). On 
average, fluoroscopy was automatically disabled during 14.6±19.5% of the foot switch 
“ON” time (range 1.2 to 56.3%). A resulting x-ray dose reduction of at least 20% occurred 
in 23% of patients.
Conclusions. Fifteen percent of the x-ray exposure during routine fluoroscopy is 
unnecessary, occurring while the operator is not viewing the display. AFL eliminates this 
unnecessary fraction of x-ray exposure and minimizes the risk of radiation injury. 
9:00 a.m.
909-217 Referrals in Acute Coronary Events for Cardiac 
Catheterization, the RACE CAR Study: What 
Factors Account for Gender Differences in Cardiac 
Catheterization Referral Rates?
Catherine Kreatsoulas, Debi Sloane, Janice M. Pogue, James L. Velianou, Sonia S. 
Anand, McMaster University, Hamilton, ON, Canada
Background: Women with acute coronary syndromes (ACS) have lower rates of cardiac 
catheterization (CC) compared to men. One possible reason for lower CC rates is the 
referring physician’s belief that women are lower risk of cardiovascular death and MI 
compared to men and thus do not require or benefit from CC. However this referral rate 
may also be influenced by age, ACS risk, or patient preference.
Methods: To determine which factors influence a physician’s decision to refer ACS 
patients for CC, we designed 12 clinical scenarios controlling for sex, age (55 or 75 
years old), patient preference (no CC, no comment, yes CC) and TIMI risk score (low, 
moderate, high). Physicians were blinded to the primary objective to detect gender bias 
for CC. Scenarios were administered to internists/cardiologists across Canada using 
a web-based computerized survey instrument. Each physician read and completed 3 
clinical scenarios and answered standardized questions using a five point Likert scale 
ranging from 1 (very unlikely to benefit from CC) to 5 (very likely will benefit from CC). 
We predetermined that 68 physicians completing 3 scenarios each would be required to 
provide 90% power to detect a 10% difference in CC referral rate.
Results: 79 physicians completed 3 randomly assigned scenarios between July and 
August 2006. Higher cardiac risk, younger age, female gender and patients desire to 
have CC were associated with higher CC referral scores. Using a mixed linear model 
we observed significant interactions between cardiac risk and gender (p=0.038), cardiac 
risk and age (p=0.001) and cardiac risk and patient preference (p=0.001). Specifically 
physicians were less likely to refer for CC, low risk woman compared to low risk men 
(3.55 +.15 vs. 4.12 +.13, p=0.04), and were more likely to refer low risk younger patients 
compared to low risk older patients 4.47 +.18 vs. 3.20 +.17, p=.001) as well as patients 
who expressed a preference to have a CC compared to patients who made no comment 
at all (3.68 +.22 vs. 2.89 +.14, p=0.001).
Conclusions:Among ACS patients in Canada, referral for cardiac catheterization appears 
to be influenced by a complex interplay of factors including cardiac risk, gender, age, and 
patient preference.
E-POSTER SESSION
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10:00 a.m.
910-209 Clinical Outcomes in Chronic Hemodialysis Patients : 
Initial and One-Year Follow-Up Results of the j-CYPHER 
Registry
Yasushi Fuku, Kazuaki Mitsudo, Tsuyoshi Goto, Kazushige Kadota, Hiyoyuki Yamamoto, 
Takeshi Kimura, j-CYPHER Registry investigators, kurashiki central hospital, okayama, 
Japan
Background: Chronic hemodialysis patients treated with bare metal stent have higher 
rates of poor outcomes after percutaneous coronary intervention, including greater 
rates of MACCE (major adverse cardiac and cerebrovascular event), TLR (target lesion 
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revascularization) and TVR (target vessel revascularization). The indications for sirolimus-
eluting stents (SES) have extended to patients with complex clinical profiles, but clinical 
outcomes in chronic hemodialysis patients treated with SES remain unknown.
Methods: Between January 2004 and August 2005, data were collected on 3084 
patients. We compared 176 hemodialysis patients and 2908 non-hemodialysis patients 
who underwent SES implantation. Clinical follow ups at one-year were conducted by 
telephone contact or office visits.
Results: Baseline characteristics revealed younger population (p<0.0001), lower 
ejection fraction (p<0.0001), higher prevalence of hypertension (p<0.0001) and 
diabetes (p<0.0001) in the hemodialysis group. Patients’ success rate was comparable 
but complete revascularization rate was lower (p=0.004) in the hemodialysis group. In 
hospital outcomes were comparable but hemodialysis group had a significantly higher 
mortality (p=0.003). One-year clinical outcomes are shown in Table.
Conclusions: This analysis of initial and one-year data collected by the j-CYPHER 
Registry suggests that clinical outcomes in chronic hemodialysis patients treated with 
SES are still poor.
Hemodialysis
N=176
Non-hemodialysis
N=2908 p
Death at 1Y (%) 19 3.0 <0.0001
Q wave MI at 1Y (%) 3.4 0.58 0.0002
Cerebrovascular event at 1Y (%) 4.5 1.1 0.0003
TLR at 1Y (%) 21 6.0 <0.0001
TVR at 1Y (%) 23 9.8 <0.0001
TLR-MACCE at 1Y (%) 43 11 <0.0001
TVR-MACCE at 1Y (%) 46 14 <0.0001
Subacute/late thrombosis (%) 2.3 0.62 0.038
10:00 a.m.
910-210 Large MI after PCI: Secondary to “Micro” Embolization 
or “Macro” Mechanical Complications?
Barry F. Uretsky, Fen Wei Wang, UTMB, Galveston, TX
BACKGROUND: CKMB elevation (MI) after successful PCI adversely affects long-
term outcome. “Micro”embolization is likely a major determinant. Intra-procedural 
“macro”mechanical complications (MC) may also be important but data are retrospective 
or not systematically collected [MC=dissection (A-F), transient/persistent side branch 
occlusion, transient threatened/abrupt closure, no reflow, angiographic cutoff]. 
OBJECTIVE: We hypothesized that MCs explain large PCI MI. 
METHODS: MC were evaluated prospectively in 550 pts and CKMB measured pre- and 
8 hrsx3 after PCI. 
RESULTS: Univariate analysis showed pts with increased CKMB (n=110, 20%) were older 
(62±12 vs 58±11, p=0.004) and had MC more frequently (38% vs 11%, p<0.0001). Of 89 
MC pts, 47% had increased CKMB vs 15% of 461 non-MC pts (p< 0.0001). (Figure). Odds 
ratio for increased CKMB using multivariate analysis was 5.6 (CI: 3.3-9.3; p<0.0001) for 
MC, 2.1 (1.2-3.6; p=0.01) for multivessel PCI, and 2.0 (1.3-3.3; p=0.003) for age >60 yrs. 
Sensitivity/specificity of MC to predict any CKMB rise was 38%/89%, for large increase 
(>3x ULN) was 66%/88% and for increase >10x ULN 100%/85%. Large (≥3xULN) CKMB 
rises occurred in 28% of MC vs 3% of no MC pts (p<0.00001). (Figure).
CONCLUSIONS: MC during PCI increases the probability of CKMB elevation after PCI. 
Small CKMB rise occurs frequently (>75%) without MC suggesting “micro” embolization. 
Large CKMB elevations (≥ 3X ULN) are associated with MC. Without MC, a large CKMB 
increase after successful PCI is rare.
10:00 a.m.
910-211 An Atrial Decompression Device: Potential Therapy for 
Congestive Heart Failure
David Meerkin, Rona Shofti, Dan Burkhoff, Gad Keren, Shaare Zedek Medical Center, 
Jerusalem, Israel
Background: Elevated left ventricular filling pressures with subsequent elevated preload 
and left atrial pressures often result in pulmonary edema and reduced exercise tolerance. 
We proposed that an atrial decompression device positioned across the interatrial septum 
would result in a reduction of LA pressure if opened during LA pressure rise.
Methods: Using a previously validated cardiovascular computer simulation model, we 
assessed the effects of opening a shunt in the interatrial septum on LA pressure. In a 
second phase, a mechanical pressure dependent valve was developed and its efficacy 
was assessed in a closed bench top model that assessed flow dependent upon pressure 
difference. In a third phase, a technique was developed for percutaneous deployment of 
the device in a juvenile pig model.
Results: In the computer simulation model, at a set heart rate of 75 bpm, with a cardiac 
output of 5.08 l/min the LA pressure could be reduced from 27.2 to 20.5 mmHg by opening 
an interatrial aperture of 7mm. This would result in a reduction of LV cardiac output to 4.69 
l/min and a mild corresponding rise in RV CO to 6.13 l/min, with RA pressure elevating 
mildly from11.5 to 13.5mmHg.
The bench top model demonstrated efficacy of the developed valve with flow increasing 
with increased pressure difference with a 10mmHg pressure difference resulting in 
550ml/min flow. This could be altered by preprogramming of the device.
In 4 animals percutaneous deployment of the device was performed under fluoroscopic 
and intracardiac echocardiographic control, following transeptal puncture. Transient 
elevation of LA pressure was performed by both manual and automatic injection of saline 
and fluoroscopic contrast though a catheter passed retrograde from the femoral artery 
via the aorta and LV to the LA. Flow was demonstrated from LA to RA with a flow rate of 
12ml/sec using PISA calculation with color flow Doppler.
Conclusions: An interatrial aperture can theoretically function to cause atrial 
decompression particularly in a milieu conducive to pulmonary edema. Feasibility of 
implantation of an atrial decompression device across the atrial septum was demonstrated 
using advanced echocardiographic techniques.
10:00 a.m.
910-212 Carotid Artery Stent Type Influences Duplex 
Ultrasonography Derived Flow Velocities - Findings of 
an In-Vitro Model
Ripple Doshi, Jocelyn Spoon, Demetrius Lopes, Christian Spies, R. Jeffrey Snell, Rush 
University Medical Center, Chicago, IL
Background: Duplex Ultrasonography (DU) has not been validated in stented carotid 
arteries. Further, considerable debate exists whether DU overestimates velocity signals 
and thus degree of stenosis in carotid arteries which have been stented in the past. The 
goal of this study is to evaluate the effect of stenting on DU velocity signals in an in-vitro 
carotid model.
Methods: Physiologic, pulsatile flow was simulated with an experimental circulatory 
system containing a non-stenotic ovine internal carotid artery segment measuring 8-12 
cm in length. Mean flow in the model was kept constant at 0.29 l/min with a frequency 
of 70 /min-1. Peak systolic velocity (PSV) was measured with an intravascular flow wire 
(FW) (FloWire, Volcano) and DU (Vivid 7 Dimension, GE Healthcare). PSV was evaluated 
at 5 predetermined locations within the vessel immediately prior and following stent 
placement. Three stents were implanted: Precise (Cordis), X-Act (Abbott), and Acculink 
(Guidant). DU and FW derived PSV before and after stenting were compared using a 
paired t-test.
Results: Eleven stents were compared, of which 6 were non-tapered and 5 were tapered. 
DU derived PSV increased significantly following placement of the X-Act stent (80±26 
cm/sec [pre] vs. 102±29 cm/sec [post], p=0.02), while FW derived PSV (65±23 cm/sec 
[pre] vs. 66±9 cm/sec [post], p=0.93) did not change. The Precise stent did not influence 
PSV with either method (DU: 76±28 cm/sec [pre] vs. 72±35 cm/sec [post], p=0.44; FW: 
64±30 cm/sec [pre] vs. 63±39 cm/sec [post], p=0.95;), while the Acculink stent showed a 
trend towards a reduction in DU (69±37 cm/sec [pre] vs. 51±10 cm/sec [post], p=0.075) 
and FW (50±27 cm/sec [pre] vs. 40±12 cm/sec [post], p=0.14) derived PSV. Tapered 
versus non-tapered stent design had no significant impact on DU or FW derived PSV 
measurements.
Conclusion: Stent type may have significant impact on DU derived velocity signals. DU 
seems to overestimate PSV in carotid arteries treated with the X-Act stent, but not with 
the Precise or Acculink stent. Larger scale clinical comparison of various stent types and 
their impact on DU are needed in order to clarify the value of DU surveillance following 
carotid artery stenting.
10:00 a.m.
910-213 The Plaque Destabilization Of Non-culprit Lesion In 
Acute Myocardial Infarction: An Optical Coherence 
Tomography Study
Hironori Kitabata, Takashi Kubo, Yu Arita, Hideyuki Ikejima, Keishi Ohkochi, Hiroto 
Tsujioka, Akio Kuroi, Satoshi Ueno, Takashi Tanimoto, Takashi Yamano, Yoshiki Matsuo, 
Takashi Masho, Shigeho Takarada, Toshio Imanishi, Yoshiaki Tomobuchi, Takashi 
Akasaka, Wakayama medical university, Wakayama, Japan
Background: Recent intravascular ultrasound (IVUS) studies frequently demonstrated 
multiple plaque rupture in cases with acute coronary syndrome. Optical coherence 
tomography (OCT) is a new intravascular imaging method with a high resolution of 
approximately 10-20 micrometer, which is 10-fold greater than that of IVUS. This may 
allow us to observe the pathophysiology of the atherosclerosis in the vessel wall in detail 
in vivo, and to estimate the vulnerable plaques. The present study sought to assess 
atherosclerotic plaque destabilization by intracoronary OCT in acute myocardial infarction 
(AMI) compared with stable angina (SAP).
Methods: The OCT examination of culprit-vessel was performed in 51 patients: 33 had 
AMI, and 18 had SAP. We evaluated not only culprit plaques (AMI: n=33, SAP: n=18) but 
also non-culprit plaques (AMI: n=43, SAP: n=25) by OCT.
Results: In the evaluation of culprit plaques, the incidences of plaque rupture (76% vs. 
6%, p<0.001), plaque erosion (24% vs. 0%, p=0.02) and intracoronary thrombus (100% 
vs. 0%, p<0.001) in AMI was significantly higher than those in SAP. In the evaluation 
of non-culprit plaques by OCT, plaque rupture or erosion (26% vs. 4%, p=0.02) and 
intracoronary thrombus (26% vs. 0%, p=0.006) in AMI were observed more often than 
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those in SAP. Furthermore, the fibrous-cap thickness of non-culprit plaque in AMI was 
significantly thinner than that in SAP (109 +/- 55.5 vs. 194 +/- 81.9 μm, p<0.001), and the 
incidence of thin-cap fibroatheroma (fibrous cap thickness < 65μm) of non-culprit plaque 
in AMI patients was significantly higher than that in SAP (35 vs. 8%, p=0.01).
Conclusions: The OCT examination demonstrates the plaque destabilization not only 
in culprit lesion but also non-culprit lesion in AMI. Intracoronary OCT provides abundant 
information regarding plaque microscopic morphology, which is thought to be essential in 
the identification of high-risk lesions.
10:00 a.m.
910-214 One Year Follow-up Of Left Ventricular Function And 
Remodeling After Intracoronary Infusion Of Bone 
Marrow - Derived Progenitor Cells After Acute Stemi: 
MRI Substudy of the Double-blind, Randomized, 
Placebo-controlled Multicenter Repair-AMI Trial.
Andreas Rolf, Thorsten Dill, Susanne Moellmann, Guido Conradi, Volker Schaechinger, 
Andreas Zeiher, Christian W. Hamm, Kerckhoff-Heart Center, Bad Nauheim, Germany
Background: The Repair-AMI trial demonstrated a positive effect of intracoronary infusion 
of bone marrow derived stem cells (BMC) on left ventricular function by LV angiography 4 
months after acute myocardial infarction. An MRI substudy to assess myocardial function, 
wall motion, and infarct size/transmurality was performed and the follow-up data after 12 
months are presented.
Methods: Consecutive patients (pts) with STEMI and primary PCI were enrolled 
(n=204) and randomly assigned to either stem cell therapy or placebo after bone-marrow 
aspiration. 74 pts participated in the MRI substudy, 60 pts were available for 4 month 
(mo) follow up (fup), 39 pts for 12 mo fup, respectively. Image analysis was performed 
at a central core lab.
Results: There is no significant difference in EF between both groups at baseline. After 
12 mo EF significantly increased in the BMC group (3%) and was unchanged in the 
placebo group (BMC 49.3% ± 2.28 to 52.3% ± 2,5, difference 3% ± 1.43, p < 0.43; 
placebo 48.83% ± 2.21 to 50.71% ± 2.44, difference 1.88% ± 1.40, p ns). Improvement 
was more pronounced in pts with EF below median of 48.9% (BMC 38.05% ± 2.04 to 
43.86% ± 3.02, difference 5.81% ± 2.6, p < 0.01; placebo 42.18% ± 1.93 to 43.36% ± 
2.84, difference 1.18% ± 2.05, p ns).
Adverse remodelling was present: enddiastolic volume increased in the placebo group 
(124.50 ml ± 6.6 to 152.62 ml ± 10.14, difference 28.13 ml ± 6.86, p < 0.01), whereas 
BMC treated patients showed no significant increase (130 ml ± 6.8 to 145.89 ml ± 10.41, 
difference 15.11 ml ± 7.05, p ns). There was no difference between groups at baseline.
There was no significant difference between both groups regarding infarct volume after 
12 mo (BMC 20.85 ml ± 3.85 to 20.32 ml ± 6.60, p ns; placebo 26.10 ml ± 3.44 to 
29.76 ml ± 5.9, p ns). Infarcts >50% transmurality improved independent of treatment 
(transmuralityscore: BMC 3.04 ± 0.14 to 2.61 ± 0.13, p <0.002; placebo 2.72 ± 0.12 to 
2.33 ± 0.12, p ± 0.002).
Conclusions: Preliminary analysis of 12 mo fup data confirms the beneficial effects of 
BMC treatment on EF and EDV that could be demonstrated after 4 mo. The positive 
additional effect of BMC treatment on infarct volume and transmurality could not be 
demonstrated with this limited number of 12 mo fup data.
10:00 a.m.
910-215 Troponin Elevation After Percutaneous Coronary 
Intervention Predicts Major Cardiac Adverse Outcomes 
in Patients with Non-ST-Segment Elevation Acute 
Coronary Syndromes: Results From the SYNERGY Trial
Pierluigi Tricoci, Kenneth W. Mahaffey, Kristi G. O’Grady, Karen S. Pieper, L. Kristin 
Newby, Robert A. Harrington, Shaun G. Goodman, Dietrich C. Gulba, Jacques 
Col, Harvey D. White, Philip E. Aylward, John K. French, Neal S. Kleiman, James J. 
Ferguson, Robert M. Califf, Duke Clinical Research Institute, Durham, NC
Background: The importance of troponin (Tn) elevation following PCI is still unclear.
Methods: The prognostic role of peak Tn post-PCI among non-ST-segment elevation 
(NSTE) myocardial infarction (MI) patients with post-PCI Tn rise (pre-PCI Tn normal 
or stable in 2 samples) was studied in the SYNERGY dataset. Post-PCI Tn/ULN ratio 
(TnR) and percentage post-PCI Tn increase (TnP) were analyzed as linear variables. 
Outcomes were 30-day death, MI and ischemia-related revascularization; 6-month death, 
MI, revascularization; 1-yr death. Cox models including baseline clinical and angiographic 
(number of diseased vessels [NDV] and unsuccessful PCI) features were generated.
Results: 4687 pts underwent PCI, 3711 had >1 Tn value checked post-PCI and 2510 
met the inclusion criteria. Significant predictors of events were at 30 days: increasing 
age, increasing time to PCI, NDV, TnR (HR 1.5 [1.27-1.70]; p<.001), and TnP (HR 1.12 
[1.01-1.16]; p<.001); at 6 months: decreasing creatinine clearance (CrCl), prior angina, 
NDV, TnR (HR 1.30 [1.16-1.45]; p<.001), and TnP (HR 1.10 [1.07-1.13]; p<.0001); at 1 yr: 
increasing age, decreasing CrCl, increasing heart rate, heart failure, ST-depression, and 
male sex. Figure shows the adjusted relationship of TnP and 6-month outcome.
Conclusions: Post-PCI Tn elevation in patients with NSTE MI is an independent predictor 
of worse short- and mid-term ischemic outcomes but not of 1-yr mortality. Further studies 
are needed to clarify the clinical significance of these results.
10:00 a.m.
910-216 X-ray Dose-Awareness in the Interventional Laboratory: 
Interactive Display Improves Safety
John C. Gurley, Abhishek Beshmukh, Kiran Saraff, Guillermo Pineda, University of 
Kentucky, Lexington, KY
Background. Radiation skin injury is a serious hazard, but interventional cardiologists 
are seldom aware of x-ray exposure rates or skin doses.
Methods. A real time Dose-Awareness Display (DAD) was developed as a “speedometer” 
for dose rate and a “fuel gauge” for accumulated skin dose (Figure). The display was 
generated by a predictive model incorporating gantry position, table height, SID and air 
KERMA. Operator awareness was ascertained by survey of 100 unselected procedures, 
25 in a DAD-equipped intervention suite and 25 in each of three conventional rooms.
Results. In DAD-equipped rooms, 89.3% of operators reported definite or probable 
awareness of exposure rate (vs. 4.0% conventional, P<.001), and 80.0% took steps 
to minimize exposure (vs. 7.7% conventional, P<.001). In DAD rooms, 92.0% reported 
awareness of skin dose (vs. 0% conventional, P<.001) and 92% took steps to avoid 
injury (vs. 5.3% conventional, P<.001). In conventional rooms, 89.3% were unaware of 
exposure rate and 81.3% were unaware of skin dose.
Conclusions. 1) Operators are generally unaware of x-ray exposure rates and skin 
doses. As a result, they take little or no action to prevent injury. 2) A Dose-Awareness 
Display alerts operators to correctible high-dose situations, reducing the risk of injury. 
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911-209 High Restenosis Rate in Patients on Hemodialysis 
Treated With Either Sirolimus-eluting Stents or Bare 
Metal Stents
Naoki Ishio, Yoshio Kobayashi, Hideo Takebayashi, Yoshihiro Iijima, Junji Kanda, Takashi 
Nakayama, Nakabumi Kuroda, Yukiyoshi Kouno, Masaru Suzuki, Seiichi Haruta, Issei 
Komuro, Chiba University, Chiba, Japan, Fukuyama Cardiovascular Hospital, Fukuyama, 
Japan
Background: Percutaneous coronary intervention (PCI) provides excellent angiographic 
success but is associated with increased restenosis in patients with end-stage renal 
disease. Drug-eluting stents have dramatically reduced restenosis rate in various lesion 
subsets. However, its efficacy in patients on dialysis is not fully evaluated. This study 
evaluated acute and long-term outcomes of sirolimus-eluting stents (SES) in hemodialysis 
patients.
Methods: PCI using SES was performed in 40 patients with 54 lesions. Acute and long-
term outcomes in these patients were compared with those in 45 patients with 50 lesions 
treated by PCI with bare metal stents (BMS).
Results: There was no significant difference in patient characteristics including diabetes 
mellitus (65% vs. 55%, p=0.38) between SES and BMS. Procedural success was achieved 
in all lesions treated with either BMS or SES. During follow-up, there was no significant 
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difference in the incidence of death (9% vs. 3%, p=0.36) and myocardial infarction (2% vs. 
0%, p>0.99) between the BMS and SES group. Follow-up angiography was performed in 
80% of lesions. There was no stent thrombosis in the SES group while it was observed in 
1 patient (2%) in the BMS group (p>0.99).
Conclusion: Restenosis rate was high in patients on hemodialysis who received either 
BMS or SES.
MLD=minimum lumen diameter, TLR=target lesion revascularization
SES BMS P-value
Stents length (mm) 29.6±18.8 19.8±10.1 0.02
Max. inflation pressure (atm) 18.20±3.35 13.66±3.19 <0.001
Lesion length (mm) 19.49±12.45 13.9±6.00 <0.01
Reference diameter (mm) 2.75±0.67 2.87±0.59 0.34
Pre-MLD (mm) 0.90±0.34 0.78±0.34 0.10
Final MLD (mm) 2.48±0.47 2.58±0.45 0.28
Follow-up MLD (mm) 1.9±0.84 1.5±0.80 0.6
Binary restenosis (%) 31 44 0.22
TLR (%) 17 27 0.26
11:00 a.m.
911-210 Time Delay To Rescue PCI And Clinical Endpoints. 
Results From The React Study.
Neil Swanson, Amanda Carver, Sarah Hughes, Gail Richardson, Anthony Gershlick, 
Glenfield Hospital, Leicester, United Kingdom
Background: REACT was a 428 patient trial of STEMI with failed reperfusion (<50% ST 
resolution) 90min after thrombolysis. Patients were randomised to repeat thrombolysis, 
conservative treatment, or rescue PCI.
The composite endpoint (death, reinfarction, stroke or severe heart failure) at 6mth 
occurred in 15% for PCI v. 29.9% conservative v. 31.3% repeat thrombolysis (overall 
P=0.004, published data).
In primary PCI, outcomes have been related to delay to PCI. Till now, no such data exist 
for rescue PCI.
Methods: Data on the timing of symptom onset, randomisation and PCI were examined 
for the REACT PCI group.
Adverse outcome risk (mean, 95% CI) were calculated above and below the median 
delay time. An hour by hour analysis was performed.
Results: 97/115 patients had data for timing of PCI. These patients had an 11.3% endpoint 
rate. Median time to PCI from randomisation was 1.5hr (18min to 19hr 25min). Median 
time to PCI from initial pain was 7hr (3hr 8min to 22hr 20). Hour by hour analysis showed 
no clear time point where benefit of PCI was lost, although at >12hr from randomisation, 
2 of 3 patients had adverse events.
Conclusions: In REACT, rescue PCI was expected to be performed speedily. This analysis 
has not shown a clear cut-off time beyond which rescue PCI is ineffective (although the 
very limited data for patients treated >12hr suggest they may be at increased risk). 
Performed promptly, rescue PCI remains the best treatment for failed thrombolysis and 
should be undertaken despite an unplanned “reasonable” delay. 
11:00 a.m.
911-211 Acute Stent Recoil of Bioabsorbable Everolimus-Eluting 
Coronary Stent and Everolimus-Eluting Coronary Metal 
Stent: Insight from the ABSORB and SPIRIT Trials
Shuzou Tanimoto, Patrick W. Serruys, Leif Thuesen, Dudek Dariusz, Bernald de Bruyne, 
Bernard Chevalier, John A. Ormiston, Thoraxcenter Erasmus MC, Rotterdam, The 
Netherlands, Auckland City Hospital, Auckland, New Zealand
Background: The bioabsorbable everolimus-eluting coronary stent (BVS) is composed 
of a poly-L-lactic acid backbone, expected to be totally metabolized and absorbed. When 
compared with metallic stents, the BVS may have less radial strength, which can result 
in more acute recoil post stent implantation. The aim of this study was to evaluate and 
compare acute stent recoil results of the BVS and metal stents.
Methods: A total of 60 patients, who underwent elective stent implantation for single de 
novo native coronary artery lesions, were enrolled: 30 patients treated with BVS from 
the ABSORB trial and 30 consecutive patients treated with the everolimus-eluting cobalt 
chromium stent from the SPIRIT trials. Acute stent recoil was measured by quantitative 
coronary angiography and defined as the difference between mean diameter of the 
last inflated balloon at the highest pressure (x) and mean lumen diameter of the stent 
immediately after the last balloon inflation divided by x and expressed as a percentage.
Results: At the time of abstract submission, 27 ABSORB trial patients and 20 SPIRIT trial 
patients were analyzed. Diseased segments were relatively simple. As preliminary data, 
mean acute stent recoil of the BVS and the metal stent was 6.9 ± 7.0% and 4.4 ± 7.6%, 
respectively (p =0.407).
Conclusion: Preliminary data show that acute stent recoil of the BVS stent is comparable 
to that of the metal stent. We will show the stent recoil data on all patients at the time of 
the presentation. 
Preliminary results
BVS (n = 27) Metal stent (n = 20)
Absolute acute stent recoil (mm) 0.20 ± 0.21 0.14 ± 0.22
Acute stent recoil (%) 6.9 ± 7.0 4.4 ± 7.6
11:00 a.m.
911-213 Multiple Thin-cap Fibroatheromas Assessed by 
Three Vessel Histological and Optical Coherence 
Tomographic Study
Teruyoshi Kume, Hiroyuki Okura, Takahiro Kawamoto, Takashi Akasaka, Eiji Toyota, 
Nozomi Watanabe, Yoji Neishi, Renan Sukmawan, Ryotaro Yamada, Kiyoshi Yoshida, 
Kawasaki Medical School, Kurashiki, Japan
Background: Recently, three vessel intravascular ultrasound studies have shown that 
plaque rupture may be present not only in the culprit lesion but also in non-culprit lesions. 
Such a plaque rupture most commonly arise from the disruption of thin-cap fibroatheromas 
(TCFA), known as the thickness of fibrous cap < 65 μm. The purpose of this study was to 
evaluate the incidence of TCFA by histological examination and investigate the feasibility 
of using optical coherence tomography (OCT) to detect of TCFA.
Methods: We examined 108 coronary arterial segments from 38 human cadavers 
(24 male and 14 female, mean ages 74 ± 7 years). Coronary arteries were imaged 
with intravascular OCT system. We evaluated the incidence of TCFA by histological 
examination and investigated the feasibility of using OCT to detect of TCFA.
Results: Thirty distinct TCFA were detected by histological examination. Patients with 
TCFA had significantly higher incidence of ischemic heart disease than in patients without 
TCFA (34% vs. 0%, p=0.003). Complete histological examination of all 3 coronary arteries 
was performed in 32 patients (84%). Among 32 patients, 6 (19%) had 1 TCFA, 6 (19%) 
had 2 TCFA, and 4 (13%) had 3 TCFA (Figure). OCT showed a high sensitivity and 
specificity for detecting TCFA (sensitivity 90% and specificity 84%).
Conclusion: Multiple TCFA were observed in about one-thirds of cadavers by histological 
examination. OCT could provide a high sensitivity and specificity for detection of TCFA. 
11:00 a.m.
911-214 The Critical Role of Magnetic Resonance Angiography 
in Evaluation of Anomalous Coronary Arteries
Vikas K. Rathi, Ronald M. Razmi, Mark Doyle, Agostino Meduri, Tony G. Farah, Benigno 
Soto, Gerald M. Pohost, Robert W. Biederman, Allegheny General Hospital, Pittsburgh, 
PA, PA, University of Alabama at Birmingham, Birmingham, AL
Background: X-ray angiography (CATH) has been the imaging modality of choice for 
assessment of the coronary arteries (CA). However, due to its 2D projectional nature, 
it does not reliably delineate the proximal course of anomalous CA. This information is 
critical to pt management. CT angiography is 3D with excellent spatial resolution but high 
radiation and contrast side effects. Preliminary data indicate that CA MRA is effective 
in defining the origin and proximal coronary course when intraluminal stenosis is not 
a primary aim. We compared the accuracy of MRCA to CATH in pts referred with an 
anomalous CA diagnosis.
Methods and Results: Pts (37) referred for anomalous CA underwent MRCA (1.5T GE 
Signa CVi, Milwaukee WI). No contrast was used.
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Blinded comparison was made with CATH and consensus reached regarding the 
anomalous course. A second blinded review by two CATH experts (> 70 yrs of cumulative 
angiography) was performed on a subset of 61% (n=22) where CATH films were available 
for second review. MRCA independently delineated the origin and proximal course of the 
CA in all 36 pts. There was only 27.7% agreement between CATH and MRCA, thereby 
MRCA completely changed the findings of CATH regarding the course of the anomalous 
CA. The most fatal anomaly, such as interarterial course of the LM, was present in 16 pts 
by MRCA, out of which only 6 were identified by CATH (concordance 37.5%). Therefore, 
a 62.5% rate of new diagnosis of interarterial course delineation was made and these 
pts were referred for timely surgical intervention. As well, 5 pts were incorrectly classified 
by CATH as having an interarterial course and appropriate MRCA diagnosis of non-
interarterial course was made thereby avoiding needless surgical intervention.
Conclusion: To our knowledge this is the largest series of independent anomalous 
coronary MRCA simultaneously compared to X-ray angiography. MRCA correctly 
identified every anomaly and prevented many needless surgeries, while identifying 
appropriate candidates for surgery in many life-threatening instances. This degree of 
accuracy qualifies tomographic MRCA as the imaging modality of choice for assessing 
proximal course of anomalous CA in a safe and expedient non-contrast manner.
11:00 a.m.
911-215 Stent Thrombosis in the Modern Drug-eluting Stent Era 
compared to the Bare-Metal Stent Era: A Comparison 
from a Large Clinical Registry
Kent G. Meredith, Rodney S. Badger, Anwar Tandar, Heidi T. May, Tami L. Bair, Douglas 
L. Kosmicki, Andrew D. Michaels, Jeffrey L. Anderson, Benjamin D. Horne, Joseph B. 
Muhlestein, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
BACKGROUND: Concern for a potential risk of late stent thrombosis (ST) associated 
with drug-eluting stents (DES) has prompted a shift toward prolonged dual anti-platelet 
therapy in patients with DES. We compared outcomes in patients who received DES since 
2003 to patients who received bare-metal stents (BMS) in the pre-DES era to determine 
whether ST has increased in clinical practice.
METHODS: Patients (N=8142) from a single center who received coronary stents 
between 1993-2005 were included. In order to control for biased stent selection in modern 
practice (i.e. BMS typically are used only in very small or large vessels, or when anti-
platelet therapy is contraindicated), we compared patients stented with DES after 2003 to 
patients who received BMS stents before DES became available (1993-2002). ST during 
the first 36 months after stent placement was studied, using multivariate regression to 
adjust for standard risk factors. Timing categories were: acute/subacute (AST) within 30 
days, Late (LaST) 1-6 months, and very late (VLaST): 6-36 months.
RESULTS: Compared to BMS (N=6193), patients with DES (N=1949) were more likely to 
have diabetes, hypertension, and hyperlipidemia. ST was more frequent in BMS patients 
than DES (157 [2.5%] vs. 12 [0.6%], p<0.001). Multivariate analysis showed a greater risk 
for ST (OR=3.78, p<0.0001) in BMS. ST timing compared as follows; AST: DES 0.3%, 
BMS 0.2%; LaST: DES 0.3%, BMS 0.8%; VLaST: DES 0.1%, BMS 1.6%. In multivariate 
analysis, there was no difference for AST (OR=1.20, p=0.72), but BMS were more likely 
to have LaST (OR=3.76, p<0.001) and VLaST (OR=22.3, p=0.002).
CONCLUSION: The incidence of ST remains very low for DES compared to BMS placed 
in the pre-DES era. Although not assessed in this study, the greater ST among BMS 
may be due to the lesser duration of intensive antiplatelet therapy whereas current 
strategies for prolonged dual anti-platelet therapy in the DES era may maintain equivalent 
or even superior ST rates regardless of the DES compared to BMS treatment strategy. 
However, the long-term risk for ST in DES after discontinuing antiplatelet therapy remains 
uncertain.
11:00 a.m.
911-216 Radiation Exposure during Flat Detector Fluoroscopy: 
Recognition of a Unique Hazard to Obese Patients
John C. Gurley, Guillermo Pineda, Kiran Saraff, University of Kentucky, Lexington, KY
Background. Modern flat detector (FD) fluoroscopy systems provide superior contrast 
resolution, enabling operators to work with heavier patients and steeper projections. 
While it is generally assumed that FD systems are safe, the potential for excessive x-ray 
exposure is unknown.
Methods. Measurements of x-ray dose and image quality were obtained in clinical 
catheterization laboratories, using acrylic blocks to simulate patients of varying size. FD 
and image intensifier-based (II) fluoroscopy systems were compared by analyzing image 
quality and x-ray dose as functions of attenuator thickness.
Results. FD fluoroscopy provided superior image quality during obese-patient simulations, 
but at the cost of escalating x-ray doses (Figure). II and FD image quality scores were 
equivalent when penetrating 30 and 38 cm of attenuator, respectively (27% greater for 
FD). Entry (skin) dose rates at this point of equivalency were 5.86 R/min for II and 16.4 
R/min for FD fluoroscopy, (2.8 times higher for FD). At these rates, FD fluoroscopy could 
cause skin injury in 12 minutes.
Conclusions. FD fluoroscopy presents a unique hazard for radiation skin injury in obese 
patients. Since image quality is preserved, operators may not be aware of high skin dose 
rates. FD systems should be used with caution in heavy patients. 
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912-209 The Impact of Glomerular Filtration Rate on the 
Outcomes of Primary Percutaneous Coronary 
Intervention in ST-elevation Myocardial Infarction
Luis Gruberg, William E. Lawson, Anil Mani, Joseph Z. Chernilas, Lisa A. Wilbert, David 
L. Brown, Stony Brook University Medical Center, Stony Brook, NY
Background: Although there is accumulating evidence that renal insufficiency is an 
independent risk factor for mortality after acute myocardial infarction, it is not clear 
whether renal dysfunction is associated with increased mortality in ST-segment elevation 
myocardial infarction (STEMI) patients undergoing primary percutaneous coronary 
intervention (PCI).
Methods: The glomerular filtration rate (GFR) was estimated by means of the four-
component Modification of Diet in Renal Disease equation using baseline serum 
creatinine levels. Patients were divided into two groups according to GFR, ≥60 ml or <60 
ml per minute per 1.73 m2. The 6-months outcomes of these two groups were compared.
Results: A total 459 STEMI patients underwent primary PCI during the study period. 
Regarding baseline clinical characteristics, patients with reduced GFR had a higher 
incidence of diabetes (Table). At 6-months follow-up, the outcome of patients with renal 
insufficiency was significantly worse when compared to those with normal renal function. 
GFR <60 
(n=132) GFR ≥60 (n=327) P
Age (years) 63.0 56.8 NS
Male gender (%) 95 (72.0%) 240 (73.4%) NS
Diabetes (%) 30 (22.7%) 45 (13.8%) p ≤ 0.025
Peripheral vascular disease (%) 11 (8.3%) 16 (4.9%) NS
Ejection fraction (%) 43.9 46.0 NS
Stroke (%) 4 (6.4%) 2 (0.6%) p ≤ 0.05
Stent thrombosis (%) 2 (1.5%) 2 (0.6%) NS
Acute occlusion (%) 2 (1.5% 2 (0.6%) NS
Death (%) 7 (5.3%) 5 (1.5%) p≤ 0.025
Conclusions: Impaired renal function, as defined by a reduced GFR is associated with 
poor outcomes in STEMI patients undergoing primary PCI, with significantly higher stroke 
and mortality rates.
Noon
912-210 Drug-Eluting Stents
An Ounce of Prevention for a Pound of Flesh?
Sanjay Kaul, George A. Diamond, Prediman K. Shah, Cedars-Sinai Medical Center, Los 
Angeles, CA
Background Even though randomized trials have consistently shown reductions in 
restenosis and revascularization with drug-eluting stents (DES), none of these trials were 
adequately powered to reliably evaluate relevant clinical endpoints such as death or MI. 
Follow-up of these trials is only now beginning to be long enough to more fully assess 
these outcomes.
Objective To analyze individual and pooled meta-analytic data from long-term follow-up 
of major DES trials.
JACC  March 6, 2007  ABSTRACTS - Innovation in Intervention: i2 Summit 2007    2B
Innovation in Intervention: i2
 S
um
m
it 2
0
0
7
Methods Reported P values are based on Fisher’s Exact test. Numbers needed to harm 
(NNH) are derived as inverse of absolute risk difference. Probability of harm is estimated 
as 1 minus one-sided P value based on Bayesian principles; threshold probability of 
significance = 97.5%.
Results The meta-analyses revealed a nonsignificant increase in death or MI with DES, 
with a significant increase in these outcomes with sirolimus-eluting stents (SES) and a 
significant increase in late stent thrombosis with paclitaxel-eluting stents (SES) at last 
follow-up. Even though the differences in death or MI were not statistically significant in 
any one of the individual trials (due to inadequate power), the NNH with DES ranged from 
12 to 111 and the probability of harm ranged from 68% to 96%.
Conclusion
These findings suggest a potential for increased risk of death or MI with DES presumably 
related to stent thrombosis. Given these observations, an adequately powered prospective 
trial to reliably estimate the true excess risk of death or MI is urgently warranted. 
Trial Endpoint Follow 
up
Incidence 
(%) P value NNH Probability
of harmDES BMS
Meta-analysis 
SES vs BMS 
(n=1748)
Death
Death or MI
Death or MI
Stent 
thrombosis
4 y
3 y
Last f/u
6-36m
6.5%
6.0%
6.3%
0.57%
5.1%
4.0%
3.9%
0.11%
0.22
0.06
0.03
0.10
71
50
71
217
89%
97%
99%
95%
Meta-analysis 
PES vs BMS 
(n=3445)
Death
Death or MI
Stent 
thrombosis
3 y
3 y
6-36m
4.6%
5.7%
0.47%
4.3%
5.3%
0.06%
0.89
0.63
0.02
333
250
244
56%
69%
99%
SIRIUS DeathDeath or MI
4 y
4 y
6.0%
8.4%
4.6%
6.7%
0.30
0.27
71
59
85%
87%
RAVEL DeathDeath or MI
5 y
5 y
12.1%
18.9%
7.1%
10.5%
0.26
0.09
20
12
87%
96%
BASKET 
Death or MI
Stent 
thrombosis
18 m
7-18m
8.4%
2.6%
7.5%
1.3%
0.63
0.23
111
77
68%
89%
Noon
912-211 Intravascular Delivery of Sirolimus with Two 
Biodegradable Polymers Using Novel Electro-Grafting 
Technology
Thierry Lefèvre, Erica J. Pacheco, Patrice Guérin, Rosy Elloy, Férial Haroun, Katina 
Lesieux, Renaud Decrop, Christophe Bureau, Renu Virmani, CVPath Institute, Inc., 
Gaithersburg, MD, Alchimer SA., Massy, France
Background: This study examined the feasibility of local drug release with biodegradable 
polymers applied to bare metal stents using an electro-grafting eG™ technique (Alchimer 
S.A., Massy, France) creating a ultra-thin layer (100-150 nm) of stable and reproducible 
bonding of polymer matrix to metal surfaces.
Methods: Rabbits were fed a high fat diet (1% cholesterol) for 2 months, during which 
animals underwent bilateral iliac artery stent implantation at 28 days. Balloon-expandable 
stainless steel stents (18 x 3mm) were coated with sirolimus incorporated in two different 
biodegradable matrices, PC1 & PC2. The arteries were randomized to one of five groups: 
uncoated stents (n=8); PC1 stents (n=8); PC2 stents (n=10); PC1/Sirolimus-eluting stents 
(n = 9); and PC2/Sirolimus eluting stents (n=7). At the completion of the in-life phase, 
stented vessels were removed and processed for histomorphometry.
Results: Percent stenosis was significantly lower in drug-loaded stents (PC1/Sirolimus 
eluting= 17.32±6.27 and PC2/Sirolimus eluting= 21.29±4.78) compared to uncoated 
(25.20±4.19), PC1 (33.50±12.25) or PC2 (26.96±7.89) stents (p≤0.0034). Intimal 
inflammation was minimal in all groups. Re-endothelialization was near complete (>90%) 
with the exception of PC1/Sirolimus stents, where cell coverage was significantly less 
(70.0±20.2, p<0.0001). The degree of endothelialization may be influenced by drug-release 
kinetics. In-vitro liberation of sirolimus from moderate release PC1/Sirolimus eluting 
stents at 3, 14 and 28-days was 48.6±3%, 55.9±2.2%, and 64.0±4.1%, respectively while 
for slow release PC2/Sirolimus eluting stents, elution rates were 1.6±0.5%, 3.7±0.6%, 
and 5.9±0.7%.
Conclusion: Sirolimus eluted from biodegradable polymer-coatings significantly reduced 
neointimal growth in 28-day iliac stents without promoting inflammation. These preliminary 
results demonstrate the potential clinical value of electro-grafting eG™ technology in 
stent-based drug delivery. Further studies are necessary to determine the influence of 
drug-release kinetics on luminal re-endothelialization and to assess the long-term effects 
of sirolimus-elution with biodegradable polymers.
Noon
912-212 Renal Frame Count Can Identify The Good Responder 
Of Stent Placement In Patients With Atherosclerotic 
Renal Artery Stenosis Which Induced Renal 
Dysfunction
Masanori shiba, Masato Nakamura, Masaki Hori, Makoto Utsunomiya, Naohiko Nemoto, 
Shingo Ito, Hirotaka Komatsu, Masamichi Wada, Rintaro Nakajima, Hisao Hara, 
Kazuyuki Ishii, Yoshinori Nagashima, Kaoru Sugi, Takuro Takagi, Toho university ohashi 
medical center, tokyo, Japan
Background: There is considerable need and interest to identify who will get benefit 
from revascularization in patient with atherosclerotic renal artery stenosis(ARAS) which 
induced renal dysfunction. Recent data suggest that renal frame count (RFC) using renal 
angiogram demonstrate the renal perfusion status. We evaluated results of renal artery 
stent placement by quantitative angiography and RFC. And we investigated the ability of 
RFC to identify the good responder of this therapy.
Methods: A total of 33 patients with renal dysfunction (serum creatinine >1.3mg/dl) 
due to ARAS (angiographically >70% stenosis by visual estimation) who underwent 
stent placement without restenosis were evaluated. We divided it into the two groups by 
reaction to this treatment, and we compared it. Patients who has improved or stabilized 
the serum creatinine value categorize good responder group. Renal frame count (RFC) 
was measured immediately after procedure as previously described.
Results: Good responder group has lower RFC number immediately after stent 
placement. In multivariate analysis, RFC numbers are independent predictor for good 
response of this therapy (odds ratio, 0.88; 95%CI, 0.77-0.99; P=0.04).
Conclusions: RFC is independent predictor for identifying the good responder of renal 
artery stent placement. Well-perfused kidney could contribute to preservation of renal 
function. Lower frame count number is better.
good 
responder(n=26)
poor 
responder(=7) P value
Diabetes mellitus 11.5% 28.5% NS
congestive heart failure 42.3% 28.5% NS
resistive index>0.8 38.5% 28.5% NS
Pre-procedural serum creatinine(mg/
dl) 2.58±1.7 2.28±0.9 NS
Pre % diameter stenosis 62.7±10 % 57.7±4% NS
Post %diameter stenosis 11.8±10% 7.6±5% NS
Post RFC (n) 24.6±7.1 32.7±9.3 0.02
Amount of contrast media(ml) 155±61 121±46 NS
serum creatinine at 6month later 
(mg/dl) 1.56±0.6 2.97±1.9 0.003
Noon
912-213 Quantitative Analysis of Vulnerable Plaque Color Using 
LCH Color Space
Yasunori Ueda, Nobuyuki Ogasawara, Jota Oyabu, Katsuki Okada, Kazunori 
Kashiwase, Atsushi Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan
Background: Although yellow plaque is regarded vulnerable, the evaluation of plaque 
color has been subjective. Therefore, we have analyzed quantitatively the characteristics 
of yellow color that is regarded a sign of vulnerable plaques.
Methods: Color of yellow plaques was quantitatively analyzed using LCH color space 
and was presented by the maximum values of lightness (Lmax), chroma (Cmax), and 
hue (Hmax). Effect of light intensity on these parameters was experimentally examined 
(5 plaque models, 6 light intensities). Relation between conventional yellow color grade 
and LCH parameters was examined (31 plaques). Color analysis with LCH color space 
was applied 1) to compare the culprit lesions of unstable angina (8 patients) and of stable 
effort angina (9 patients), and 2) to evaluate the regression of yellow plaque by 80-weeks 
statin treatment (4 patients, 19 plaques).
Results: Cmax and Hmax were not influenced by light intensity so far as it was within 
appropriate range. Cmax (13±3, 25±5, and 28±4) became higher and Hmax (178±26, 
134±10, and 91±16) became lower as the grade became higher (p<0.0001). Culprit 
lesions of unstable angina had higher Cmax (22.8±7.9 vs. 14.8±7.5, p=0.04) and lower 
Hmax (73.3±19.7 vs. 168.0±71.5, p=0.002) than stable effort angina. Statin treatment 
reduced Cmax (21.3±9.6 vs. 14.6±3.1, p=0.004) and increased Hmax (82.6±25.8 vs. 
142.3±54.1, p=0.0005).
Conclusions: Plaque color was consistently and quantitatively measurable using LCH 
color space uninfluenced by light intensity of appropriate range. Vulnerable yellow color 
had high chroma and low hue, indicating vivid and reddish yellow color.
Noon
912-214 Coronary Stent Assessability by 64 Slice Multi-Detector 
Computed Tomography
Tej Sheth, Jonathan Dodd, Alok Finn, Herman Gold, Ricardo C. Cury, Massachusetts 
General Hospital, Boston, MA
Background: We evaluated the assessability of contemporary stent platforms by 64-
slice MDCT.
Methods: Patients undergoing coronary stenting were included in a prospective protocol 
of MDCT imaging within 48 hours of stent implantation. MDCT data were acquired using a 
`Sensation 64` MDCT scanner (Siemens Medical Solutions, Forchheim, Germany). Stent 
assessability was assessed by two independent blinded observers and disagreement 
was resolved by a third observer. Assessability was defined at visualization of the in-stent 
lumen without influence of partial volume effects, beam hardening, motion, calcification, 
or contrast to noise limitations.
Results: 54 stents (Cypher n=25, Vision/Minivision n=19, Taxus Express n=8, Liberte 
n=1, Driver n=1) in 44 patients were included in the study. The two independent observers 
classified 30 of 54 stents (56%) as assessable without any degree of artifact. Interobserver 
reproducibility was high with kappa =0.66. Stent size was the most important determinant 
of assessability. Consistently assessable stents were 3.0 mm or larger, whereas those 
under 3 mm were mostly non-assessable (see figure).
Conclusions: Contemporary stent designs evaluated on a 64-slice MDCT scanner 
showed artifact free assessability only in larger stents. Increase in spatial resolution or 
modifications in stent design will be necessary in order to evaluate stents less than 3 mm 
in diameter, where in-stent restenosis is more frequent. 
26B    ABSTRACTS - Innovation in Intervention: i2 Summit 2007  JACC  March 6, 2007
In
no
va
ti
on
 in
 I
nt
er
ve
nt
io
n:
 i2
 S
um
m
it
 2
0
0
7
Noon
912-215 Polymorphisms of Interleukin-1 Genes and Neointimal 
Proliferation After Percutaneous Coronary Intervention
Andrejs Erglis, Sanda Jegere, Inga Narbute, Gustavs Latkovskis, Normunds Licis, 
Latvian Centre of Cardiology, Riga, Latvia
Objectives. Polymorphisms in genes coding for inflammatory cytokines have been 
investigated as markers of increased cardiovascular risk. Some studies have shown the 
association between polymorphisms in the genes of the Interleukin-1 and single-vessel 
coronary artery disease as well as the development of restenosis after percutaneous 
coronary intervention (PCI). The purpose of our study was to assess the role of Interleukin-
1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) genes polymorphisms in promotion 
of neointimal proliferation after PCI.
Methods. We analysed DNA polymorphisms within IL-1 genes cluster: IL-1B (-511), IL-1B 
(+3954) and IL-1RN variable number tandem repeat (VNTR) in 135 patients undergoing 
intravascular ultrasound (IVUS) guided PCI. Clinical, angiographic and IVUS follow-up 
was performed at 6 months. We compared combined heterozygous and homozygous 
carriers of the allele T with homozygous carriers of the allele C in IL-1B (-511), IL-1B 
(+3954) and heterozygous and homozygous carriers of the allele 2 with homozygous 
carriers of the allele 1 in IL-1RN (VNTR).
Results. There were no statistically significant differences in restenosis rate, target lumen 
revascularization (TLR) and target vessel revascularization (TVR) between carriers and 
non-carriers of allele T in IL-1B (-511), IL-1B (+3954) and allele 2 in IL-1RN (VNTR) at 
follow-up. But IVUS data showed that minimum lumen diameter (MLD) late lumen loss 
was 0.47±0.31 mm in non-carriers of the allele 2 in IL-1RN (VNTR) and 0.34±0.32 mm 
in carriers, p=0.02, but minimal square area (MSA) late lumen loss was 2.00±1.46 vs. 
1.51±1.19 mm respectively, p=0.04. No significant differences were noticed in IL-1B (-
511), IL-1B (+3954).
Conclusions. Allele 2 of IL-1RN (VNTR) polymorphism was associated with significant 
lower stented segment late loss in MLD and MSA at 6 months. This finding supports the 
hypothesis that genetic programming of the inflammatory response may be relevant to 
the pathogenesis of restenosis.
Noon
912-216 The Impact of Multivessel Disease on Long-term 
Mortality in Patients with ST-segment Elevation 
Myocardial Infarction with Cardiogenic Shock Treated 
with PCI
René J. van der Schaaf, Krischan D. Sjauw, Marije M. Vis, Karel T. Koch, Jan Baan, 
Jr., Jan G.P. Tijssen, Robbert J. de Winter, Jan J. Piek, José P.S. Henriques, Academic 
Medical Centre, Amsterdam, The Netherlands
Background: In acute ST-segment elevation myocardial infarction (STEMI), patients with 
multivessel disease (MVD) are considered to be a subgroup with an increased risk of 
mortality compared with patients with single vessel disease (SVD). We demonstrated that 
the impact of MVD on mortality in STEMI patients is mainly determined by the presence 
of a chronic total occlusion (CTO). However, the impact of MVD and or CTO on one-year 
mortality in patients with STEMI and cardiogenic shock (CS) is unclear.
Methods: From 1997 through March 2005, 292 consecutive STEMI CS patients were 
treated with primary percutaneous coronary intervention (PCI). The same vessels (size 
and location) applied for definition of CTO or MVD. Multivessel disease was present in 161 
patients (55%) and a CTO was present in 69 patients (24%).
Results: Mortality in patients with SVD, MVD and a CTO was 31%, 52% and 62% 
respectively. After correction for age>60, left ventricular function<40%, TIMI 3 flow after 
PCI and infarct location, MVD was an independent predictor of mortality (OR 2.03; 
95%CI: 1.05 - 3,95). However, when CTO was included in the model, MVD was no longer 
an independent predictor for mortality (OR 1.32; 95CI: 0.61 - 2.85), whereas CTO was a 
stronger and independent predictor for one-year mortality in STEMI patients treated with 
PCI (OR 2.43; 95CI: 1.11 - 5.34).
Conclusions: STEMI CS patients with MVD have a higher one-year mortality rate 
compared with patients with SVD. However, the impact on mortality is mainly determined 
by the presence of a CTO in a non-infarct related artery. Also, in STEMI patients with CS, 
even in the setting of primary PCI the presence of a CTO, and not the mere presence of 
MVD, is an independent predictor of mortality.
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913-209 Statin Pre-treatment Prevents Contrast-induced 
Nephropathy and Improves Long-term Outcome 
in Patients Undergoing Percutaneous Coronary 
Intervention: Results of the ARMYDA-RENAL study
Annunziata Nusca, Giuseppe Patti, George W. Vetrovec, Vincenzo Pasceri, Massimo 
Chello, Andrea D’Ambrosio, Germano Di Sciascio, Department of Cardiovascular 
Sciences, Campus Bio-Medico University, Rome, Italy, Cardiology Division, Virginia 
Commonwealth University, Richmond, VA
Background: Contrast-induced nephropathy (CIN) is an important cause of mortality and 
morbidity in patients undergoing cardiac angiography. Aim of this study was to investigate 
whether statins reduce the incidence of contrast-induced nephropathy (CIN) in the setting 
of percutaneous coronary intervention (PCI) and to evaluate the influence of such therapy 
on long-term clinical outcome.
Methods: A total of 434 patients undergoing PCI were prospectively enrolled and followed 
at least 4 years after the procedure. Patients were stratified according to pre-procedural 
statin therapy (260 statin-treated and 174 without statins). Blood samples were drawn 
before and 24 hours after PCI for detection of serum creatinine and other hematological 
parameters. CIN was defined as a post-procedural increase in serum creatinine of ≥0.5 
mg/dL or >25% from baseline. Follow-up assessment included the 4-year occurrence of 
major adverse cardiac events (MACE).
Results: Statin-treated patients had a significantly lower incidence of CIN (3% vs. 27% 
in patients without statins; P<0.0001), corresponding to a 90% risk reduction (Odds ratio 
0.10, 95% CI 0.02-0.18; P=0.0001), and had higher post-procedural creatinine clearance 
(80±25 vs. 65±19 mL/min; P<0.0001). Benefit of pre-treatment with statins was observed 
in all subgroups, except in patients with pre-existing renal failure (OR 0.42, 0.1-2.8; 
P=0.37). During follow-up statin therapy was independently associated with lower risk 
of MACE, and CIN was a predictor of poorer outcome; 4-year event-free survival was 
highest in patients statin-treated and no CIN (95%, P≤0.015) and lowest in those without 
statins and CIN (53%, P≤0.018).
Conclusions: Patients treated with statin therapy prior to percutaneous coronary 
intervention have a significantly lower incidence of contrast-induced nephropathy; 
importantly, this protective effect translates into a better long-term cardiac event-free 
survival. These data may support routine utilization of statins as adjuvant pharmacological 
therapy before percutaneous coronary revascularization.
1:00 p.m.
913-210 Long-term (one Year) Follow-up After Treatment of 
Drug-eluting Stent Restenosis (DES-ISR) with Repeat 
DES: To SWITCH or Not To SWITCH?
Emilia Solinas, Ajay J. Kirtane, George Dangas, Eugenia Nikolsky, Tereza Pucelikova, 
Alexandra J. Lansky, Theresa Franklin-Bond, Paul Boland, George Syros, Koichi Sano, 
Satya Atmakuri, Kotaro Obunai, LeRoy Rabbani, Issam Moussa, Giora Weisz, Edward 
Kreps, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, Roxana Mehran, Columbia 
University Medical Center, Cardiovascular Research Foundation, New York, NY
Background: Although the incidence of in-stent restenosis (ISR) after drug eluting stent 
(DES) implantation is markedly diminished compared to bare metal stents, when DES-
ISR occurs, whether repeat DES is safe and effective (and which DES to use) has not 
been established.
Methods and Results: We identified 182 DES ISR lesions in 151 consecutive pts since 
September 2004. After exclusion of multiple ISR lesions treated with multiple strategies, 
and those treated with balloon alone, 117 DES ISR lesions in 101 pts remained and were 
grouped according to original stent type: sirolimus-ISR (SES-ISR, n=86) or paclitaxel-ISR 
(PES-ISR, n=31) and DES-ISR treatment using the alternative DES (SWITCH, n=76) or 
the same DES (no-SWITCH, n=41). Baseline clinical and angiographic features were 
well matched between SES-ISR and PES-ISR except that pts with PES-ISR had more 
frequently renal failure and congestive heart failure. At mean follow-up of 13 months, 
available in 83% of pts (n=82 pts, 97 lesions), clinical recurrence in the entire population 
was 3.1% (0/35 for DES-ISR lesions treated with SES vs. 3/62 for DES-ISR lesions 
treated with PES, p= 0.30). Pts treated with the SWITCH strategy had decreased TLR 
compared to the no-SWITCH strategy (0/61 vs. 3/36, p=0.04) (see table).
Conclusions: Treatment of DES-ISR with repeat DES is safe and results in excellent 1 
year outcomes. Implantation of a different DES type (SWITCH Strategy) may result in 
more favorable outcomes compared to using the same DES which failed originally. 
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SWITCH NO SWITCH
SES-PES + PES-SES
N=65 pts, 76 lesions
SES-SES + PES-PES
N= 36 pts, 41 lesions P
Diffuse Pattern of ISR, % 18.7 14.6 0.79
13 months events (cumulative)
Cardiac death, % 2.0 0.0 1.00
Myocardial infarction, % 0.0 3.2 0.37
Major adverse cardiac events, % 2.0 6.5 0.55
Target lesion revascularization, % 0.0 8.3 0.04
Stent thrombosis, % 0.0 2.8 0.37
1:00 p.m.
913-211 Treatment Of Side Branch Plaque Shift In Coronary 
Bifurcation Lesions With Balloon Cryoangioplasty
Ravikanth Chiravuri, Mehul R. Bhatt, Kenneth Zelnick, Urwa Barakat, Alexandre C. 
Ferreira, Stewart Levine, Alan Schob, Veteran’s Administration Medical Center, Miami, 
FL
Background: Cryoangioplasty has been shown to prevent restenosis in lower extremity 
atherosclerotic lesions by reducing smooth muscle proliferation and extracellular matrix 
synthesis. Percutaneous coronary revascularization of coronary bifurcation lesions 
remains a challenge due to plaque shift into small side vessels after stenting to the main 
vessel. Here, we report on the outcome of cryoangioplasty for the treatment of side 
branches after plaque shift from main vessel percutaneous intervention.
Methods: Eleven male veterans (age=60.6 ± 8.6 years) with complex bifurcation lesions 
who had plaque shift into a side branch after main vessel intervention with drug eluting 
stent(s) in the main vessel were treated with cryoangioplasty (2.5-mm PolarCath™, 
Boston Scientific Corp., Natick, MA) in the side branch vessel. Post-plaque shift and post-
cryoangioplasty quantitative coronary analysis were conducted. Patients were followed 
for major adverse cardiac events (MACE).
Results: Bifurcation lesions involved the left anterior descending/diagonal branch arteries 
in 55% of patients and the circumflex/obtuse marginal branch arteries in 45% of patients. 
The initial maximal luminal diameter (MaxLD) of the side branches was 1.5 ± 0.4 mm. 
The minimal luminal diameter (MinLD) of the side branch decreased significantly after 
plaque shift from main vessel angioplasty from 1.0 ± 0.3 mm to 0.6 ± 0.2 mm (p=0.0005). 
After cryoangioplasty the MinLD was increased significantly to 1.2 ± 0.3mm (p<0.0001). 
Plaque shift increased the initial side branch stenosis from 33 ± 7.3% to 67 ± 19% 
(p<0.0001). After cryotherapy side branch stenosis was not significantly different from the 
pre intervention value (31 ± 4.1%, p=0.19). Patients were followed for an average of 7.6 ± 
3.6 months. One patient had target vessel revascularization(TVR) with sustained patency 
at the cryoangioplasty site. None had angina or ischemia on nuclear perfusion study.
Conclusions: Cryoangioplasty is a novel treatment of stenosis of small side branches after 
plaque shifts in coronary bifurcation lesions. Small coronary side branch cryotherapy was 
technically successful in all patients, with low incidence of TVR at 7 month follow-up.
1:00 p.m.
913-212 CT Scan Versus EndoSure™ For Endoleak Detection 
After Endovascular Repair of Abdominal Aortic 
Aneurysm
Joaquin Solis, Daniel Hemsworth, Suresh Ramamurthy, Mohamed Djelmami-Hani, 
Fareed Shaikh, Ashok Kumar, Tanvir Bajwa, Aurora Sinai/St. Luke’s Medical Ctrs, Univ 
of Wisconsin School of Medicine and Public Health-MCC, Milwaukee, WI
Background: Endovascular repair (EVAR) is an alternative to open surgical repair for 
abdominal aortic aneurysm (AAA). Post-procedure follow up requires CT scan for early 
detection of endoleaks which may be deleterious in patients with renal impairment. We 
compared CT scan with the EndoSure™ Wireless AAA Pressure Measurement System 
(CardioMEMS, Inc, Atlanta, GA) in the detection of endoleaks.
Methods: We present our experience in 30 patients who underwent EVAR of AAA with 
implantation of EndoSure device. Pressure measurement was compared with angiogram 
immediately after procedure and with CT scan at one month.
Results: All 30 patients had successful EVAR of AAA. Average pulse pressure inside 
the aneurysm sac decreased from 64.6 to 29.5 (range 2 to 78) immediately after the 
procedure. Five endoleaks resulted in minimal pressure drop. Type I and III endoleaks, 
were repaired successfully resulting in decreased pressure. Type II endoleaks required no 
additional procedures. At follow up average pulse pressure was 19.25 (-7 to 24). Patients 
in whom the pressure decreased, CT scan showed no endoleak. Patients with elevated 
pressure had Type II leak (2 patients) or no leak (2 patients)
Conclusion: Non-invasive evaluation of sac pressure during EVAR of AAA is reliable for 
evaluating procedure success and predicting endoleaks at follow up. Correlation with CT 
scan in patients who had decrease pressure is 100%. This technique is useful in guiding 
additional therapy and decreasing the need for repeat angiograms or CTs. 
Table 1. (*NPV: negative predictive value)
No. pts 30
male 27 (91%)
co-morbidities
coronary artery disease
hypertension
peripheral vascular disease
cardiomyopathy
renal insufficiency
25 (83.3%)
25 (83.3%)
7 (23.3%)
5 (17%)
5 (17%)
Size of AAA 4.77 cm (3.5-6.5 cm)
Post procedure endoleak 5
Type I 2
Type II 2
Type III 1
One Month follow up 13
No endoleak by CT 11
No endoleak by Endosure 9
NPV* of Endosure 100%
1:00 p.m.
913-213 Vulnerable and Stable Lesion Characteristics Assessed 
by Optical Coherence Tomography (OCT), Integrated-
Backscatter IVUS (IB-IVUS), Angioscopy and 64-slice 
Multidetector CT (MDCT)
Yukio Ozaki, Masanori Okumura, Shino Kan, Masanori Kawasaki, Hiroyuki Naruse, 
Shigeru Matsui, Yasusi Anno, Tadashi Nakano, Makoto Ishikawa, Shigeru Kato, Takahisa 
Sato, Sadako Motoyama, Masayoshi Sarai, Shinya Hiramitsu, Junichi Ishii, Masanori 
Nomura, Kazuhiro Katada, Hitoshi Hishida, Division of Cardiology, Fujita Heath 
University Hospital, Toyoake, Japan, Division of Regulation and Advanced Medical 
Science, Gifu University Graduate School of Medicine, Gifu, Japan
Background: Pathological studies suggest that disruption of thin-cap (<65μm) 
fibroatheroma (TCFA) leads to acute coronary syndrome (ACS; i.e. vulnerable plaque). 
While OCT (LightLab Imaging, Westford, MA) offers a novel high-resolution image 
(10μm), integrated-backscatter intravascular ultrasound (IB-IVUS) would provide tissue 
characterization and 64-slice MDCT (Aquilion 64 system, Toshiba, Tokyo) could offer 
precise density profile of the plaque (Hounsfield-units; HU).
Methods: We prospectively performed 64-slice MDCT with a slice thickness of 0.5mm, 
OCT, IB-IVUS and angioscopy prior to coronary intervention (PCI) and follow-up in 65 
lesions (27; ACS lesions and 38; stable lesions) in 46 patients with ACS and SAP.
Results: No difference was found in age, gender and coronary risk factors between ACS 
and SAP. Cap thickness detected by OCT was significantly thinner in ACS than SAP. While 
IB-IVUS indicated greater lipid area in ACS than SAP, angioscopy revealed significantly 
higher incidence of the presence of thrombus or rupture. Plaque density provided by MDCT 
was significantly lower in ACS than SAP. While all patients were treated by drug-eluting stent 
(DES), target lesion revascularization (TLR) rate was similar between the two at 8 monhts.
Conclusions: While OCT, IB-IVUS, angioscopy and 64-slice MDCT could clearly 
differentiate vulnerable lesions from stable lesions, DES subsequently conveyed similar 
clinical outcome at 8-month follow-up.
Results
Vulnerable lesions (n=27) Stable lesions (n=38) p
OCT
cap thickness 40+/-15 274+/-150 <.0001
IB-IVUS
% lipid area 35+/-10 24+/-8 <.01
Angioscopy
thrombus or rupture 74% 21% <.0001
64-slice MDCT
plaque density (HU) 34+/-20 116+/-60 <.0001
TLR at 8 months 5.0% 3.5% ns
1:00 p.m.
913-214 Short- and Long-term Outcomes After Stent-assisted 
Percutaneous Treatment of Saphenous Vein Grafts with 
Drug-eluting Stents: Have We Made Any Progress?
Tereza Pucelikova, Ajay J. Kirtane, George Dangas, Eugenia Nikolsky, Emilia Solinas, 
Alexandra J. Lansky, Theresa Franklin-Bond, Paul Boland, Andy Morales, Masashi 
Kimura, Jiro Aoki, Young-Hak Kim, Matthew Williams, Abdi Agahtehrani, Issam Moussa, 
William Gray, Michael Collins, Edward Kreps, Giora Weisz, Susheel Kodali, Gregg W. 
Stone, Jeffrey W. Moses, Martin B. Leon, Roxana Mehran, Columbia University Medical 
Center, Cardiovascular Research Foundation, New York, NY
Background: Percutaneous treatment of saphenous vein grafts (SVGs) is associated 
with peri-procedural complications and higher incidence of restenosis. The safety and 
efficacy of DES in SVG PCI had not been established.
Methods and Results: From August 2004 to the December 2005, 116 SVGs (113 pts) 
were treated with DES (82.3% men, mean age 69.2±10.9 yr, 39.6% diabetics, 12.7% MI 
on admission, 21.6% restenotic lesions, mean graft age 11.5±6.2 yr). Cypher, Taxus, and 
bare metal stents were implanted in 62.9%, 31.9%, and 8.6% of grafts, respectively. At 
one year, 9.2% had required target lesion revascularization, however, the overall major 
adverse cardiac events were high (41.5%), driven mostly by death or MI, especially in 
patients with treated with longer (>40mm) stent lengths (see table).
Conclusion: Even with usage of DES and EPD, treatment of saphenous vein grafts is 
associated with unfavorable outcomes, especially when the grafts are treated with long 
and/or multiple stents.
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All
n=113
Total stent length 
< 40mm
n=85
Total stent length > 
40mm
n=27
P 
value
30-days follow-up
*Major adverse cardiac 
event 15.0% 11.7% 27.3% 0.077
Death 2.0% 2.6% 0.0% NS
Myocardial infarction 14.1% 10.4% 27.3% 0.048
Target vessel 
revascularization 0.0% 0.0% 0.0% -
1-year follow-up
*Major adverse cardiac 
event 41.5% 36.5% 61.5% 0.102
Death 10.8% 7.7% 23.1% 0.110
Myocardial infarction 20.0% 17.3% 30.8% 0.278
Target lesion 
revascularization 9.2% 7.7% 15.4% NS
Target vessel 
revascularization 23.1% 21.2% 30.8% NS
*MACE was defined as death, MI, and/or target vessel revascularization
1:00 p.m.
913-215 Non Polymer Elution Of Biolimus From A Stent Inhibits 
Intimal Hyperplasia In A Porcine Model
Saibal Kar, Vladimir Royter, Gordon Grant, John Shulze, Douglas Savage, Michael C. 
Fishbein, Cedars Sinai Medical Center, Los Angeles, CA, University of California, Los 
Angeles, Los Angeles, CA
Background: Recent data suggest that even though first generation drug eluting stents 
reduce restenosis, there is a slight increase in late stent thrombosis and concurrent 
mortality, Persistent polymer and/or drug may be causal. Local delivery of a Biolimus 
A9 (B), an engineered rapamycin derivative from a specially designed porous stent not 
coated with Polymer can inhibit hyperplasia.
Methods: We compared a specially designed porous metal BioMatrix III Stent containing 
225 µg of B versus Bare metal BioFlex II (C). Seven C and 4 B stents were deployed in 
the coronary arteries of 4 farm swine. All animals were sacrificed at 1 month. Endpoints 
were assessed by quantitative coronary angiography, histomorphometry and histology. 
Histology assessment of each of the stented segments were analyzed by an experienced 
cardiovascular pathologist who was blinded to the groups.
Results. There was a 57% reduction of area stenosis of B versus C. There was complete 
endothelialization in both groups, with a slight increase in fibrin in the drug group. There 
was no significant medial or initimal inflammation in either group.
Conclusions. BiolimusA9 delivered from a non polymer coated porous metal stent inhibits 
intimal hyperplasia in a porcine model. There is normal healing of treated arteries at 28 
days and no inflammation as compared to controls. Long term animal studies are ongoing 
to confirm the safety and efficacy of this novel non polymer coated drug eluting stent.
. 
1:00 p.m.
913-216 The Impact of an Acute Percutaneous Coronary 
Intervention on Survival Rates for Women With and 
Without Diabetes Admitted to a Community Hospital 
With Acute Myocardial Infarction
Aaron D. Kugelmass, Allan Anderson, Lynn G. Tarkington, Margaret Lanham, Steven 
D. Culler, April W. Simon, Henry Ford Healthcare System, Detroit, MI, HCA CCMN, 
Nashville, TN
Background: Women who sustain acute myocardial infarction (AMI) have worse risk-
adjusted outcomes than men, however, the basis for this is poorly understood. This study 
investigates whether acute PCI in the setting of AMI is beneficial for women.
Methods: A retrospective analysis was conducted using the HCA Casemix Database, an 
administrative database of consecutive patients admitted to any HCA hospital. The study 
population includes 26,667 women admitted with a primary diagnosis of AMI in one of 
112 hospitals that perform PCI and annually treat more than 52 AMI patients between 
1/1/2004 and 6/30/2006. An acute PCI was defined as having a PCI on the same day as 
their hospital admission. A logistic regression equation (controlling for 24 demographic 
characteristics and co-morbidities) was estimated to evaluate the survival impact of an 
acute PCI for women with and without diabetes. The reference group was non-diabetic 
women not undergoing an acute PCI for AMI.
Results: The average survival rate was 91.6%. Primary ST-Elevation MI (STEMI) 
represented 34.2% (9,113) of the sample and 65.8% (15,613) had non-STEMI (NSTEMI). 
Acute PCI was performed on 26.4% (7,045) of the women, and 35.3% (9,409) were 
diabetic. The table indicates that women who undergo acute PCI (non-diabetic OR 2.46x 
and diabetic OR 1.84x) have significantly improved hospital survival.
Conclusion: This study demonstrates that acute PCI confers a survival benefit in both 
diabetic and non-diabetic women with AMI.
Impact of Acute PCI on In-Hospital Survival in Women With a Primary 
Diagnosis of AMI
Study Variable Odds Ratio p-Value
Non-Diabetic, Acute PCI 2.46x p<0.001
Diabetic, Acute PCI 1.84x p<0.001
Diabetic, No Acute PCI 1.07x p=0.619
Non-Diabetic, No Acute PCI Reference Group
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914-209 Initial Experience and Efficacy of the Retrograde 
Approach Technique for Chronic Total Occlusions
Hiroyuki Tanaka, Kazuaki Mitsudo, Tsuyoshi Goto, Kazushige Kadota, Harumi Kato, 
Hiroyuki Yamamoto, Yasushi Fuku, Shingo Hosogi, Akitoshi Hirono, Junpei Maekawa, 
Sachiko Maekawa, Seiji Habara, Daiji Hasegawa, Yukinobu Nakamura, Tsuyoshi 
Miyaji, Chinatsu Yamada, Youji Okamoto, Suguru Ohtsuru, Kurashiki Central Hospital, 
Kurashiki, Japan
Background: Our hypothesis was that chronic total occlusions (CTO) lesions with good 
collateral circulation supply should be reached by the guidewire via the collateral artery 
retrogradely. We evaluate the safety and efficacy of the retrograde approach technique 
which is a new CTO recanalization method.
Methods: The procedures of the retrograde approach were as follows. First, the retrograde 
guidewire reached the distal point of the occluded segment. If possible, it penetrated and 
advanced into the occluded lumen. Then, a channeling by balloon dilatation was created 
retrogradely.
Results: Between October 2005 and August 2006, 55 patients with 57 CTO lesions 
(20 LAD, 6 LCx, 30 RCA, and 1 left main) underwent the retrograde approach at our 
institution. Baseline lesion characteristics were calcification (38.6%), moderate to severe 
tortuousity (14.0%), length >20mm (52.6%), abrupt morphology (38.6%), and bridging 
collateral (40.4%). The intercoronary collaterals used for the retrograde approach were 
septal in 32 lesions, epicardial in 20, and bypass graft with stenosis in 5. The retrograde 
guidewire reached the distal point of the occluded segment in 37 lesions, of which 
we created a channeling (Group A, n=15), and we used the retrograde guidewire as 
a landmark for antegrade wiring (Group B, n=22). In the other lesions, the retrograde 
guidewire did not reach the target vessel because of exessive tortuousity and impassably 
tightness of collateral circulation, then we performed the antegrade approach (Group 
C, n=20). The procedural success rate was 93.3%, 68.2%, and 45.0% for Group A, B, 
and C, respectively (Group A vs. C, p=0.003, B vs. C, p=0.130). There were 2 cases of 
extravasation by balloon inflation of septal connection, and 1 case of Q-wave myocardial 
infarction of the collateral vessel occlusion.
Conclusions: This technique appears a promising approach for cases, in which the 
retrograde guidewire reached the distal point of the occluded segment. If a balloon 
dilatation of the occluded segment retrogradely is possible, it is especially an effective 
method in treating CTO lesions. The retrograde approach technique was safe and feasible 
percutaneous coronary intervention for CTO.
2:00 p.m.
914-210 SPIRIT II Study: A Clinical Evaluation of the XIENCE 
V Everolimus Eluting Coronary Stent System in the 
Treatment of Patients with de novo Native Coronary 
Artery Lesions.
Peter Ruygrok, Auckland City Hospital, Auckland, New Zealand
Background: SPIRIT FIRST results demonstrated continued safety of the XIENCE V 
Everolimus Eluting Coronary Stent in a limited number of patients.
Methods: The purpose of the SPIRIT II study is a continuation in the assessment of the 
safety and performance of the XIENCE V Everolimus Eluting Coronary Stent System in 
the treatment of patients with a maximum of 2 de novo native coronary artery lesions (from 
2.5 mm to 4.25 mm in diameter and ≤ 28 mm in length). In this study, the XIENCE V stent 
is compared (non-inferiority) to the TAXUS® Paclitaxel-Eluting Coronary Stent System. 
The primary endpoint is in-stent late loss at 180 days. The secondary analyses include 
comparisons between the two groups, for measures including acute success, in-segment 
late loss, proximal and distal late loss, in-stent percentage volume obstruction, in-stent 
and in-segment percentage diameter stenosis and angiographic binary restenosis at 180 
days and 2 years. Ischemia Driven Major Adverse Cardiac Events (MACE) are assessed 
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through to 2 years.
Results: Three hundred patients were randomised in the proportion of 3:1 (XIENCE V: 
TAXUS®) at 28 sites in Europe, New Zealand and India.
The in-stent late loss for the analysis lesions was 0.11 mm for the XIENCE V versus 
0.36 mm for the TAXUS® arm. For all lesions the in-stent late loss was 0.12 mm versus 
0.37 mm for the XIENCE V and the TAXUS® respectively. In the XIENCE V group the 
in-stent diameter stenosis was 16%, the in-stent binary restenosis 1.3%, the neointimal 
volume 3.8 mm and the % volume obstruction was 2.5%. In the TAXUS® group the in-
stent diameter stenosis was 21%, the in-stent binary restenosis 3.5%, the neointimal 
volume 14.4 mm and the % volume obstruction was 7.4 %.
Conclusions: Based on the protocol design and statistics, XIENCE V showed non-
inferiority (primary endpoint) and superiority to TAXUS® in terms of late loss. Additionally, 
at 6 months a low MACE and stent thrombosis rate were observed. The one-year clinical 
results will be presented at ACC.
2:00 p.m.
914-211 Preliminary Experience of the MACH 2 trial: Safety 
and Feasibility of Left Ventricular Support with the 
Impella LP 2.5 device in patients with acute ST-segment 
Elevation Myocardial Infarction
Krischan D. Sjauw, Maurice Remmelink, Jan Baan, Jr., René J. van der Schaaf, Marije 
M. Vis, Karel T. Koch, Jan G.P. Tijssen, Robbert J. de Winter, Jan J. Piek, José P.S. 
Henriques, Academic Medical Centre, Amsterdam, The Netherlands
Background: Unloading the left ventricle may in addition to reperfusion therapy reduce 
mortality in STEMI patients, particularly in cardiogenic shock (CS) patients. Hypothetically 
it gives the myocardium time to recuperate from ischemic stunning, which is especially 
important with a large ischemic area at risk. The Impella LP 2.5 device is a percutaneous 
implantable left ventricular assist device capable of unloading the left ventricle. Before 
initiation of a trial in CS patients the safety and feasibility of Impella support should be 
determined in haemodynamical less ill patients.
Methods:  The study concerns a single centre non-randomized controlled open trial. 20 
consecutive patients with large anterior STEMI were immediately post-PCI alternately 
assigned to either 3 days support with the Impella or to no support (or IABP on a intention 
to treat basis). Co-primary endpoints are safety and feasibility of Impella support, and left 
ventricular recovery at 4 months follow-up.
Results: The Impella group constituted a sicker group; It scored higher on conventional 
risk factors, admission hsCRP, NTproBNP and Peak CK-MB. All patients underwent 
successful primary PCI. Placement of the Impella pump was successful in all cases; The 
device did not induce or increase aortic valve regurgitation. There were no device related 
adverse events during left ventricular support with the Impella.
The median assist time in the Impella supported patients was 71 hours and 43 minutes. 
3 control group patients received IABP therapy. Mean hemoglobin drop was respectively 
3.3 ± 0.7 and 1.8 ± 0.7 mmol/l in the Impella and control group; the number of packet cells 
needed was respectively 1.2 ± 2.2 and 0.2 ± 0.6. Free haemoglobin levels, a measure of 
hemolysis, showed a peak in the first 24 hours and a subsequent normalization during 
further Impella support.
Conclusions: The findings, concerning the safety and feasibility of Impella support in the 
setting of STEMI are encouraging. An important point of concern is bleeding, which in our 
experience can be controlled by a tight aPTT scheme.
Conclusions about the more pathophysiological endpoint of left ventricular recovery will 
follow; NT-proBNP, echo and MRI data are under evaluation.
2:00 p.m.
914-212 True Lumen Re-Entry Catheter Availability Improves 
Procedural Success in Endovascular Intervention of 
Peripheral Chronic Total Occlusions
John A. Riddick, Caroline J. Cates, Khusrow Niazi, Christopher U. Cates, Emory 
University, Atlanta, GA
Background: Inability to re-access the true lumen is the most common cause of failure 
during percutaneous transluminal angioplasty (PTA) of long chronic total occlusions 
(CTO). We examined the relationship between the availability of the Pioneer catheter, an 
IVUS-guided re-entry catheter, and procedural success.
Methods: 52 consecutive cases of PTA to a lower extremity CTO were identified. 25 
cases (2001-03) were performed prior to Pioneer availability while 27 cases (2004-
06) were performed with Pioneer availability. In all cases initial attempts were made to 
cross the lesion with a guidewire and support catheter. Adjunctive devices (i.e. laser or 
blunt microdissection catheter vs. Pioneer) were used only after wiring failure. Lesion 
characteristics were evaluated with QCA and calcium was scored visually.
Results: Procedural success was higher with Pioneer availability (100% vs. 76%; p<.009) 
while the mean number of adjunctive devices used per case was lower. Pioneer-available 
cases tended to be longer lesions with significantly more calcium. Significantly less 
contrast volume was required in Pioneer cases. Complications were similar in both groups 
and there were no cases of death, limb loss, or emergency surgery. Long term outcomes 
favored Pioneer-available cases but were not statistically different.
Discussion: Availability of the Pioneer catheter allows for more aggressive wiring with 
higher true lumen re-entry and improved procedural success compared to standard CTO 
techniques alone. 
Pioneer Catheter 
Available Cases 
(n=27)
Pioneer Catheter 
Unavailable Cases 
(n=25)
P-value
Procedural Success,n (%) 27 (100) 19 (76) .009
Pioneer Catheter Used,n (%) 9 (33) 0 N/A
Laser or Blunt Microdissection 
Catheter Used,n (%) 0 14 (56) N/A
Mean Number of Adjunctive 
Devices per Case (+/- SE) 0.33 +/- 0.09 0.84 +/- 0.21 .025
Femoropopliteal Cases,n (%) 20 (74) 12 (48) .087
Iliac Cases,n (%) 7 (26) 13 (52) .087
Claudication as Indication,n (%) 23 (85) 20 (80) 0.722
Mean Occlusion Length, mm 
(+/- SE) 91.3 +/- 12.9 75.3 +/- 13.2 0.39
Calcium Score (+/- SE) 1.6 +/- 0.16 1.0 +/- 0.16 0.019
Mean Stented Length,mm 
(+/- SE) 148.8 +/- 17.4 67.0 +/- 14.2 .001
Fluoroscopy Time, min (+/-SE) 37.5 +/- 5.2 42.0 +/- 4.7 0.529
Contrast Volume, cc (+/- SE) 231 +/- 14.3 327.5 +/- 22.4 .001
Procedure-Related 
Complications,n (%) 3 (11) 3 (12) 1.00
Symptom Improvement Post-
Procedure,n (%) 13/16 (81) 11/16 (69) 0.685
Anatomic Primary Patency at 
1-year mean Follow-up,n (%) 9/14 (64) 4/9 (44) 0.417
2:00 p.m.
914-213 Characterization of the Intravascular Ultrasound 
Radiofrequency Signal within Regions of Acoustic 
Shadowing Behind Calcium
Kaoru Tanaka, Stephane G. Carlier, Amin Katouzian, Gary S. Mintz, Cardiovascular 
Research Foundation and Columbia University, New York, NY
Background: Acoustic shadowing limits grey-scale intravascular ultrasound (IVUS) plaque 
assessment behind calcium (Ca). VH (Virtual Histology) IVUS derives plaque composition 
from spectral analysis of radiofrequency (RF) signal. However, the effect of Ca and 
acoustic shadowing on the RF signal and VH analysis has not been reported.
Methods: 20 lesions with a significant dense Ca (arc>90°) imaged at 20 MHz were 
analyzed. ROIs behind Ca were traced, and the corresponding RF signals were compared 
to the noise signal far behind a perfect reflector (tip of guiding)
Results: RF signals had high amplitude (>1000, arbitrary units) for the brightest Ca echoes. 
Noise amplitude was ~10. More than 80% of the ROIs within the acoustic shadowing 
demonstrated a signal of very low amplitude; however, a coherent periodic pattern 
between successive scan lines and a slight signal increase in the region of adventitia 
indicated that these ROIs contained not only noise, but also reflected ultrasound waves. 
(Figure) However, the possibility of secondary echoes and reverberation against the 
calcium could not be excluded. In 20% of the ROIs, there was only noise, without any 
coherent pattern, coded as fibrofatty tissue (light green) by VH.
Conclusion: Although there are coherent RF signals within zones of acoustic shadowing, 
these are low amplitude signals close to the noise level. Therefore, the accuracy and 
specificity of the VH plaque characterization algorithm in these regions requires further 
specific histological validation 
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914-214 Randomized Evaluation of the Effect of Thrombus 
Aspiration by two different Thrombectomy devices on 
Myocardial Blush during Primary PCI.
Gennaro Sardella, Massimo Mancone, Riccardo Colantonio, Giulia Conti, Angelo Di 
Roma, Francesco Fedele, Dept.of Cardiovascular Sciences-Policlinico Umberto I, 
Rome, Italy
Background:In STEMI pts impairment of microcirculatory function is a negative 
independent predictor of myocardial function recovery. Compared with conventional 
stenting pretreatment with thrombectomy during primary PCI improves the parameters 
of myocardial tissue perfusion reducing the incidence of left ventricular remodeling at 6 
months.In the present single-center, prospective randomized study we sought to evaluate 
the safety and efficacy of two different manual thrombectomy devices (Diver-Invatec® 
and Export-Medtronic®) in STEMI patients undergoing to primary angioplasty.
Methods:We randomized 103 pts (mean age 64.3±10.2 85 male) referred to our Hospital 
with a STEMI in order to undergo primary PCI (<9 hours from symptoms onset), to Invatec 
(n=52) (I) and Export (n=51) (E) devices. The primary end points of the study were the 
comparison of TIMI ≥ II post thrombectomy, thrombus score (TS) ≤ 1, MBG ≥ 2 and ST-
segment resolution (STr)≥ 70% post-stenting, between patients randomized to I or to 
E.Secondary end points were peak of creatine kinase-MB and direct stenting.
Results: No differences on baseline,clinical and angiographic preprocedural findings 
were observed between the two groups. Presence of an intracoronary thrombus at 
basal angiography was observed in all pts. (Pre-thrombectomy TS 3.57±0.66 (I) vs. 
3.60±0.72 (I) p=ns). At baseline TIMI 0 flow was found in 71.1%(I) vs 82.3%(E), and 
TIMI 1 in 29.9%(I) vs 17.7%(E) (p=ns). After trombectomy, we observed a TIMI II flow 
in 38.6%(I) vs 19.6% (E) (p=0.054) and TIMI III was 30.7 (I) vs 72.5% (E) (p<0.0001). 
Patients treated with E had a highly significant reduction in the culprit artery thrombus 
burden (1.27±0.82 E vs 2.15±0.75 I ) ( p<0.0001). The patients enrolled in E group had a 
significantly higher incidence of TS 1 post thrombectomy (49.01%(25) E vs 13.5%(7) (I) 
(p<0.001). No difference was observed between two groups in postprocedural MBG and 
STr.No difference were observed in the secondary endpoints.
Conclusions: The procedural and clinical final result is identical but a pretreatment 
with the Export provides greater epicardial flow in STEMI patients, suggesting that this 
thrombectomy device could remove more thrombotic burden.
2:00 p.m.
914-215 A Prospective Randomized Antiplatelet Trial Of 
Cilostazol Versus Clopidogrel In Patients With 
Diabetic Patients Who Underwent Drug Eluting Stent 
Implantation
Youngkeun Ahn, Myung Ho Jeong, Tae Hoon Ahn, Chang-Gyu Park, Jong Hyn Kim, 
In-Ho Chae, Seung Ho Hur, Jang Ho Bae, Seok Kyu Oh, Chonnam National University 
Hopsital, Gwangju, South Korea
Background: Previous studies have shown that cilostazol not only prevent subacute 
stent thrombosis, but also habe positive effect in the prevention of restenosis in bare 
stent. However, the effect of cilostazol on restenosis after successful deployment of drug-
eluting stent (DES) in patients with diabetes mellitus was not evaluated. The prospective 
randomized trial was designed for this purpose.
Methods: A total of 320 patients at 8 clinical sites were included. The patients who 
underwent successful stenting were randomized to aspirin (100 mg/day) and cilostazol 
(200 mg/day) (group I, n=160, 60.1±9.8 years old) vs. aspirin and clopidogrel (75mg/
day) (group II, n=160, 62.8±9.8 years old) after one month of aspirin, cilostazol, and 
clopidogrel combination treatment.
Results: Baseline patient characteristics were not different between the groups. The type 
of DES implanted was ot different between the groups. There were no differences in 
angiographic and procedural characteristics between the groups. Acute (within 24 hours) 
and subacute (from 24 hours to 30 days) stent thrombosis were not observed. Late stent 
(>30 days) thrombosis by angiographic evidence were observed in two patients in both 
groups. There were no differences in bleeding, myocardial infarction, rehospitalization, 
or death between the groups during 1-year follow-up time. The follow-up quantitative 
coronary angiography (mean time = 6.7±1.2 months) was performed in 154 patients 
until now. The angiographic in-stent restenosis occurred in 5.3% of patients in cilostazol 
group and in 13.3% of patients in clopidogrel group (p=0.03). Follow-up minimum lumen 
diameter were 2.84±0.56 mm in cilostazol group and 2.68±0.61 mm in clopidogrel group 
(p=NS). Late lumen loss were 0.32±0.18 mm in cilostazol group and 0.37±0.31 mm in 
clopidogrel group (p=NS)
Conclusions: Our results demonstrated that the effects of combination therapy with 
aspirin and cilostazol for the prevention of restenosis were comparable or superior to 
those of aspirin and clopidogrel.
2:00 p.m.
914-216 Rescue Angioplasty after Failed Fibrinolysis for Acute 
Myocardial Infarction: Predictors of a Failed Procedure 
and One Year Mortality
Babu Kunadian, Andrew R. Thornley, Kunadian Vijayalakshmi, Joel Dunning, Andrew 
GC Sutton, Douglas F. Muir, Robert A. Wright, James A. Hall, Mark A. de Belder, The 
James Cook University Hospital, Middlesbrough, United Kingdom
Background: Rescue angioplasty (rPCI) for failed fibrinolysis is associated with a low 
mortality if successful, but a high mortality if it fails. The latter may reflect a high-risk group 
or harm in some patients. Predictors of success or failure of rPCI may aid selection of 
patients to be treated.
Methods: Unselected patients referred for rPCI from March 1994 to March 2005 were 
studied to determine the predictors of a failed procedure and 1yr mortality.
Results: Of 440 pts undergoing emergency coronary angiography for failed fibrinolysis 
(1yr mortality 18%), 101 had TIMI flow grade (TFG) 3 in the infarct related vessel 
(IRV). rPCI was attempted in 318/339 patients with <TFG 3 flow but not in 21 patients 
(angiography produced TFG 3 [n = 7] or unsuitable anatomy [n = 14]). Of the rPCI cohort, 
77% had a successful procedure (no in-lab death or emergency CABG and TFG 3 in the 
IRV); rPCI failed in 23%. 1yr mortality rates for successful and failed rPCI were 14% and 
43% respectively. Patients with failed rPCI were older and more likely to be diabetic, have 
anterior MI, be inter-hospital transfers, be in cardiogenic shock and less likely to be a 
current smoker. Shock was the only independent predictor of failed rPCI. Age group >75 
yrs, shock and final TFG < 3 were independent predictors of 1yr mortality.
Conclusions: Cardiogenic shock is an independent predictor of a failed rPCI. Age group 
> 75 yrs and shock were the only independent clinical predictors of 1yr mortality. These 
variables may help select patients for a strategy of rPCI. 
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915-209 The CROSSER Chronic Total Occlusion Recanalization 
System: Multi-center U.S. and European Study Results
Richard R. Heuser, David T. Cragun, Phoenix Heart Center for the U.S. FACTOR Study 
and E.U. CROSSER Study Investigators, Phoenix, AZ
Background: Chronic total occlusions (CTO’s) remain a technical and clinical challenge 
to the interventionalist. The CROSSER-14 catheter (FlowCardia, Inc., Sunnyvale, CA) 
(1mm OD, 6F compatible) is advanced over any conventional 0.014” guidewire where the 
stainless steel catheter tip then delivers vibrational energy at 20,000 cycles per second to 
mechanically recanalize the CTO allowing for guidewire passage.
Methods: 201 patients with guidewire-refractory CTO’s were enrolled in separate U.S. 
FACTOR Pivotal (n=125) and the European CROSSER Post-Feasibility (n=76) multi-
center, prospective studies to assess the safety and efficacy of the CROSSER CTO 
Recanalization System. Primary endpoints were successful CTO recanalization and 
MACE.
Results: US and European combined technical success (guidewire access into true 
lumen distal to CTO) was obtained in 62.2% of wire refractory CTO’s (23% LAD, 23% 
LCX, 53% RCA) with overall procedural success (CTO recanalization followed by stenting 
and TIMI 2/3 flow) of 58.2%. The average CTO length was 19.8 mm (3-50 mm) and the 
average CTO age was 26 months. There were no deaths or clinical perforations in the 
worldwide post-feasibility patient set (n=201). There was an 8.8% rate of MACE including 
a 1.6% incidence of urgent coronary bypass surgery, 4.8% elective bypass surgery, and 
4.0% non-Q wave myocardial infarction.
Conclusions: In these combined studies, the CROSSER CTO recanalization system 
was successfully used to recanalize 62% of conventional guidewire-refractory CTO’s 
without significant procedural complications. The CROSSER CTO recanalization system 
appears to be a safe and clinically effective technology to support percutaneous coronary 
intervention of CTO’s.
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915-210 Angiographic Presentation of Stent Thrombosis in the 
Drug-Eluting Stent Era
Gregory Mishkel, Anna Moore, Christopher Slater, Marc Shelton, Prairie Heart Institute, 
Springfield, IL, Prairie Education & Research Cooperative, Springfield, IL
Background: Whether or not implantation of drug eluting stents (DES) is associated with 
an increased incidence of stent thrombosis (ST) compared to bare metal stents (BMS) 
remains to be proven. We sought to evaluate the clinical presentation and outcomes of 
ST at our institution in the DES era.
Methods: We retrospectively identified all patients who received a DES at our single 
center tertiary care center between 5/1/03 - 7/1/06. Clinical follow-up is routinely collected 
at 6 months, 1 year and annually thereafter. Time to ST was categorized as acute (AST; 
<24 hrs), subacute (SST; 24 hrs - 30 days), late (LST; 1-6 months) or very late (VLST; 
>6 months).
Results: During our study period, a total of 10848 (10056 DES, 792 BMS) stents were 
implanted in 5801 patients (10113 lesions). DES distribution was 81% sirolimus and 
19% paclitaxel. A total of 351 deaths were recorded in follow-up. 41 patients (42 lesions) 
presented to the cath lab with ST. Prior to discharge, ST adverse events included: 4 
deaths, 1 peri-procedural MI, 1 acute renal failure and 1 vascular bleed. 
Description of ST Events
AST
(n=5)
SST
(n=17)
LST
(n=5)
VLST
(n=14)
Baseline 
characteristics,
n (%)
*stent type unknown in 2 VLST patients.
Male gender 4 (80.0) 10 (58.8) 4 (80.0)
10 
(71.4)
Current or former smoker 4 (80.0) 12 (70.6) 4 (80.0)
11 
(78.6)
STEMI presentation 5 (100.0)
12 
(70.6) 2 (40.0)
10 
(71.4)
Lesion in graft 3 (60.0) 1 (5.9) 0 0
Sirolimus ST* 2 (40.0) 10 (58.8) 2 (40.0) 9 (64.3)
Paclitaxel ST* 1 (20.0) 6 (35.3) 2 (40.0) 1 (7.1)
BMS ST* 2 (40.0) 1 (5.9) 1 (20.0) 2 (14.3)
Discontinued anti-platelet 
meds 0 0
5 
(100.0) 9 (64.3)
In-hospital adverse 
events,
n (%)
In-hospital death 1 (20.0) 2 (11.8) 1 (20.0) 0
Conclusions: From a cath lab perspective, ST occurs in <1% of DES patients. 
Furthermore, VLST may also occur in BMS and not all ST are associated with STEMI. 
Late thrombotic events were proportionately distributed between sirolimus and paclitaxel. 
Discontinuation of antiplatelet meds is prevalent in the LST/VLST groups. Because 
this type of analysis underestimates the true ST incidence, data will be included at 
presentation regarding deaths recorded in follow-up.
3:00 p.m.
915-211 A Novel Noninvasive Digital Arterial Pulse Wave 
Analysis During a Deep Breathing Exercise as an 
Indicator of Coronary Artery Disease
David Brosh, Amos Katz, Ronen Arbel, Yoram Tal, Dan Greenberg, Ran Kornowski, 
Rabin Medical Center, Petach Tikva, Israel
Background: Previous studies have shown that fluctuations in pulse wave amplitude 
(PWA) may predict coronary artery disease (CAD). Recently, we introduced a noninvasive 
parameter, respiratory modulation response (RMR), derived from spectral analysis 
of PWA, during controled breathing at 0.1Hz. We evaluated RMR as an indicator of 
significant CAD. 
Methods: RMR was calculated as respiratory peak area divided by total peak area of the 
pulse wave spectrum. RMR results of 124 consecutive pts (mean age 63±12 years, 81% 
male) referred for coronary angiography were compared with their angiography results. 
Patients undergoing PCI or CABG were classified as having significant CAD. RMR was 
analyzed after baseline 20 secs spontaneous breathing, followed by 70 secs of guided 
breathing at 0.1Hz. The test was repeated post procedure in 93 pts. 
Results: RMR was significantly lower in pts with significant CAD (n=85) vs. pts with 
nonsignificant CAD (n=39) (18±20 vs. 39±16, P<0.001). The improvement in post 
procedure RMR was significantly higher in pts undergoing successful PCI compared 
to pts undergoing diagnostic catheterization only (25± 24vs. 0±18, P<0.001). RMR was 
lowest at the subgroup of pts with recent MI (0±1 vs. 27± 21, P<0.001). By using a receiver 
operating characteristic analysis, we identified an RMR<30% (sensitivity 0.75, specificity 
0.85) to be the optimal cutoff value for predicting significant CAD.
Conclusions: The RMR is a novel noninvasive parameter for the physiologic assessment 
of significant CAD. 
3:00 p.m.
915-212 Morphology of the Stent Fracture Influences the 
Outcome Following Superficial Femoral Artery Stenting
Osamu Iida, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Tetsuya 
Watanabe, Masaki Awata, Toshinari Onishi, Fusako Sera, Hitoshi Minamiguchi, 
Hirokuni Akahori, Masamichi Yano, Hiroki Yasui, Seiki Nagata, Kansai Rosai Hospital, 
Amagasaki, Japan
[Background] Although stent fracture affects long-term patency in the superficial femoral 
artery (SFA), whether the morphology of stent fracture influences long-term patency is 
unknown.
[Methods] To clarify if stent fracture morphology in the SFA influences long term patency 
in patients who underwent SFA stenting with a nitinol stent (Luminexx, Bard), we studied 
consecutive 70 patients who underwent rescue stenting in the SFA and gave consent to 
receive follow-up arteriography (10.6±6.6 months). Stent fracture was diagnosed by X-ray 
with multiple projections. The morphology of the stent fracture was classified based on the 
Cardiovascular Institute of the South Nitinol Stent Fracture classification system: single 
strut fracture (I); multiple strut fracture (II); complete transverse linear separation without 
stent displacement (III); complete transverse linear separation with stent displacement 
(IV). Long term patency was determined angiographically at follow-up.
[Results] Stent fracture occurred in 39% lesions (27/70). Angiographic restenosis rate at 
follow-up was 36% (25/70). Type II revealed the worst restenosis rate (I= 27%, 3/11; II= 
73%, 8/11; III= 33%, 2/6; None = 29%, 12/42, P=0.04). The follow up periods were not 
different between the groups.
[Conclusion] Stent fracture morphology, in particular, the multiple strut fracture affects the 
long-term patency following SFA stent implantation.
3:00 p.m.
915-213 Coronary Plaque Composition and Creatine Kinase MB 
Fraction Enzyme Level after Percutaneous Coronary 
Stenting: A Virtual Histology Intravascular Ultrasound 
Analysis
Myeong-Ki Hong, Cheol Whan Lee, Duk-Woo Park, In-Hyun Jung, Sang Hyun Kim, 
Hyuk Ko, Kyoung-Ha Park, Seung-Whan Lee, Young-Hak Kim, Jae-Joong Kim, Seong-
Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Using Virtual Histology (VH) intravascular ultrasound (IVUS), we evaluated the 
relationship between coronary plaque composition and creatine kinase MB fraction 
(CK-MB) enzyme level after percutaneous coronary intervention (PCI). Pre-intervention 
VH-IVUS study was performed in 80 patients who underwent PCI (stent length < 30 
mm) for single de novo lesion during hospitalization periods. Patients with acute or 
recent myocardial infarction were excluded in this study. In qualitative VH-IVUS analysis, 
atheromatous plaque composition were characterized into 4 types; fibrotic, fibrofatty, 
dense calcium, and necrotic core. Quantitative VH-IVUS analysis of area and volumetric 
measurements were performed at segment with minimal lumen area. Elevation of CK-MB 
enzyme level above normal cut-off values (< 5 ng/ml) occurred in 4 patients (5%) after 
PCI. In univariable linear regression analysis, absolute amounts of plaque and necrotic 
core area and volume, and external elastic membrane area are associated with post-PCI 
CK-MB enzyme level. Multivariable linear regression analysis indicated that larger area 
of necrotic core component was the only independent predictor of CK-MB enzyme level 
after PCI (r=0.371, 95% CI= 0.546 to 1.957 and p=0.001, Figure 1). Conclusion: Post-
PCI CK-MB enzyme level may be associated with the lesions with larger area of necrotic 
core at segments with minimal lumen area by VH-IVUS analysis.
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915-214 One-Year Results of Combined Embolic Protection and 
Thrombectomy in Percutaneous Coronary Intervention 
of Acute Myocardial Infarction Using the Proxis®-
device.
J. D. Haeck, K. T. Koch, J. P. Henriques, A. C. Van der Wal, R. J. Van der Schaaf, J. 
G. Tijssen, G. Sutsch, R. J. De Winter, Academic Medical Center, Amsterdam, The 
Netherlands
Background: Distal embolization may occur during recanalization of thrombotic coronary 
occlusion, leading to poor results during PCI. The Proxis® device (St. Jude Medical, St. 
Paul, Minnesota), a novel proximal embolic protection system that completely blocks 
antegrade flow during PCI, may prevent this complication and thus improve outcome.
Methods: Between February 2004 and October 2005, 174 patients with STEMI underwent 
primary PCI with combined embolic protection and thrombectomy. The Proxis® device 
consists of a short flexible catheter attached to a hypertube- cathetershaft, with a short 
circumferential balloon at the distal tip. This 8 or 7 French guiding catheter compatible 
device was advanced just proximal of the occlusion and the balloon at the tip of the 
Proxis® was inflated. The wire-crossing of the occlusion and balloon dilatation/stenting 
was carried out under total proximal blockage of the vessel. After withdrawal of dilatation/ 
stent-balloons, aspiration of the stagnant column was performed and continued when 
coronary flow was restored during deflation of Proxis®. Temporary proximal vessel 
occlusions and aspirations were repeated during PCI. Procedural success and 
angiographic recovery parameters (TIMI and MBG), ST- segment elevation resolution 
(STRES) and the retrieved embolic material were analysed. Follow-up of MACCE was 
collected until 1 year after PCI.
Results: The Proxis® device was used in all 174 patients during primary PCI. 96% of 
patients had TIMI-3 flow; 3% had TIMI-2 flow, 1% had TIMI-1 flow and MBG 2-3 was 
present in 97% of patients. The mean immediate STRES was 61.7% ± 24; immediate 
STRES > 50% was in 75% and > 70% in 43% of patients. The mean STRES at 1 hour was 
75.3% ± 19; STRES > 50% in 91% and > 70% in 68% of patients. Debris was retrieved 
from 77% of patients. The 30-day, 6-months and 1-year cumulative MACCE- rate was 4, 
9.1 and 10.3%.
Conclusions: The Proxis® is feasible and safe in the setting of primary PCI. The results 
suggest that this device is effective for aspiration of embolic material during PCI. Moreover, 
angiographic and myocardial recovery with Proxis® are excellent. Randomized trials are 
needed to prove whether these observations can be reproduced on a larger scale.
3:00 p.m.
915-215 Three-year Outcome Of Intracoronary Stand-alone 
Bolus Administration Of Eptifibatide During Coronary 
Intervention
Walid Hassan, Hani Al-Sergani, Jehad Al Buraiki, Nathem Akhras, Fayez ELShaer, 
Fawaz Al Turki, Suliman Kharabsheh, Mohamed Fawzy, King Faisal Specialist Hospital 
and Research Canter, Riyadh, Saudi Arabia
Background: There is no present data available considering giving eptifibatide during 
percutaneous coronary intervention (PCI) as intracoronary (IC) bolus alone. This study 
evaluated the 3-year results of IC eptifibatide administration during PCI.
Methods: Clinical outcomes of 376 patients who received stents + eptifibatide by 3 different 
routes during PCI and were followed up for over 36 months. Group A (119 patients) had IC 
eptifibatide bolus only; group B (119 patients) had IC bolus and continuous IV infusion and 
group C (138 patients) had IV bolus and continuous IV infusion. The standard systemic 
bolus doses of eptifibatide 180 micg /kg was given either via IC or IV route and only 
groups B and C received continuous IV infusion at 2 micg /kg/min for 18-24 hours.
Results: Patients, procedural characteristics and outcomes are shown (Table). The 6, 12, 
36-month cumulative TVR was lower in group A (6.7, 11.7, 12.5%) compared to group 
B (9.2, 14.2, 15 %) and group C (17.4, 30.4, 34 %) P = 0.018 as well as the composite 
endpoint of death or MI (2.5, 5.8, 10.1) P = 0.015. The frequency of major, minor bleeding 
and rehospitalization was significantly lower in-group A (2.4, 5.8, 10.9%) compared to 
group B (7.5, 11.7, 16.8%) and group C (9.5, 17, 28%) P ‹ 0.005. 
A (119 pts) B (119 Pts) C (138 Pts) P Value
Diabetes 53% 50% 49% 0.156
ACS/unstable angina 40% 43% 39% 0.956
Clopidogrel 94% 96% 95% 0.839
Thrombus 27% 20% 26% 0.360
DES 32% 40% 37% 0.394
TIMI III 98% 91% 91% 0.037 *
Subacute Thrombosis 0% 2% 2.40% 0.292
Six- month MI/Death 2.50% 5.8% 9.40% 0.015 *
TVR 6.70% 9.20% 17.40% 0.018 *
Rehospit 10.90% 16.80% 28% 0.0009 *
Minor Bleed 5.80% 11.7% 17% 0.018 *
12- month TVR 5% 5% 13% 0.022 *
36-month TVR 0.80% 0.80% 3.60% 0.012 *
Conclusion: The IC bolus alone route of eptifibatide may be safer and superior to the IV 
route and continuous infusion may not be necessary. Large-scale prospective randomized 
trials are needed to validate these findings.
3:00 p.m.
915-216 Intravascular Ultrasound Assessment of Impaired 
Myocardial Perfusion After Stent Implantation in 
Patients With ST-segment Elevation Myocardial 
Infarction
Kenichi Fujii, Motomaru Masutani, Takahiro Okumura, Tsuyoshi Sakoda, Tohru 
Masuyama, Mitsumasa Ohyanagi, Hyogo College of Medicine, Nishinomiya, Japan
Background: Several studies have reported that inadequate tissue perfusion after primary 
angioplasty in patients with ST-elevation myocardial infarction (STEMI) is associated with 
adverse cardiac events. We assessed the impact of intravascular ultrasound (IVUS) 
findings on ST-segment resolution (STR) after primary angioplasty in STEMI.
Methods: We analyzed consecutive 125 patients with a first STEMI who underwent 
successful revascularization with pre- and post-intervention IVUS. Maximum ST-segment 
elevation was measured before and 60 minutes after revascularization. Patients were 
divided into 2 groups according to the degree of STR: complete (≥50%) or incomplete 
(<50%). Qualitative and quantitative IVUS analyses were performed using standard 
methods. Deep ultrasound attenuation (UA) was IVUS finding with backward signal 
attenuation>120° behind plaque without dense calcium. Percent stent expansion was 
calculated as minimum stent / reference lumen area.
Results: Ninety-one patients had complete STR and 34 had incomplete STR. The 
incidence of in-hospital heart failure was higher in incomplete STR patients than in 
complete STR patients (p=0.01). IVUS data was shown in the Table. Multivariate analysis 
showed that only presence of UA predicted incomplete STR (p<0.001).
Conclusions: The presence of UA, plaque burden, and stent overexpansion in STEMI 
patients are related to higher incidence of impaired myocardial perfusion after primary 
angioplasty that leads to in-hospital heart failure.
Incomplete ST-segment 
resolution(n=34)
Complete ST-segment 
resolution(n=91)
P 
value
Vessel area (mm2) 16.8 ± 5.6 16.2 ± 5.6 0.6
Plaque burden (%) 88.5 ± 4.2 86.7 ± 4.7 0.04
Remodeling index 1.10 ± 0.31 1.03 ± 0.24 0.2
Lesion length 
(mm) 25.0 ± 9.7 23.7 ± 10.4 0.5
% stent expansion 
(%) 92.8 ± 19.6 82.3 ± 18.4 0.006
Presence of UA 
(%) 59 12
Presence of 
calcium (%) 35 55 0.1
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916-209 Impact of Glycoprotein IIb/IIIa Inhibitors on Outcomes 
of Diabetic Patients Undergoing Percutaneous 
Coronary Interventions with Sirolimus-Eluting Stents
Eugenia Nikolsky, David R. Holmes, Roxana Mehran, George Dangas, Erick 
Schampaert, Marie-Claude Morice, Joachim Schofer, J. Eduardo Sousa, Dennis 
Donohoe, Jeffrey W. Moses, Martin B. Leon, Columbia University Medical Center, New 
York, NY, The Cardiovascular Research Foundation, New York, NY
Background: There has been ongoing debate whether glycoprotein (GP) IIb/IIIa inhibitors 
improve prognosis of patients with diabetes mellitus treated with percutaneous coronary 
intervention (PCI). We assessed the outcomes in diabetic patients undergoing PCI using 
sirolimus-eluting stents (SES) as a function of treatment with GP IIb/IIIa inhibitors.
Methods and Results: Of 551 diabetic patients treated with a SES in 9 trials (RAVEL, 
SIRIUS, E-SIRIUS, C-SIRIUS, REALITY, SVELTE, DIRECT, SIRIUS 2.25, and SIRIUS 
4.0), 187 patients (33.9%) were administered GP IIb/IIIa inhibitors during PCI. In the entire 
cohort, GP IIb/IIIa blockade was associated with lower rates of myocardial infarction (MI) 
at 30 days (1.1% vs. 3.3%, P=0.12) and 1 year (1.1% vs. 4.7%, P=0.04) and composite 
endpoint of cardiac death/MI at 1 year (2.2% vs. 6.2%, P=0.05). Benefit from GP IIb/IIIa 
inhibitors was confined to 128 insulin-treated diabetics who had remarkable reduction 
in MI and cardiac death/MI at 1-year (Figure). There were no significant differences in 
outcomes as a function of GP IIb/IIIa blockade in diabetics not treated with insulin. 
Conclusion: In this analysis, 1-year outcomes of insulin-requiring diabetic patients 
undergoing PCI with SES were considerably improved with adjunctive GP IIb/IIIa inhibitors 
by decreasing the rates of MI and composite endpoint of cardiac death/MI. 
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916-210 Are Drug-Eluting Stents Superior to Bare Metal Stents 
in Large Coronary Arteries?
Daniel H. Steinberg, Sandeep Mishra, Tina L. Pinto Slottow, Aamir Javaid, Probal 
Roy, Ashesh N. Buch, Teruo Okabe, Kimberly A. Smith, Natalie Gevorkian, Rebecca 
Torguson, Zhenyi Xue, Kenneth M. Kent, William O. Suddath, Lowell F. Satler, Augusto 
D. Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: The benefit of drug-eluting stents (DES) over bare metal stents (BMS) 
is driven primarily by restenosis, especially in high-risk patients and those with small 
(<3.0mm) coronary vessels; however, they are associated with increased cost and the 
need for prolonged antiplatelet therapy. This study aimed to investigate whether DES 
remain advantageous in large coronary vessels (>3.5mm).
Methods: 233 patients undergoing single vessel percutaneous coronary intervention 
(PCI) in vessels >3.5mm with DES were compared to 233 propensity-matched patients 
with similarly sized vessels undergoing PCI with BMS. Patients were followed for up to 
1-year with respect to major adverse cardiovascular events (MACE): Death, myocardial 
infarction, and target lesion revascularization (TLR).
Results: Baseline characteristics of these groups were similar. At 1-year, overall cardiac 
events were low and comparable between the two groups. Overall MACE occurred in 
7.7% of BMS patients and 8.5% of DES patients (p=0.80). TLR occurred in 3.5% of BMS 
patients and 3.4% of DES patients (p=1.00). Death and Q-wave myocardial infarction 
occurred in 4.2% in the BMS patients and 5.7% in the DES patients (p=0.70). No subacute 
or late thrombosis occurred in either group. 
Conclusions: In patients with large coronary vessels (>3.5mm), BMS perform as well as 
DES regarding both clinical outcomes and TLR. As DES offer no advantage to BMS in this 
setting, BMS should be the treatment of choice for patients with large coronary vessels. 
4:00 p.m.
916-211 Initial Assessment of a Novel Anti-inflammatory 
Salicylic Acid-based Absorbable Polymer for Use in 
Fully Biodegradable Coronary Stents
Refat Jabara, Nicolas Chronos, Patrick Rivelli, Keith Robinson, SJRI / Saint Joseph’s 
Hospital, Atlanta, GA
Background: Permanent polymers have been shown to result in chronic inflammation and 
hypersensitivity reactions which may contribute to increased risk of late thrombosis and 
rebound restenosis. Optimal polymer selection and the use of erodible but biocompatible 
polymers are expected to minimize these risks.
Purpose: To assess the coronary artery compatibility of two novel variants of a potentially 
innately anti-inflammatory, salicylic acid-based bioabsorbable polymer, in a clinically 
relevant animal model.
Methods: Four different types of stents were implanted in pig coronary arteries using 
QCA to optimize stent apposition; bare metal stents (BMS), poly lactic acid stents (PLA),
salicylic acid/sebacic acid coated stents (SA/SA; sebacic acid as a linker molecule in the 
polymer), and salicylic acid/adipic acid coated stents (SA/AA; adipic acid as a linker). 
Both linkers are similar in structure and have been used in FDA-approved drug delivery 
products. In-vitro studies showed complete polymer degradation in 4-6 weeks. Animals 
were terminated at 3 days for flow cytometric analysis and at 1 month for histopathologic 
and histomorphometric study.
Results: There was no significant effect of stent type on inflammatory cell proportions 
in the vessel at three days post-implant by flow cytometric analysis. At 1 month, intimal 
thickness varied significantly according to stent type with the lowest level of 0.18mm±0.04 
for SA/AA group vs. 0.56mm±0.13 for SA/SA, 0.23mm±0.05 for BMS and 0.24mm±0.07 
for PLA groups respectively (one way ANOVA, P=0.032). Histological % stenosis was 
26%±4 for SA/AA vs. 50%±8 for SA/SA, 33%±5 for BMS and 35%±8 for PLA group 
respectively. The SA/AA group showed a mild inflammatory cell reaction similar to the 
BMS and PLA groups. 
Conclusion: This study showed favorable vascular compatibility for a novel salicylic 
acid/adipic acid biodegradable polymer as a coating for coronary artery stents. Ongoing 
research is directed towards inclusion of neointima-limiting drugs, further investigation of 
the potential innate anti-inflammatory nature of salicylic acid polymers, and development 
of completely bioabsorbable stents from this interesting class of polymer materials.
4:00 p.m.
916-212 Octogenarian Status Is An Independent Risk Factor For 
Adverse Outcomes After Carotid Stenting
Vivek Rajagopal, Samir R. Kapadia, Hitinder S. Gurm, Deepak L. Bhatt, Surabhi 
Madhwal, Alex Abou-Chebl, Juhana Karha, Mikael Mazighi, Matthews Chacko, Brian 
K. Jefferson, Christian Simpfendorfer, Chris Bajzer, Jay S. Yadav, Cleveland Clinic 
Foundation, Cleveland Heights, OH
Background: Octogenarians undergoing carotid stenting have more major adverse 
events after carotid stenting than younger patients. It is unclear if age alone or associated 
comorbitidies imparts this risk.
Methods: We evaluated 30-day outcomes of 915 patients who underwent carotid stenting 
between Feb 1998 and Aug 2005 at our institution, according to octogenarian status.
Results: This cohort contained 760 patients less than 80 years old, and 155 octogenarians. 
Octogenarians and younger patients did not differ in history of hypertension, stroke, renal 
insufficiency, congestive heart failure, or peripheral vascular disease. Octogenarians 
were more likely to have history of smoking, neck radiation, prior carotid endarterectomy, 
and restenosis after endarterectomy. Octogenarians received embolic protection 
devices (EPD) just as frequently as younger patients (83% vs. 82%, P=0.67). The 30-
day incidence of death, MI, or stroke was 11.0% for octogenarians compared to 5.0% 
for younger patients (P=0.004). Among patients treated with EPD, 30-day incidence of 
death, MI, or stroke was 8.7% for octogenarians compared to 3.3% for younger patients 
(P=0.011). After adjusting for differences in baseline characteristics and significant 
univariate predictors, octogenarian status was an independent predictor of outcomes (OR 
1.97, 95% CI 1.02 - 3.83, P=0.045)
Conclusion: Octogenarians have a higher incidence of major adverse events by 30 days, 
even with use of embolic protection devices, and octogenarian status is an independent 
predictor of major adverse events.
4:00 p.m.
916-213 Superficial Fibro-Fatty Area Detected By Virtual 
Histology IVUS Is Associated With Thrombus Detected 
By Angioscopy
Nobuyuki Ogasawara, Yasunori Ueda, Jota Oyabu, Katsuki Okada, Atsushi Hirayama, 
Kazuhisa Kodama, Osaka Police Hospital, Osaka, Japan
Background: Recently, Virtual Histology intravascular ultrasound (VH-IVUS) technology 
provides “virtual” histology information of vessel wall using backscattered radiofrequency 
(RF) signals. Although this technique has been validated by histology in ex-vivo study, 
limited information from in-vivo study is available. One of the most important limitations 
of VH-IVUS is inability to identify thrombus. Angioscopy is the most powerful tool for the 
detection of fresh thrombus in vivo. Therefore, we examined the characteristics of VH-
IVUS image of intracoronary thrombus detected by angioscopy.
Methods: Examination of 71 coronary segments both by angioscopy and VH-IVUS was 
performed in 21 patients (effort angina n=14, unstable angina n=3, acute myocardial 
infarction n=4). Segments were divided into two groups according to the presence (n=13) 
or absence (n=58) of thrombus. Characteristics of VH-IVUS image of those segments 
were determined as the %area of Fibrous (FI), Fibro-Fatty (FF), Dense-Calcified (DC), 
and Necrotic (NC) area. Superficial existence of FF, DC and NC was also determined.
Results: Prevalence of superficial FF area was significantly higher in the segments with 
thrombus than in those without thrombus (77% vs. 41% p=0.03). Prevalence of superficial 
NC and DC area was not different between the groups. %Area of FF, NC, DC and FI area 
was not different between the groups.
Conclusions: Thrombus detected by angioscopy was significantly associated with the 
presence of superficial FF area by VH-IVUS.
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916-214 Drug Eluting Stents in the Treatment of Saphenous Vein 
Graft Disease: Poor Outcome in Diffusely Diseased 
Grafts
Nicholas J. Ruggiero, II, Stuart Gould, Deborah DeEugenio, Heath Saltzman, Abhijit 
DasGupta, David L. Fischman, Paul Walinsky, J. David Ogilby, Michael Savage, Thomas 
Jefferson University Hospital, Philadelphia, PA
Background: Although drug eluting stents (DES) have been demonstrated to be superior 
to bare metal stents in native coronary vessels, there is a paucity of data defining the 
long term outcome of DES in saphenous vein grafts (SVG). The goal of this study was to 
evaluate the outcome of DES in diseased SVG.
Methods: 70 consecutive patients (75 SVG) treated with DES were evaluated. Procedural 
outcomes and major adverse cardiac events (MACE) were assessed at a mean follow-up 
of 17 +/- 9 months. MACE was defined as death, MI, stent thrombosis, or target vessel 
revascularization (TVR).
Results: The study population consisted of 61 men and 9 women with a mean age of 70 
+/- 8 years. 28 (40 %) patients had diabetes. 43 (61 %) patients had an acute coronary 
syndrome. Mean SVG age was 12 +/- 2 years. Diffuse disease (defined as > 30 mm of 
disease or > 3 lesions in 1 vessel) was present in 29 grafts (39 %). A total of 94 lesions 
were treated with 114 stents; 104 (91%) Cypher and 10 (9 %) Taxus. Total stent length was 
31 +/- 5 mm. Distal protection was utilized in 55% of interventions. PCI was successful in 
all patients, with no peri-procedural deaths, CABG or stent thrombosis. There was 1 acute 
non Q-wave MI (1.3%). At 1 year, actuarial TVR free survival was 84% in all patients. TVR 
free survival was 97% in focal disease versus 64% in diffuse disease (p <0.01). Freedom 
from any MACE is shown in the Figure.
Conclusions: In contrast to the excellent results achieved with focal SVG disease, the 
long-term outcome of PCI in diffuse SVG disease remains poor despite DES. 
4:00 p.m.
916-215 Optimal Platelet Inhibition in Patients undergoing 
PCI: Data from the Multicenter Registry of High-Risk 
Percutaneous Coronary Intervention and Adequate 
Platelet Inhibition (MR PCI) Study
H. M. Mardikar, M. S. Hiremath, David J. Moliterno, Rony Mathew, Rangolee Arora, 
Dhananjay Deo, J. S. Hiremath, Niteen V. Deshpande, Aziz Khan, Jacob Joseph, 
Debabrata Mukherjee, Spandan Heart Institute, Nagpur, India, University of Kentucky, 
Lexington, KY
Background: The primary objective was to test several antiplatelet regimens in elective 
high-risk PCI comparing different combinations of IV (GP IIb/IIIa inhibitors) and oral 
(thienopyridine loading) antiplatelet agents.
Methods: Patients were randomized to one of four groups: Group A: Tirofiban; 
Group B: Eptifibatide; Group C: Tirofiban+Clopidogrel 600-mg loading; and Group D: 
Eptifibatide+Clopidogrel 600-mg. All patients received a clopidogrel maintenance dose 
after PCI. Tirofiban was given as 25mcg/kg bolus + infusion 0.15mcg/kg/min for period 
of 6-8 hrs and eptifibatide as double bolus of 180-mcg/kg followed by 2-mcg/kg/min for 
a period of 6-8 hrs. The primary endpoint was degree of platelet inhibition at 6-8 hours 
using UltegraTM Verify Now Assay. Inhibition of platelet aggregation (IPA) was calculated 
as [(Aggregation at baseline - Aggregation at time t)/ Aggregation at baseline] X 100.
Results: Inhibition of platelet aggregation was significantly higher with high-dose Tirofiban 
compared to Eptifibatide at 10 minutes and at 6-8 hours (Table). A 600-mg loading dose of 
clopidogrel did not initially increase IPA with a trend towards higher IPA at 24 hours. There 
were no significant differences in in-hospital events among the different groups (p=0.55)
Conclusions: This is the first head-to-head study comparing high-dose tirofiban with 
double-bolus eptifibatide and demonstrates greater platelet inhibition with high-dose 
tirofiban. Clinical outcomes at 30-days are now being collected.
Inhibition of Platelet Aggregation (IPA) in the four Groups at 10-mins, 6-8 
hours and at 24 hours
Tirofiban Eptifibatide Tirofiban + 600 mg Clopidogrel
Eptifibatide + 600 
mg Clopidogrel P value
IPA-10 min 
(%)
95.7 ± 
5.2 89.4 ± 8.6 96.1 ± 6.5 92.9 ± 5.8 0.0037
IPA-6-8 
hours(%)
91.9 ± 
8.5
84.8 ± 
12.1 94.2 ± 6.4 86.1 ± 10.1 0.0002
IPA-24 
hours(%)
12.1 ± 
42.4
11.1 ± 
55.7 28.3 ± 28.6 31.1 ± 28.6 0.1134
4:00 p.m.
916-216 Does Diabetic Mellitus Predict a higher In-hospital 
Mortality Following Percutaneous Saphenous Vein 
Graft Intervention in the Setting of Acute Myocardial 
Infarction?
Shing-Chiu Wong, Robert Minutello, The New York Presbyterian Hospital - Cornell 
Campus, New York, NY
Background: Patients with diabetes mellitus (DM) have a higher incidence of peri-
procedural complications and worse clinical outcomes following percutaneous coronary 
interventions (PCI). Whether DM patients would have similarly worse clinical outcomes 
compared with non-DM patients post saphenous vein graft (SVG) PCI in the acute (<24-
hour) MI setting is unclear.
Methods: Using the New York State 2001-2002 combined PCI database, we examined the 
clinical characteristics and in-hospital procedural outcomes in patients undergoing SVG 
PCIs for acute MI. Renal insufficiency included pts with Cr >2.5mg/dL or on dialysis.
Results: See table (*PVD = peripheral vascular disease, #CVA = cerebral vascular 
accident). Patients with DM more frequently had peripheral disease, CHF on admission 
and renal insufficiency. In addition, diabetic patients had a higher incidence of mortality 
and CVA following PCI. Multivariate logistic regression reveals age, LVEF, PVD, 
cardiogenic shock, and renal insufficiency but NOT DM as independent predictors for 
in-hospital mortality.
Conclusions: DM Pts who underwent SVG PCI in acute MI setting had more frequent 
adverse clinical characteristics. There is a higher incidence of peri-procedural 
complications in DM than non-DM patients. Importantly, DM is not an independent 
predictor for in-hospital mortality following SVG PCI in acute MI.
Patient Characteristics Non-DM (N=192) DM (N=98) P value
Male (%)/Age (yrs)/Hypertension (%) 81.3/68/84.7 77.6/68/73.4 0.54/0.96/0.038
Smoker (%)/PVD* (%) 17.3/19.8 14.1/34.7 0.49/0.006
LVEF (%)/Cardiogenic Shock (%) 43/2.6 41/2.0 0.23/1.00
Multi-vessel disease (%) 93.8 90.8 0.35
CHF on admission (%) 14.6 30.6 0.002
Renal Insufficiency (%) 1.6 7.1 0.034
In-Hospital Complications
Death (%)/ CVA# (%) 3.6/0.5 11.2/4.1 0.018/0.046
Emergent CABG (%) 0.0 1.0 0.338
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917-209 New Value of Intraseptal Collateral for Percutaneous 
Coronary Intervention to Chronic Total Occlusion With 
Retrograde Approach
quanxiu zheng, Osamu Katoh, Mitsuyasu Terashima, Tetsuo Matsubara, Etsuo 
Tsuchikane, Yoshihisa Kinoshita, Kenya Nasu, Takahiko Suzuki, Toyohashi Heart Center, 
Toyohashi, Japan
Background: Despite of improvement in percutaneous coronary intervention(PCI). 
techniques and materials, chronic total occlusion (CTO) recanalization success rate is 
still suboptimal. Recently we have developed a new PCI technique for CTO lesions at 
the proximal to mid left anterior descending coronary artery (LAD) or the right coronary 
artery(RCA) ; controlled antegrade and retrograde subintimal tracking technique(CART 
technique). This technique requires intraseptal collateral as a retrograde approach 
channel. In the cases of CTO at the proximal to mid LAD or RCA, we evaluated the 
anatomy of intraseptal collateral, identified the feasible channel for retrograde approach, 
and examined the frequencies of such a feasible intraseptal collateral channel.
Methods: Angiographical retrospective investigation was performed in 515 patients with 
consecutive CTO lesions at proximal to mid LAD or RCA eligible for PCI. The condition of 
septal collateral was evaluated based on the following collateral connection (CC) grades: 
grade CC 0: no continuous connection, grade CC 1: threadlike continuous connection, 
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grade CC 2: side branch size connection. Septal collaterals of grade CC 1 and CC 2 
were divided into six types according to grade of tortuosity (mild, moderate and severe) 
and presence of side branches, respectively. Feasible intraseptal collateral for retrograde 
approach was defined as CC 1 or CC 2 with mild to moderate tortuosity and without 
branches.
Results: Seventy-six percent of proximal/middle LAD and RCA CTO had at least one 
collateral connection of grade CC 1 or CC 2. Of CC 1 connections, 81% had mild or 
moderate tortuosity, of which 66.7% had no branchs. Of CC 2 connections, 75% had mild 
or moderate tortuosity, of which 80% had no branchs. For all CTO lesions, 52.7% had at 
least one feasible intraseptal collateral channel for retrograde approach.
Conclusions: Although patterns of intraseptal collateral channel were various, more than 
half of CTO lesions at the proximal to mid LAD or RCA would be capable of retrograde 
approach through intraseptal collateral channels.
9:00 a.m.
917-210 Stent Strut Apposition of Cypher Select and Taxus 
Liberte: A Prospective Optical Coherence Tomography 
Study
Jun Tanigawa, Peter Barlis, Konstantinos Dimopoulos, Carlo Di Mario, Royal Brompton 
Hospital, London, United Kingdom
Background: Stent strut malapposition correlates with suboptimal intimal coverage 
after drug-eluting stent (DES) implantation and this may increase the risk of late stent 
thrombosis. The aim of this study was to assess the degree of strut apposition of the 2 
most commonly used DESs: Cypher Select and Taxus Liberte using Optical Coherence 
Tomography (OCT).
Methods: Twenty-one lesions in 18 patients immediately after implanting DESs (13 
Cypher and 8 Taxus) for complex lesions (type B: 15 and C: 6) were included (mean age 
65, 83% male). Distance of struts from the intima was assessed using OCT and adjusted 
for strut thickness of each stent type (160μm for Cypher and 130μm for Taxus). Strut 
apposition was defined as follows: embedded with more than half its thickness buried in 
the intima, protruding when apposed to the intima but not embedded and malapposed 
with no contact with the intima, and expressed as % of total struts examined.
Results: No significant differences were detected in demographic, lesion and procedural 
characteristics. Cypher Select stent struts were less likely to be embedded and more 
likely to be protruding or malapposed compared with Taxus Liberte stents (Figure).
Conclusions: The use of Taxus Liberte stent was associated with greater apposition 
compared with Cypher Select. Further studies are needed to confirm this finding and 
determine its potential relation to late thrombotic complications.
9:00 a.m.
917-211 Preclinical Safety Evaluation of a Novel Helical 
Rotational Thrombectomy Device
Adrian Fluture, Stuart L. Houser, Todd Wood, Kreg A. Howk, Quincey R. Simmons, 
Dennis Sauro, Dan Badway, Chad Smith, Gregory R. Giugliano, Baystate Medical 
Center / Tufts University School of Medicine, Springfield, MA
Background: Mechanical endovascular thrombectomy is effective for removing thrombus 
in multiple vascular beds, but coronary artery thrombectomy with current devices has 
been fraught with lengthy set-up time and potentially larger MIs. We evaluated the 
safety of a simple, hand-held, powerful, helical rotational (700mmHg, internalized cutter) 
thrombectomy device, the ThromCat™ (TC), in coronary arteries of healthy pigs.
Methods: Ten anesthetized pigs underwent coronary angiography via 7F guide. 
Thrombectomy runs (3 passes over 2 cm length) in 2 vessels per animal were performed 
using the TC (n=6) and the ev3 X-Sizer® (n=4) for comparison. Catheter dwell time within 
the vessel was measured. Half of the animals in each group were sacrificed after the 
procedure and half at 30 days. Macroscopic and histological examination of the hearts 
and coronary arteries were performed. Baseline and serial CBC, CKMB and troponin T 
were measured. Clincal hemorrhagic or cardiac complications were tracked.
Results: Online QCA parameters (vessel size, length, flow) were similar in both groups. 
At autopsy, no macroscopic or histological abnormalities were observed. There were no 
significant differences in bleeding, cardiac myonecrosis, or clinical events.
Conclusion: Thrombectomy using the TC in porcine coronary arteries appears safe 
and feasible without evidence of histologic or angiographic complications. This newer 
generation device may offer clinical advantages over other devices, particularly with ease 
of use 
Angiographic, Clinical and Histologic Data
X-Sizer
N = 4
ThromCat
N = 6 p-value
Dwell time/vessel mean + SD 51+ 15.1 sec 41+ 11.3 sec 0.24
Segments with endothelial lesions on microscopy, 
n (%) 0 (0) 0 (0) N/A
Vessels with final clinical TIMI-3 flow, n (%) 8 (100) 12 (100) N/A
Hb change post procedure (g/dl) mean + SD - 1.13 + 0.49 - 1.22 + 0.35 0.71
Hb change at 24 hours (g/dl) mean + SD + 0.4 + 0.14 + 0.7 + 0.49 0.53
Maximum CKMB change (U/l) mean + SD + 16.30 + 6.64
+ 22.80 + 
3.15 0.22
Maximum Troponin T (ng/ml) mean + SD 0.04 + 0.04 0.08 + 0.11 0.51
9:00 a.m.
917-212 Safety And Efficacy Of Carotid Artery Stenting In 
Patients With A History Of Neck Irradiation.
Brian K. Jefferson, Vivek Rajagopal, Samir R. Kapadia, Hitinder S. Gurm, Alex Abou-
Chebl, Mikhael Mazighi, Matthews Chacko, Christian Simpfendorfer, Edurado Infante de 
Oliveira, Deepak L. Bhatt, Chris Bajzer, Jay S. Yadav, Cleveland Clinic, Cleveland, OH, 
CardioMEMS, Atlanta, GA
Background: The incidence of significant carotid stenosis following head and neck 
irradiation ranges from 30% to 50%. Carotid endarterectomy (CEA) for radiation 
associated stenosis is often technically challenging and carries a high surgical risk. We 
sought to determine outcomes for carotid artery stenting (CAS) in patients with a prior 
history of neck irradiation (XRT).
Methods: We evaluated 30-day outcomes of 823 patients who underwent CAS between 
Feb 1998 and Aug 2005 at our institution, according to whether they had a history of prior 
neck irradiation.
Results: This cohort contained 62 patients with a history of XRT. Patients with a history 
of XRT were younger (67 vs. 71 p=0.008) and less likely to have diabetes mellitus, 
known coronary artery disease, history of myocardial infarction (MI) or percutaneous 
intervention, hypertension, and hypercholesterolemia. Patients with XRT were less likely 
to have the use of embolic protection devices (EPD) (51% vs. 68%, P=0.009). There was 
no difference in the groups with respect to contralateral occlusion, chronic obstructive 
pulmonary disease, or history of tobacco use. The 30-day incidence of stroke was 1.6% in 
patients with a history of XRT compared to 2.5% in those without (p=0.67). The composite 
endpoint of death, MI, or stroke was 4.8% for patients with a history of XRT compared to 
6.4% for patients without (P=0.62). On multivariate analysis, a history of XRT was not an 
independent predictor of major adverse events (OR 0.97, 95% CI 0.28-3.39, p=0.97). In 
long term followup, there was a trend for higher target vessel revascularization rates in 
patients with a history of XRT (3.23% vs. 1.31%, p=0.23).
Conclusion: CAS is safe and efficacious for treatment of carotid artery stenosis in 
patients with a history of XRT. In view of the increased surgical risk associated with these 
patients, CAS may be the treatment of choice.
9:00 a.m.
917-213 Abnormal Neoangiogenesis Evaluated by CD105 
Expression of Endothelial Precursor Cells is 
Associated With Restenosis After Percutaneous 
Coronary Intervention
Francesco Pelliccia, Giulio Binaghi, Guido Meoni, Vincenzo Pasceri, Christian Pristipino, 
Sebastiano La Rocca, Giuseppe Richichi, San Filippo Neri Hospital, Rome, Italy, 
University of Cagliari, Cagliari, Italy
Background: Levels of endothelial progenitor cells (EPCs) expressing surface markers 
of endothelialization (i.e. CD34 and CD133) have been shown to relate to restenosis 
after percutanoeus coronary intervention (PCI). No previous investigation, conversely, 
has investigated if restenosis is associated also with an abnormal neo-angiogenesis. 
Accordingly, we tested the hypothesis that higher level of CD105 expressing EPCs, that 
are the more powerful markers of neovascularization in malignancies, are also associated 
with the occurrence of restenosis after PCI.
Methods: Out of the 569 patients who underwent PCI and had >1 bare metal stents 
in 2004, we selected 25 patients who had restenosis 8 months after PCI (Gr. A) and 
compared them with 25 age- and sex-matched patients who had no restenosis at 
follow-up angiography (Gr.B). Peripheral blood samples were drawn before PCI in all 
patients. FACSCalibur flow-cytometer was used for EPCs assay and absolute number 
of mononuclear cells, as well as of CD34+, CD45+, CD105+, and CD133+ cells were 
evaluated.
Results: Comparison of the two groups did not show any difference in risk factors, 
cardiac function, extension of coronary artery disease, and pharmacologic treatment. 
Also, there were no differences in treated vessel, quantitative coronary angiography 
data and procedural characteristics. Flow cytometry showed that the two groups had 
similar absolute numbers of mononuclear cells (6,820±1,140 vs 6,760±1,300 103/mL, 
NS). Compared with Gr.B, conversely, Gr. A patients showed significantly lower absolute 
numbers of CD45+ (72.28±12.32 vs 83.08±7.24 cells/μL, p=0.002), as well as of 
CD105+ (1.79±0.71 vs 2.16±0.63 cells/μL, p=0.04). On the opposite, Gr. A patients had 
significantly higher absolute numbers of the endothelial markers CD34+ (1.40±0.74 vs 
1.01±0.54 cells/μL, p=0.04), and CD133+ (0.63±0.22 vs 0.34±0.26 cells/μL, p=0.0001).
Conclusions: The results of our study provide evidence that restenosis at 6-month 
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is associated not only to an excessive endothelialization but also to an impaired 
neoangiogenesis. Assessment of CD105 expression of EPCs at time of PCI may be 
considered as a novel tool for identifying patients at higher risk of restenosis.
9:00 a.m.
917-214 Despite Safety and Benefit, Distal Embolic Protection 
is Underutilized in Saphenous Vein Graft Percutaneous 
Intervention (SVG-PCI): An Analysis of 19,562 Patients 
from the NCDRTM.
Sameer K. Mehta, Andrew D. Frutkin, Sarah Milford-Beland, Steven P. Marso, The Mid 
America Heart Institute, Kansas City, MO, Duke Cardiovascular Research Institute, 
Durham, NC
Background: Use of distal embolic protection devices (EPDs) in SVG lesions decreases 
the incidence of no reflow and post PCI myocardial infarction (MI), which are associated 
with late cardiac mortality. Previous studies estimate that 50% of SVG lesions meet ACC 
Class I indications for EPD deployment. However, the actual use of EPDs in SVG-PCI 
is unknown.
Methods: We determined whether an EPD was deployed in the 19,562 patients who 
underwent SVG-PCI at 452 centers in the ACC-NCDR from 1/1/2004 to 3/30/2006. 
Patients with ST elevation MI were excluded. Baseline characteristics and outcomes 
were compared between two groups, those who received EPD (EPD) and those who 
did not (No EPD).
Results: EPDs were used in 22% of patients who underwent SVG-PCI. EPDs were used 
more often in men (22.9% vs. women, 19.6%, P<0.001) and patients with increased age 
(P for trend <0.001), worse renal function (P for trend 0.001), and LVEF <45% (36% vs. 
32%, P=0.008). SVG lesions with decreased pre-procedure TIMI flow (TIMI 0-2) were 
treated less often with EPDs (P<0.001). The prevalence of decreased post-procedure 
TIMI flow (TIMI 0-2) was less in the EPD group, (2.7% vs. 4.0%, P=0.005) as was final 
TIMI 0 flow (0.5% vs. 1.2%, P<0.001). EPD and No EPD groups had similar rates of in-
hospital death (1.0% both groups, P=NS), vessel dissection (1.5% vs. 1.0%, P=NS) and 
perforation (0.5% vs. 0.4%, P=NS). Total fluoroscopic time was increased in the EPD 
group (P for trend <0.001).
Conclusions: Compared to estimates of SVG lesions suitable for EPD deployment, EPDs 
are currently underutilized in SVG-PCI. Although EPD use is associated with increased 
fluoroscopic time, EPD use appears safe and beneficial. To improve patient outcomes 
during SVG-PCI, efforts should be made to increase the use of EPDs.
9:00 a.m.
917-215 Prevalence of Aspirin and Clopidogrel Resistance 
in Patients Undergoing Percutaneous Coronary 
Intervention: Comparison of Triple versus Dual 
Antiplatelet Therapy
Chi Young Shim, Se-Jung Yoon, Sungha Park, Young-Guk Ko, Donghoon Choi, Yangsoo 
Jang, Namsik Chung, Won-Heum Shim, Seung-Yun Cho, Yonsei Cardiovascular Center 
and Research Institute, Seoul, South Korea
Background: Triple antiplatelelet therapy might have additional beneficial effect on 
prevention of thrombotic complication through additional suppression of platelet function 
in patients undergoing coronary stenting. We investigated the prevalence of aspirin and 
clopidogrel resistance in patients with dual antiplatelet and triple antiplatelet therapy after 
percutaneous coronary stenting.Methods: A total 251 consecutive patient scheduled for 
elective coronary stenting was enrolled. Patients undergoing successful coronary stenting 
were divided into dual antiplatelet therapy (aspirin 100 mg plus clopidogrel 75 mg, group 
I, n = 86) and triple antiplatelet therapy (aspirin 100 mg plus clopidogrel 75 mg plus 
cilostazol 200 mg, group II, n=165) groups. At 2 weeks after coronary stenting, aspirin 
resistance was assayed with the VerifyNowTM -ASA and clopidogrel resistance with the 
VerifyNowTM-P2Y12 (Accumetrics, San Diego, California). Results: Eight (9.3%) patients 
were resistant to aspirin and 13 (16%) to clopidogrel in group I. Seventeen (10.3%) were 
resistant to aspirin and 11 (7.0%) to clopidogrel in group II. The ARU was not different 
between groups (436±71 vs. 440±66, p=0.591), but the % inhibition was higher in group II 
(53.3±29.4 %, p=0.022) compared with that of group I (44.5±25.2 %). Conclusions: With 
triple antipletalet therapy, the prevalence of aspirin resistance was not reduced, but that of 
clopidogrel resistance was significantly reduced compared with dual antiplatelet therapy. 
9:00 a.m.
917-216 Blood Transfusion is Independently Associated with 
Death in Acute Myocardial Infarction: Insights from 
APEX-AMI (Assessment of Pexelizumab in Acute 
Myocardial Infarction) Trial
William W. O’Neill, Paul W. Armstrong, Hussein R. Alkhalidi, Christian W. Hamm, David 
R. Holmes, Jr., Thomas G. Todaro, Peter X. Adams, Frans J. Van de Werf, Christopher 
B. Granger, for the APEX Investigators, University of Miami, Miami, FL, Duke Clinical 
Research Institute, Durham, NC
Background: Blood transfusion is related to worse outcome in acute coronary syndromes, 
but this relationship in acute myocardial infarction (MI) is controversial.
Methods: To define the relationship of transfusion and mortality in contemporary treatment 
of MI, we used the database of the APEX-AMI trial that enrolled 5,745 patients with ST 
elevation MI treated with primary PCI in 17 countries in 2004 to 2006.
Results: Mean age was 62 yrs, 23% were female. Pts were randomized to pexelizumab 
(an inhibitor of complement) or placebo. Six percent of pts received blood transfusion 
during admission, who had median length of hospital stay of 10 days compared to 6 
days for non-transfused pts. Transfusion was most common in the US (10.7%) and 
least common in Europe (3.3%). Transfused pts were older (mean=68 yrs vs. 61 yrs), 
more commonly females (42% vs. 22%) and more commonly diabetic (23% vs. 15%) as 
compared to those who were not transfused. Using multivariable Cox regression (figure), 
transfused pts had a hazard ratio (HR) of 30-day death of 3.7 (95% CI 2.7 - 5.1; p<0.0001) 
compared to those who did not receive transfusion after adjustment for age, MI location, 
sex and diabetes. Excluding 199 CABG pts (62% of whom received transfusion) from the 
analysis, the HR was 6.8.
Conclusions: In this acute MI population, transfusion was strongly and independently 
associated with death. Strategies to reduce bleeding and transfusion should be studied, 
as well as strategies to improve outcome in patients requiring transfusion. 
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918-210 Safety and Efficacy of a New Guidewire (CTOSTM 
Device) for Crossing Chronic Total Occlusions: First in 
Man Results
Alexandre Abizaid, Andrea S. Abizaid, Fausto Feres, Daniel Chamié, Rodolfo Staico, 
Luis Alberto P. Mattos, Ibraim Pinto, Paulo Márcio S. Nunes, Amanda G.M.R. Sousa, J. 
Eduardo Sousa, Institute Dante Pazzanese of Cardiology, São Paulo, Brazil
Background: Percutaneous treatment of chronic total occlusions (CTO) represents one 
of the last frontiers in Interventional Cardiology. True prevalence of CTO is unknown, but 
it may represent 5-30% of all coronary angiograms and yet, recanalization is attempted in 
only 8-15% of patients (pts). A major limitation is the ability to cross the lesion. Objective: 
To evaluate the safety and efficacy of a new guidewire (gdw) system for pts with CTO.
Methods: The Chronic Total Occlusion System (CTOSTM - ReVascular Therapeutics, Inc. 
Sunnyvale, California), is a new device designed to provide enhanced penetration and 
positioning control for crossing total occlusions via 1) an 0.014” gdw with a mechanically 
active radio-opaque distal end, 2) a handle attached proximally to the gdw, with torque 
controls, and interfaced to 3) a non-disposable, battery-operated, control unit, that 
provides activation control and audio feedback during the CTO crossing procedure.
Patients: We selected 21 pts with CTO to enter the study. Per protocol 10 pts were 
excluded (4-regular gdw crossed;4-no viability on stress echo;1-presence of thrombus;1-
very long and tortuous segment). Therefore, the CTOSTM device has been used in 11 pts 
after > 5 minutes (min) failed attempt of conventional gdw to cross the lesions.
Results: Mean age was 56.7 ± 20.5 y, 54% were men, and 27% diabetics. Average 
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duration of occlusion was 3.18 ± 1.83 months. Mean vessel reference diameter was 2.93 
± 0.15 mm and the mean occlusion length, 17.35 ± 8.9 mm (4.37-35 mm). The occlusion 
ended in tapered stump in 9 pts (81%), and side branch was involved in 7 (63%). Distal 
vessel filling could be seen in 8 pts (72%). In all 11 pts contralateral circulation was 
present, and bridging collaterals were seen in only 2 (18%). Success in crossing the 
occlusion with CTOSTM was achieved in 9 pts (81%), with an average time of attempt 
of 31.72 ± 40.64 min (3-130 min). No death, target vessel revascularization, myocardial 
infarction or clinical perforation occurred at hospital discharge and at 30-day follow-up.
Conclusions: This first in man study suggests that the Revascular Therapeutics CTOSTM 
is technically feasible, safe and effective in crossing chronically occluded coronary 
arteries.
10:00 a.m.
918-211 Incidence of Late Angiographic Stent Thrombosis of 
Sirolimus-Eluting Stents
Ravishankar V. Kalaga, Zulfiqar A. Mirza, Ahmed Shafeeq, Hemal H. Kadakia, Richard 
T. Ruffin, Jr., Aravind Rao Kokkirala, Francis J. Kiernan, Justin B. Lundbye, Marcin Dada, 
Amyn Malik, Deborah Murphy, Jeff Mather, Raymond G. McKay, Hartford Hospital, 
Hartford, CT
Background: Recent reports have described isolated cases of very late angiographic 
stent thrombosis (LAST) of drug-eluting stents (DES) occurring more than 12 months 
following DES implantation. The incidence of this complication remains controversial.
Methods: Retrospective analysis of 5,040 consecutive percutaneous coronary 
interventions (PCI) performed at a tertiary center between 1/03 and 6/06 was made to 
identify patients (pts) with LAST. Medical records and coronary angiograms of all pts 
treated with one or more DES who underwent repeat catheterization, were reviewed.
Results: One or more DES were implanted in a total of 3, 642 procedures, including 
sirolimus-eluting stents (SES) in 3,260 procedures and paclitaxel-eluting stents in 382 
procedures. All pts with DES implantation discharged from the hospital were treated with 
aspirin (ASA) and clopidogrel for atleast 6 months. LAST was noted to occur in 7 pts with 
SES (0.21%) at a mean of 25.6 ± 7.4 months following SES implantation. The study group 
included 5 males and 2 females with a mean age of 63.3 ± 16.2 years. Cardiac risk factors 
included ongoing tobacco use in 6 pts, hyperlipidemia in 7 pts, hypertension in 5 pts and a 
family history for premature atherosclerosis in 5 pts. At the time of LAST, 3 pts were taking 
ASA, 2 pts clopidogrel and 1 pt, both. Six pts presented with an ST-segment elevation 
myocardial infarction (STEMI) including 2 pts with cardiogenic shock, and 1 pt with non-
STEMI. Coronary angiography demonstrated occlusive thrombus at the initial site of SES 
implantation in all pts. Two pts had thrombosis at the site of contiguous stents. None 
had thrombosis of bifurcation lesions or at the site of stent overlap. Six pts underwent 
emergent PCI with repeat stent implantation. All 7 pts were subsequently discharged on 
life-long ASA and clopidogrel.
Conclusions: Results from this single center study have demonstrated that the incidence 
of angiographically proven LAST in pts treated with sirolimus-eluting stents is 0.21%. 
LAST typically presents as either STEMI or non- STEMI, and can occur in previously 
stable pts while taking both ASA and clopidogrel.
10:00 a.m.
918-212 New Technology of Three-dimensional Coronary 
Bifurcation Imaging
Takaaki Shiono, Shigeru Saito, Hideaki Kaneda, Yuusuke Miyashita, Saeko Takahashi, 
Hiroshi Domae, Heart Center of Shonankamakura General Hospital, Kamakura, Japan
Background: Silorims-eluting stent (SES) dramatically decreased restenosis but it is 
not satisfactory in the treatment for bifurcation lesion. For appropriate stent implantation 
in bifurcation lesion, it is thought that coronary arteries divergence angle as well as 
vessel diameter is important factor. Recently, new software named Leonardo introduced 
to constitute a three-dimensional image by coronary angiogram of two directions. We 
analyzed a divergence angle of coronary arteries before and after the crush-T stent 
treatment for the left main coronary artery (LMCA) lesion.
Methods: Since August 2003, SES was treated with crush-T technique for LMCA lesion 
of consecutive 38 cases in our hospital. Of these, about 29 cases, we could measure 
coronary arteries divergence angle by Leonardo before and after Crush-T treatment.
Results: Results are shown in Table.
Conclusions: There were few changes before and after stenting in the divergence angle. 
But the restenosis tended to more often in the group which an angle decreased more 
than 10% after treatment. Further prospective study is necessary to determine efficacy 
of Leonardo. 
10:00 a.m.
918-213 Efficacy and Safety of Carotid Artery Stenting in 
Patients Scheduled for Cardiac Surgery
Uwe Zeymer, Ralf Zahn, Mathias Hochadel, Bernd Mark, Jochen Senges, for the ALKK-
Study Group, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
Background - There is still debate about the optimal treatment strategy for a high grade 
carotid stenosis in patients scheduled for coronary artery bypass grafting or cardiac valve 
replacement procedures. Therefore we analysed data from a large registry to evaluate 
outcome and complications of carotid artery stenting (CAS) in asymptomatic patients 
scheduled for cardiac surgery.
Methods - In a retrospective analysis of the prospective CAS registry of the ALKK all 
asymptomatic patients were included in this analysis. Concomitant diseases, procedural 
data and hospital complications were prospectively recorded and analyzed centrally.
Results - A total of 1096 patients fulfilled our inclusion criteria for this analysis. Mean 
age was 71 years, 74% were men, 31% diabetics, 5% had had previous CAS and 6% 
previous carotis endarterectomy. The median degree of the stenosis was 90%, CAS of 
the A.carotis interna was performed in 95% and of the A. carotis communis in 5% of the 
patients. The inhospital events are shown in the table.
Conclusions - In clinical practice in unselected patients with high grade carotid stenosis 
and planned cardiac surgery CAS is safe and effective. Therefore this approach is an 
alternative to combined or staged cardiac and carotid surgery. A randomized clinical trial 
seems warranted to determine the optimal strategy in these patients. 
Planned surgery (n=250) Others (n=846) p-value
Death 0.4 % 0.4 % 1.0
Stroke 1.7 % 0.7 % 0.2
TIA 4.5 % 3.5 % 0.4
Myocardial infarction 0 % 0.1 % 0.4
10:00 a.m.
918-214 The Effects of Balloon Occlusion and Aspiration Device 
during Primary Percutaneous Coronary Intervention 
on Infarct Size and Remodeling: Mid-term Contrast-
Enhanced Magnetic Resonance Imaging Follow-up
Joo-Yong Hahn, Hyeon-Cheol Gwon, Yeon Hyeon Choe, Il Rhee, Jun Hyung Kim, Ji 
Hyun Yang, Seung Hyuk Choi, Jin Ho Choi, Sang Hoon Lee, Kyong Pyo Hong, Jung Euy 
Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
South Korea
Background: Distal embolization of debris and soluble factors released from plaque 
during primary percutaneous coronary intervention (PCI) may impede myocardial 
reperfusion. We investigated whether distal protection with balloon occlusion and 
aspiration device can reduce infarct size and left ventricular (LV) remodeling by serial 
analysis of contrast-enhanced magnetic resonance imaging (CE-MRI).
Methods: Patients undergoing primary PCI for ST-segment elevation myocardial 
infarction within 12 hours after symptom onset were randomized to either the distal 
protection group (n=19) or to the control group (n=20). Infarct size was assessed by 
delayed hyperenhancement on CE-MRI obtained at 3 days after index procedures and 
at 6 months after myocardial infarction. LV remodeling was defined as an increase in LV 
end-diastolic volume ≥20% at 6-month follow-up CE-MRI.
Results: Baseline clinical and angiographic characteristics were not significantly different 
between 2 groups. Angioplasty procedures were fully protected with balloon occlusion 
and aspiration device in all patients of the distal protection group. Visible debris was 
retrieved in 18 patients (91%) of the distal protection group. Infarct size was 25.9±7.8% 
of the left ventricular mass in the distal protection group and 26.1±8.2% in the control 
group (P=0.93). Perfusion defect size was similar in 2 groups. At 6 months, Infarct size 
decreased significantly compared with initial CE-MRI, however there was no significant 
difference in 2 groups (21.4±9.1% in the distal protection group vs. 18.5±9.1% in the 
control group, P=0.51). LV remodeling occurred in 19% and 33% of the distal protection 
group and the control group, respectively (P=0.43). There was no significant difference 
in the rate of 6-month MACEs between 2 groups (none in the distal protection group and 
20% in the control group, P=0.11).
Conclusions: Serial CE-MRI showed that distal protection with balloon occlusion 
and aspiration device during primary PCI did not reduce infarct size nor prevent LV 
remodeling.
10:00 a.m.
918-215 Should Bivalirudin be the Preferred Antithrombotic 
Agent of Choice During Elective or Urgent 
Percutaneous Coronary Intervention? A Bayesian 
Analysis of REPLACE-2 and ACUITY Trials
Sanjay Kaul, Jayanta R. Das, George A. Diamond, Cedars-Sinai Medical Center, Los 
Angeles, CA
Background: A recent trial, ACUITY, concluded that bivalirudin (Bv) alone is noninferior 
to heparin/enoxaparin (hep/enox) + glycoprotein 2b/3a inhibitor (GPI) in preventing 
ischemic complications in ACS patients undergoing early intervention.
Objective: To perform a Bayesian analysis of noninferiority (NI) with regards to efficacy 
(E) and efficacy + safety (E+S).
Methods: Evidence from ACUITY was integrated with prior data from REPLACE-2 trial 
to generate an updated posterior using the Bayes’ theorem. A conservative NI margin 
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(d) was derived as 50% of the 95% lower limit (d
max
) of a random-effects meta-analytic 
estimate of historical placebo-controlled trials (EPISTENT, ESPRIT), and compared with 
the reported margin of 1.25 risk ratio (RR). NI is supported if 95% upper limit of CI of 
RR < margin.
Results: NI is established for E using d
max
 but not the more restrictive d. For E+S, NI is 
established for both margins. NI for E+S is driven in favor of Bv by a greater difference in 
S (46% risk reduction) compared to E (8% risk increase). In contrast, NI is established for 
both E and E+S using the reported margin.
Conclusions: Despite the investigators claims to the contrary, we conclude that Bv has 
not been shown to be noninferior to hep+GPI with respect to efficacy using conservative 
interpretive criterion. These analyses are consistent with the FDA’s conclusion regarding 
REPLACE-2 and call into question the enthusiastic claims for considering Bv as the 
antithrombotic agent of choice during elective or urgent PCI. 
Variable
Evidence
(ACUITY)
Prior
(REPLACE-2)
Posterior 
(REPLACE-2 
+ ACUITY)
Historical 
placebo-
controlled 
data
(EPISTENT, 
ESPRIT)
Margin (RR) Noninferiority
conclusion 
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) d
max
d Published 
margin dmax d
Published
margin
Bv vs Hep/
Enox+GPI
(Efficacy)
1.08 (0.93, 
1.24)
1.07 (0.89, 
1.28) 1.07 (0.95, 1.21)
1.72 (1.32, 
2.27) 1.32 1.15 1.25 Yes No Yes
Bv vs Hep/
Enox+GPI
(Efficacy + 
Safety)
0.86 (0.77, 
0.97)
1.08 (0.93, 
1.26) 0.94 (0.85, 1.04)
1.59 (1.12, 
2.22) 1.12 1.06 1.25 Yes Yes Yes
10:00 a.m.
918-216 ST-Segment Analysis Using Wireless Technology in 
Acute Myocardial Infarction (STAT-MI) Trial
Vivek N. Dhruva, Samir Abdelhadi, Ather Anis, William Gluckman, Hosseinali Shahidi, 
Samir Ahuja, Suzanne Atkin, Marc Klapholz, UMDNJ-New Jersey Medical School, 
Newark, NJ
Background: Studies have shown the benefit of early primary angioplasty in decreasing 
morbidity and mortality in ST-segment elevation myocardial infarction (STEMI). The use 
of wireless technology has helped to decrease door to balloon (D2B) times but has 
unrealized potential.
Methods: A fully automated wireless network that facilitates near simultaneous 12-lead 
ECG transmission from emergency medical services (EMS) personnel in the field to the 
Emergency Department (ED) and offsite cardiologists via smart phones was developed. 
This system is automatically activated through a combination of preconfigured bluetooth 
devices and pre-programmed receiving and transmitting stations. The network allows 
direct communication between the offsite cardiologist and EMS facilitating patient triage 
directly to the cath lab from the field. Demographic, laboratory and time interval data were 
prospectively collected and compared to prior 12-month data.
Results: From June to August 2006, 50 ECGs with suspected STEMI were transmitted 
via the STAT-MI network. Ten patients with confirmed STEMI were triaged to the cath lab. 
Cardiology notification was earlier and mean door to needle, first angiographic injection 
and D2B times were shorter.
STAT-MI Time Interval Measures
Previous 12 
Month STAT-MI P-value
Door to Cardiologist Notification (minutes) 61.4 -11.5 0.001
Door to Needle Time (minutes) 108.1 54.7 0.001
Door to First Angiographic Injection 
(minutes) 119.2 67.6 0.004
Door to Balloon Time (minutes) 145.7 81.8 0.01
Conclusions: A fully automated wireless network that transmits ECGs simultaneously to 
the ED and offsite cardiologists for the early evaluation and triage of patients with STEMI 
can decrease D2B times to <90 minutes and has the potential to be broadly applied in 
clinical practice.
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919-209 The Importance of Fundoscopy for the Interventional 
Cardiologist
Simon J. Corbett, John Cosgrave, Gloria Melzi, Carlo Briguori, Tiziana Aranzulla, Flavio 
Airoldi, Iassen Michev, Alaide Chieffo, Matteo Montorfano, Mauro Carlino, Giuseppe M. 
Sangiorgi, Antonio Colombo, EMO Centro Cuore Columbus, Milan, Italy, San Raffaele 
Scientific Institute, Milan, Italy
BACKGROUND: Diabetic micro-vascular complications are associated with poorer 
outcomes after bare metal stent implantation. Whether this holds true for drug-eluting 
stents is unknown.
METHODS: Retrospective analysis of diabetic patients who had implantation of sirolimus-
eluting (SES) or paclitaxel-eluting (PES) stents from March 2003 to March 2005. Diabetic 
microvascular complications prior to intervention were sought by fundoscopy and 
immunometric assay for the detection of albuminuria. The endpoint was angiographic 
restenosis, defined as ≥50% diameter stenosis at follow-up angiography.
RESULTS: 343 diabetic patients with 647 lesions were treated (172 patients with 323 
lesions received SES, while the remainder received PES). The mean age of the patients 
was 63.8 ± 9.9 years, 81.3% were male, 28% were insulin-treated and 83% had multi-
vessel disease. Angiographic follow-up was done in 74.2% of patients (72.8% of lesions). 
Restenosis occurred in 102 lesions from 81 patients (binary angiographic restenosis rate 
21.7%). In order to identify independent predictors of restenosis, all significant (p<0.05) 
baseline predictors on univariate analysis were entered into a binary logistic regression 
model (see Table).
CONCLUSIONS: Retinopathy and female gender are independent predictors of restenosis 
after drug-eluting stent implantation in diabetics. The need for ophthalmological review 
before intervention in diabetic patients as part of their baseline risk assessment appears 
warranted. 
Univariate analysis Multi-variate analysis
Variable
No 
restenosis
n=262
Restenosis
n=81 p-value OR 95% CI p-value
Women 16% (42) 27.2% (22) 0.033 2.16 1.12-4.18 0.022
Retinopathy 17.2% (45) 43.2% (35) <0.001 3.11 1.69-5.73 <0.001
Micro-albuminuria 24.4% (64) 39.5% (32) 0.011 0.97 0.39-2.37 0.938
Nephropathy 15.3% (40) 27.2% (22) 0.02 1.44 0.54-3.85 0.469
Number of stents per 
patient 1.98 ± 1.40 2.72 ± 1.6 <0.001 1.30 0.67-2.50 0.442
Stent length per patient 
(mm) 50.7 ± 39.8 70.3 ± 46.2 <0.001 1.00 0.98-1.02 0.960
11:00 a.m.
919-210 Platelet Activation and Deposition Patterns After 
Exposure to the Surface of Paclitaxel Eluting Stents: An 
Vitro Flow Chamber Study
Carlos L. Alviar, Juan F. Granada, Matthew O’Steen, David Wallace-Bradley, Armando 
Tellez, Greg L. Kaluza, Angela Builes, Albert E. Raizner, Neal S. Kleiman, Eli I. Lev, The 
Methodist Hospital, Houston, TX
Background: Drug eluting stents (DES) are suspected of higher stent thrombosis risk than 
bare metal stents (BMS). . We hypothesized that DES may increase platelet activation 
and deposition compared with bare metal stents (BMS). We, therefore, quantified platelet 
activation and deposition in a flow chamber model with DES vs. BMS.
Methods: Anticoagulated blood drawn from volunteers was circulated in a flow chamber 
at 10 ml/min (tubing diameter 3 mm) for 60 min. Stents (3.0*28 mm) were deployed 
inside the tubing system - DES (Paclitaxel)(n = 19), BMS (Express)(n = 14) or no stent 
(Control group, n= 6). Blood was extracted at 0, 10, 30 and 60 min. Platelet activation was 
evaluated by flow cytomeric determination of P-selectin expression, PAC-1 binding and 
platelet-monocyte complexes (PMC) formation. Following 60 min perfusion, stents were 
fixed and surface coverage by platelets was quantified by electron microsocopy.
Results: PMC formation and PAC-1 binding increased after 60 min perfusion in the 
DES group but not the BMS or control groups. Levels of PMC and PAC-1 binding were 
higher after exposure to DES vs BMS (Table). There were no differences in P-selectin 
expression. Percentage of the stent surface covered by clusters of platelets was higher in 
the DES than BMS group (2.28±4.1% vs. 1.11±1.6%, P=0.024).
Conclusions: DES placement in an in vitro flow chamber is associated with higher platelet 
activation markers and increased deposition over the stent surface, compared with BMS.
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Platelet activation markers, expressed as % of baseline, in DES vs. BMS 
(* P=<0.05)
10 min 30 min 60 min
PMC - DES (% of baseline)* 14.68 23.19 60.31
PMC - BMS (% of baseline)* -12.64 -9.09 -4.99
PAC-1 - DES (% of baseline)* -6.7 4.73 48.67
PAC-1 BMS (% of baseline)* -15.29 -17.15 -17.94
P-selectin DES (% of baseline) 15.8 14.1 18.3
P-selectin BMS (% of baseline) 14.4 13.79 12.09
11:00 a.m.
919-211 Initial Clinical Experience with Right Ventricular 
Endocardial Thermography in Transplanted and 
Coronary Artery Disease Patients.
Athanassios Manginas, Elias Andreanides, Evangelos Leontiadis, Petros Sfyrakis, Peter 
A. Alivizatos, Dennis V. Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece
Backround: Invasive temperature measurement (thermography) has been previously 
used to detect increased thermal heterogeneity in vulnerable coronary atheromatous 
plaques. Intracavitary right ventricular (RV) endocardial thermography, however has not 
yet been evaluated to assess temperature differences between transplanted and hearts 
with coronary disease. Aim: To examine the safety of RV endocardial thermography and 
to document differences between native and transplanted hearts.
Methods: Using a validated catheter with a tip thermistor connected to commercially 
available software, we measured temperature difference (ΔΤ) between contact RV 
endocardial septum temperature (ET) and circulating blood (BT), in 2 groups of patients. 
Group 1 consisted of 20 patients (17 males, aged 40±25.8 years) with an orthotopic heart 
transplantaion (OHT) performed 563±695 days before the procedure, who underwent 52 
RV thermography measurements immediately prior to endomyocardial biopsy. Group 2 
included 16 patients (15 males, aged 52±8.2 years) with documented history of coronary 
artery disease (CAD), who underwent RV thermography before coronary angioplasty (16 
procedures).
Results: No complications were noted during RV thermography. Three procedures in 
Group 1 were unsuccessful due to technical reasons. BTs were similar in both groups 
(36.87±0.670C and 36.89±0.210 C in Group 1 and Group 2 respectively, p=0.89). ΔΤs, 
however, were significantly lower in Group 1 compared to Group 2 (0.094±0.060C vs 
0.195±0.110C respectively, p=0.002). In Group 1 only 2 patients had documented mild 
cellular rejection.
Conclusion: RV thermography is safe and feasible using a dedicated commercial catheter. 
The graft RV endocardium is significantly cooler compared to the native endocardium of 
patients with CAD. A possible relation to cardiac denervation or impaired subendocardial 
flow in transplanted hearts remains to be elucidated. The relation between temperature 
changes and rejection needs further evaluation with larger group of patients.
11:00 a.m.
919-212 Feasibility and Safety of Drug Eluting Stent Implantaton 
in The Treatment of Stenosis of Vertebrobasilar Arteries
Santhosh K.G. Koshy, Vijay K. Misra, University of Alabama at Birmingham, Birmingham, 
AL, Baylor College of Medicine, Houston, TX
Background: Despite widespread use of drug eluting stents (DES) in percutaneous 
coronary interventions, the feasibility of its use in vetebrobasilar and other cerebrovascular 
interventions is limited. Hence, we analyzed the feasibility and safety of DES implantation 
in the treatment of vertebral and basilar arterial stenoses.
Methods: This was a prospective single center study on patients who underwent DES 
implantation for vertebrobasilar arterial stenosis. Baseline and follow up data were 
collected on symptoms and signs during complete clinical examination of these patients. 
Procedure related events and complications were also collected in these patients.
Results: Out of a total of 156 consecutive patients (from 1999 to 2005) who underwent 
stent implantation for the vertebral or basilar arterial stenoses, 13 patients (mean age 
66.5 years; 7 males and 6 females) were treated with DES (Sirolimus eluting) after 
diagnostic cerebral angiography. The procedure was done for prior history of transient 
ischemic attacks (TIA) in 8 patients, history of stroke in 4 patients and asymptomatic 
severe stenosis on non-invasive imaging in one patient. The stenosis was located in V1 
segment of left vertebral artery (LVA) in 8 patients, V1 segment of right vertebral artery 
(RVA) in one patient, basilar artery in 2 patients and V4 segment of LVA and RVA in one 
patient each. Technical success was obtained in all patients and there were no inhospital 
neurological events or mortality (median hospital stay 1 day; range 1-2 days). One patient 
with LVA ostial stenosis had minor dissection warranting stenting of V2 segment. Clinical 
follow up (mean 489 days; range 395 to 550 days) was available in 12 patients and none 
had recurrence of neurological symptoms or new deficits. At follow up, 11 patients were 
on clopidogrel and aspirin and one patient on ticlopidine.
Conclusions: To date, this is the first report on the feasibility and safety of drug eluting 
stent implantation in the treatment of vertebrobasilar arterial stenosis. Percutaneous drug 
eluting stent implantation for treatment of vertebrobasilar arterial stenosis is feasible and 
safe. However, long term safety of this strategy needs to be tested in a larger cohort.
11:00 a.m.
919-213 Bifurcation Lesion Intervention with Cypher and 
Endeavour Drug Eluting Stents-A Comparison.
Gaurav Minocha, Rajesh Jindal, Praveer Agarwal, Sanjay Kumar, Sanjeev Bhardawaj, 
Aseem Dhall, Madhukar Shahi, Atul Mathur, Balbir Singh, Suman Bhandari, T. S. Kler, 
Escorts heart institute and Research Centre, New Delhi, India
Background: Drug Eluting Stents (DES) have improved outcomes in patients undergoing 
coronary interventions including those with bifurcation lesions. Cypher and Endeavour 
stents are DESs but have fundamental differences in stent design including cell 
architecture and polymer apart from the drug coating.
Method: We randomized 110 patients with bifurcation lesions in a single artery to 
treatment with either Cypher (n= 55) or Endeavour (n= 55) stent. Side Branch(SB) 
intervention with kissing balloon or stenting was done at operator’s discretion.. The 2 
groups were compared for procedural outcomes,in-hospital complications and follow up 
at 30 days and 6 months.
Results: Baseline clinical and lesion characteristics were similar between the 2 groups. 
Diabetics constituted 32.7% in Cypher versus 36.6% in Endeavour arm (p=0.84). There 
was no difference in patients with baseline SB stenosis ≥ 70% between the 2 arms (49% 
versus 54.5%; p = 0.70). During the procedure ,SB intervention was required more often 
in the Cypher arm (63.6% vs 36.3%; p = 0.008) because of worsening SB stenosis or 
reduced TIMI flow. Procedure time was more in the Cypher arm (60 ± 18 vs 45 ± 20 mins; 
p > 0.001). There was however no difference in the procedural success between the 
two groups (96.3% vs 98.1%; p = 1.00). There was no death or in hospital target vessel 
revascularisation (TVR) in either group. 9% patients in the Cypher arm versus 5.4% in 
the Endeavour arm had significant enzyme elevation following the procedure (p = 0.71). 
At 30 days,no patient in the Cypher arm versus 1 in the Endeavour arm had subacute 
thrombosis (p = 1.00). There was no difference in major adverse events in the two arms 
(1.8% vs 3.6%; p = 1.00)at 30 days. On follow up at 6 months there was no difference 
in TVR (1.8% vs 3.6%; p = 1.00) or composite mace (7.2% vs 9.0%; p= 1.00) between 
the two groups.
Conclusion: Bifurcation lesion treatment with Cyher and Endeavour DESs are associated 
with good clinical outcomes at mid term follow up. SB intervention is required more often 
with Cypher compared to Endeavour stent because of worsening of SB stenosis or TIMI 
flow. There is no difference in in- hospital complications, procedural success and the 
clinical follow up at 30 days and six months.
11:00 a.m.
919-214 Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting 
Stent on the Outcome of Patients with Sirolimus-Eluting 
Stent Failure: Multicenter Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo H. Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan
Background and Purpose: Sirolimus-eluting stent failure (restenosis after Sirolimus-
eluting stent implantation: SES-F) remains challenging problem and optimal treatment 
has not been established. 
Methods: A total of 308 patients with 359 SES-F lesions (male 71.4%, mean age 70.8%, 
LMT 7.0%, LAD 45.1%, LCX 26.2%, RCA 17.8%, SVG 3.9%) were treated with SES 
(mean lesion length 25.9±12.2 mm, mean stent length 30.9±15.5 mm) and Paclitaxel-
eluting stent (PES) (mean lesion length 28.8±11.9 mm, mean stent length 33.1±18.9 mm). 
We evaluate immediate and long-term clinical results by 6 and 12 months angiography.
Results: The baseline clinical characteristics between 2 groups were similar. See table 
for clinical results. 
Conclusion: The use of SES and PES in patients with restenosis after SES implantation 
was safe with low complications. Patients treated with SES showed lesser rate of 
restenosis compared with PES. 
SES PES
Number of patients/lesions 156/198 152/161
Procedural success (%) 100 100
MACE at 30 days (%) 0.6 1.3 (2 stent thrombosis)
Proximal reference diameter (mm) 2.96±0.77 2.80±0.70
Minimum lumen diameter post procedure (mm) 2.78±0.88 2.65±0.66
Minimum lumen diameter at 6 months (mm) 2.50±0.79 2.39±0.70
Minimum lumen diameter at 12 months (mm) 2.48±0.84 2.15±0.70
Restenosis rate (%) 7.7 15.7*
Target lesion revascularization (%) 6.4 15.7*
MACE at 12 months (%) 7.0 17.0*
*p<0.05 vs SES
11:00 a.m.
919-215 Association of Antiplatelet and Antithrombin Therapy 
With Ischemia on Holter Monitoring Following 
Percutaneous Coronary Intervention (PCI): A PROTECT 
TIMI 30 Analysis
C. Michael Gibson, Jacqueline L. Buros, Saumil Shah, Lauren Ciaglo, David Morrow, 
Benjamin Scirica, Peter H. Stone, Beth Israel Deaconess Medical Center, Boston, MA, 
Brigham & Women’s Hospital, Boston, MA
Background: While post PCI Holter ischemia has been associated with MI, the 
association of antiplatelet & antithrombin therapy (tx) with the magnitude & timing of 
ischemia on Holter monitoring post PCI has not been characterized. 
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Objectives and Methods: Using a time series analysis which accounts for repeated 
failures in pts, the cumulative incidence, duration, as well as timing of Holter monitoring 
ischemia was evaluated in 857 pts with non ST elevation acute coronary syndromes 
(NSTEACS) who were randomized to eptifibatide (epti) + reduced dose unfractionated 
heparin (UFH) (n=298) or reduced dose enoxaparin (enox) (n=275) vs bivalirudin (bival) 
monotherapy (n=284). Pts were txd with a loading & maintenance dose of clopidogrel 
either before PCI (pre PCI Clop) or at PCI (post PCI clop) in a non randomized fashion at 
operator discretion. Post PCI presence of ST deviation > 1 mm per min for > 18 hrs was 
evaluated on Holter. 
Results: Epti + UFH or enox was associated with less ischemia / 24 hrs compared to bival 
monotherapy (6.6 (n= 527) vs 12.1 (n=263) min/pt, p=0.039). The lowest rates of ischemia 
were observed with pre PCI clop + epti therapy, & the highest with bival + post-PCI clop 
(3.4 vs 11.2 min/pt, p=0.039, fig). Non-randomized pre-PCI clop reduced ischemia among 
bival pts from 4-24 hrs (fig, HR 7.28, p=0.04). 
Conclusions: Among all pts, epti is associated with a reduction in post-PCI ischemia 
compared to bival, but pre-PCI clop reduces late ischemia from 4-24 hrs among bival 
pts. 
11:00 a.m.
919-216 Direct Stenting is an Independent Predictor of 30-Day 
Survival in Unselected Patients Admitted for Acute 
Myocardial Infarction
Philippe Garot, Thierry Lefèvre, Yves Louvard, Claude Pougès, Jean-Yves Le Tarnec, 
Alain Margenet, Thierry Unterseeh, Jean-Claude Robart, Karim Tazarourte, Pierre 
Dumas, Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, Quincy, France
Background : Direct stenting (DS) has been shown to improve myocardial reflow by 
reducing the incidence and magnitude of post-ischemic myocardial injury.
Objectives : Between 1995 and 2005, a total of 2,300 pts were directly admitted to the 
cath-lab of our institution for acute MI and were treated by immediate PCI. In 1998, 
we have provided data from a randomised trial showing the benefit of DS in improving 
ST-segment resolution on ECG after immediate PCI for acute MI. Since 1998, DS has 
become routine in our practice. The objective of this work is to assess the benefit of DS in 
term of reduced mortality in AMI-patients.
Methods and results : A total of 2,300 patients presenting with acute MI were treated 
between 1995 and 2005. Their mean age was 62±14 and 78% were males. Infarct 
location was anterior in 45% and shock was present on admission in 11% of the pts. The 
mean time elapsed between chest pain onset and admission was 295±251 minutes and 
22% of the pts were treated by prehospital lysis. Predictors of 30 day survival were by 
multivariate analysis as follows: 
Survival Death P Variable OR [95%CI]
61+13 68+14 <0.0001 Age 1.03 [1.01-1.05]
2% 18% <0.0001 Resuscitated CA 2.09 [1.11-3.94]
6% 63% <0.0001 Killip 4 18.17 [11.28-29.27]
44% 53% <0.05 Anterior MI -
23% 11% <0.0005 Prehospital lysis -
24% 13% <0.005 Pre-PCI TIMI-3 -
48% 30% <0.0005 Direct stenting 0.58 [0.37-0.91]
91% 69% <0.0001 Post-PCI TIMI-3 0.48 [0.27-0.85]
Conclusion: Among classical variables, such as younger age, lower killip class and final 
TIMI 3 flow, direct stenting is an independent predictors of 30 day survival in unselected 
pts treated by emergency PCI for acute MI.
i2.ORAL CONTRIBUTIONS
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Multivessel Disease: Percutaneous 
Coronary Intervention Versus Coronary 
Artery Bypass Grafting
Saturday, March 24, 2007, Noon-12:45 p.m.
Room 242
Noon
2801-3 A Comparison of Short-and Long-Term Outcomes of 
Coronary Artery Disease Patients Treated With Bare 
Metal Stents or Bypass Surgery
Muhammad S. Munir, Craig Delaughter, Amany H. Ahmed, Vei-Vei Lee, MacArthur A. 
Elayda, James M. Wilson, Texas Heart Institute, Houston, TX
Background: Careful use of Bare Metal Stents (BMS) in appropriately selected patients 
may be beneficial. We sought to compare the incidence of early MACE (Major acute 
coronary event) and long term mortality in patients receiving (BMS) or bypass surgery 
(CAB).
Methods: Patients undergoing revascularization at the Texas Heart Institute have 
demographic, comorbidity and anatomic data entered into an ongoing database (THI-
RDbase). To compare BMS with CAB, patients treated by either method were matched 
using propensity score. Early (30 day) MACE (Major acute coronary event including 
death, MI & Stroke) and long term survival are reported. Outcomes were compared, using 
Chi-Square statistics. Survival was compared using Kaplan Meier Statistics.
Results: A total of 3518 patients were included (1759 BMS ; 1759 CAB). MACE was more 
frequent in CAB patients (CAB=6.65% vs BSM=3.7%; p<0.01). This high MACE incidence 
in CAB was driven by more frequent stroke (CAB=1.88% vs BMS=0.23%; p<0.01) and re-
infarction (CAB=3.75% vs BMS= 0.85%; p<0.01). Mortality at mean followup of 10 years 
was lower in CAB (CAB=23 vs BMS=32%; p<0.05)
Conclusions: Although when compared to CAB, the use of BMS for coronary 
revascularization is associated with a lower risk of periprocedural/early post procedural 
morbidity, survival is superior in CAB patients at 10 years.
12:15 p.m.
2801-7 Is There a Lack of Initial Benefit With Drug Eluting 
Stents? Insights From 3-Year Follow-Up of ERACI III 
Study
Alfredo E. Rodriguez, Andrew Mauree, Liliana Grinfeld, Juan Mieres, Daniel Berrocal, 
Carlos Fernandez-Pereira, Alfredo M. Rodriguez-Granillo, Diego Grinfeld, William O 
Neill, Igor Palacios, Cardiovascular Research Center(CECI), Buenos Aires, Argentina, 
Otamendi Hospital, Buenos Aires, Argentina
Background: Long term follow up results of drug eluting stents(DES) in multiple vessel 
disease(MVD) and n relation to bare metal stents(BMS) and coronary artery bypass 
surgery(CABG) is not well known.We previously reported the one year follow up results 
of the ERACI III trial.
Methods: ERACI III was a multicenter, prospective study designed to compared patients 
with MVD treated with DES (225) with similar cohort of patients previously included in 
the ERACI II (Argentina Randomized Study of Coronary Bypass Surgery vs Coronary 
Angioplasty), treated with BMS(225) or CABG(225). Primary end points were to compare 
major adverse events (MACCE) defined as death, myocardial infarction(MI), stroke, and 
repeat revascularization procedures (TVR) at one, three and five years of follow up among 
the three groups. Outcome of Diabetics (DBT) and incidence of confirmed or suspected 
stent thrombosis (SET) were secondary end points of the study. Patients were under 
thienopyridines during six and one months in DES and BMS groups respectively .
Results: Patients in DES group were older, received higher number of stents and longer 
stent length per patient.Three years follow up results appears in Table. DBT was an 
independent predictor of death and MACCE either in BMS or DES group p=0.003.
Conclusions: At three years of follow up the three groups had non significant differences 
of MACCE although lower in DES and CABG group. DBT patients had poor outcome 
either in DES or BMS group. SET was more frequent in DES patients.
CABG (n=225) BMS (n=225) DES (n=225) p value
Death 9.8% (22) 4.8% (11) 5.7% (13) 0.12
MI 6.3 %(14) 2.7% (6) 6.2% (14) 0.21
Stroke 1.3% (3) 1.8 %(4) 3.1 %(7) 0.4
TVR 5.8% (13) 24.4% (55) 14.2% (32) 0.0001
MACCE 22.7% (51) 33.3% (75) 22.7% (51) 0.081
SET -- 1.3%(3) 4.4 %(10) 0.091
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12:30 p.m.
2801-9 Experience With the Self-Expanding 21 French 
Percutaneous CoreValve Aortic Valve Prosthesis in 
High-Risk and Inoperable Patients With Symptomatic 
Aortic Valve Stenosis
Eberhard Grube, Jean-Claude Laborde, Ulrich Gerckens, Raymond Cartier, Patrick 
W. Serruys, Peter De Jaegere, Lutz Buellesfeld, Gerhard Schuler, Carlos Ruiz, Raoul 
Bonan, HELIOS Heart Center Siegburg, Siegburg, Germany
Background: Percutaneous aortic valve replacement (PAVR) is an emerging, alternative 
to palliative medical therapy for high risk and non-surgical patients with severe aortic 
stenosis (AS). We report the experience of PAVR with the CoreValve Revalving™ system, 
21 french generation 2, which evaluates a self-expandable porcine bioprosthesis within 
in a nitinol frame.
Methods: Patients with symptomatic, severe (area < 0.6 cm2/m2) AS aged ≥80 y. and/
or Logistic Euroscore( LEs) ≥ 20% and/or ≥65 y. + severe comorbidities were enrolled. 
A multi-disciplinary approach involved general anesthesia, surgical peripheral arterial 
access and femoral vein-femoral artery cardiopulmonary bypass (CPB). Aortic balloon 
valvuloplasty was performed first, then retrograde 21 Fr CoreValve PAVR.
Results: Since August 2005, a total of 60 patients (pts)(49 high risk pts, LEs = 23.4 ± 
14%, 11 inoperable pts, LEs = 31.6 ± 16%) were recruited; mean age: 80.9 ± 6.5 years, 
41 females, mean aortic valve area: 0.64±0.2 cm2. Technical failure happened in 5 cases, 
two inability to cross the valve and three misplacements with immediate conversions 
to surgery. Immediate results by TEE in 55 successful procedures showed: mean AVA: 
1.6±0.4 cm2 and 45 pts with paravalvular leak grade 0 or 1. Overall in-hospital mortality 
was 8/60 pts, 4/11 in the inoperable patient subgroup and 4/49 (8%) in the high risk 
patient subgroup. Follow-up (mean 5.0±2.5 months; 1-18) confirmed hemodynamic and 
functional improvements in all discharged PAVR cases.
Conclusions: Percutaneous aortic valve replacement with the 21 french self-expandable 
CoreValve prosthesis is feasible and safe. When successful, the procedure results in 
marked hemodynamic and clinical improvement and follow-up up to 18 months confirms 
sustained clinical and hemodynamic benefit.
i2.ORAL CONTRIBUTIONS
2802 
Complex Coronary Intervention
Sunday, March 25, 2007, 10:30 a.m.-11:45 a.m.
Room 242
10:30 a.m.
2802-3 Drug-Eluting Stents Are No Better Than Bare Metal in 
Vein Grafts: Results From the Strategic Transcatheter 
Evaluation of New Therapies (STENT) Group
B. Hadley Wilson, Angela D. Humphrey, John C. Cedarholm, Charles M. Elliott, Robert 
H. Haber, Glen T. Kowalchuk, Michael S. Rinaldi, Charles A. Simonton, III, Carolinas 
Heart Institute, Charlotte, NC
Background: Higher rates of thromboembolic and repeat revascularization events in 
saphenous vein graft (SVG) stent procedures have raised questions about the efficacy of 
drug-eluting stents (DES) in these vessels.
Methods: The STENT Group is the first U.S. prospective multicenter registry for DES 
since approval in May 2003. Consecutive patients are enrolled at the time of percutaneous 
coronary intervention with key clinical and procedural variables collected and analyzed 
for 9 month outcomes.
Results: Of the 13,267 patients enrolled from 5/03-9/05 and having completed 9 month 
follow-up there were 923 SVGs. Of these, 418 (45%) were single vessel DES procedures 
(243 sirolimus, 171 paclitaxel, 4 combined) and 281 (30%) were single vessel bare 
metal stent (BMS) procedures. DES and BMS showed comparable lesion length (18.0 
mm vs 16.2 mm, p=0.1) but differences in vessel diameter (3.4 mm vs 3.7 mm, p<0.0001) 
and stent length (23.7 vs 22.1, p=0.007). DES lesions had more distal graft locations 
(16% vs 8%, p=0.0007). The DES lesions had significantly less distal emboli (0.4% and 
3.3%, p=0.003) and acute closures (0.4% and 2.1%, p=0.04). Unadjusted cumulative 
9 month rates comparing DES to BMS: death (5.0% and 6.8%, p=0.41); myocardial 
infarction (MI) (4.3% and 8.2%, p=0.05); target vessel revascularization (TVR) (5.7% and 
8.5%, p=0.17); and subacute thrombosis (0.5% and 1.4%, p=0.23). MACE (major adverse 
cardiac events) occurred in 12.7% of DES and 20.3% of BMS (p=0.008), with an adjusted 
proportional hazard ratio 0.61 (95% CI 0.40, 0.91, p=0.0157) favoring DES. However, 
the individual adjusted hazard ratio for MI (0.55, 95% CI 0.28, 1.10, p=0.0919) and TVR 
(0.60, 95% CI 0.33, 1.11, p=0.1031) remained non-significant.
Conclusions: The incidence of subacute thrombosis and other thromboembolic 
complications was not statistically different between DES and BMS suggesting no safety 
concern for DES in SVGs. Furthermore, the individual outcomes of MI and TVR were no 
different for DES or BMS and only the composite endpoint of MACE had a lower hazard 
ratio for DES. Overall these results show no consistent superior benefits for the use of 
DES in SVGs as reported previously in stenotic native coronary arteries.
10:45 a.m.
2802-5 Trends in Outcomes Following Percutaneous Coronary 
Intervention for Chronic Total Occlusions: 25-Year 
Experience From the Mayo Clinic
Abhiram Prasad, Charanjit Rihal, Ryan J. Lennon, Mandeep Singh, David R. Holmes, 
Jr., Mayo Clinic, Rochester, MN
Background: The percutaneous treatment of chronic total occlusions (CTO) remains a 
major challenge. Past studies have used variable definitions of CTO and there is limited 
data from contemporary practice. The aim of our study was to examine the trends in 
procedural success, in-hospital and long-term outcomes following percutaneous coronary 
intervention (PCI) for CTO over the last 25-years from a single PCI registry, and examine 
the impact of drug eluting stents (DES).
Methods: We evaluated the outcomes of 1262 patients from the Mayo Clinic registry 
requiring PCI for a CTO. The patients were divided into four groups according to the time 
of their intervention: Group 1 (PTCA era), Group 2 (early stent era), Group 3 (bare metal 
stent era), and Group 4 (drug-eluting stent era).
Results: Procedural success rate were 51%, 72%, 73%, 70% (p<0.001), respectively, in 
the four groups. In-hospital mortality (2%, 1%, 0.4%, 0%, p=0.009), emergency CABG 
(15%, 3%, 2%, 0.7%, p<0.001), and major adverse cardiac event (MACE) rates (8%, 
5%, 3%, 4%, p=0.052) decreased over time. During follow-up, the combined endpoint 
of death, myocardial infarction or target lesion revascularization was significantly lower 
in the two most recent cohorts compared to those patients treated before (p=0.001 for 
trend). Technical failure to treat the CTO was not an independent predictor of long-term 
survival (hazard ratio and 95% confidence intervals; 1.16 [0.90-1.5], p=0.25).
Conclusions: Procedural success rate for CTO have not improved over time in the 
stent era, highlighting the need for developing new techniques and devices. There has 
been a progressive reduction in in-hospital MACE rates, and the need for target lesion 
revascularization, a trend that that appears to be continuing in the DES era. 
11:00 a.m.
2802-7 Relationship Between the 3D Structure of the Left Main 
Coronary Artery Bifurcation and Double Stenting
Yoshinobu Murasato, Masataka Horiuchi, Yoshitaka Muraoka, Tomiya Yasumasu, 
Haruhisa Hirakawa, Chikuho Social Insurance Hospital, Nogata, Japan
Background: The 3 dimensional (3-D) structure of the left main coronary artery (LMCA) 
bifurcation influences the efficacy of double stenting. The impact of the structure on 
restenosis has not been described.
Methods: The crush, modified-T and kissing stent techniques using BX Velocity stents were 
performed in at phantom LMCA bifurcation 3-D model reproducing actual bifurcated angles. 
The model was then examined by fluoroscopic, macroscopic and micro-focus CT methods.
Results: In the 3-D model, one stent overlapped perpendicularly the other in the distal 
LMCA. Micro-focus CT images of the bifurcated carina demonstrate that in any technique 
of double stenting, stent overlapping created an incomplete stent apposition at the ostium 
of the left circumflex (LCX) artery at either the myocardial or epicardial site despite 
additional kissing balloon inflations. The modified-T stenting technique did not always 
ensure full coverage of the epicardial ostium of the LCX. A narrow LMCA - LCX angle was 
associated with inadequate expansion of the LCX stent at the ostium rather than at the 
distal end, resulting in a higher likelihood of incomplete stent apposition.
Conclusions: Using double stenting in the 3-D structure of the LMCA bifurcation greatly 
affects stent expansion, distortion and potential for stent gaps. Incomplete stent apposition 
at the ostium of LCX may result in a higher likelihood of focal restenosis. 
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2802-9 Fractional Flow Reserve-Guided Side Branch 
Intervention Versus Conventional Intervention in 
Bifurcation Lesions: Comparison of Long-Term Clinical 
Outcomes
Bon Kwon Koo, Jung-Won Suh, Keun-Ho Park, Hae-Young Lee, Hyun-Jai Kang, Young-
Suk Cho, Woo-Young Chung, In-Ho Chae, Dong-Ju Choi, Hyo-Soo Kim, Byung-Hee Oh, 
Young-Bae Park, Yoon-Sik Choi, Seoul National University Hospital, Seoul, South Korea
Backgrounds: Angiographic evaluation overestimates the functional significance of 
jailed side branch (SB) lesions. We performed this study to assess the clinical outcomes 
of fractional flow reserve (FFR)-guided jailed SB intervention strategy. 
Methods: Patients with de novo bifurcation lesions with SB diameter >2mm and SB lesion 
length <10mm were consecutively enrolled. Patients with unstable clinical condition, ST-
elevation myocardial infarction (MI) at target lesion territory, depressed LV function, chronic 
total occlusion and renal dysfunction were excluded. In FFR group (n=110), jailed SB FFR 
was measured after main branch stent implantation. SB intervention was performed if 
jailed SB FFR <0.75 and side branch stenting was permitted only in cases of < TIMI 3 
flow. Conventional intervention group (n=110) was selected from SNUH database with 
the same patients’ selection criteria. All lesions were treated with drug-eluting stents. 
Nine-month major adverse cardiac events (MACE: cardiac death, MI and target vessel 
revascularization (TVR)) and 2-year event free survival rate were evaluated. 
Results: There were no clinical and angiographic differences between 2 groups. In FFR 
group, SB intervention was performed in 24 lesions among 26 lesions with FFR<0.75. 
Conventional group had more SB intervention (45% vs. 30%, p=0.02) and less post-
procedural SB residual stenosis (60% vs. 74%, p<0.01) and had a tendency of more 
peri-procedural MI(12% vs. 7%, p=0.2) than FFR group. Within 9 months, there was no 
difference in TVR rate between 2 groups (FFR-group: 4.6%, Conventional group: 3.7%). 
There was no death or MI. After 9 month, late MACE occurred in 4 patients (2 ST elevation 
MI due to stent thrombosis, 2 non-ST elevation MI) of conventional group. However, there 
was no difference in 2 year event free survival rate between 2 groups. 
Conclusion: FFR-guided SB intervention strategy seems to be feasible and effective in 
reducing unnecessary complex interventional procedures in bifurcation lesions
11:30 a.m.
2802-11 Favorable One-Year Outcome Following Drug-Eluting 
Stent Implantation in Non-Bifurcational Lesions 
Involving Unprotected Left Main Coronary Artery:  
A Multicenter Registry
Alaide Chieffo, Seung Jung Park, Marco Valgimigli, Young Hak Kim, Imad Sheiban, 
Joost Daemen, Flavio Airoldi, Cheol Whan Lee, Myeong Ki Hong, Seong Wook Park, 
Nuccia Morici, Claudio Moretti, Patrick Serruys, Antonio Colombo, San Raffaele 
Scientific Institute, Milan, Italy
Background: The presence of a lumen narrowing at the ostium and the body of an 
unprotected left main coronary artery (LMCA), which does not require bifurcation 
treatment, is a class I indication to surgical revascularization. The aim of the study was to 
assess the safety and mid-term efficacy of drug-eluting stent (DES) implantation in the 
ostium and/or body of unprotected LMCA stenosis.
Methods: All consecutive patients (pts) who had a stenosis in the ostium and/or the mid-
shaft of an unprotected LMCA (not requiring the treatment of the bifurcation) electively 
treated, from April 2002 to May 2005, with PCI and sirolimus (SES, Cypher, Cordis, 
Johnson and Johnson Company, Warren, NJ) or paclitaxel (PES, Taxus, Boston Scientific, 
Natick, MA) -eluting stents in 5 Centres( San Raffaele Hospital and EMO Centro Cuore 
Columbus in Milan, San Giovanni Battista Hospital in Turin, Italy; Erasmus Medical 
Center- Thoraxcenter, in the Netherlands and Asan Medical Center, in Korea).
Results: One-hundred forty four patients were included: 105 were treated with SES and 
39 with PES. Seventy-five patients had ostial LMCA stenosis, 41 in the body and 28 had 
diffuse disease in either ostium or the body of the left main. In 73 (50.7 %) patients IVUS 
guidance was performed.Procedural success was achieved in 99% of the pts; in one 
patient with stenosis in the LMCA ostium, a residual stenosis, more than 30%, persisted 
at the end of the procedure and the patient was referred for coronary artery by-pass 
grafting (CABG). During hospitalization no patient had Q wave myocardial infarction (MI) 
or died. One patient died 19 days after the procedure because of pulmonary infection. At 
12months no other patient died or had MI. Two patients had TVR (1 re-PCI and 1 CABG). 
Angiographic follow-up was performed in 100pts (70%) with a late loss of -0.09 mm. 
Restenosis in left main trunk occurred only in 1 (1%) patient (in-stent Taxus).
Conclusions: PCI with DES implantation in non-bifurcation LMCA lesions appears safe 
with a favorable 2.7 % overall MACE occurrence at twelve months and an encouraging 
1% restenosis rate.
i2.ORAL CONTRIBUTIONS
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Acute Myocardial Infarction and 
Percutaneous Coronary Intervention
Sunday, March 25, 2007, 1:30 p.m.-2:30 p.m.
Room 242
1:30 p.m.
2803-3 Time-Dependent Inhibition of the Ischemia-Induced 
Mobilization of Bone Marrow Mesenchymal Stem Cells 
by Ischemic Preconditioning During Porcine Coronary 
Occlusion/Reperfusion
Mariann Gyongyosi, Serdar Farhan, Noemi Pavo, Heda Kvakan, Rayyan Hemetsberger, 
Sabine Steiner-Boker, Christoph Kopp, Rita GaramvÃ¶lgyi, Zsolt Petrasi, Akos Hevesi, 
Ferenc Manczur, Ferenc Manczur, Imre jr Pavo, Istvan F. Edes, Dietmar Glogar, Kurt 
Huber, Johann Wojta, Medical University of Vienna, Vienna, Austria
Background: The effect of the coronary occlusion duration with/without ischemic 
preconditioning (IP) on the mobilization of bone marrow hematopoietic (BM-HSCs) and 
mesenchymal (BM-MSCs) stem cells was determined in a porcine model of percutaneous 
balloon coronary occlusion/reperfusion.
Methods: Under general anesthesia, the mid-LAD was occluded for 30 (AMI-30, n=5), 
60 (AMI-60, n=6) or 90-min (AMI-90, n=5), followed by 60-min reperfusion. Additionally, 
17 pigs underwent IP (2x5-min balloon occlusion with 2x5-min reperfusion) before the 30 
(IP-30, n=5), 60 (IP-60, n=5) or 90-min (IP-90, n=7) coronary occlusion followed by 60-min 
reperfusion. Venous blood samples were taken at baseline, after occlusion and reperfusion 
for determination of vascular endothelial growth factor (VEGF) and stromal derived factor-1 
(SDF-1) by using ELISA. The rate of mobilization of BM-HSCs (CD31+, CD44-, CD45+) and 
BM-MSCs (CD44+, CD45-, CD90+) was analyzed by flow cytometry, and were expressed 
as the relative increases (ratio between the number measured after the final reperfusion 
and the baseline) of the BM-HSCs and BM-MSCs in the peripheral blood.
Results: The increase in the number of the circulating BM-HSCs was dependent on the 
occlusion duration in both IP and AMI groups, with a significantly higher level in IP-90 
as compared with AMI-90. In the AMI groups, the mobilization of BM-MSCs displayed a 
similar pattern (105% /94-163%/ in AMI-30; 113% /103-138%/ in AMI-60; and 126% /109-
136%/ in AMI-90; median /interquartile ranges). In contrast, in the IP groups, the level of 
circulating BM-MSCs was slightly increased during the first 30-min occlusion (112% /100-
113%/), and then decreased time-dependently from the occlusion duration (79% /60-
98%/ in IP-60 and 67% /45-73%/ in IP-90). The plasma VEGF and SDF-1 were increased 
slightly after IP, with further enhancement during the occlusion and final reperfusion in 
both groups, with more pronounced increase in IP group.
Conclusions: Our results suggest important difference between the mobilization of BM 
HSCs and MSCs, indicating a time-dependent decrease of mobilization of BM-MSCs in 
response to ischemic preconditioning in a porcine ischemia/reperfusion model.
1:45 p.m.
2803-5 Faster Times to Primary Percutaneous Coronary 
Intervention Are Associated With Better Survival: 
Insights From the APEX-AMI (Assessment of 
Pexelizumab in Acute Myocardial Infarction) Trial
Michael P. Hudson, Christopher B. Granger, William W. O’Neill, Amanda L. Stebbins, Petr 
Widimsky, Phillip Aylward, Witold Ruzyllo, David Holmes, Kenneth W. Mahaffey, Paul W. 
Armstrong, for the APEX Investigators, Henry Ford Hospital, Detroit, MI, Duke Clinical 
Research Institute, Durham, NC
Background: Prior studies demonstrate a direct relationship between treatment delays 
and mortality in patients undergoing primary percutaneous coronary intervention (PCI) for 
ST elevation myocardial infarction (STEMI). It is uncertain, however, whether prolonged 
symptom onset-to-balloon time or door-to-balloon time has greater effect on STEMI 
mortality.
Methods: The relationship times to reperfusion on TIMI flow grade and 30-day mortality 
was analyzed among 5,745 patients in the Assessment of Pexelizumab in Myocardial 
Infarction (APEX-AMI) Trial.
Results: 37% of patients had symptom-to-balloon ≤ 3 hours and 42% of patients achieved 
door-to-balloon ≤ 90 minutes. Men were more likely than women to achieve symptom-to-
balloon ≤ 3 hours, (42% vs.32%, p< 0.01). Patients enrolled outside the United States 
were more likely than U.S. patients to have door-to-balloon ≤ 90 minutes, (49% vs. 37%, p 
< 0.01). As shown in table, symptom-to-balloon was more strongly associated with 30-day 
mortality and postprocedure TIMI grade 3 flow.
Time to Primary PCI Balloon Inflation
Door-to-Balloon Times
<90 min
(n=2422)
90-120 
min
(n=1186)
≥ 120 min
(n=1761) P value
Mortality (%) 3.0 3.9 4.4 0.047
TIMI 3 flow (%) 93.2 89.9 91.3 0.056
Symptom Onset-to-Balloon Times
< 3 hrs 
(n=2123)
3-5 hrs
(n=2264)
≥ 5 hrs
(n=985) P value
Mortality (%) 3.2 3.5 5.5 0.007
TIMI 3 flow (%) 93.2 91.8 87.0 <0.001
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Door-to-Balloon time (min, median 
(interquart range)) 73 (53,99)
109 
(80,144)
130 
(87,185) <0.001
Delayed presentation to emergency department and increased door-to-balloon both 
contributed to longer symptom-to-balloon.
Conclusions: In the largest prospective, randomized, clinical trial of primary PCI for 
STEMI, we demonstrated that longer symptom-to-balloon is associated with worse 
survival and lower rates of TIMI grade 3 flow. Health care systems should strive to 
minimize total ischemic time in STEMI patients before and after hospital arrival to improve 
outcomes.
2:00 p.m.
2803-7 Impact of Techniques to Reduce or Prevent Distal 
Embolization During Primary Percutaneous Coronary 
Intervention for Acute Myocardial Infarction: Meta-
Analysis of Randomized Clinical Trials
Scott R. Martin, Daniel R. Montellese, Luis Gruberg, David L. Brown, Stony Brook 
University Medical Center, Stony Brook, NY
Background: Distal embolization during primary percutaneous coronary intervention 
(PPCI) for acute myocardial infarction (AMI) may limit recovery of left ventricular function, 
increase infarct size and reduce survival. Thrombectomy and distal embolic protection 
devices employing filters or occlusive balloons have been developed to prevent or limit 
distal embolization during PPCI for AMI. However, studies of these devices have yielded 
inconsistent results.
Methods: We conducted a meta-analysis of all randomized, controlled trials investigating 
thrombectomy or distal protection devices (T-DPD) during PCI for AMI. Angiographic, 
electrocardiographic and clinical endpoints were extracted from each study. A random 
effects model was used to combine the results from individual trials.
Results: The 17 studies randomized 1,036 patients to T-DPD and 1,048 to control 
treatment. Follow-up ranged from in-hospital to 6 months. Acute (60-90-minutes) 
resolution of ST-segment elevations was enhanced by treatment with T-DPD (OR, 1.64, 
95% CI, 1.15-2.34, P=0.006). However, thrombectomy was significantly more effective 
than distal protection devices at achieving acute ST-segment resolution (P=0.04). The risk 
of no-reflow was reduced by T-DPD treatment (OR, 0.37, 95% CI, 0.19-0.73, P=0.004) 
with no significant difference between thrombectomy or distal protection devices (P=0.31). 
Distal embolization was reduced by treatment with T-DPD (OR, 0.61, 95% CI, 0.36-1.04, 
P=0.68). However, a significant reduction in distal embolization was only achieved with 
thrombectomy devices (OR, 0.52, 95% CI, 0.28-0.95, P=0.34). The achievement of TIMI-3 
flow or TIMI-3 blush was not significantly impacted by T-DPD. The risks of mortality (OR, 
1.03, 95% CI, 0.82-1.71, P=0.90) or reinfarction (OR, 0.72, 95% CI, 0.39-1.33, P=0.29) 
were not altered by the use of T-DPD
Conclusions: The use of T-DPD during PPCI for AMI results in improvement in acute 
ST-segment resolution and reduces no-reflow. Thrombectomy devices reduce the risk of 
distal embolization. However, these electrocardiographic and angiographic benefits do 
not translate into a reduction in mortality or reinfarction.
2:15 p.m.
2803-9 Quality Improvement: Reducing Door-to-Balloon Times 
in Patients With ST Elevation Myocardial Infarction - The 
Penn State HVI Heart Alert Program
Steven M. Ettinger, Charles Chambers, Ian Gilchrist, Mark Kozak, Craig Lauder, 
Lawrence I. Sinoway, Penn State Heart and Vascular Institute, Hershey, PA
Background: Primary PCI for ST-segment elevation MI is superior to fibrinolytic therapy. 
While recent ACC/AHA PCI guidelines recommend a door-to-balloon (D2B) time of < 90 
mins, a review of the National Registry of MI (NRMI-3/4) demonstrated only 35% of the 
PCI cohort were treated within this time. 
Methods: A team of physicians and nurses developed a Heart Alert (HA) program 
that focused on the rapid identification of patients presenting with STEMI. University 
paramedics underwent an ECG training program designed to identify patients with STEMI 
in the field and were provided with technology to transmit ECGs via a cellphone. Once 
transmitted to the ED command center, the HA system was activated for all STEMI. The 
admitting cardiologist, interventional team, nurses, radiology technologist, and admission 
staff were alerted simultaneously. A HA triage worksheet providing patient information 
was completed in the ED. Specific parameters measured included door-to-ECG, ECG-
to-HA activation, HA activation-to-cath lab arrival, and patient arrival to cath lab-to-first 
balloon inflation. Each case utilizing the HA program was analyzed within 24 hours 
inorder to provide feedback to all members involved.
Results: Since initiation of the HA program in September of 2005, 70 patients were 
enrolled. The historical control mean D2B time was 143 mins based upon a chart review 
conducted prior to implementation of the HA program. Specific predefined times were 
established for each point of care. Median D2B time was 85 min with a mean D2B time 
of 93.8 min. 56.1% of patients underwent successful PCI within 90 min and 87.7% of 
patients underwent successful PCI within 120 min. Mean door-to-ECG time was 10.0 min; 
ECG-to-HA activation: 9.8 min; HA activation-to-patient arrival in cath lab: 37.6 min; and 
patient arrival-to-first balloon inflation: 36.4 min.
Conclusions: Collaborative effects within a hospital can have a significant impact upon 
myocardial reperfusion times for patients presenting with acute STEMI. Prehospital 
activation further reduces D2B times. Given the recent ACC/AHA update PCI guidelines, 
all hospitals should develop a “Heart Alert” program as a quality initiative for the treament 
of patients with ACS.
i2.ORAL CONTRIBUTIONS
2804 
Subacute Thrombosis and Drug-Eluting 
Stents
Monday, March 26, 2007, 10:30 a.m.-12:15 p.m.
Room 242
10:30 a.m.
2804-3 Are Patients With Drug Eluting Stents at Increased Risk 
for Late Stent Thrombosis? Results From a Nested-
Case-Control Study
Peter Wenaweser, Stephan Windecker, Marcel Zwahlen, Cyrill Morger, Gerrit Hellige, 
Stephane Cook, Mario Togni, Michael Billinger, Rolf Vogel, Christian Seiler, Otto M. 
Hess, Bernhard Meier, Peter Jüni, Cardiology University Hospital, Bern, Switzerland, 
Clinical Epidemiology and Biostatistics, University Bern, Bern, Switzerland
Background: The phenomenon of late coronary stent thrombosis (ST) has emerged as a 
safety concern. It is unknown whether the incidence of late ST is higher in patients treated 
with drug-eluting stents (DES) than with bare-metal stents (BMS).
Methods and Results: We conducted a nested case-control study among 9,189 
consecutive patients who underwent implantation of BMS or DES between 1995 and 
2005 (BMS: 5048 patients from 1995-2002; DES: 4141 patients from 2002-2005). Only 
patients with angiographically proven ST were included in the analysis. We randomly 
selected four controls from the risk set for each ST case (81 patients with a BMS ST and 
76 with a DES ST). We used conditional logistic regression accounting for the matched 
design to determine the association between type of stent and ST for early (<30 days), 
late (30-180 days) and very late periods (>180 days). We estimated crude odds ratios 
(OR) and OR adjusted for diabetes, antiplatelet treatment with aspirin or clopidogrel, 
current smoking, renal failure, left ventricular ejection fraction, number of stents and total 
stent length. The adjusted OR for early and late ST showed no increased risk for the use 
of DES. However, for ST occurring later than 180 days, the use of DES was associated 
with a significantly higher risk compared with the use of BMS (figure).
Conclusions: DES have a similar risk of ST during the first 6 months after stent implantation, 
but a significantly higher risk of very late ST (>180 days) compared with BMS. 
10:45 a.m.
2804-5 Differential Predictors for Subacute, Late, and Very 
Late Drug-Eluting Stent Thrombosis: Results From the 
Multicenter “ESTROFA” Study
Jose M. de la Torre Hernandez, Felipe Hernandez, Marcelo San Martin, Iñigo Lozano, 
Juan Sanchis, Armando Perez de Prado, Jose R Rumoroso, Juan M Ruiz Nodar, Javier 
Rodriguez Collado, Josefa Mauri, Jose M Vazquez, Jose A Diarte, Jose M Hernandez, 
Jose R Lopez Minguez, Eduardo Pinar, Fernando Alfonso, ESTROFA group, Santander, 
Spain
Background: Late stent thrombosis (LST), specially very LST (> 6 months after procedure), 
is a particular serious complication of drug eluting stents (DES). The incidence of these 
events and their predictors are not completely elucidated. Moreover, these predictors could 
be different to those described for acute-subacute thrombosis (SAT).
Methods: We have performed a registry involving 16 Spanish centers in order to collect 
detailed data regarding angiographically documented DES thrombosis.
Results: From a total cohort of 11000 patients treated with DES since june 2002, 136 
cases presented angiographic evidence of stent thrombosis (1.23%). The ST were: 76 
SAT and 60 LST (among these 48 were very LST). These LST events occurred at 13±10 
months (1-46) after procedure. LST rate for Taxus was 0,53% and 0,57% for Cypher. 
Antiplatelet treatment discontinuation was a common observation in all periods, 30% in 
SAT and 38% in LST. Other independent predictors for SAT were the following: renal 
failure, stent implantation in STEMI or in ACS, stent implanted in left anterior descending 
artery, stent diameter ≤2.5mm, longer stent, stent under-expansion by angiography, 
female sex and Cypher stent. For LST only stent implantation in STEMI (OR 7; 95%CI 3.6-
13; p<0.0001) and stent implanted in left anterior descending artery (OR 4.2; 95%CI 2.2-
8.1; p<0.0001) were identified as independent predictors along with antiplatelet therapy 
B    ABSTRACTS - Innovation in Intervention: i2 Summit 2007  JACC  March 6, 2007
In
no
va
ti
on
 in
 I
nt
er
ve
nt
io
n:
 i2
 S
um
m
it
 2
0
0
7
discontinuation. These same predictors were also found for very LST: implantation in 
STEMI (OR 6.2; 95%CI 3,2 -12; p<0,0001) and stent in left anterior descending artery 
(OR 3.6; 95%CI 1.7-7.3; p<0,001).
Conclusions: LST and very LST after DES implantation although not frequent are no a 
rarity and may occur over a extended period of time after procedure. Many of the variables 
involved in SAT are not predictive for LST. DES implantation in a setting of STEMI, stent 
in left anterior descending artery and antiplatelet therapy cessation resulted strong 
predictors for these late events.
11:00 a.m.
2804-7 Late Thrombosis in Drug-Eluting Stents: Meta-Analysis 
of All Published Case Reports.
Ramin Artang, Ghazanfar Khadim, Robert S. Dieter, Medical College of Wisconsin, 
Milwaukee, WI
Background: Drug Eluting Stents (DES) have significantly reduced the incidence of 
instent restenosis observed with bare metal stents. Several cases of late stent thrombosis 
(LAST) have been reported with discontinuation of clopidogrel as the major risk factor. 
The current guidelines for DES recommend dual anti-platelet therapy for 3-6 months. The 
aim of this study was to review all published cases of LAST in DES to explore possible 
trends.
Methods: With the key words “drug eluting stents” medline search was used to identify 
all case reports of LAST in DES defined as angiographic stent thrombosis at least 30 
days after deployment. We included cases from randomized trials, observational registry 
reports and letters to editor, if information of the timing from stent deployment to clinical 
event, vessel, stent diameter and length, and antiplatelet regimen at the time of event 
were available.
Results: Baseline characteristics (table 1) were similar in both groups. There was a 
striking association between cessation of dual anti-platelet therapy and the occurrence 
of LAST, with discontinuation of clopidogrel alone resulting in significant delay in time to 
event.
Overall Sirolimus Paclitaxel P-value
Number of patients 36 16 20 ns
Male Gender 97% 93% 100% ns
Stent length mm (mean±SD) 23 ± 11 23 ± 11 24 ± 12 ns
Stent diameter mm (mean±SD) 3.0±0.34 2.9 ± 0.34 3.0 ± 0.35 ns
Days from stent deployment to event.
Median (total range) for the next 3 rows
242
(39-927)
240
(49-570)
289
(39-927) ns
Days from discontinuation of dual 
anti-platelet therapy to event
7
(3-150)
10
(4-45)
7
(3-150) ns
Days from discontinuation of 
clopidogrel to event
* p< 0.001 compared to discontinuation 
of dual regimen
30*
(14-690)
127
(14-690)
30
(15-84)
ns (small 
sample 
size)
Event occurrence related to a 
surgical procedure 42% 44% 40% ns
Coronary artery distribution
LAD 74%
RCA 17%
Circ 9%
LAD 73%
RCA 13%
Circ 13%
LAD 75%
RCA 20%
Circ 5%
ns
Conclusion: We present the largest collection of cases of LAST in DES published to date. 
This data supports the need for dual anti-platelet therapy beyond the current guidelines. 
The optimal duration of dual anti-platelet therapy remains to be determined. Efforts should 
be made to maintain patients at least on aspirin during routine surgical procedures.
11:15 a.m.
2804-9 Four-Year Clinical Follow-Up of the Research Registry
Joost Daemen, Hector Garcia-Garcia, Neville Kukreja, Yvette van Gestel, Ron van 
Domburg, Patrick Serruys, Erasmus MC - Thoraxcenter, Rotterdam, The Netherlands
Background: Sirolimus-Eluting Stents (SES) proved to effectively reduce restenosis 
and target lesion revascularization as compared to bare metal stents (BMS). To date, 
little is known about the long-term safety and efficacy, in particular mortality and stent 
thrombosis, of SES after 4 years of follow-up in a “real world” patient population.
Methods: Since April 2002, a cohort of 508 consecutive patients treated exclusively 
with sirolimus-eluting stents, has been followed. Prior to this, from October 2001 to April 
2002, 450 consecutive patients were treated with standard bare metal stents and form 
the control group. Four-year follow-up is still ongoing and already complete for 87.5% of 
our patients (mean 1440 days). We will be able to present the complete follow-up at the 
meeting.
Results: Patients treated with SES had significantly more multivessel disease and more 
type C lesions, furthermore more stents per patient were implanted. The history of prior 
myocardial infarction was higher in the BMS group. Diabetes was present in 15% of the 
BMS population versus 18% in the SES population. Preliminary cumulative survival 
percentages are 88.9% in BMS population versus 89.1% in the SES population (log rank 
p-value = 0.959) (Figure). Major Adverse Cardiac Event (MACE) rates will be presented 
at the meeting.
Conclusions: Our preliminary results show that after 4 years of follow-up the use of 
SES in an unselected patient population remains safe with comparable mortality rates 
as BMS. 
11:30 a.m.
2804-11 Comparison of Sirolimus-Versus Paclitaxel-Eluting 
Stents in an Unselected Population With Coronary 
Artery Disease: Two-Year Results From the REWARDS 
Registry
Probal Roy, Ashesh N. Buch, Vikram Raya, Teruo Okabe, Tina L. Pinto Slottow, Daniel H. 
Steinberg, Kimberly Smith, Zhenyi Xue, Natalie Gevorkian, Lowell L. Satler, Kenneth M. 
Kent, Augusto D. Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Superiority has been established for both sirolimus- (SES) and paclitaxel-
eluting stents (PES) over bare metal stents. A true difference between the 2 drug-eluting 
stents (DES) remains uncertain. We report 2-year results of the REWARDS registry 
comparing SES vs. PES in an unselected population undergoing percutaneous coronary 
intervention.
Methods: Consecutive patients undergoing DES implantation were entered into the 
REWARDS registry. Demographic, clinical, procedural, and follow-up data were collected. 
The 1-year outcomes of 2765 patients and outcomes from 1 to 2 years of 894 patients 
were analyzed.
Results: Patients receiving SES were more likely to have a greater number of diseased 
vessels (p<0.001), ostial lesions (p=0.04), in-hospital complications (p=0.03), IIb/IIIa 
inhibitor use (p=0.002), and longer stent lengths (p<0.001). PES patients had greater 
unstable anigina (p<0.001), type C lesions (p=0.02) and number of stents implanted 
per patient (p<0.001). A significantly higher rate of stent thrombosis with SES at 1 year 
(p=0.034) was observed. There were no other significant outcome differences at 1 year 
and from 1 to 2 years (Table).
Conclusions: Both DES types prove to be efficacious in reducing repeat revascularization 
with no appreciable difference in MACE between the two. A higher rate of stent thrombosis 
was observed in the SES group at 1 year. Stent thrombosis continued to be reported 
between 1 and 2 years in both groups.
Table. Outcomes for SES vs. PES in an unselected population with CAD at 
1 yr and between 1 to 2 yrs
Outcomes at 1yr SES (n=1923) PES (n=842) P
TVR-MACE 17.3% 17.4% 0.92
Death 6.6% 8.4% 0.09
Q wave MI 2.8% 2.8% 0.97
Stent Thrombosis 1.9% 0.8% 0.03
Outcomes 1-2yrs SES (n= 652) PES (n=242) P
TVR-MACE 13.0% 9.0% 0.12
Death 5.2% 3.3% 0.23
Q wave MI 0.8% 1.3% 0.49
Late Stent Thrombosis 0.1% 0.3% 0.49
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2804-13 Two-Year Outcomes From the ENDEAVOR III Trial: A 
Randomized Trial of the Endeavor Zotarolimus-Eluting 
Stent Compared With the Cypher Sirolimus-Eluting 
Stent
Martin B. Leon, David E. Kandzari, Medtronic, Inc, Santa Rosa, CA
Background: Endeavor III is a randomized, multicenter trial comparing angiographic and 
clinical outcomes among patients randomized to treatment with either the Endeavor 
zotarolimus-eluting stent (ZES) or Cypher sirolimus-eluting stent (SES). Whether 
disparities in angiographic measures at 8 months between the two stents translated into 
differences in late (eg, 1 and 2 year) clinical outcome is uncertain.
Methods: A total of 436 patients were randomized to treatment with either ZES (N=316) 
or SES (N=110) in a single-blinded fashion. Clinical outcomes of composite endpoints 
and the individual rates of death, myocardial infarction, angiographically-determined 
stent thrombosis and clinically-driven repeat target lesion (TLR) and target vessel 
revascularization (TVR) were prospectively evaluated at 1 and 2 years following the index 
procedure.
Results: No significant differences in baseline reference vessel diameter, lesion length or 
the presence of diabetes were observed between ZES and SES cohorts. Despite higher 
8-month angiographic late lumen loss with ZES, at 12 months, rates of major adverse 
events were identical in both groups (8.2%), and there were no significant differences 
in the individual endpoints of death, MI or clinically-driven TLR. Stent thrombosis did not 
occur in either group at 1 year. The 2-year clinical follow-up data will be available in March 
2007.
Conclusion: Despite differences in angiographic outcome at 8 month follow-up, rates of 
clinically-driven TLR and major adverse events appear similar between patients treated 
with ZES and SES. Long-term (2 year) follow-up will clarify further not only safety with 
ZES but also whether early angiographic disparities translate into differences in late 
clinical restenosis.
Noon
2804-15 Arterial Revascularization Therapies Study Part II - 
Sirolimus-Eluting Stents for the Treatment of Patients 
With Multivessel De Novo Coronary Artery Lesions: 
Three-Year Clinical Outcomes
Patrick W. Serruys, Antonio Colombo, Keith Dawkins, Bernard De Bruyne, Christian 
Hamm, Carlos Macaya, Marie-Claude Morice, Gert Richardt, Hans-Peter Stoll, 
Thoraxcenter - Erasmus University Medical Center, Rotterdam, The Netherlands
Background: The Arterial Revascularization Therapies Study (ARTSI) was a randomized 
multicenter trial of 1205 patients with multivessel disease (MVD), comparing surgery 
(ARTSI-CABG, n=605) with bare metal stenting (ARTSI-BMS, n=600) on clinical 
outcome and cost effectiveness. At 1 year, survival free from major adverse cardiac and 
cerebrovascular events (MACCE) was 87.8% in the ARTSI-CABG vs 73.8% in ARTSI-
BMS, driven by a 17.2% difference in repeat revascularization. As the sirolimus stent 
(SES) has reduced restenosis compared to BMS, further evaluation of MVD stenting with 
SES is warranted to compare outcomes with the two ARTSI-arms, CABG and BMS.
Methods: ARTSII is a multicenter (n=45), non-randomized, stratified trial of 607 patients 
treated with SES. Primary aim is to compare the effectiveness of SES with ARTSI-CABG 
measured as MACCE-free survival at 1 year. Secondary objectives are MACCE at 1 & 6 
months, 1, 3 & 5 years, quality of life and cost effectiveness.
Results: In ARTSII the number of diseased vessels was 2.5 ± 0.5 vs 2.3 ± 0.5 in ARTSI-
CABG and 2.2 ± 0.5 in ARTS I-BMS. The number of treated lesions was 3.2 ± 1.1 (ARTSII) 
vs 2.6 ± 1.0 anastomosed segments (ARTSI-CABG) and 2.5 ± 1.0 treated lesions 
(ARTSI-BMS). Postprocedural CK-MB release > 5 x upper normal limit was observed in 
1.5% in ARTSII vs 12.7% in ARTSI-CABG and 6.2% in ARTSI-BMS. Mean stented length 
was 72.5 ± 32.1mm with 3.7 ± 1.5 stents implanted per ARTSII patient, vs 48 ± 22mm and 
2.8 ± 1.3 stents implanted per ARTSI-BMS patient.
In ARTSII, the incidence of angiographically documented late stent occlusion (30 days 
to 1 year) was 0.3% (n=2). This was not measured in ARTSI. The ARTSII 1-year MACCE 
rate was in the same range as ARTSI-CABG results (10.5% vs 11.7%), with less events in 
the combined death, stroke or myocardial infarction endpoint (3.0% vs 8.0%) balanced by 
a significantly higher need for repeat revascularization in ARTSII (8.5% vs 4.2%). The 1-
year MACCE rate in ARTSII was much lower than the ARTSI-BMS group (26.5%), driven 
by a higher incidence of events in all measured endpoints, with the biggest difference 
being in repeat revascularization (21.3%).
Conclusions: 3-year clinical outcomes will be presented at the meeting.
i2.ORAL CONTRIBUTIONS
2805 
Outcomes and Antiplatelet Therapy
Monday, March 26, 2007, 1:30 p.m.-2:30 p.m.
Room 242
1:30 p.m.
2805-3 Implications of Hemoglobin Decrease in the Absence 
of Overt Bleeding After Percutaneous Coronary 
Intervention
Eugenia Nikolsky, A. Michael Lincoff, Roxana Mehran, Robert A. Harrington, John A. 
Bittle, Frederick Feit, George Dangas, Emilia Solinas, Tereza Pucelikova, Masashi 
Kimura, Florencia De Los Santos, Gregg W. Stone, Columbia University Medical Center, 
New York, NY, the Cardiovascular Research Foundation, New York, NY
Background: Bleeding is increasingly being recognized as an adverse prognostic factor 
after percutaneous coronary intervention (PCI). Several PCI trials include a significant 
decrease in hemoglobin (Hb) as a major hemorrhage even in the absence of an overt 
source of bleeding. The prognostic impact of such an event is unknown. We examined the 
database from the multicenter, randomized, double-blind REPLACE-2 trial to assess the 
prognostic implications of PCI-related decreases in Hb without a bleeding overt source.
Methods: By protocol Hb levels were drawn at baseline, 24 hours post-PCI and at 
discharge. Outcomes were stratified by the difference in baseline to nadir Hb. Patients 
experiencing any overt bleeding and pts treated with blood transfusion were excluded.
Results: Of 4,323 pts without overt bleeding and with serial Hb data, 2,720 pts (62.9%) 
had a post-PCI decrease in Hb <1 g/dl, 1,239 (28.7%) had a decrease in Hb ≥1 to <2 g/dl, 
and 364 (8.4%) had a decrease in Hb ≥2 g/dl. Patients with larger Hb decreases were 
older, more frequently female, and had worse renal function. Larger Hb decreases were 
associated with a higher incidence of CK-MB elevation post PCI, more frequent adverse 
ischemic endpoints at 30 days and at 6 months (Table). By multivariable analysis, a larger 
decrease in Hb was an independent predictor of 6-month death (HR=3.33, P=0.011).
Conclusion: Even in the absence of overt bleeding, a decrease in hemoglobin post PCI 
is strongly associated with increased early and late ischemic complications. 
Events
Decrease in Hb
P<1 g/dl
N=2,720
≥1 to <2 g/dl,
N=1,239
≥2 g/dl
N=364
CK-MB peak post PCI >3x normal 5.9% 8.7% 10.0% 0.0003
At 30 days
Death 0.1% 0.2% 0.6% 0.07
MI 5.3% 7.8% 8.8% 0.002
Non Q-wave MI 5.1% 7.3% 8.3% 0.004
Urgent revascularization 0.6% 1.2% 3.0% <0.0001
Death/MI/Urgent revascularization 5.7% 8.3% 9.9% 0.0004
At 6 months
Death 0.7% 0.9% 2.2% 0.015
MI 6.3% 9.2% 10.7% 0.0007
Non Q-wave MI 5.7% 7.5% 9.2% 0.009
Urgent revascularization 2.8% 4.1% 4.4% 0.037
Death/MI/Urgent revascularization 9.0% 12.3% 13.5% 0.001
1:45 p.m.
2805-5 Chronic Kidney Disease Is Associated With Increased 
Mortality, Bleeding, and Ischemic Events in Moderate 
and High-Risk Patients With Acute Coronary 
Syndromes: An ACUITY Substudy
Roxana Mehran, Ajay J. Kirtane, George Dangas, Magnus Ohman, Stuart Pocock, 
Bernard Gersh, Michael Bertrand, Martial Hamon, Steven Manoukian, James Hoekstra, 
Charles Pollack, Walter Desmet, Frederick Feit, Joseph Stella, Angel Cequier, Thomas 
Stuckey, David Cohen, Gregg W. Stone, Columbia University Medical Center, New York, 
NY, Cardiovascular Research Foundation, New York, NY
Background: Chronic Kidney Disease (CKD) is an important predictor of adverse 
outcomes in pts with ACS, but there are incomplete data on this association among 
patients undergoing an early invasive treatment strategy treated with current anti-
thrombotic regimens.
Methods: The ACUITY trial randomized 13,819 moderate and high risk ACS pts 
undergoing early invasive management to bivalirudin (BIV) alone, BIV + glycoprotein IIb/
IIa inhibition (GPI), or heparin + GPI. Clinical outcomes were compared among pts with 
creatinine clearance <60 ml/min (low CrCl) vs. ≥ 60 ml/min (normal CrCl).
Results: Pts with low CrCl were older, more frequently presented with ST-segment 
deviation, and were in general higher risk. Patients with low CrCl were slightly less 
frequently treated with PCI (54.7% vs. 57.3% for normal CrCl, p=0.02), though CABG 
was performed in similar proportions (11.0% vs. 11.2%, p=NS). The rate of death/MI/
unplanned revascularization/major bleeding was significantly higher among pts with low 
CrCl (17.5% vs. 9.8%, p<0.001), (Table) in univariate and fully adjusted multivariable 
analyses. Importantly, CKD was an independent predictor of 30-day mortality (OR=2.7, 
CI= 1.9-3.9).
Conclusion: Despite an early invasive strategy with a high rate of revascularization 
in ACUITY, baseline low CrCl was independently associated with mortality, adverse 
ischemic outcomes, and hemorrhagic complications. One year outcomes will be available 
for presentation. 
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CrCl<60
(N=2468)
CrCl≥60
(N=10,472)
Composite Ischemic 10.7 6.9 <0.001
- Death/MI 8.9 5.6 <0.001
- Death 3.0 1.1 <0.001
- MI 6.6 4.8 <0.001
- Q-wave MI 1.2 1.0 0.42
- Non Q-wave MI 5.5 3.8 <0.001
- Unplanned Revasc 3.1 2.3 0.03
Non CABG Major Bleed 9.2 3.6 <0.001
Composite net clinical outcomes 17.5 9.8 <0.001
2:00 p.m.
2805-7 Prevention of Radiocontrast Medium Induced 
Nephropathy Using High-Dose Statin in Patients 
Undergoing Coronary Angiography: The PROMISS Trial 
- A Randomized Controlled Study
Sang-Ho Jo, Bon-Kwon Koo, Jin-Shik Park, Hyun-Jae Kang, Young-Seok Cho, Yong-Jin 
Kim, Woo-Young Chung, In-Ho Chae, Dong-Ju Choi, Dae-Won Sohn, Byung-Hee Oh, 
Young-Bae Park, Yun-Shik Choi, Hyo-Soo Kim, Hallym Univesity Sacred Heart Hospital, 
Gyeonggido, South Korea, Seoul National University Hospital, Seoul, South Korea
Background: Oxidative stress caused by contrast media has been suggested for one 
mechanism of contrast induced nephropathy (CIN). The statin has been reported to 
have pleiotropic effects one of which may be derived from its antioxidant property. We 
investigated to determine whether statin has preventive effect for CIN in patients with 
renal insufficiency undergoing coronary angiography.
Methods: We conducted a prospective, randomized, double-blind, placebo-controlled, 2-
center trial. A total of 247 consecutive patients with chronic renal insufficiency (calculated 
creatinine clearance ≤ 60mL/min or serum creatinine ≥ 1.1mg/dL) who underwent 
coronary angiography were enrolled. Half iso-tonic saline was given intravenously at 
a rate of 1ml/kg/hour at least for 12hours before and 12hours after administration of 
contrast agent to both groups. Only iso-osmolar contrast medium-iodixanol was used 
in coronary angiography. Serum creatinine (Scr) was measured on the day1 and day2 
after coronary angiography. Patients were randomly assigned to simvastatin group 
(n=124, simvastatin 40mg orally twice daily before and on the day [2 days] of coronary 
angiography) or placebo (n=123).
Results: The primary end point was peak increase of Scr from baseline within two days 
after coronary angiography, and secondary end point was development of CIN defined 
as increase of either ≥ 25% or ≥ 0.5 mg/dL in Scr, length of hospital stay, 30-day and 
6-month clinical outcomes. There were no differences in demographic and procedural 
characteristics between two groups. The mean peak increase of SCr was not different 
between simvastatin and placebo group (0.002±0.16 vs 0.02±0.23mg/mL respectively, 
p=0.56). In the secondary endpoint, CIN occurred in 2.5% (3 of 118 patients) in 
simvastatin group and 3.4% (4 of 118 patients) in placebo (p=1.0). The length of hospital 
stay, in-hospital, 30-day and 6-month clinical event rates were not different between two 
groups.
Conclusions: Simvastatin which have antioxidant property does not prevent renal 
function deterioration after administration of contrast medium in patients with baseline 
renal insufficiency undergoing coronary angiography.
2:15 p.m.
2805-9 Effects of Aspirin Dose on Ischemic Events and 
Bleeding After Percutaneous Coronary Intervention: 
Insights From the PCI-CURE Study
Sanjit S. Jolly, Feng Zhao, Salim Yusuf, Ron J.G. Peters, Keith A.A. Fox, Hans Jurgen 
Rupprecht, Michel Bertrand, Shamir R. Mehta, Hamilton Health Sciences, Hamilton, 
ON, Canada
Background: Percutaneous coronary intervention (PCI) trials in the stent era have 
universally used high dose ASA (≥200 mg) in combination with thienopyridines to prevent 
stent thrombosis and ischemic events. The objective was to explore the safety and 
efficacy of low (≤100 mg), intermediate (101-199 mg) and high (≥200 mg) dose ASA after 
PCI in non- ST elevation acute coronary syndromes (ACS).
Methods: In the CURE trial, 2658 patients with ACS undergoing PCI were stratified 
according to most commonly used ASA dose after randomization. The crude event rates 
for cardiovascular (CV) death, MI or stroke as well as major bleeding were evaluated 
for each ASA dose group. These data were adjusted, using a cox proportional hazard 
model, for age, gender, weight, other components of TIMI risk score, hypertension and 
clopidogrel/placebo use.
Results: The composite of CV death, MI or stroke was similar in all the ASA dose groups 
at 30 days and 8 months. The incidence of major bleeding was not significantly different 
between the groups at 30 days, but the rate of major bleeding was significantly increased 
with high dose of ASA at 8 months.
Conclusion: In this large observational analysis, of patients with ACS undergoing PCI, 
low dose ASA appeared to be as effective as high dose ASA in preventing recurrent 
cardiac events with no significant differences in bleeding within 30 days. Longer-term 
treatment with high dose ASA demonstrated a similar efficacy benefit but significantly 
higher bleeding when compared with low dose ASA. 
Table: Outcomes with low, intermediate and high dose ASA
Outcomes at 
30 days
ASA≤100 
mg 
(N=1056)
ASA 101-
199 mg
(N=538)
ASA ≥200 
mg
(N=1064)
Adjusted HR
(95%CI)
ASA≥200 mg vs 
≤100 mg
Adjusted HR
(95%CI)
ASA101-199 mg 
vs ≤100 mg
CV Death, MI 
or stroke 43 (4.1%) 17 (3.2%) 43 (4.0%) 0.96 (0.62-1.48) 0.78 (0.44-1.39)
Major 
Bleeding 16 (1.5%) 3 (0.6%) 22 (2.1%) 1.29 (0.67-2.51) 0.39 (0.11-1.36)
Outcomes at 
8 months
CV Death, MI 
or stroke 75 (7.1%) 40 (7.4%) 91 (8.6%) 1.18 (0.86-1.61) 1.09 (0.74-1.61)
Major 
Bleeding 20 (1.9%) 8 (1.5%) 41 (3.9%) 2.21 (1.25-3.89) 0.89 (0.38-2.06)
